Word	Tag	Begin-End
Genetic	O	0-7
mapping	O	8-15
of	O	16-18
the	O	19-22
copper	B	23-29
toxicosis	I	30-39
locus	O	40-45
in	O	46-48
Bedlington	O	49-59
terriers	O	60-68
to	O	69-71
dog	O	72-75
chromosome	O	76-86
10	O	87-89
,	O	89-90
in	O	91-93
a	O	94-95
region	O	96-102
syntenic	O	103-111
to	O	112-114
human	O	115-120
chromosome	O	121-131
region	O	132-138
2p13	O	139-143
-	O	143-144
p16	O	144-147
.	O	147-148

Abnormal	O	149-157
hepatic	B	158-165
copper	I	166-172
accumulation	I	173-185
is	O	186-188
recognized	O	189-199
as	O	200-202
an	O	203-205
inherited	B	206-215
disorder	I	216-224
in	O	225-227
man	O	228-231
,	O	231-232
mouse	O	233-238
,	O	238-239
rat	O	240-243
and	O	244-247
dog	O	248-251
.	O	251-252

The	O	253-256
major	O	257-262
cause	O	263-268
of	O	269-271
hepatic	B	272-279
copper	I	280-286
accumulation	I	287-299
in	O	300-302
man	O	303-306
is	O	307-309
a	O	310-311
dysfunctional	O	312-325
ATP7B	O	326-331
gene	O	332-336
,	O	336-337
causing	O	338-345
Wilson	B	346-352
disease	I	353-360
(	O	361-362
WD	B	362-364
)	O	364-365
.	O	365-366

Mutations	O	367-376
in	O	377-379
the	O	380-383
ATP7B	O	384-389
genes	O	390-395
have	O	396-400
also	O	401-405
been	O	406-410
demonstrated	O	411-423
in	O	424-426
mouse	O	427-432
and	O	433-436
rat	O	437-440
.	O	440-441

The	O	442-445
ATP7B	O	446-451
gene	O	452-456
has	O	457-460
been	O	461-465
excluded	O	466-474
in	O	475-477
the	O	478-481
much	O	482-486
rarer	O	487-492
human	O	493-498
copper	B	499-505
overload	I	506-514
disease	O	515-522
non	B	523-526
-	I	526-527
Indian	I	527-533
childhood	I	534-543
cirrhosis	I	544-553
,	O	553-554
indicating	O	555-565
genetic	O	566-573
heterogeneity	O	574-587
.	O	587-588

By	O	589-591
investigating	O	592-605
the	O	606-609
common	O	610-616
autosomal	O	617-626
recessive	O	627-636
copper	B	637-643
toxicosis	I	644-653
(	O	654-655
CT	B	655-657
)	O	657-658
in	O	659-661
Bedlington	O	662-672
terriers	O	673-681
,	O	681-682
we	O	683-685
have	O	686-690
identified	O	691-701
a	O	702-703
new	O	704-707
locus	O	708-713
involved	O	714-722
in	O	723-725
progressive	O	726-737
liver	B	738-743
disease	I	744-751
.	O	751-752

We	O	753-755
examined	O	756-764
whether	O	765-772
the	O	773-776
WD	B	777-779
gene	O	780-784
ATP7B	O	785-790
was	O	791-794
also	O	795-799
causative	O	800-809
for	O	810-813
CT	B	814-816
by	O	817-819
investigating	O	820-833
the	O	834-837
chromosomal	O	838-849
co	O	850-852
-	O	852-853
localization	O	853-865
of	O	866-868
ATP7B	O	869-874
and	O	875-878
C04107	O	879-885
,	O	885-886
using	O	887-892
fluorescence	O	893-905
in	O	906-908
situ	O	909-913
hybridization	O	914-927
(	O	928-929
FISH	O	929-933
)	O	933-934
.	O	934-935

C04107	O	936-942
is	O	943-945
an	O	946-948
anonymous	O	949-958
microsatellite	O	959-973
marker	O	974-980
closely	O	981-988
linked	O	989-995
to	O	996-998
CT	B	999-1001
.	O	1001-1002

However	O	1003-1010
,	O	1010-1011
BAC	O	1012-1015
clones	O	1016-1022
containing	O	1023-1033
ATP7B	O	1034-1039
and	O	1040-1043
C04107	O	1044-1050
mapped	O	1051-1057
to	O	1058-1060
the	O	1061-1064
canine	O	1065-1071
chromosome	O	1072-1082
regions	O	1083-1090
CFA22q11	O	1091-1099
and	O	1100-1103
CFA10q26	O	1104-1112
,	O	1112-1113
respectively	O	1114-1126
,	O	1126-1127
demonstrating	O	1128-1141
that	O	1142-1146
WD	B	1147-1149
cannot	O	1150-1156
be	O	1157-1159
homologous	O	1160-1170
to	O	1171-1173
CT	B	1174-1176
.	O	1176-1177

The	O	1178-1181
copper	O	1182-1188
transport	O	1189-1198
genes	O	1199-1204
CTR1	O	1205-1209
and	O	1210-1213
CTR2	O	1214-1218
were	O	1219-1223
also	O	1224-1228
excluded	O	1229-1237
as	O	1238-1240
candidate	O	1241-1250
genes	O	1251-1256
for	O	1257-1260
CT	B	1261-1263
since	O	1264-1269
they	O	1270-1274
both	O	1275-1279
mapped	O	1280-1286
to	O	1287-1289
canine	O	1290-1296
chromosome	O	1297-1307
region	O	1308-1314
CFA11q22	O	1315-1323
.	O	1323-1324

2	O	1325-1326
-	O	1326-1327
22	O	1327-1329
.	O	1329-1330
5	O	1331-1332
.	O	1332-1333

A	O	1334-1335
transcribed	O	1336-1347
sequence	O	1348-1356
identified	O	1357-1367
from	O	1368-1372
the	O	1373-1376
C04107	O	1377-1383
-	O	1383-1384
containing	O	1384-1394
BAC	O	1395-1398
was	O	1399-1402
found	O	1403-1408
to	O	1409-1411
be	O	1412-1414
homologous	O	1415-1425
to	O	1426-1428
a	O	1429-1430
gene	O	1431-1435
expressed	O	1436-1445
from	O	1446-1450
human	O	1451-1456
chromosome	O	1457-1467
2p13	O	1468-1472
-	O	1472-1473
p16	O	1473-1476
,	O	1476-1477
a	O	1478-1479
region	O	1480-1486
devoid	O	1487-1493
of	O	1494-1496
any	O	1497-1500
positional	O	1501-1511
candidate	O	1512-1521
genes	O	1522-1527
.	O	1527-1528

Molecular	O	0-9
analysis	O	10-18
of	O	19-21
the	O	22-25
APC	B	26-29
gene	O	30-34
in	O	35-37
205	O	38-41
families	O	42-50
:	O	50-51
extended	O	52-60
genotype	O	61-69
-	O	69-70
phenotype	O	70-79
correlations	O	80-92
in	O	93-95
FAP	B	96-99
and	O	100-103
evidence	O	104-112
for	O	113-116
the	O	117-120
role	O	121-125
of	O	126-128
APC	B	129-132
amino	O	133-138
acid	O	139-143
changes	O	144-151
in	O	152-154
colorectal	B	155-165
cancer	I	166-172
predisposition	O	173-187
.	O	187-188

BACKGROUND	O	189-199
/	O	199-200
AIMS	O	200-204
The	O	206-209
development	O	210-221
of	O	222-224
colorectal	B	225-235
cancer	I	236-242
and	O	243-246
a	O	247-248
variable	O	249-257
range	O	258-263
of	O	264-266
extracolonic	O	267-279
manifestations	O	280-294
in	O	295-297
familial	B	298-306
adenomatous	I	307-318
polyposis	I	319-328
(	O	329-330
FAP	B	330-333
)	O	333-334
is	O	335-337
the	O	338-341
result	O	342-348
of	O	349-351
the	O	352-355
dominant	O	356-364
inheritance	O	365-376
of	O	377-379
adenomatous	B	380-391
polyposis	I	392-401
coli	I	402-406
(	O	407-408
APC	B	408-411
)	O	411-412
gene	O	413-417
mutations	O	418-427
.	O	427-428

In	O	429-431
this	O	432-436
study	O	437-442
,	O	442-443
direct	O	444-450
mutation	O	451-459
analysis	O	460-468
of	O	469-471
the	O	472-475
APC	B	476-479
gene	O	480-484
was	O	485-488
performed	O	489-498
to	O	499-501
determine	O	502-511
genotype	O	512-520
-	O	520-521
phenotype	O	521-530
correlations	O	531-543
for	O	544-547
nine	O	548-552
extracolonic	O	553-565
manifestations	O	566-580
and	O	581-584
to	O	585-587
investigate	O	588-599
the	O	600-603
incidence	O	604-613
of	O	614-616
APC	B	617-620
mutations	O	621-630
in	O	631-633
non	O	634-637
-	O	637-638
FAP	O	638-641
colorectal	B	642-652
cancer	I	653-659
.	O	659-660

METHODS	O	661-668
The	O	670-673
APC	B	674-677
gene	O	678-682
was	O	683-686
analysed	O	687-695
in	O	696-698
190	O	699-702
unrelated	O	703-712
FAP	B	713-716
and	O	717-720
15	O	721-723
non	O	724-727
-	O	727-728
FAP	O	728-731
colorectal	B	732-742
cancer	I	743-749
patients	O	750-758
using	O	759-764
denaturing	O	765-775
gradient	O	776-784
gel	O	785-788
electrophoresis	O	789-804
,	O	804-805
the	O	806-809
protein	O	810-817
truncation	O	818-828
test	O	829-833
,	O	833-834
and	O	835-838
direct	O	839-845
sequencing	O	846-856
.	O	856-857

RESULTS	O	858-865
Chain	O	867-872
terminating	O	873-884
signals	O	885-892
were	O	893-897
only	O	898-902
identified	O	903-913
in	O	914-916
patients	O	917-925
belonging	O	926-935
to	O	936-938
the	O	939-942
FAP	B	943-946
group	O	947-952
(	O	953-954
105	O	954-957
patients	O	958-966
)	O	966-967
.	O	967-968

Amino	O	969-974
acid	O	975-979
changes	O	980-987
were	O	988-992
identified	O	993-1003
in	O	1004-1006
four	O	1007-1011
patients	O	1012-1020
,	O	1020-1021
three	O	1022-1027
of	O	1028-1030
whom	O	1031-1035
belonged	O	1036-1044
to	O	1045-1047
the	O	1048-1051
non	O	1052-1055
-	O	1055-1056
FAP	O	1056-1059
group	O	1060-1065
of	O	1066-1068
colorectal	B	1069-1079
cancer	I	1080-1086
patients	O	1087-1095
.	O	1095-1096

Genotype	O	1097-1105
-	O	1105-1106
phenotype	O	1106-1115
correlations	O	1116-1128
identified	O	1129-1139
significant	O	1140-1151
differences	O	1152-1163
in	O	1164-1166
the	O	1167-1170
nature	O	1171-1177
of	O	1178-1180
certain	O	1181-1188
extracolonic	O	1189-1201
manifestations	O	1202-1216
in	O	1217-1219
FAP	B	1220-1223
patients	O	1224-1232
belonging	O	1233-1242
to	O	1243-1245
three	O	1246-1251
mutation	O	1252-1260
subgroups	O	1261-1270
.	O	1270-1271

CONCLUSIONS	O	1272-1283
Extended	O	1285-1293
genotype	O	1294-1302
-	O	1302-1303
phenotype	O	1303-1312
correlations	O	1313-1325
made	O	1326-1330
in	O	1331-1333
this	O	1334-1338
study	O	1339-1344
may	O	1345-1348
have	O	1349-1353
the	O	1354-1357
potential	O	1358-1367
to	O	1368-1370
determine	O	1371-1380
the	O	1381-1384
most	O	1385-1389
appropriate	O	1390-1401
surveillance	O	1402-1414
and	O	1415-1418
prophylactic	O	1419-1431
treatment	O	1432-1441
regimens	O	1442-1450
for	O	1451-1454
those	O	1455-1460
patients	O	1461-1469
with	O	1470-1474
mutations	O	1475-1484
associated	O	1485-1495
with	O	1496-1500
life	O	1501-1505
threatening	O	1506-1517
conditions	O	1518-1528
.	O	1528-1529

This	O	1530-1534
study	O	1535-1540
also	O	1541-1545
provided	O	1546-1554
evidence	O	1555-1563
for	O	1564-1567
the	O	1568-1571
pathological	O	1572-1584
nature	O	1585-1591
of	O	1592-1594
amino	O	1595-1600
acid	O	1601-1605
changes	O	1606-1613
in	O	1614-1616
APC	O	1617-1620
associated	O	1621-1631
with	O	1632-1636
both	O	1637-1641
FAP	B	1642-1645
and	O	1646-1649
non	O	1650-1653
-	O	1653-1654
FAP	O	1654-1657
colorectal	B	1658-1668
cancer	I	1669-1675
patients	O	1676-1684
.	O	1684-1685
.	O	1684-1685

A	O	0-1
European	O	2-10
multicenter	O	11-22
study	O	23-28
of	O	29-31
phenylalanine	B	32-45
hydroxylase	I	46-57
deficiency	I	58-68
:	O	68-69
classification	O	70-84
of	O	85-87
105	O	88-91
mutations	O	92-101
and	O	102-105
a	O	106-107
general	O	108-115
system	O	116-122
for	O	123-126
genotype	O	127-135
-	O	135-136
based	O	136-141
prediction	O	142-152
of	O	153-155
metabolic	O	156-165
phenotype	O	166-175
.	O	175-176

Phenylketonuria	B	177-192
(	O	193-194
PKU	B	194-197
)	O	197-198
and	O	199-202
mild	B	203-207
hyperphenylalaninemia	I	208-229
(	O	230-231
MHP	B	231-234
)	O	234-235
are	O	236-239
allelic	B	240-247
disorders	I	248-257
caused	O	258-264
by	O	265-267
mutations	O	268-277
in	O	278-280
the	O	281-284
gene	O	285-289
encoding	O	290-298
phenylalanine	O	299-312
hydroxylase	O	313-324
(	O	325-326
PAH	O	326-329
)	O	329-330
.	O	330-331

Previous	O	332-340
studies	O	341-348
have	O	349-353
suggested	O	354-363
that	O	364-368
the	O	369-372
highly	O	373-379
variable	O	380-388
metabolic	O	389-398
phenotypes	O	399-409
of	O	410-412
PAH	B	413-416
deficiency	I	417-427
correlate	O	428-437
with	O	438-442
PAH	O	443-446
genotypes	O	447-456
.	O	456-457

We	O	458-460
identified	O	461-471
both	O	472-476
causative	O	477-486
mutations	O	487-496
in	O	497-499
686	O	500-503
patients	O	504-512
from	O	513-517
seven	O	518-523
European	O	524-532
centers	O	533-540
.	O	540-541

On	O	542-544
the	O	545-548
basis	O	549-554
of	O	555-557
the	O	558-561
phenotypic	O	562-572
characteristics	O	573-588
of	O	589-591
297	O	592-595
functionally	O	596-608
hemizygous	O	609-619
patients	O	620-628
,	O	628-629
105	O	630-633
of	O	634-636
the	O	637-640
mutations	O	641-650
were	O	651-655
assigned	O	656-664
to	O	665-667
one	O	668-671
of	O	672-674
four	O	675-679
arbitrary	O	680-689
phenotype	O	690-699
categories	O	700-710
.	O	710-711

We	O	712-714
proposed	O	715-723
and	O	724-727
tested	O	728-734
a	O	735-736
simple	O	737-743
model	O	744-749
for	O	750-753
correlation	O	754-765
between	O	766-773
genotype	O	774-782
and	O	783-786
phenotypic	O	787-797
outcome	O	798-805
.	O	805-806

The	O	807-810
observed	O	811-819
phenotype	O	820-829
matched	O	830-837
the	O	838-841
predicted	O	842-851
phenotype	O	852-861
in	O	862-864
79	O	865-867
%	O	867-868
of	O	869-871
the	O	872-875
cases	O	876-881
,	O	881-882
and	O	883-886
in	O	887-889
only	O	890-894
5	O	895-896
of	O	897-899
184	O	900-903
patients	O	904-912
was	O	913-916
the	O	917-920
observed	O	921-929
phenotype	O	930-939
more	O	940-944
than	O	945-949
one	O	950-953
category	O	954-962
away	O	963-967
from	O	968-972
that	O	973-977
expected	O	978-986
.	O	986-987

Among	O	988-993
the	O	994-997
seven	O	998-1003
contributing	O	1004-1016
centers	O	1017-1024
,	O	1024-1025
the	O	1026-1029
proportion	O	1030-1040
of	O	1041-1043
patients	O	1044-1052
for	O	1053-1056
whom	O	1057-1061
the	O	1062-1065
observed	O	1066-1074
phenotype	O	1075-1084
did	O	1085-1088
not	O	1089-1092
match	O	1093-1098
the	O	1099-1102
predicted	O	1103-1112
phenotype	O	1113-1122
was	O	1123-1126
4	O	1127-1128
%	O	1128-1129
-	O	1130-1131
23	O	1131-1133
%	O	1133-1134
(	O	1135-1136
P	O	1136-1137
<	O	1138-1139
.	O	1139-1140
0001	O	1141-1145
)	O	1145-1146
,	O	1146-1147
suggesting	O	1148-1158
that	O	1159-1163
differences	O	1164-1175
in	O	1176-1178
methods	O	1179-1186
used	O	1187-1191
for	O	1192-1195
mutation	O	1196-1204
detection	O	1205-1214
or	O	1215-1217
phenotype	O	1218-1227
classification	O	1228-1242
may	O	1243-1246
account	O	1247-1254
for	O	1255-1258
a	O	1259-1260
considerable	O	1261-1273
proportion	O	1274-1284
of	O	1285-1287
genotype	O	1288-1296
-	O	1296-1297
phenotype	O	1297-1306
inconsistencies	O	1307-1322
.	O	1322-1323

Our	O	1324-1327
data	O	1328-1332
indicate	O	1333-1341
that	O	1342-1346
the	O	1347-1350
PAH	O	1351-1354
-	O	1354-1355
mutation	O	1355-1363
genotype	O	1364-1372
is	O	1373-1375
the	O	1376-1379
main	O	1380-1384
determinant	O	1385-1396
of	O	1397-1399
metabolic	O	1400-1409
phenotype	O	1410-1419
in	O	1420-1422
most	O	1423-1427
patients	O	1428-1436
with	O	1437-1441
PAH	B	1442-1445
deficiency	I	1446-1456
.	O	1456-1457

In	O	1458-1460
the	O	1461-1464
present	O	1465-1472
study	O	1473-1478
,	O	1478-1479
the	O	1480-1483
classification	O	1484-1498
of	O	1499-1501
105	O	1502-1505
PAH	O	1506-1509
mutations	O	1510-1519
may	O	1520-1523
allow	O	1524-1529
the	O	1530-1533
prediction	O	1534-1544
of	O	1545-1547
the	O	1548-1551
biochemical	O	1552-1563
phenotype	O	1564-1573
in	O	1574-1576
>	O	1577-1578
10	O	1579-1581
,	O	1581-1582
000	O	1583-1586
genotypes	O	1587-1596
,	O	1596-1597
which	O	1598-1603
may	O	1604-1607
be	O	1608-1610
useful	O	1611-1617
for	O	1618-1621
the	O	1622-1625
management	O	1626-1636
of	O	1637-1639
hyperphenylalaninemia	B	1640-1661
in	O	1662-1664
newborns	O	1665-1673
.	O	1673-1674

Disruption	O	0-10
of	O	11-13
splicing	O	14-22
regulated	O	23-32
by	O	33-35
a	O	36-37
CUG	O	38-41
-	O	41-42
binding	O	42-49
protein	O	50-57
in	O	58-60
myotonic	B	61-69
dystrophy	I	70-79
.	O	79-80

Myotonic	B	81-89
dystrophy	I	90-99
(	O	100-101
DM	B	101-103
)	O	103-104
is	O	105-107
caused	O	108-114
by	O	115-117
a	O	118-119
CTG	O	120-123
expansion	O	124-133
in	O	134-136
the	O	137-140
3	O	141-142
untranslated	O	143-155
region	O	156-162
of	O	163-165
the	O	166-169
DM	B	170-172
gene	O	173-177
.	O	177-178

One	O	179-182
model	O	183-188
of	O	189-191
DM	B	192-194
pathogenesis	O	195-207
suggests	O	208-216
that	O	217-221
RNAs	O	222-226
from	O	227-231
the	O	232-235
expanded	O	236-244
allele	O	245-251
create	O	252-258
a	O	259-260
gain	O	261-265
-	O	265-266
of	O	266-268
-	O	265-266
function	O	269-277
mutation	O	278-286
by	O	287-289
the	O	290-293
inappropriate	O	294-307
binding	O	308-315
of	O	316-318
proteins	O	319-327
to	O	328-330
the	O	331-334
CUG	O	335-338
repeats	O	339-346
.	O	346-347

Data	O	348-352
presented	O	353-362
here	O	363-367
indicate	O	368-376
that	O	377-381
the	O	382-385
conserved	O	386-395
heterogeneous	O	396-409
nuclear	O	410-417
ribonucleoprotein	O	418-435
,	O	435-436
CUG	O	437-440
-	O	440-441
binding	O	441-448
protein	O	449-456
(	O	457-458
CUG	O	458-461
-	O	461-462
BP	O	462-464
)	O	464-465
,	O	465-466
may	O	467-470
mediate	O	471-478
the	O	479-482
trans	O	483-488
-	O	488-489
dominant	O	489-497
effect	O	498-504
of	O	505-507
the	O	508-511
RNA	O	512-515
.	O	515-516

CUG	O	517-520
-	O	520-521
BP	O	521-523
was	O	524-527
found	O	528-533
to	O	534-536
bind	O	537-541
to	O	542-544
the	O	545-548
human	O	549-554
cardiac	O	555-562
troponin	O	563-571
T	O	572-573
(	O	574-575
cTNT	O	575-579
)	O	579-580
pre	O	581-584
-	O	584-585
messenger	O	585-594
RNA	O	595-598
and	O	599-602
regulate	O	603-611
its	O	612-615
alternative	O	616-627
splicing	O	628-636
.	O	636-637

Splicing	O	638-646
of	O	647-649
cTNT	O	650-654
was	O	655-658
disrupted	O	659-668
in	O	669-671
DM	B	672-674
striated	O	675-683
muscle	O	684-690
and	O	691-694
in	O	695-697
normal	O	698-704
cells	O	705-710
expressing	O	711-721
transcripts	O	722-733
that	O	734-738
contain	O	739-746
CUG	O	747-750
repeats	O	751-758
.	O	758-759

Altered	O	760-767
expression	O	768-778
of	O	779-781
genes	O	782-787
regulated	O	788-797
posttranscriptionally	O	798-819
by	O	820-822
CUG	O	823-826
-	O	826-827
BP	O	827-829
therefore	O	830-839
may	O	840-843
contribute	O	844-854
to	O	855-857
DM	B	858-860
pathogenesis	O	861-873
.	O	873-874
.	O	873-874

Maternal	B	0-8
disomy	I	9-15
and	O	16-19
Prader	B	20-26
-	I	26-27
Willi	I	27-32
syndrome	I	33-41
consistent	O	42-52
with	O	53-57
gamete	O	58-64
complementation	O	65-80
in	O	81-83
a	O	84-85
case	O	86-90
of	O	91-93
familial	O	94-102
translocation	O	103-116
(	O	117-118
3	O	118-119
;	O	119-120
15	O	120-122
)	O	122-123
(	O	124-125
p25	O	125-128
;	O	128-129
q11	O	129-132
.	O	132-133
2	O	126-127
)	O	134-135
.	O	132-133

Maternal	B	137-145
uniparental	I	146-157
disomy	I	158-164
(	I	165-166
UPD	I	166-169
)	I	169-170
for	I	171-174
chromosome	I	175-185
15	I	186-188
is	O	189-191
responsible	O	192-203
for	O	204-207
an	O	208-210
estimated	O	211-220
30	O	221-223
%	O	223-224
of	O	225-227
cases	O	228-233
of	O	234-236
Prader	B	237-243
-	I	243-244
Willi	I	244-249
syndrome	I	250-258
(	O	259-260
PWS	B	260-263
)	O	263-264
.	O	264-265

We	O	266-268
report	O	269-275
on	O	276-278
an	O	279-281
unusual	O	282-289
case	O	290-294
of	O	295-297
maternal	B	298-306
disomy	I	307-313
15	I	314-316
in	O	317-319
PWS	B	320-323
that	O	324-328
is	O	329-331
most	O	332-336
consistent	O	337-347
with	O	348-352
adjacent	O	353-361
-	O	361-362
1	O	362-363
segregation	O	364-375
of	O	376-378
a	O	379-380
paternal	O	381-389
t	O	390-391
(	O	392-393
3	O	393-394
;	O	394-395
15	O	396-398
)	O	398-399
(	O	400-401
p25	O	401-404
;	O	404-405
q11	O	406-409
.	O	409-410

2	O	411-412
)	O	412-413
with	O	414-418
simultaneous	O	419-431
maternal	O	432-440
meiotic	O	441-448
nondisjunction	O	449-463
for	O	464-467
chromosome	O	468-478
15	O	479-481
.	O	481-482

The	O	483-486
patient	O	487-494
(	O	495-496
J	O	496-497
.	O	497-498

B	O	499-500
.	O	500-501
)	O	501-502
,	O	502-503
a	O	504-505
17	O	506-508
-	O	508-509
year	O	509-513
-	O	508-509
old	O	514-517
white	O	518-523
male	O	524-528
with	O	529-533
PWS	B	534-537
,	O	537-538
was	O	539-542
found	O	543-548
to	O	549-551
have	O	552-556
47	O	557-559
chromosomes	O	560-571
with	O	572-576
a	O	577-578
supernumerary	O	579-592
,	O	592-593
paternal	O	594-602
der	O	603-606
(	O	607-608
15	O	608-610
)	O	610-611
consisting	O	612-622
of	O	623-625
the	O	626-629
short	O	630-635
arm	O	636-639
and	O	640-643
the	O	644-647
proximal	O	648-656
long	O	657-661
arm	O	662-665
of	O	666-668
chromosome	O	669-679
15	O	680-682
,	O	682-683
and	O	684-687
distal	O	688-694
chromosome	O	695-705
arm	O	706-709
3p	O	710-712
.	O	712-713

The	O	714-717
t	O	718-719
(	O	720-721
3	O	721-722
;	O	722-723
15	O	724-726
)	O	726-727
was	O	728-731
present	O	732-739
in	O	740-742
the	O	743-746
balanced	O	747-755
state	O	756-761
in	O	762-764
the	O	765-768
patients	O	769-777
father	O	778-784
and	O	785-788
a	O	789-790
sister	O	791-797
.	O	797-798

Fluorescent	O	799-810
in	O	811-813
situ	O	814-818
hybridization	O	819-832
analysis	O	833-841
demonstrated	O	842-854
that	O	855-859
the	O	860-863
PWS	B	864-867
critical	O	868-876
region	O	877-883
resided	O	884-891
on	O	892-894
the	O	895-898
derivative	O	899-909
chromosome	O	910-920
3	O	921-922
and	O	923-926
that	O	927-931
there	O	932-937
was	O	938-941
no	O	942-944
deletion	O	945-953
of	O	954-956
the	O	957-960
PWS	B	961-964
region	O	965-971
on	O	972-974
the	O	975-978
normal	O	979-985
pair	O	986-990
of	O	991-993
15s	O	994-997
present	O	998-1005
in	O	1006-1008
J	O	1009-1010
.	O	1010-1011
B	O	1012-1013
.	O	1013-1014
Methylation	O	1015-1026
analysis	O	1027-1035
at	O	1036-1038
exon	O	1039-1043
alpha	O	1044-1049
of	O	1050-1052
the	O	1053-1056
small	O	1057-1062
nuclear	O	1063-1070
ribonucleoprotein	O	1071-1088
-	O	1088-1089
associated	O	1089-1099
polypeptide	O	1100-1111
N	O	1112-1113
(	O	1114-1115
SNRPN	O	1115-1120
)	O	1120-1121
gene	O	1122-1126
showed	O	1127-1133
a	O	1134-1135
pattern	O	1136-1143
characteristic	O	1144-1158
of	O	1159-1161
only	O	1162-1166
the	O	1167-1170
maternal	O	1171-1179
chromosome	O	1180-1190
15	O	1191-1193
in	O	1194-1196
J	O	1197-1198
.	O	1198-1199
B	O	1200-1201
.	O	1201-1202
Maternal	B	1203-1211
disomy	I	1212-1218
was	O	1219-1222
confirmed	O	1223-1232
by	O	1233-1235
polymerase	O	1236-1246
chain	O	1247-1252
reaction	O	1253-1261
analysis	O	1262-1270
of	O	1271-1273
microsatellite	O	1274-1288
repeats	O	1289-1296
at	O	1297-1299
the	O	1300-1303
gamma	O	1304-1309
-	O	1309-1310
aminobutyric	O	1310-1322
acid	O	1323-1327
receptor	O	1328-1336
beta3	O	1337-1342
subunit	O	1343-1350
(	O	1351-1352
GABRB3	O	1352-1358
)	O	1358-1359
locus	O	1360-1365
.	O	1365-1366

A	O	1367-1368
niece	O	1369-1374
(	O	1375-1376
B	O	1376-1377
.	O	1377-1378

B	O	1379-1380
.	O	1380-1381
)	O	1381-1382
with	O	1383-1387
45	O	1388-1390
chromosomes	O	1391-1402
and	O	1403-1406
the	O	1407-1410
derivative	O	1411-1421
3	O	1422-1423
but	O	1424-1427
without	O	1428-1435
the	O	1436-1439
der	O	1440-1443
(	O	1444-1445
15	O	1445-1447
)	O	1447-1448
demonstrated	O	1449-1461
a	O	1462-1463
phenotype	O	1464-1473
consistent	O	1474-1484
with	O	1485-1489
that	O	1490-1494
reported	O	1495-1503
for	O	1504-1507
haploinsufficiency	O	1508-1526
of	O	1527-1529
distal	O	1530-1536
3	O	1537-1538
p	O	1539-1540
.	O	1540-1541

Uniparental	B	1542-1553
disomy	I	1554-1560
associated	O	1561-1571
with	O	1572-1576
unbalanced	O	1577-1587
segregation	O	1588-1599
of	O	1600-1602
non	O	1603-1606
-	O	1606-1607
Robertsonian	O	1607-1619
translocations	O	1620-1634
has	O	1635-1638
been	O	1639-1643
reported	O	1644-1652
previously	O	1653-1663
but	O	1664-1667
has	O	1668-1671
not	O	1672-1675
,	O	1675-1676
to	O	1677-1679
our	O	1680-1683
knowledge	O	1684-1693
,	O	1693-1694
been	O	1695-1699
observed	O	1700-1708
in	O	1709-1711
a	O	1712-1713
case	O	1714-1718
of	O	1719-1721
PWS	B	1722-1725
.	O	1725-1726

Furthermore	O	1727-1738
,	O	1738-1739
our	O	1740-1743
findings	O	1744-1752
are	O	1753-1756
best	O	1757-1761
interpreted	O	1762-1773
as	O	1774-1776
true	O	1777-1781
gamete	O	1782-1788
complementation	O	1789-1804
resulting	O	1805-1814
in	O	1815-1817
maternal	B	1818-1826
UPD	I	1827-1830
15	I	1831-1833
and	O	1834-1837
PWS	B	1838-1841

Segregation	O	0-11
distortion	O	12-22
in	O	23-25
myotonic	B	26-34
dystrophy	I	35-44
.	O	44-45

Myotonic	B	46-54
dystrophy	I	55-64
(	O	65-66
DM	B	66-68
)	O	68-69
is	O	70-72
an	O	73-75
autosomal	B	76-85
dominant	I	86-94
disease	I	95-102
which	O	103-108
,	O	108-109
in	O	110-112
the	O	113-116
typical	O	117-124
pedigree	O	125-133
,	O	133-134
shows	O	135-140
a	O	141-142
three	O	143-148
generation	O	149-159
anticipation	O	160-172
cascade	O	173-180
.	O	180-181

This	O	182-186
results	O	187-194
in	O	195-197
infertility	B	198-209
and	O	210-213
congenital	B	214-224
myotonic	I	225-233
dystrophy	I	234-243
(	O	244-245
CDM	B	245-248
)	O	248-249
with	O	250-254
the	O	255-258
disappearance	O	259-272
of	O	273-275
DM	B	276-278
in	O	279-281
that	O	282-286
pedigree	O	287-295
.	O	295-296

The	O	297-300
concept	O	301-308
of	O	309-311
segregation	O	312-323
distortion	O	324-334
,	O	334-335
where	O	336-341
there	O	342-347
is	O	348-350
preferential	O	351-363
transmission	O	364-376
of	O	377-379
the	O	380-383
larger	O	384-390
allele	O	391-397
at	O	398-400
the	O	401-404
DM	B	405-407
locus	O	408-413
,	O	413-414
has	O	415-418
been	O	419-423
put	O	424-427
forward	O	428-435
to	O	436-438
explain	O	439-446
partially	O	447-456
the	O	457-460
maintenance	O	461-472
of	O	473-475
DM	B	476-478
in	O	479-481
the	O	482-485
population	O	486-496
.	O	496-497

In	O	498-500
a	O	501-502
survey	O	503-509
of	O	510-512
DM	B	513-515
in	O	516-518
Northern	O	519-527
Ireland	O	528-535
,	O	535-536
59	O	537-539
pedigrees	O	540-549
were	O	550-554
ascertained	O	555-566
.	O	566-567

Sibships	O	568-576
where	O	577-582
the	O	583-586
status	O	587-593
of	O	594-596
all	O	597-600
the	O	601-604
members	O	605-612
had	O	613-616
been	O	617-621
identified	O	622-632
were	O	633-637
examined	O	638-646
to	O	647-649
determine	O	650-659
the	O	660-663
transmission	O	664-676
of	O	677-679
the	O	680-683
DM	B	684-686
expansion	O	687-696
from	O	697-701
affected	O	702-710
parents	O	711-718
to	O	719-721
their	O	722-727
offspring	O	728-737
.	O	737-738

Where	O	739-744
the	O	745-748
transmitting	O	749-761
parent	O	762-768
was	O	769-772
male	O	773-777
,	O	777-778
58	O	779-781
.	O	781-782

3	O	783-784
%	O	784-785
of	O	786-788
the	O	789-792
offspring	O	793-802
were	O	803-807
affected	O	808-816
,	O	816-817
and	O	818-821
in	O	822-824
the	O	825-828
case	O	829-833
of	O	834-836
a	O	837-838
female	O	839-845
transmitting	O	846-858
parent	O	859-865
,	O	865-866
68	O	867-869
.	O	869-870

7	O	871-872
%	O	872-873
were	O	874-878
affected	O	879-887
.	O	887-888

Studies	O	889-896
on	O	897-899
meiotic	O	900-907
drive	O	908-913
in	O	914-916
DM	B	917-919
have	O	920-924
shown	O	925-930
increased	O	931-940
transmission	O	941-953
of	O	954-956
the	O	957-960
larger	O	961-967
allele	O	968-974
at	O	975-977
the	O	978-981
DM	B	982-984
locus	O	985-990
in	O	991-993
non	O	994-997
-	O	997-998
DM	O	998-1000
heterozygotes	O	1001-1014
for	O	1015-1018
CTGn	O	1019-1023
.	O	1023-1024

This	O	1025-1029
study	O	1030-1035
provides	O	1036-1044
further	O	1045-1052
evidence	O	1053-1061
that	O	1062-1066
the	O	1067-1070
DM	B	1071-1073
expansion	O	1074-1083
tends	O	1084-1089
to	O	1090-1092
be	O	1093-1095
transmitted	O	1096-1107
preferentially	O	1108-1122
.	O	1122-1123

Ataxia	B	0-6
-	I	6-7
telangiectasia	I	7-21
:	O	21-22
identification	O	23-37
and	O	38-41
detection	O	42-51
of	O	52-54
founder	O	55-62
-	O	62-63
effect	O	63-69
mutations	O	70-79
in	O	80-82
the	O	83-86
ATM	O	87-90
gene	O	91-95
in	O	96-98
ethnic	O	99-105
populations	O	106-117
.	O	117-118

To	O	119-121
facilitate	O	122-132
the	O	133-136
evaluation	O	137-147
of	O	148-150
ATM	O	151-154
heterozygotes	O	155-168
for	O	169-172
susceptibility	O	173-187
to	O	188-190
other	O	191-196
diseases	O	197-205
,	O	205-206
such	O	207-211
as	O	212-214
breast	B	215-221
cancer	I	222-228
,	O	228-229
we	O	230-232
have	O	233-237
attempted	O	238-247
to	O	248-250
define	O	251-257
the	O	258-261
most	O	262-266
common	O	267-273
mutations	O	274-283
and	O	284-287
their	O	288-293
frequencies	O	294-305
in	O	306-308
ataxia	B	309-315
-	I	315-316
telangiectasia	I	316-330
(	O	331-332
A	B	332-333
-	I	333-334
T	I	334-335
)	O	335-336
homozygotes	O	337-348
from	O	349-353
10	O	354-356
ethnic	O	357-363
populations	O	364-375
.	O	375-376

Both	O	377-381
genomic	O	382-389
mutations	O	390-399
and	O	400-403
their	O	404-409
effects	O	410-417
on	O	418-420
cDNA	O	421-425
were	O	426-430
characterized	O	431-444
.	O	444-445

Protein	O	446-453
-	O	453-454
truncation	O	454-464
testing	O	465-472
of	O	473-475
the	O	476-479
entire	O	480-486
ATM	O	487-490
cDNA	O	491-495
detected	O	496-504
92	O	505-507
(	O	508-509
66	O	509-511
%	O	511-512
)	O	512-513
truncating	O	514-524
mutations	O	525-534
in	O	535-537
140	O	538-541
mutant	O	542-548
alleles	O	549-556
screened	O	557-565
.	O	565-566

The	O	567-570
haplotyping	O	571-582
of	O	583-585
patients	O	586-594
with	O	595-599
identical	O	600-609
mutations	O	610-619
indicates	O	620-629
that	O	630-634
almost	O	635-641
all	O	642-645
of	O	646-648
these	O	649-654
represent	O	655-664
common	O	665-671
ancestry	O	672-680
and	O	681-684
that	O	685-689
very	O	690-694
few	O	695-698
spontaneously	O	699-712
recurring	O	713-722
ATM	O	723-726
mutations	O	727-736
exist	O	737-742
.	O	742-743

Assays	O	744-750
requiring	O	751-760
minimal	O	761-768
amounts	O	769-776
of	O	777-779
genomic	O	780-787
DNA	O	788-791
were	O	792-796
designed	O	797-805
to	O	806-808
allow	O	809-814
rapid	O	815-820
screening	O	821-830
for	O	831-834
common	O	835-841
ethnic	O	842-848
mutations	O	849-858
.	O	858-859

These	O	860-865
rapid	O	866-871
assays	O	872-878
detected	O	879-887
mutations	O	888-897
in	O	898-900
76	O	901-903
%	O	903-904
of	O	905-907
Costa	O	908-913
Rican	O	914-919
patients	O	920-928
(	O	929-930
3	O	930-931
)	O	931-932
,	O	932-933
50	O	934-936
%	O	936-937
of	O	938-940
Norwegian	O	941-950
patients	O	951-959
(	O	960-961
1	O	961-962
)	O	962-963
,	O	963-964
25	O	965-967
%	O	967-968
of	O	969-971
Polish	O	972-978
patients	O	979-987
(	O	988-989
4	O	989-990
)	O	990-991
,	O	991-992
and	O	993-996
14	O	997-999
%	O	999-1000
of	O	1001-1003
Italian	O	1004-1011
patients	O	1012-1020
(	O	1021-1022
1	O	1022-1023
)	O	1023-1024
,	O	1024-1025
as	O	1026-1028
well	O	1029-1033
as	O	1034-1036
in	O	1037-1039
patients	O	1040-1048
of	O	1049-1051
Amish	O	1052-1057
/	O	1057-1058
Mennonite	O	1058-1067
and	O	1068-1071
Irish	O	1072-1077
English	O	1078-1085
backgrounds	O	1086-1097
.	O	1097-1098

Additional	O	1099-1109
mutations	O	1110-1119
were	O	1120-1124
observed	O	1125-1133
in	O	1134-1136
Japanese	O	1137-1145
,	O	1145-1146
Utah	O	1147-1151
Mormon	O	1152-1158
,	O	1158-1159
and	O	1160-1163
African	O	1164-1171
American	O	1172-1180
patients	O	1181-1189
.	O	1189-1190

These	O	1191-1196
assays	O	1197-1203
should	O	1204-1210
facilitate	O	1211-1221
screening	O	1222-1231
for	O	1232-1235
A	B	1236-1237
-	I	1237-1238
T	I	1238-1239
heterozygotes	O	1240-1253
in	O	1254-1256
the	O	1257-1260
populations	O	1261-1272
studied	O	1273-1280
.	O	1280-1281
.	O	1280-1281

Constitutional	O	0-14
RB1	O	15-18
-	O	18-19
gene	O	19-23
mutations	O	24-33
in	O	34-36
patients	O	37-45
with	O	46-50
isolated	O	51-59
unilateral	B	60-70
retinoblastoma	I	71-85
.	O	85-86

In	O	87-89
most	O	90-94
patients	O	95-103
with	O	104-108
isolated	O	109-117
unilateral	B	118-128
retinoblastoma	I	129-143
,	O	143-144
tumor	B	145-150
development	O	151-162
is	O	163-165
initiated	O	166-175
by	O	176-178
somatic	O	179-186
inactivation	O	187-199
of	O	200-202
both	O	203-207
alleles	O	208-215
of	O	216-218
the	O	219-222
RB1	O	223-226
gene	O	227-231
.	O	231-232

However	O	233-240
,	O	240-241
some	O	242-246
of	O	247-249
these	O	250-255
patients	O	256-264
can	O	265-268
transmit	O	269-277
retinoblastoma	B	278-292
predisposition	O	293-307
to	O	308-310
their	O	311-316
offspring	O	317-326
.	O	326-327

To	O	328-330
determine	O	331-340
the	O	341-344
frequency	O	345-354
and	O	355-358
nature	O	359-365
of	O	366-368
constitutional	O	369-383
RB1	O	384-387
-	O	387-388
gene	O	388-392
mutations	O	393-402
in	O	403-405
patients	O	406-414
with	O	415-419
isolated	O	420-428
unilateral	B	429-439
retinoblastoma	I	440-454
,	O	454-455
we	O	456-458
analyzed	O	459-467
DNA	O	468-471
from	O	472-476
peripheral	O	477-487
blood	O	488-493
and	O	494-497
from	O	498-502
tumor	B	503-508
tissue	O	509-515
.	O	515-516

The	O	517-520
analysis	O	521-529
of	O	530-532
tumors	B	533-539
from	O	540-544
54	O	545-547
(	O	548-549
71	O	549-551
%	O	551-552
)	O	552-553
of	O	554-556
76	O	557-559
informative	O	560-571
patients	O	572-580
showed	O	581-587
loss	O	588-592
of	O	593-595
constitutional	O	596-610
heterozygosity	O	611-625
(	O	626-627
LOH	O	627-630
)	O	630-631
at	O	632-634
intragenic	O	635-645
loci	O	646-650
.	O	650-651

Three	O	652-657
of	O	658-660
13	O	661-663
uninformative	O	664-677
patients	O	678-686
had	O	687-690
constitutional	O	691-705
deletions	O	706-715
.	O	715-716

For	O	717-720
39	O	721-723
randomly	O	724-732
selected	O	733-741
tumors	B	742-748
,	O	748-749
SSCP	O	750-754
,	O	754-755
hetero	O	756-762
-	O	762-763
duplex	O	763-769
analysis	O	770-778
,	O	778-779
sequencing	O	780-790
,	O	790-791
and	O	792-795
Southern	O	796-804
blot	O	805-809
analysis	O	810-818
were	O	819-823
used	O	824-828
to	O	829-831
identify	O	832-840
mutations	O	841-850
.	O	850-851

Mutations	O	852-861
were	O	862-866
detected	O	867-875
in	O	876-878
21	O	879-881
(	O	882-883
91	O	883-885
%	O	885-886
)	O	886-887
of	O	888-890
23	O	891-893
tumors	B	894-900
with	O	901-905
LOH	O	906-909
.	O	909-910

In	O	911-913
6	O	914-915
(	O	916-917
38	O	917-919
%	O	919-920
)	O	920-921
of	O	922-924
16	O	925-927
tumors	B	928-934
without	O	935-942
LOH	O	943-946
,	O	946-947
one	O	948-951
mutation	O	952-960
was	O	961-964
detected	O	965-973
,	O	973-974
and	O	975-978
in	O	979-981
9	O	982-983
(	O	984-985
56	O	985-987
%	O	987-988
)	O	988-989
of	O	990-992
the	O	993-996
tumors	B	997-1003
without	O	1004-1011
LOH	O	1012-1015
,	O	1015-1016
both	O	1017-1021
mutations	O	1022-1031
were	O	1032-1036
found	O	1037-1042
.	O	1042-1043

Thus	O	1044-1048
,	O	1048-1049
a	O	1050-1051
total	O	1052-1057
of	O	1058-1060
45	O	1061-1063
mutations	O	1064-1073
were	O	1074-1078
identified	O	1079-1089
in	O	1090-1092
tumors	B	1093-1099
of	O	1100-1102
36	O	1103-1105
patients	O	1106-1114
.	O	1114-1115

Thirty	O	1116-1122
-	O	1122-1123
nine	O	1123-1127
of	O	1128-1130
the	O	1131-1134
mutations	O	1135-1144
-	O	1144-1145
including	O	1145-1154
34	O	1155-1157
small	O	1158-1163
mutations	O	1164-1173
,	O	1173-1174
2	O	1175-1176
large	O	1177-1182
structural	O	1183-1193
alterations	O	1194-1205
,	O	1205-1206
and	O	1207-1210
hypermethylation	O	1211-1227
in	O	1228-1230
3	O	1231-1232
tumors	O	1233-1239
-	O	1239-1240
were	O	1240-1244
not	O	1245-1248
detected	O	1249-1257
in	O	1258-1260
the	O	1261-1264
corresponding	O	1265-1278
peripheral	O	1279-1289
blood	O	1290-1295
DNA	O	1296-1299
.	O	1299-1300

In	O	1301-1303
6	O	1304-1305
(	O	1306-1307
17	O	1307-1309
%	O	1309-1310
)	O	1310-1311
of	O	1312-1314
the	O	1315-1318
36	O	1319-1321
patients	O	1322-1330
,	O	1330-1331
a	O	1332-1333
mutation	O	1334-1342
was	O	1343-1346
detected	O	1347-1355
in	O	1356-1358
constitutional	O	1359-1373
DNA	O	1374-1377
,	O	1377-1378
and	O	1379-1382
1	O	1383-1384
of	O	1385-1387
these	O	1388-1393
mutations	O	1394-1403
is	O	1404-1406
known	O	1407-1412
to	O	1413-1415
be	O	1416-1418
associated	O	1419-1429
with	O	1430-1434
reduced	O	1435-1442
expressivity	O	1443-1455
.	O	1455-1456

The	O	1457-1460
presence	O	1461-1469
of	O	1470-1472
a	O	1473-1474
constitutional	O	1475-1489
mutation	O	1490-1498
was	O	1499-1502
not	O	1503-1506
associated	O	1507-1517
with	O	1518-1522
an	O	1523-1525
early	O	1526-1531
age	O	1532-1535
at	O	1536-1538
treatment	O	1539-1548
.	O	1548-1549

In	O	1550-1552
1	O	1553-1554
patient	O	1555-1562
,	O	1562-1563
somatic	O	1564-1571
mosaicism	O	1572-1581
was	O	1582-1585
demonstrated	O	1586-1598
by	O	1599-1601
molecular	O	1602-1611
analysis	O	1612-1620
of	O	1621-1623
DNA	O	1624-1627
and	O	1628-1631
RNA	O	1632-1635
from	O	1636-1640
peripheral	O	1641-1651
blood	O	1652-1657
.	O	1657-1658

In	O	1659-1661
2	O	1662-1663
patients	O	1664-1672
without	O	1673-1680
a	O	1681-1682
detectable	O	1683-1693
mutation	O	1694-1702
in	O	1703-1705
peripheral	O	1706-1716
blood	O	1717-1722
,	O	1722-1723
mosaicism	O	1724-1733
was	O	1734-1737
suggested	O	1738-1747
because	O	1748-1755
1	O	1756-1757
of	O	1758-1760
the	O	1761-1764
patients	O	1765-1773
showed	O	1774-1780
multifocal	O	1781-1791
tumors	B	1792-1798
and	O	1799-1802
the	O	1803-1806
other	O	1807-1812
later	O	1813-1818
developed	O	1819-1828
bilateral	B	1829-1838
retinoblastoma	I	1839-1853
.	O	1853-1854

In	O	1855-1857
conclusion	O	1858-1868
,	O	1868-1869
our	O	1870-1873
results	O	1874-1881
emphasize	O	1882-1891
that	O	1892-1896
the	O	1897-1900
manifestation	O	1901-1914
and	O	1915-1918
transmissibility	O	1919-1935
of	O	1936-1938
retinoblastoma	B	1939-1953
depend	O	1954-1960
on	O	1961-1963
the	O	1964-1967
nature	O	1968-1974
of	O	1975-1977
the	O	1978-1981
first	O	1982-1987
mutation	O	1988-1996
,	O	1996-1997
its	O	1998-2001
time	O	2002-2006
in	O	2007-2009
development	O	2010-2021
,	O	2021-2022
and	O	2023-2026
the	O	2027-2030
number	O	2031-2037
and	O	2038-2041
types	O	2042-2047
of	O	2048-2050
cells	O	2051-2056
that	O	2057-2061
are	O	2062-2065
affected	O	2066-2074
.	O	2074-2075
.	O	2074-2075

Missense	O	0-8
mutations	O	9-18
in	O	19-21
the	O	22-25
most	O	26-30
ancient	O	31-38
residues	O	39-47
of	O	48-50
the	O	51-54
PAX6	O	55-59
paired	O	60-66
domain	O	67-73
underlie	O	74-82
a	O	83-84
spectrum	O	85-93
of	O	94-96
human	O	97-102
congenital	B	103-113
eye	I	114-117
malformations	I	118-131
.	O	131-132

Mutations	O	133-142
of	O	143-145
the	O	146-149
human	O	150-155
PAX6	O	156-160
gene	O	161-165
underlie	O	166-174
aniridia	B	175-183
(	O	184-185
congenital	B	185-195
absence	I	196-203
of	I	204-206
the	I	207-210
iris	I	211-215
)	O	215-216
,	O	216-217
a	O	218-219
rare	O	220-224
dominant	O	225-233
malformation	B	234-246
of	I	247-249
the	I	250-253
eye	I	254-257
.	O	257-258

The	O	259-262
spectrum	O	263-271
of	O	272-274
PAX6	O	275-279
mutations	O	280-289
in	O	290-292
aniridia	B	293-301
patients	O	302-310
is	O	311-313
highly	O	314-320
biased	O	321-327
,	O	327-328
with	O	329-333
92	O	334-336
%	O	336-337
of	O	338-340
all	O	341-344
reported	O	345-353
mutations	O	354-363
leading	O	364-371
to	O	372-374
premature	O	375-384
truncation	O	385-395
of	O	396-398
the	O	399-402
protein	O	403-410
(	O	411-412
nonsense	O	412-420
,	O	420-421
splicing	O	422-430
,	O	430-431
insertions	O	432-442
and	O	443-446
deletions	O	447-456
)	O	456-457
and	O	458-461
just	O	462-466
2	O	467-468
%	O	468-469
leading	O	470-477
to	O	478-480
substitution	O	481-493
of	O	494-496
one	O	497-500
amino	O	501-506
acid	O	507-511
by	O	512-514
another	O	515-522
(	O	523-524
missense	O	524-532
)	O	532-533
.	O	533-534

The	O	535-538
extraordinary	O	539-552
conservation	O	553-565
of	O	566-568
the	O	569-572
PAX6	O	573-577
protein	O	578-585
at	O	586-588
the	O	589-592
amino	O	593-598
acid	O	599-603
level	O	604-609
amongst	O	610-617
vertebrates	O	618-629
predicts	O	630-638
that	O	639-643
pathological	O	644-656
missense	O	657-665
mutations	O	666-675
should	O	676-682
in	O	683-685
fact	O	686-690
be	O	691-693
common	O	694-700
even	O	701-705
though	O	706-712
they	O	713-717
are	O	718-721
hardly	O	722-728
ever	O	729-733
seen	O	734-738
in	O	739-741
aniridia	B	742-750
patients	O	751-759
.	O	759-760

This	O	761-765
indicates	O	766-775
that	O	776-780
there	O	781-786
is	O	787-789
a	O	790-791
heavy	O	792-797
ascertainment	O	798-811
bias	O	812-816
in	O	817-819
the	O	820-823
selection	O	824-833
of	O	834-836
patients	O	837-845
for	O	846-849
PAX6	O	850-854
mutation	O	855-863
analysis	O	864-872
and	O	873-876
that	O	877-881
the	O	882-885
missing	O	886-893
PAX6	O	894-898
missense	O	899-907
mutations	O	908-917
frequently	O	918-928
may	O	929-932
underlie	O	933-941
phenotypes	O	942-952
distinct	O	953-961
from	O	962-966
textbook	O	967-975
aniridia	B	976-984
.	O	984-985

Here	O	986-990
we	O	991-993
present	O	994-1001
four	O	1002-1006
novel	O	1007-1012
PAX6	O	1013-1017
missense	O	1018-1026
mutations	O	1027-1036
,	O	1036-1037
two	O	1038-1041
in	O	1042-1044
association	O	1045-1056
with	O	1057-1061
atypical	O	1062-1070
phenotypes	O	1071-1081
ectopia	B	1083-1090
pupillae	I	1091-1099
(	O	1100-1101
displaced	B	1101-1110
pupils	I	1111-1117
)	O	1117-1118
and	O	1119-1122
congenital	B	1123-1133
nystagmus	I	1134-1143
(	O	1144-1145
searching	B	1145-1154
gaze	I	1155-1159
)	O	1159-1160
,	O	1160-1161
and	O	1162-1165
two	O	1166-1169
in	O	1170-1172
association	O	1173-1184
with	O	1185-1189
more	O	1190-1194
recognizable	O	1195-1207
aniridia	B	1208-1216
phenotypes	O	1217-1227
.	O	1227-1228

Strikingly	O	1229-1239
,	O	1239-1240
all	O	1241-1244
four	O	1245-1249
mutations	O	1250-1259
are	O	1260-1263
located	O	1264-1271
within	O	1272-1278
the	O	1279-1282
PAX6	O	1283-1287
paired	O	1288-1294
domain	O	1295-1301
and	O	1302-1305
affect	O	1306-1312
amino	O	1313-1318
acids	O	1319-1324
which	O	1325-1330
are	O	1331-1334
highly	O	1335-1341
conserved	O	1342-1351
in	O	1352-1354
all	O	1355-1358
known	O	1359-1364
paired	O	1365-1371
domain	O	1372-1378
proteins	O	1379-1387
.	O	1387-1388

Our	O	1389-1392
results	O	1393-1400
support	O	1401-1408
the	O	1409-1412
hypothesis	O	1413-1423
that	O	1424-1428
the	O	1429-1432
under	O	1433-1438
-	O	1438-1439
representation	O	1439-1453
of	O	1454-1456
missense	O	1457-1465
mutations	O	1466-1475
is	O	1476-1478
caused	O	1479-1485
by	O	1486-1488
ascertainment	O	1489-1502
bias	O	1503-1507
and	O	1508-1511
suggest	O	1512-1519
that	O	1520-1524
a	O	1525-1526
substantial	O	1527-1538
burden	O	1539-1545
of	O	1546-1548
PAX6	B	1549-1553
-	I	1554-1555
related	I	1555-1562
disease	I	1563-1570
remains	O	1571-1578
to	O	1579-1581
be	O	1582-1584
uncovered	O	1585-1594
.	O	1594-1595
.	O	1594-1595

Somatic	O	0-7
instability	O	8-19
of	O	20-22
the	O	23-26
CTG	O	27-30
repeat	O	31-37
in	O	38-40
mice	O	41-45
transgenic	O	46-56
for	O	57-60
the	O	61-64
myotonic	B	65-73
dystrophy	I	74-83
region	O	84-90
is	O	91-93
age	O	94-97
dependent	O	98-107
but	O	108-111
not	O	112-115
correlated	O	116-126
to	O	127-129
the	O	130-133
relative	O	134-142
intertissue	O	143-154
transcription	O	155-168
levels	O	169-175
and	O	176-179
proliferative	O	180-193
capacities	O	194-204
.	O	204-205

A	O	206-207
(	O	208-209
CTG	O	209-212
)	O	212-213
nexpansion	O	214-224
in	O	225-227
the	O	228-231
3	O	232-233
-	O	233-234
untranslated	O	234-246
region	O	247-253
(	O	254-255
UTR	O	255-258
)	O	258-259
of	O	260-262
the	O	263-266
DM	O	267-269
protein	O	270-277
kinase	O	278-284
gene	O	285-289
(	O	290-291
DMPK	O	291-295
)	O	295-296
is	O	297-299
responsible	O	300-311
for	O	312-315
causing	O	316-323
myotonic	B	324-332
dystrophy	I	333-342
(	O	343-344
DM	B	344-346
)	O	346-347
.	O	347-348

Major	O	349-354
instability	O	355-366
,	O	366-367
with	O	368-372
very	O	373-377
large	O	378-383
expansions	O	384-394
between	O	395-402
generations	O	403-414
and	O	415-418
high	O	419-423
levels	O	424-430
of	O	431-433
somatic	O	434-441
mosaicism	O	442-451
,	O	451-452
is	O	453-455
observed	O	456-464
in	O	465-467
patients	O	468-476
.	O	476-477

There	O	478-483
is	O	484-486
a	O	487-488
good	O	489-493
correlation	O	494-505
between	O	506-513
repeat	O	514-520
size	O	521-525
(	O	526-527
at	O	527-529
least	O	530-535
in	O	536-538
leucocytes	O	539-549
)	O	549-550
,	O	550-551
clinical	O	552-560
severity	O	561-569
and	O	570-573
age	O	574-577
of	O	578-580
onset	O	581-586
.	O	586-587

The	O	588-591
trinucleotide	O	592-605
repeat	O	606-612
instability	O	613-624
mechanisms	O	625-635
involved	O	636-644
in	O	645-647
DM	B	648-650
and	O	651-654
other	O	655-660
human	O	661-666
genetic	B	667-674
diseases	I	675-683
are	O	684-687
unknown	O	688-695
.	O	695-696

We	O	697-699
studied	O	700-707
somatic	O	708-715
instability	O	716-727
by	O	728-730
measuring	O	731-740
the	O	741-744
CTG	O	745-748
repeat	O	749-755
length	O	756-762
at	O	763-765
several	O	766-773
ages	O	774-778
in	O	779-781
various	O	782-789
tissues	O	790-797
of	O	798-800
transgenic	O	801-811
mice	O	812-816
carrying	O	817-825
a	O	826-827
(	O	828-829
CTG	O	829-832
)	O	832-833
55expansion	O	834-845
surrounded	O	846-856
by	O	857-859
45	O	860-862
kb	O	863-865
of	O	866-868
the	O	869-872
human	O	873-878
DM	B	879-881
region	O	882-888
,	O	888-889
using	O	890-895
small	O	896-901
-	O	901-902
pool	O	902-906
PCR	O	907-910
.	O	910-911

These	O	912-917
mice	O	918-922
have	O	923-927
been	O	928-932
shown	O	933-938
to	O	939-941
reproduce	O	942-951
the	O	952-955
intergenerational	O	956-973
and	O	974-977
somatic	O	978-985
instability	O	986-997
of	O	998-1000
the	O	1001-1004
55	O	1005-1007
CTG	O	1008-1011
repeat	O	1012-1018
suggesting	O	1019-1029
that	O	1030-1034
surrounding	O	1035-1046
sequences	O	1047-1056
and	O	1057-1060
the	O	1061-1064
chromatin	O	1065-1074
environment	O	1075-1086
are	O	1087-1090
involved	O	1091-1099
in	O	1100-1102
instability	O	1103-1114
mechanisms	O	1115-1125
.	O	1125-1126

As	O	1127-1129
observed	O	1130-1138
in	O	1139-1141
some	O	1142-1146
of	O	1147-1149
the	O	1150-1153
tissues	O	1154-1161
of	O	1162-1164
DM	B	1165-1167
patients	O	1168-1176
,	O	1176-1177
there	O	1178-1183
is	O	1184-1186
a	O	1187-1188
tendency	O	1189-1197
for	O	1198-1201
repeat	O	1202-1208
length	O	1209-1215
and	O	1216-1219
somatic	O	1220-1227
mosaicism	O	1228-1237
to	O	1238-1240
increase	O	1241-1249
with	O	1250-1254
the	O	1255-1258
age	O	1259-1262
of	O	1263-1265
the	O	1266-1269
mouse	O	1270-1275
.	O	1275-1276

Furthermore	O	1277-1288
,	O	1288-1289
we	O	1290-1292
observed	O	1293-1301
no	O	1302-1304
correlation	O	1305-1316
between	O	1317-1324
the	O	1325-1328
somatic	O	1329-1336
mutation	O	1337-1345
rate	O	1346-1350
and	O	1351-1354
tissue	O	1355-1361
proliferation	O	1362-1375
capacity	O	1376-1384
.	O	1384-1385

The	O	1386-1389
somatic	O	1390-1397
mutation	O	1398-1406
rates	O	1407-1412
in	O	1413-1415
different	O	1416-1425
tissues	O	1426-1433
were	O	1434-1438
also	O	1439-1443
not	O	1444-1447
correlated	O	1448-1458
to	O	1459-1461
the	O	1462-1465
relative	O	1466-1474
inter	O	1475-1480
-	O	1480-1481
tissue	O	1481-1487
difference	O	1488-1498
in	O	1499-1501
transcriptional	O	1502-1517
levels	O	1518-1524
of	O	1525-1527
the	O	1528-1531
three	O	1532-1537
genes	O	1538-1543
(	O	1544-1545
DMAHP	O	1545-1550
,	O	1550-1551
DMPK	O	1552-1556
and	O	1557-1560
59	O	1561-1563
)	O	1563-1564
surrounding	O	1565-1576
the	O	1577-1580
repeat	O	1581-1587
.	O	1587-1588
.	O	1587-1588

ATM	O	0-3
mutations	O	4-13
and	O	14-17
phenotypes	O	18-28
in	O	29-31
ataxia	B	32-38
-	I	38-39
telangiectasia	I	39-53
families	O	54-62
in	O	63-65
the	O	66-69
British	O	70-77
Isles	O	78-83
:	O	83-84
expression	O	85-95
of	O	96-98
mutant	O	99-105
ATM	O	106-109
and	O	110-113
the	O	114-117
risk	O	118-122
of	O	123-125
leukemia	B	126-134
,	O	134-135
lymphoma	B	136-144
,	O	144-145
and	O	146-149
breast	B	150-156
cancer	I	157-163
.	O	163-164

We	O	165-167
report	O	168-174
the	O	175-178
spectrum	O	179-187
of	O	188-190
59	O	191-193
ATM	O	194-197
mutations	O	198-207
observed	O	208-216
in	O	217-219
ataxia	B	220-226
-	I	226-227
telangiectasia	I	227-241
(	O	242-243
A	B	243-244
-	I	244-245
T	I	245-246
)	O	246-247
patients	O	248-256
in	O	257-259
the	O	260-263
British	O	264-271
Isles	O	272-277
.	O	277-278

Of	O	279-281
51	O	282-284
ATM	O	285-288
mutations	O	289-298
identified	O	299-309
in	O	310-312
families	O	313-321
native	O	322-328
to	O	329-331
the	O	332-335
British	O	336-343
Isles	O	344-349
,	O	349-350
11	O	351-353
were	O	354-358
founder	O	359-366
mutations	O	367-376
,	O	376-377
and	O	378-381
2	O	382-383
of	O	384-386
these	O	387-392
11	O	393-395
conferred	O	396-405
a	O	406-407
milder	O	408-414
clinical	O	415-423
phenotype	O	424-433
with	O	434-438
respect	O	439-446
to	O	447-449
both	O	450-454
cerebellar	B	455-465
degeneration	I	466-478
and	O	479-482
cellular	O	483-491
features	O	492-500
.	O	500-501

We	O	502-504
report	O	505-511
,	O	511-512
in	O	513-515
two	O	516-519
A	B	520-521
-	I	521-522
T	I	522-523
families	O	524-532
,	O	532-533
an	O	534-536
ATM	O	537-540
mutation	O	541-549
(	O	550-551
7271T	O	551-556
-	O	556-557
-	O	556-557
>	O	559-560
G	O	561-562
)	O	562-563
that	O	564-568
may	O	569-572
be	O	573-575
associated	O	576-586
with	O	587-591
an	O	592-594
increased	O	595-604
risk	O	605-609
of	O	610-612
breast	B	613-619
cancer	I	620-626
in	O	627-629
both	O	630-634
homozygotes	O	635-646
and	O	647-650
heterozygotes	O	651-664
(	O	665-666
relative	O	666-674
risk	O	675-679
12	O	680-682
.	O	682-683
7	O	684-685
;	O	685-686
P	O	687-688
=	O	689-690
.	O	690-691
0025	O	692-696
)	O	696-697
,	O	697-698
although	O	699-707
there	O	708-713
is	O	714-716
a	O	717-718
less	O	719-723
severe	O	724-730
A	B	731-732
-	I	732-733
T	I	733-734
phenotype	O	735-744
in	O	745-747
terms	O	748-753
of	O	754-756
the	O	757-760
degree	O	761-767
of	O	768-770
cerebellar	B	771-781
degeneration	I	782-794
.	O	794-795

This	O	796-800
mutation	O	801-809
(	O	810-811
7271T	O	811-816
-	O	816-817
-	O	816-817
>	O	819-820
G	O	821-822
)	O	822-823
also	O	824-828
allows	O	829-835
expression	O	836-846
of	O	847-849
full	O	850-854
-	O	854-855
length	O	855-861
ATM	O	862-865
protein	O	866-873
at	O	874-876
a	O	877-878
level	O	879-884
comparable	O	885-895
with	O	896-900
that	O	901-905
in	O	906-908
unaffected	O	909-919
individuals	O	920-931
.	O	931-932

In	O	933-935
addition	O	936-944
,	O	944-945
we	O	946-948
have	O	949-953
studied	O	954-961
18	O	962-964
A	B	965-966
-	I	966-967
T	I	967-968
patients	O	969-977
,	O	977-978
in	O	979-981
15	O	982-984
families	O	985-993
,	O	993-994
who	O	995-998
developed	O	999-1008
leukemia	B	1009-1017
,	O	1017-1018
lymphoma	B	1019-1027
,	O	1027-1028
preleukemic	O	1029-1040
T	O	1041-1042
-	O	1042-1043
cell	O	1043-1047
proliferation	O	1048-1061
,	O	1061-1062
or	O	1063-1065
Hodgkin	B	1066-1073
lymphoma	I	1074-1082
,	O	1082-1083
mostly	O	1084-1090
in	O	1091-1093
childhood	O	1094-1103
.	O	1103-1104

A	O	1105-1106
wide	O	1107-1111
variety	O	1112-1119
of	O	1120-1122
ATM	O	1123-1126
mutation	O	1127-1135
types	O	1136-1141
,	O	1141-1142
including	O	1143-1152
missense	O	1153-1161
mutations	O	1162-1171
and	O	1172-1175
in	O	1176-1178
-	O	1178-1179
frame	O	1179-1184
deletions	O	1185-1194
,	O	1194-1195
were	O	1196-1200
seen	O	1201-1205
in	O	1206-1208
these	O	1209-1214
patients	O	1215-1223
.	O	1223-1224

We	O	1225-1227
also	O	1228-1232
show	O	1233-1237
that	O	1238-1242
25	O	1243-1245
%	O	1245-1246
of	O	1247-1249
all	O	1250-1253
A	B	1254-1255
-	I	1255-1256
T	I	1256-1257
patients	O	1258-1266
carried	O	1267-1274
in	O	1275-1277
-	O	1277-1278
frame	O	1278-1283
deletions	O	1284-1293
or	O	1294-1296
missense	O	1297-1305
mutations	O	1306-1315
,	O	1315-1316
many	O	1317-1321
of	O	1322-1324
which	O	1325-1330
were	O	1331-1335
also	O	1336-1340
associated	O	1341-1351
with	O	1352-1356
expression	O	1357-1367
of	O	1368-1370
mutant	O	1371-1377
ATM	O	1378-1381
protein	O	1382-1389
.	O	1389-1390

Low	O	0-3
frequency	O	4-13
of	O	14-16
BRCA1	O	17-22
germline	O	23-31
mutations	O	32-41
in	O	42-44
45	O	45-47
German	O	48-54
breast	B	55-61
/	I	61-62
ovarian	I	62-69
cancer	I	70-76
families	O	77-85
.	O	85-86

In	O	87-89
this	O	90-94
study	O	95-100
we	O	101-103
investigated	O	104-116
45	O	117-119
German	O	120-126
breast	B	127-133
/	I	133-134
ovarian	I	134-141
cancer	I	142-148
families	O	149-157
for	O	158-161
germline	O	162-170
mutations	O	171-180
in	O	181-183
the	O	184-187
BRCA1	O	188-193
gene	O	194-198
.	O	198-199

We	O	200-202
identified	O	203-213
four	O	214-218
germline	O	219-227
mutations	O	228-237
in	O	238-240
three	O	241-246
breast	B	247-253
cancer	I	254-260
families	O	261-269
and	O	270-273
in	O	274-276
one	O	277-280
breast	B	281-287
-	I	287-288
ovarian	I	288-295
cancer	I	296-302
family	O	303-309
.	O	309-310

among	O	311-316
these	O	317-322
were	O	323-327
one	O	328-331
frameshift	O	332-342
mutation	O	343-351
,	O	351-352
one	O	353-356
nonsense	O	357-365
mutation	O	366-374
,	O	374-375
one	O	376-379
novel	O	380-385
splice	O	386-392
site	O	393-397
mutation	O	398-406
,	O	406-407
and	O	408-411
one	O	412-415
missense	O	416-424
mutation	O	425-433
.	O	433-434

The	O	435-438
missense	O	439-447
mutation	O	448-456
was	O	457-460
also	O	461-465
found	O	466-471
in	O	472-474
2	O	475-476
.	O	476-477
8	O	478-479
%	O	479-480
of	O	481-483
the	O	484-487
general	O	488-495
population	O	496-506
,	O	506-507
suggesting	O	508-518
that	O	519-523
it	O	524-526
is	O	527-529
not	O	530-533
disease	O	534-541
associated	O	542-552
.	O	552-553

The	O	554-557
average	O	558-565
age	O	566-569
of	O	570-572
disease	O	573-580
onset	O	581-586
in	O	587-589
those	O	590-595
families	O	596-604
harbouring	O	605-615
causative	O	616-625
mutations	O	626-635
was	O	636-639
between	O	640-647
32	O	648-650
.	O	650-651
3	O	652-653
and	O	654-657
37	O	658-660
.	O	660-661
4	O	662-663
years	O	664-669
,	O	669-670
whereas	O	671-678
the	O	679-682
family	O	683-689
harbouring	O	690-700
the	O	701-704
missense	O	705-713
mutation	O	714-722
had	O	723-726
an	O	727-729
average	O	730-737
age	O	738-741
of	O	742-744
onset	O	745-750
of	O	751-753
51	O	754-756
.	O	756-757
2	O	758-759
years	O	760-765
.	O	765-766

These	O	767-772
findings	O	773-781
show	O	782-786
that	O	787-791
BRCA1	O	792-797
is	O	798-800
implicated	O	801-811
in	O	812-814
a	O	815-816
small	O	817-822
fraction	O	823-831
of	O	832-834
breast	B	835-841
/	I	841-842
ovarian	I	842-849
cancer	I	850-856
families	O	857-865
suggesting	O	866-876
the	O	877-880
involvement	O	881-892
of	O	893-895
another	O	896-903
susceptibility	O	904-918
gene	O	919-923
(	O	924-925
s	O	925-926
)	O	926-927

Oral	O	0-4
contraceptives	O	5-19
and	O	20-23
the	O	24-27
risk	O	28-32
of	O	33-35
hereditary	B	36-46
ovarian	I	47-54
cancer	I	55-61
.	O	61-62

Hereditary	B	63-73
Ovarian	I	74-81
Cancer	I	82-88
Clinical	O	89-97
Study	O	98-103
Group	O	104-109
.	O	109-110

BACKGROUND	O	111-121
Women	O	123-128
with	O	129-133
mutations	O	134-143
in	O	144-146
either	O	147-153
the	O	154-157
BRCA1	O	158-163
or	O	164-166
the	O	167-170
BRCA2	O	171-176
gene	O	177-181
have	O	182-186
a	O	187-188
high	O	189-193
lifetime	O	194-202
risk	O	203-207
of	O	208-210
ovarian	B	211-218
cancer	I	219-225
.	O	225-226

Oral	O	227-231
contraceptives	O	232-246
protect	O	247-254
against	O	255-262
ovarian	B	263-270
cancer	I	271-277
in	O	278-280
general	O	281-288
,	O	288-289
but	O	290-293
it	O	294-296
is	O	297-299
not	O	300-303
known	O	304-309
whether	O	310-317
they	O	318-322
also	O	323-327
protect	O	328-335
against	O	336-343
hereditary	B	344-354
forms	I	355-360
of	I	361-363
ovarian	I	364-371
cancer	I	372-378
.	O	378-379

METHODS	O	380-387
We	O	389-391
enrolled	O	392-400
207	O	401-404
women	O	405-410
with	O	411-415
hereditary	B	416-426
ovarian	I	427-434
cancer	I	435-441
and	O	442-445
161	O	446-449
of	O	450-452
their	O	453-458
sisters	O	459-466
as	O	467-469
controls	O	470-478
in	O	479-481
a	O	482-483
case	O	484-488
-	O	488-489
control	O	489-496
study	O	497-502
.	O	502-503

All	O	504-507
the	O	508-511
patients	O	512-520
carried	O	521-528
a	O	529-530
pathogenic	O	531-541
mutation	O	542-550
in	O	551-553
either	O	554-560
BRCA1	O	561-566
(	O	567-568
179	O	568-571
women	O	572-577
)	O	577-578
or	O	579-581
BRCA2	O	582-587
(	O	588-589
28	O	589-591
women	O	592-597
)	O	597-598
.	O	598-599

The	O	600-603
control	O	604-611
women	O	612-617
were	O	618-622
enrolled	O	623-631
regardless	O	632-642
of	O	643-645
whether	O	646-653
or	O	654-656
not	O	657-660
they	O	661-665
had	O	666-669
either	O	670-676
mutation	O	677-685
.	O	685-686

Lifetime	O	687-695
histories	O	696-705
of	O	706-708
oral	O	709-713
-	O	713-714
contraceptive	O	714-727
use	O	728-731
were	O	732-736
obtained	O	737-745
by	O	746-748
interview	O	749-758
or	O	759-761
by	O	762-764
written	O	765-772
questionnaire	O	773-786
and	O	787-790
were	O	791-795
compared	O	796-804
between	O	805-812
patients	O	813-821
and	O	822-825
control	O	826-833
women	O	834-839
,	O	839-840
after	O	841-846
adjustment	O	847-857
for	O	858-861
year	O	862-866
of	O	867-869
birth	O	870-875
and	O	876-879
parity	O	880-886
.	O	886-887

RESULTS	O	888-895
The	O	897-900
adjusted	O	901-909
odds	O	910-914
ratio	O	915-920
for	O	921-924
ovarian	B	925-932
cancer	I	933-939
associated	O	940-950
with	O	951-955
any	O	956-959
past	O	960-964
use	O	965-968
of	O	969-971
oral	O	972-976
contraceptives	O	977-991
was	O	992-995
0	O	996-997
.	O	997-998
5	O	999-1000
(	O	1001-1002
95	O	1002-1004
percent	O	1005-1012
confidence	O	1013-1023
interval	O	1024-1032
,	O	1032-1033
0	O	1034-1035
.	O	1035-1036
3	O	1037-1038
to	O	1039-1041
0	O	1042-1043
.	O	1043-1044
8	O	1045-1046
)	O	1046-1047
.	O	1047-1048

The	O	1049-1052
risk	O	1053-1057
decreased	O	1058-1067
with	O	1068-1072
increasing	O	1073-1083
duration	O	1084-1092
of	O	1093-1095
use	O	1096-1099
(	O	1100-1101
P	O	1101-1102
for	O	1103-1106
trend	O	1107-1112
,	O	1112-1113
<	O	1114-1115
0	O	1116-1117
.	O	1117-1118
001	O	1119-1122
)	O	1122-1123
;	O	1123-1124
use	O	1125-1128
for	O	1129-1132
six	O	1133-1136
or	O	1137-1139
more	O	1140-1144
years	O	1145-1150
was	O	1151-1154
associated	O	1155-1165
with	O	1166-1170
a	O	1171-1172
60	O	1173-1175
percent	O	1176-1183
reduction	O	1184-1193
in	O	1194-1196
risk	O	1197-1201
.	O	1201-1202

Oral	O	1203-1207
-	O	1207-1208
contraceptive	O	1208-1221
use	O	1222-1225
protected	O	1226-1235
against	O	1236-1243
ovarian	B	1244-1251
cancer	I	1252-1258
both	O	1259-1263
for	O	1264-1267
carriers	O	1268-1276
of	O	1277-1279
the	O	1280-1283
BRCA1	O	1284-1289
mutation	O	1290-1298
(	O	1299-1300
odds	O	1300-1304
ratio	O	1305-1310
,	O	1310-1311
0	O	1312-1313
.	O	1313-1314
5	O	1315-1316
;	O	1316-1317
95	O	1318-1320
percent	O	1321-1328
confidence	O	1329-1339
interval	O	1340-1348
,	O	1348-1349
0	O	1350-1351
.	O	1351-1352
3	O	1353-1354
to	O	1355-1357
0	O	1358-1359
.	O	1359-1360
9	O	1361-1362
)	O	1362-1363
and	O	1364-1367
for	O	1368-1371
carriers	O	1372-1380
of	O	1381-1383
the	O	1384-1387
BRCA2	O	1388-1393
mutation	O	1394-1402
(	O	1403-1404
odds	O	1404-1408
ratio	O	1409-1414
,	O	1414-1415
0	O	1416-1417
.	O	1417-1418
4	O	1419-1420
;	O	1420-1421
95	O	1422-1424
percent	O	1425-1432
confidence	O	1433-1443
interval	O	1444-1452
,	O	1452-1453
0	O	1454-1455
.	O	1455-1456
2	O	1457-1458
to	O	1459-1461
1	O	1462-1463
.	O	1463-1464
1	O	1465-1466
)	O	1466-1467
.	O	1467-1468

CONCLUSIONS	O	1469-1480
Oral	O	1482-1486
-	O	1486-1487
contraceptive	O	1487-1500
use	O	1501-1504
may	O	1505-1508
reduce	O	1509-1515
the	O	1516-1519
risk	O	1520-1524
of	O	1525-1527
ovarian	B	1528-1535
cancer	I	1536-1542
in	O	1543-1545
women	O	1546-1551
with	O	1552-1556
pathogenic	O	1557-1567
mutations	O	1568-1577
in	O	1578-1580
the	O	1581-1584
BRCA1	O	1585-1590
or	O	1591-1593
BRCA2	O	1594-1599
gene	O	1600-1604

Founder	O	0-7
BRCA1	O	8-13
and	O	14-17
BRCA2	O	18-23
mutations	O	24-33
in	O	34-36
French	O	37-43
Canadian	O	44-52
breast	B	53-59
and	I	60-63
ovarian	I	64-71
cancer	I	72-78
families	O	79-87
.	O	87-88

We	O	89-91
have	O	92-96
identified	O	97-107
four	O	108-112
mutations	O	113-122
in	O	123-125
each	O	126-130
of	O	131-133
the	O	134-137
breast	B	138-144
cancer	I	145-151
-	O	151-152
susceptibility	O	152-166
genes	O	167-172
,	O	172-173
BRCA1	O	174-179
and	O	180-183
BRCA2	O	184-189
,	O	189-190
in	O	191-193
French	O	194-200
Canadian	O	201-209
breast	B	210-216
cancer	I	217-223
and	O	224-227
breast	B	228-234
/	I	234-235
ovarian	I	235-242
cancer	I	243-249
families	O	250-258
from	O	259-263
Quebec	O	264-270
.	O	270-271

To	O	272-274
identify	O	275-283
founder	O	284-291
effects	O	292-299
,	O	299-300
we	O	301-303
examined	O	304-312
independently	O	313-326
ascertained	O	327-338
French	O	339-345
Canadian	O	346-354
cancer	B	355-361
families	O	362-370
for	O	371-374
the	O	375-378
distribution	O	379-391
of	O	392-394
these	O	395-400
eight	O	401-406
mutations	O	407-416
.	O	416-417

Mutations	O	418-427
were	O	428-432
found	O	433-438
in	O	439-441
41	O	442-444
of	O	445-447
97	O	448-450
families	O	451-459
.	O	459-460

Six	O	461-464
of	O	465-467
eight	O	468-473
mutations	O	474-483
were	O	484-488
observed	O	489-497
at	O	498-500
least	O	501-506
twice	O	507-512
.	O	512-513

The	O	514-517
BRCA1	O	518-523
C4446T	O	524-530
mutation	O	531-539
was	O	540-543
the	O	544-547
most	O	548-552
common	O	553-559
mutation	O	560-568
found	O	569-574
,	O	574-575
followed	O	576-584
by	O	585-587
the	O	588-591
BRCA2	O	592-597
8765delAG	O	598-607
mutation	O	608-616
.	O	616-617

Together	O	618-626
,	O	626-627
these	O	628-633
mutations	O	634-643
were	O	644-648
found	O	649-654
in	O	655-657
28	O	658-660
of	O	661-663
41	O	664-666
families	O	667-675
identified	O	676-686
to	O	687-689
have	O	690-694
a	O	695-696
mutation	O	697-705
.	O	705-706

The	O	707-710
odds	O	711-715
of	O	716-718
detection	O	719-728
of	O	729-731
any	O	732-735
of	O	736-738
the	O	739-742
four	O	743-747
BRCA1	O	748-753
mutations	O	754-763
was	O	764-767
18	O	768-770
.	O	770-771
7x	O	772-774
greater	O	775-782
if	O	783-785
one	O	786-789
or	O	790-792
more	O	793-797
cases	O	798-803
of	O	804-806
ovarian	B	807-814
cancer	I	815-821
were	O	822-826
also	O	827-831
present	O	832-839
in	O	840-842
the	O	843-846
family	O	847-853
.	O	853-854

The	O	855-858
odds	O	859-863
of	O	864-866
detection	O	867-876
of	O	877-879
any	O	880-883
of	O	884-886
the	O	887-890
four	O	891-895
BRCA2	O	896-901
mutations	O	902-911
was	O	912-915
5	O	916-917
.	O	917-918
3x	O	919-921
greater	O	922-929
if	O	930-932
there	O	933-938
were	O	939-943
at	O	944-946
least	O	947-952
five	O	953-957
cases	O	958-963
of	O	964-966
breast	B	967-973
cancer	I	974-980
in	O	981-983
the	O	984-987
family	O	988-994
.	O	994-995

Interestingly	O	996-1009
,	O	1009-1010
the	O	1011-1014
presence	O	1015-1023
of	O	1024-1026
a	O	1027-1028
breast	B	1029-1035
cancer	I	1036-1042
case	O	1043-1047
<	O	1048-1049
36	O	1050-1052
years	O	1053-1058
of	O	1059-1061
age	O	1062-1065
was	O	1066-1069
strongly	O	1070-1078
predictive	O	1079-1089
of	O	1090-1092
the	O	1093-1096
presence	O	1097-1105
of	O	1106-1108
any	O	1109-1112
of	O	1113-1115
the	O	1116-1119
eight	O	1120-1125
mutations	O	1126-1135
screened	O	1136-1144
.	O	1144-1145

Carriers	O	1146-1154
of	O	1155-1157
the	O	1158-1161
same	O	1162-1166
mutation	O	1167-1175
,	O	1175-1176
from	O	1177-1181
different	O	1182-1191
families	O	1192-1200
,	O	1200-1201
shared	O	1202-1208
similar	O	1209-1216
haplotypes	O	1217-1227
,	O	1227-1228
indicating	O	1229-1239
that	O	1240-1244
the	O	1245-1248
mutant	O	1249-1255
alleles	O	1256-1263
were	O	1264-1268
likely	O	1269-1275
to	O	1276-1278
be	O	1279-1281
identical	O	1282-1291
by	O	1292-1294
descent	O	1295-1302
for	O	1303-1306
a	O	1307-1308
mutation	O	1309-1317
in	O	1318-1320
the	O	1321-1324
founder	O	1325-1332
population	O	1333-1343
.	O	1343-1344

The	O	1345-1348
identification	O	1349-1363
of	O	1364-1366
common	O	1367-1373
BRCA1	O	1374-1379
and	O	1380-1383
BRCA2	O	1384-1389
mutations	O	1390-1399
will	O	1400-1404
facilitate	O	1405-1415
carrier	O	1416-1423
detection	O	1424-1433
in	O	1434-1436
French	O	1437-1443
Canadian	O	1444-1452
breast	B	1453-1459
cancer	I	1460-1466
and	O	1467-1470
breast	B	1471-1477
/	I	1477-1478
ovarian	I	1478-1485
cancer	I	1486-1492
families	O	1493-1501
.	O	1501-1502

Truncation	O	0-10
mutations	O	11-20
in	O	21-23
the	O	24-27
transactivation	O	28-43
region	O	44-50
of	O	51-53
PAX6	O	54-58
result	O	59-65
in	O	66-68
dominant	O	69-77
-	O	77-78
negative	O	78-86
mutants	O	87-94
.	O	94-95

PAX6	O	96-100
is	O	101-103
a	O	104-105
transcription	O	106-119
factor	O	120-126
with	O	127-131
two	O	132-135
DNA	O	136-139
-	O	139-140
binding	O	140-147
domains	O	148-155
(	O	156-157
paired	O	157-163
box	O	164-167
and	O	168-171
homeobox	O	172-180
)	O	180-181
and	O	182-185
a	O	186-187
proline	O	188-195
-	O	195-196
serine	O	196-202
-	O	195-196
threonine	O	203-212
(	O	213-214
PST	O	214-217
)	O	217-218
-	O	219-220
rich	O	220-224
transactivation	O	225-240
domain	O	241-247
.	O	247-248

PAX6	O	249-253
regulates	O	254-263
eye	O	264-267
development	O	268-279
in	O	280-282
animals	O	283-290
ranging	O	291-298
from	O	299-303
jellyfish	O	304-313
to	O	314-316
Drosophila	O	317-327
to	O	328-330
humans	O	331-337
.	O	337-338

Heterozygous	O	339-351
mutations	O	352-361
in	O	362-364
the	O	365-368
human	O	369-374
PAX6	O	375-379
gene	O	380-384
result	O	385-391
in	O	392-394
various	O	395-402
phenotypes	O	403-413
,	O	413-414
including	O	415-424
aniridia	B	425-433
,	O	433-434
Peters	B	435-441
anomaly	I	442-449
,	O	449-450
autosomal	B	451-460
dominant	I	461-469
keratitis	I	470-479
,	O	479-480
and	O	481-484
familial	B	485-493
foveal	I	494-500
dysplasia	I	501-510
.	O	510-511

It	O	512-514
is	O	515-517
believed	O	518-526
that	O	527-531
the	O	532-535
mutated	O	536-543
allele	O	544-550
of	O	551-553
PAX6	O	554-558
produces	O	559-567
an	O	568-570
inactive	O	571-579
protein	O	580-587
and	O	588-591
aniridia	B	592-600
is	O	601-603
caused	O	604-610
due	O	611-614
to	O	615-617
genetic	O	618-625
haploinsufficiency	O	626-644
.	O	644-645

However	O	646-653
,	O	653-654
several	O	655-662
truncation	O	663-673
mutations	O	674-683
have	O	684-688
been	O	689-693
found	O	694-699
to	O	700-702
occur	O	703-708
in	O	709-711
the	O	712-715
C	O	716-717
-	O	717-718
terminal	O	718-726
half	O	727-731
of	O	732-734
PAX6	O	735-739
in	O	740-742
patients	O	743-751
with	O	752-756
Aniridia	B	757-765
resulting	O	766-775
in	O	776-778
mutant	O	779-785
proteins	O	786-794
that	O	795-799
retain	O	800-806
the	O	807-810
DNA	O	811-814
-	O	814-815
binding	O	815-822
domains	O	823-830
but	O	831-834
have	O	835-839
lost	O	840-844
most	O	845-849
of	O	850-852
the	O	853-856
transactivation	O	857-872
domain	O	873-879
.	O	879-880

It	O	881-883
is	O	884-886
not	O	887-890
clear	O	891-896
whether	O	897-904
such	O	905-909
mutants	O	910-917
really	O	918-924
behave	O	925-931
as	O	932-934
loss	O	935-939
-	O	939-940
of	O	940-942
-	O	939-940
function	O	943-951
mutants	O	952-959
as	O	960-962
predicted	O	963-972
by	O	973-975
haploinsufficiency	O	976-994
.	O	994-995

Contrary	O	996-1004
to	O	1005-1007
this	O	1008-1012
theory	O	1013-1019
,	O	1019-1020
our	O	1021-1024
data	O	1025-1029
showed	O	1030-1036
that	O	1037-1041
these	O	1042-1047
mutants	O	1048-1055
are	O	1056-1059
dominant	O	1060-1068
-	O	1068-1069
negative	O	1069-1077
in	O	1078-1080
transient	O	1081-1090
transfection	O	1091-1103
assays	O	1104-1110
when	O	1111-1115
they	O	1116-1120
are	O	1121-1124
coexpressed	O	1125-1136
with	O	1137-1141
wild	O	1142-1146
-	O	1146-1147
type	O	1147-1151
PAX6	O	1152-1156
.	O	1156-1157

We	O	1158-1160
found	O	1161-1166
that	O	1167-1171
the	O	1172-1175
dominant	O	1176-1184
-	O	1184-1185
negative	O	1185-1193
effects	O	1194-1201
result	O	1202-1208
from	O	1209-1213
the	O	1214-1217
enhanced	O	1218-1226
DNA	O	1227-1230
binding	O	1231-1238
ability	O	1239-1246
of	O	1247-1249
these	O	1250-1255
mutants	O	1256-1263
.	O	1263-1264

Kinetic	O	1265-1272
studies	O	1273-1280
of	O	1281-1283
binding	O	1284-1291
and	O	1292-1295
dissociation	O	1296-1308
revealed	O	1309-1317
that	O	1318-1322
various	O	1323-1330
truncation	O	1331-1341
mutants	O	1342-1349
have	O	1350-1354
3	O	1355-1356
-	O	1356-1357
5	O	1357-1358
-	O	1356-1357
fold	O	1359-1363
higher	O	1364-1370
affinity	O	1371-1379
to	O	1380-1382
various	O	1383-1390
DNA	O	1391-1394
-	O	1394-1395
binding	O	1395-1402
sites	O	1403-1408
when	O	1409-1413
compared	O	1414-1422
with	O	1423-1427
the	O	1428-1431
wild	O	1432-1436
-	O	1436-1437
type	O	1437-1441
PAX6	O	1442-1446
.	O	1446-1447

These	O	1448-1453
results	O	1454-1461
provide	O	1462-1469
a	O	1470-1471
new	O	1472-1475
insight	O	1476-1483
into	O	1484-1488
the	O	1489-1492
role	O	1493-1497
of	O	1498-1500
mutant	O	1501-1507
PAX6	O	1508-1512
in	O	1513-1515
causing	O	1516-1523
aniridia	B	1524-1532
.	O	1532-1533
.	O	1532-1533

Crystal	O	0-7
structure	O	8-17
of	O	18-20
the	O	21-24
hemochromatosis	B	25-40
protein	O	41-48
HFE	O	49-52
and	O	53-56
characterization	O	57-73
of	O	74-76
its	O	77-80
interaction	O	81-92
with	O	93-97
transferrin	O	98-109
receptor	O	110-118
.	O	118-119

HFE	O	120-123
is	O	124-126
an	O	127-129
MHC	O	130-133
-	O	133-134
related	O	134-141
protein	O	142-149
that	O	150-154
is	O	155-157
mutated	O	158-165
in	O	166-168
the	O	169-172
iron	B	173-177
-	I	177-178
overload	I	178-186
disease	I	187-194
hereditary	B	195-205
hemochromatosis	I	206-221
.	O	221-222

HFE	O	223-226
binds	O	227-232
to	O	233-235
transferrin	O	236-247
receptor	O	248-256
(	O	257-258
TfR	O	258-261
)	O	261-262
and	O	263-266
reduces	O	267-274
its	O	275-278
affinity	O	279-287
for	O	288-291
iron	O	292-296
-	O	296-297
loaded	O	297-303
transferrin	O	304-315
,	O	315-316
implicating	O	317-328
HFE	O	329-332
in	O	333-335
iron	O	336-340
metabolism	O	341-351
.	O	351-352

The	O	353-356
2	O	357-358
.	O	358-359
6	O	360-361
A	O	362-363
crystal	O	364-371
structure	O	372-381
of	O	382-384
HFE	O	385-388
reveals	O	389-396
the	O	397-400
locations	O	401-410
of	O	411-413
hemochromatosis	B	414-429
mutations	O	430-439
and	O	440-443
a	O	444-445
patch	O	446-451
of	O	452-454
histidines	O	455-465
that	O	466-470
could	O	471-476
be	O	477-479
involved	O	480-488
in	O	489-491
pH	O	492-494
-	O	494-495
dependent	O	495-504
interactions	O	505-517
.	O	517-518

We	O	519-521
also	O	522-526
demonstrate	O	527-538
that	O	539-543
soluble	O	544-551
TfR	O	552-555
and	O	556-559
HFE	O	560-563
bind	O	564-568
tightly	O	569-576
at	O	577-579
the	O	580-583
basic	O	584-589
pH	O	590-592
of	O	593-595
the	O	596-599
cell	O	600-604
surface	O	605-612
,	O	612-613
but	O	614-617
not	O	618-621
at	O	622-624
the	O	625-628
acidic	O	629-635
pH	O	636-638
of	O	639-641
intracellular	O	642-655
vesicles	O	656-664
.	O	664-665

TfR	O	666-669
HFE	O	671-674
stoichiometry	O	675-688
(	O	689-690
2	O	690-691
1	O	693-694
)	O	694-695
differs	O	696-703
from	O	704-708
TfR	O	709-712
transferrin	O	714-725
stoichiometry	O	726-739
(	O	740-741
2	O	741-742
2	O	744-745
)	O	745-746
,	O	746-747
implying	O	748-756
a	O	757-758
different	O	759-768
mode	O	769-773
of	O	774-776
binding	O	777-784
for	O	785-788
HFE	O	789-792
and	O	793-796
transferrin	O	797-808
to	O	809-811
TfR	O	812-815
,	O	815-816
consistent	O	817-827
with	O	828-832
our	O	833-836
demonstration	O	837-850
that	O	851-855
HFE	O	856-859
,	O	859-860
transferrin	O	861-872
,	O	872-873
and	O	874-877
TfR	O	878-881
form	O	882-886
a	O	887-888
ternary	O	889-896
complex	O	897-904
.	O	904-905

Stable	O	0-6
interaction	O	7-18
between	O	19-26
the	O	27-30
products	O	31-39
of	O	40-42
the	O	43-46
BRCA1	O	47-52
and	O	53-56
BRCA2	O	57-62
tumor	B	63-68
suppressor	O	69-79
genes	O	80-85
in	O	86-88
mitotic	O	89-96
and	O	97-100
meiotic	O	101-108
cells	O	109-114
.	O	114-115

BRCA1	O	116-121
and	O	122-125
BRCA2	O	126-131
account	O	132-139
for	O	140-143
most	O	144-148
cases	O	149-154
of	O	155-157
familial	O	158-166
,	O	166-167
early	O	168-173
onset	O	174-179
breast	B	180-186
and	I	187-190
/	I	190-191
or	I	191-193
ovarian	I	194-201
cancer	I	202-208
and	O	209-212
encode	O	213-219
products	O	220-228
that	O	229-233
each	O	234-238
interact	O	239-247
with	O	248-252
hRAD51	O	253-259
.	O	259-260

Results	O	261-268
presented	O	269-278
here	O	279-283
show	O	284-288
that	O	289-293
BRCA1	O	294-299
and	O	300-303
BRCA2	O	304-309
coexist	O	310-317
in	O	318-320
a	O	321-322
biochemical	O	323-334
complex	O	335-342
and	O	343-346
colocalize	O	347-357
in	O	358-360
subnuclear	O	361-371
foci	O	372-376
in	O	377-379
somatic	O	380-387
cells	O	388-393
and	O	394-397
on	O	398-400
the	O	401-404
axial	O	405-410
elements	O	411-419
of	O	420-422
developing	O	423-433
synaptonemal	O	434-446
complexes	O	447-456
.	O	456-457

Like	O	458-462
BRCA1	O	463-468
and	O	469-472
RAD51	O	473-478
,	O	478-479
BRCA2	O	480-485
relocates	O	486-495
to	O	496-498
PCNA	O	499-503
+	O	504-505
replication	O	506-517
sites	O	518-523
following	O	524-533
exposure	O	534-542
of	O	543-545
S	O	546-547
phase	O	548-553
cells	O	554-559
to	O	560-562
hydroxyurea	O	563-574
or	O	575-577
UV	O	578-580
irradiation	O	581-592
.	O	592-593

Thus	O	594-598
,	O	598-599
BRCA1	O	600-605
and	O	606-609
BRCA2	O	610-615
participate	O	616-627
,	O	627-628
together	O	629-637
,	O	637-638
in	O	639-641
a	O	642-643
pathway	O	644-651
(	O	652-653
s	O	653-654
)	O	654-655
associated	O	656-666
with	O	667-671
the	O	672-675
activation	O	676-686
of	O	687-689
double	O	690-696
-	O	696-697
strand	O	697-703
break	O	704-709
repair	O	710-716
and	O	717-720
/	O	720-721
or	O	721-723
homologous	O	724-734
recombination	O	735-748
.	O	748-749

Dysfunction	O	750-761
of	O	762-764
this	O	765-769
pathway	O	770-777
may	O	778-781
be	O	782-784
a	O	785-786
general	O	787-794
phenomenon	O	795-805
in	O	806-808
the	O	809-812
majority	O	813-821
of	O	822-824
cases	O	825-830
of	O	831-833
hereditary	B	834-844
breast	I	845-851
and	I	852-855
/	I	855-856
or	I	856-858
ovarian	I	859-866
cancer	I	867-873
.	O	873-874
.	O	873-874

A	O	0-1
novel	O	2-7
Arg362Ser	O	8-17
mutation	O	18-26
in	O	27-29
the	O	30-33
sterol	O	34-40
27	O	41-43
-	O	43-44
hydroxylase	O	44-55
gene	O	56-60
(	O	61-62
CYP27	O	62-67
)	O	67-68
:	O	68-69
its	O	70-73
effects	O	74-81
on	O	82-84
pre	O	85-88
-	O	88-89
mRNA	O	89-93
splicing	O	94-102
and	O	103-106
enzyme	O	107-113
activity	O	114-122
.	O	122-123

A	O	124-125
novel	O	126-131
C	O	132-133
to	O	134-136
A	O	137-138
mutation	O	139-147
in	O	148-150
the	O	151-154
sterol	O	155-161
27	O	162-164
-	O	164-165
hydroxylase	O	165-176
gene	O	177-181
(	O	182-183
CYP27	O	183-188
)	O	188-189
was	O	190-193
identified	O	194-204
by	O	205-207
sequencing	O	208-218
amplified	O	219-228
CYP27	O	229-234
gene	O	235-239
products	O	240-248
from	O	249-253
a	O	254-255
patient	O	256-263
with	O	264-268
cerebrotendinous	B	269-285
xanthomatosis	I	286-299
(	O	300-301
CTX	B	301-304
)	O	304-305
.	O	305-306

The	O	307-310
mutation	O	311-319
changed	O	320-327
the	O	328-331
adrenodoxin	O	332-343
cofactor	O	344-352
binding	O	353-360
residue	O	361-368
362Arg	O	369-375
to	O	376-378
362Ser	O	379-385
(	O	386-387
CGT	O	387-390
362Arg	O	391-397
to	O	398-400
AGT	O	401-404
362Ser	O	405-411
)	O	411-412
,	O	412-413
and	O	414-417
was	O	418-421
responsible	O	422-433
for	O	434-437
deficiency	O	438-448
in	O	449-451
the	O	452-455
sterol	O	456-462
27	O	463-465
-	O	465-466
hydroxylase	O	466-477
activity	O	478-486
,	O	486-487
as	O	488-490
confirmed	O	491-500
by	O	501-503
expression	O	504-514
of	O	515-517
mutant	O	518-524
cDNA	O	525-529
into	O	530-534
COS	O	535-538
-	O	538-539
1	O	539-540
cells	O	541-546
.	O	546-547

Quantitative	O	548-560
analysis	O	561-569
showed	O	570-576
that	O	577-581
the	O	582-585
expression	O	586-596
of	O	597-599
CYP27	O	600-605
gene	O	606-610
mRNA	O	611-615
in	O	616-618
the	O	619-622
patient	O	623-630
represented	O	631-642
52	O	643-645
.	O	645-646
5	O	647-648
%	O	648-649
of	O	650-652
the	O	653-656
normal	O	657-663
level	O	664-669
.	O	669-670

As	O	671-673
the	O	674-677
mutation	O	678-686
occurred	O	687-695
at	O	696-698
the	O	699-702
penultimate	O	703-714
nucleotide	O	715-725
of	O	726-728
exon	O	729-733
6	O	734-735
(	O	736-737
-	O	737-738
2	O	738-739
position	O	740-748
of	O	749-751
exon	O	752-756
6	O	757-758
-	O	758-759
intron	O	759-765
6	O	766-767
splice	O	768-774
site	O	775-779
)	O	779-780
of	O	781-783
the	O	784-787
gene	O	788-792
,	O	792-793
we	O	794-796
hypothesized	O	797-809
that	O	810-814
the	O	815-818
mutation	O	819-827
may	O	828-831
partially	O	832-841
affect	O	842-848
the	O	849-852
normal	O	853-859
splicing	O	860-868
efficiency	O	869-879
in	O	880-882
exon	O	883-887
6	O	888-889
and	O	890-893
cause	O	894-899
alternative	O	900-911
splicing	O	912-920
elsewhere	O	921-930
,	O	930-931
which	O	932-937
resulted	O	938-946
in	O	947-949
decreased	O	950-959
transcript	O	960-970
in	O	971-973
the	O	974-977
patient	O	978-985
.	O	985-986

Transfection	O	987-999
of	O	1000-1002
constructed	O	1003-1014
minigenes	O	1015-1024
,	O	1024-1025
with	O	1026-1030
or	O	1031-1033
without	O	1034-1041
the	O	1042-1045
mutation	O	1046-1054
,	O	1054-1055
into	O	1056-1060
COS	O	1061-1064
-	O	1064-1065
1	O	1065-1066
cells	O	1067-1072
confirmed	O	1073-1082
that	O	1083-1087
the	O	1088-1091
mutant	O	1092-1098
minigene	O	1099-1107
was	O	1108-1111
responsible	O	1112-1123
for	O	1124-1127
a	O	1128-1129
mRNA	O	1130-1134
species	O	1135-1142
alternatively	O	1143-1156
spliced	O	1157-1164
at	O	1165-1167
an	O	1168-1170
activated	O	1171-1180
cryptic	O	1181-1188
5	O	1189-1190
splice	O	1191-1197
site	O	1198-1202
88	O	1203-1205
bp	O	1206-1208
upstream	O	1209-1217
from	O	1218-1222
the	O	1223-1226
3	O	1227-1228
end	O	1229-1232
of	O	1233-1235
exon	O	1236-1240
6	O	1241-1242
.	O	1242-1243

Our	O	1244-1247
data	O	1248-1252
suggest	O	1253-1260
that	O	1261-1265
the	O	1266-1269
C	O	1270-1271
to	O	1272-1274
A	O	1275-1276
mutation	O	1277-1285
at	O	1286-1288
the	O	1289-1292
penultimate	O	1293-1304
nucleotide	O	1305-1315
of	O	1316-1318
exon	O	1319-1323
6	O	1324-1325
of	O	1326-1328
the	O	1329-1332
CYP27	O	1333-1338
gene	O	1339-1343
not	O	1344-1347
only	O	1348-1352
causes	O	1353-1359
the	O	1360-1363
deficiency	B	1364-1374
in	I	1375-1377
the	I	1378-1381
sterol	I	1382-1388
27	I	1389-1391
-	I	1391-1392
hydroxylase	I	1392-1403
activity	I	1404-1412
,	O	1412-1413
but	O	1414-1417
also	O	1418-1422
partially	O	1423-1432
leads	O	1433-1438
to	O	1439-1441
alternative	O	1442-1453
pre	O	1454-1457
-	O	1457-1458
mRNA	O	1458-1462
splicing	O	1463-1471
of	O	1472-1474
the	O	1475-1478
gene	O	1479-1483
.	O	1483-1484

To	O	1485-1487
our	O	1488-1491
knowledge	O	1492-1501
,	O	1501-1502
this	O	1503-1507
is	O	1508-1510
the	O	1511-1514
first	O	1515-1520
report	O	1521-1527
regarding	O	1528-1537
effects	O	1538-1545
on	O	1546-1548
pre	O	1549-1552
-	O	1552-1553
mRNA	O	1553-1557
splicing	O	1558-1566
of	O	1567-1569
a	O	1570-1571
mutation	O	1572-1580
at	O	1581-1583
the	O	1584-1587
-	O	1588-1589
2	O	1589-1590
position	O	1591-1599
of	O	1600-1602
a	O	1603-1604
5	O	1605-1606
splice	O	1607-1613
site	O	1614-1618
.	O	1618-1619

A	O	0-1
Japanese	O	2-10
family	O	11-17
with	O	18-22
adrenoleukodystrophy	B	23-43
with	O	44-48
a	O	49-50
codon	O	51-56
291	O	57-60
deletion	O	61-69
:	O	69-70
a	O	71-72
clinical	O	73-81
,	O	81-82
biochemical	O	83-94
,	O	94-95
pathological	O	96-108
,	O	108-109
and	O	110-113
genetic	O	114-121
report	O	122-128
.	O	128-129

We	O	130-132
report	O	133-139
a	O	140-141
Japanese	O	142-150
family	O	151-157
with	O	158-162
adrenoleukodystrophy	B	163-183
(	O	184-185
ALD	B	185-188
)	O	188-189
with	O	190-194
a	O	195-196
three	O	197-202
base	O	203-207
pair	O	208-212
deletion	O	213-221
(	O	222-223
delGAG	O	223-229
291	O	230-233
)	O	233-234
in	O	235-237
the	O	238-241
ALD	B	242-245
gene	O	246-250
.	O	250-251

A	O	252-253
variety	O	254-261
of	O	262-264
phenotypes	O	265-275
were	O	276-280
observed	O	281-289
within	O	290-296
this	O	297-301
family	O	302-308
.	O	308-309

While	O	310-315
the	O	316-319
proband	O	320-327
(	O	328-329
patient	O	329-336
1	O	337-338
)	O	338-339
was	O	340-343
classified	O	344-354
as	O	355-357
having	O	358-364
a	O	365-366
rare	O	367-371
intermediate	O	372-384
type	O	385-389
of	O	390-392
adult	O	393-398
cerebral	O	399-407
and	O	408-411
cerebello	O	412-421
-	O	421-422
brain	O	422-427
stem	O	428-432
forms	O	433-438
,	O	438-439
his	O	440-443
younger	O	444-451
brother	O	452-459
(	O	460-461
patient	O	461-468
2	O	469-470
)	O	470-471
and	O	472-475
nephew	O	476-482
(	O	483-484
patient	O	484-491
3	O	492-493
)	O	493-494
had	O	495-498
a	O	499-500
childhood	O	501-510
ALD	B	511-514
type	O	515-519
.	O	519-520

Another	O	521-528
nephew	O	529-535
(	O	536-537
patient	O	537-544
4	O	545-546
)	O	546-547
of	O	548-550
patient	O	551-558
1	O	559-560
was	O	561-564
classified	O	565-575
as	O	576-578
having	O	579-585
an	O	586-588
adolescent	O	589-599
form	O	600-604
.	O	604-605

The	O	606-609
tau	O	610-613
level	O	614-619
in	O	620-622
the	O	623-626
cerebrospinal	O	627-640
fluid	O	641-646
(	O	647-648
CSF	O	648-651
)	O	651-652
in	O	653-655
patient	O	656-663
1	O	664-665
was	O	666-669
as	O	670-672
high	O	673-677
as	O	678-680
that	O	681-685
of	O	686-688
patients	O	689-697
with	O	698-702
Alzheimers	B	703-713
disease	I	714-721
(	O	722-723
AD	B	723-725
)	O	725-726
.	O	726-727

His	O	728-731
brain	O	732-737
magnetic	O	738-746
resonance	O	747-756
image	O	757-762
(	O	763-764
MRI	O	764-767
)	O	767-768
showed	O	769-775
abnormalities	B	776-789
in	I	790-792
the	I	793-796
bilateral	I	797-806
cerebellar	I	807-817
hemispheres	I	818-829
and	O	830-833
brain	O	834-839
stem	O	840-844
,	O	844-845
but	O	846-849
not	O	850-853
in	O	854-856
the	O	857-860
cerebral	O	861-869
white	O	870-875
matter	O	876-882
,	O	882-883
where	O	884-889
marked	O	890-896
reductions	O	897-907
of	O	908-910
the	O	911-914
cerebral	O	915-923
blood	O	924-929
flow	O	930-934
and	O	935-938
oxygen	O	939-945
metabolism	O	946-956
were	O	957-961
clearly	O	962-969
demonstrated	O	970-982
by	O	983-985
positron	O	986-994
emission	O	995-1003
tomography	O	1004-1014
(	O	1015-1016
PET	O	1016-1019
)	O	1019-1020
.	O	1020-1021

In	O	1022-1024
patients	O	1025-1033
2	O	1034-1035
and	O	1036-1039
3	O	1040-1041
,	O	1041-1042
the	O	1043-1046
autopsy	O	1047-1054
findings	O	1055-1063
showed	O	1064-1070
massive	O	1071-1078
demyelination	B	1079-1092
of	I	1093-1095
the	I	1096-1099
cerebral	I	1100-1108
white	I	1109-1114
matter	I	1115-1121
with	O	1122-1126
sparing	O	1127-1134
of	O	1135-1137
the	O	1138-1141
U	O	1142-1143
-	O	1143-1144
fibers	O	1144-1150
,	O	1150-1151
compatible	O	1152-1162
with	O	1163-1167
the	O	1168-1171
findings	O	1172-1180
of	O	1181-1183
childhood	O	1184-1193
ALD	B	1194-1197
.	O	1197-1198

Oleic	O	1199-1204
and	O	1205-1208
erucic	O	1209-1215
acids	O	1216-1221
(	O	1222-1223
Lorenzos	O	1223-1231
Oil	O	1232-1235
)	O	1235-1236
were	O	1237-1241
administered	O	1242-1254
to	O	1255-1257
patients	O	1258-1266
1	O	1267-1268
and	O	1269-1272
4	O	1273-1274
,	O	1274-1275
but	O	1276-1279
sufficient	O	1280-1290
effectiveness	O	1291-1304
was	O	1305-1308
not	O	1309-1312
obtained	O	1313-1321
.	O	1321-1322

The	O	1323-1326
findings	O	1327-1335
in	O	1336-1338
this	O	1339-1343
family	O	1344-1350
suggest	O	1351-1358
that	O	1359-1363
delGAG291	O	1364-1373
is	O	1374-1376
part	O	1377-1381
of	O	1382-1384
the	O	1385-1388
cause	O	1389-1394
of	O	1395-1397
Japanese	O	1398-1406
ALD	B	1407-1410
with	O	1411-1415
phenotypic	O	1416-1426
variations	O	1427-1437
.	O	1437-1438

Moreover	O	1439-1447
,	O	1447-1448
although	O	1449-1457
the	O	1458-1461
scale	O	1462-1467
of	O	1468-1470
the	O	1471-1474
study	O	1475-1480
is	O	1481-1483
limited	O	1484-1491
,	O	1491-1492
there	O	1493-1498
is	O	1499-1501
a	O	1502-1503
possibility	O	1504-1515
that	O	1516-1520
PET	O	1521-1524
can	O	1525-1528
detect	O	1529-1535
an	O	1536-1538
insidious	B	1539-1548
lesion	I	1549-1555
which	O	1556-1561
is	O	1562-1564
undetectable	O	1565-1577
by	O	1578-1580
computed	O	1581-1589
tomogram	O	1590-1598
(	O	1599-1600
CT	O	1600-1602
)	O	1602-1603
or	O	1604-1606
MRI	O	1607-1610
analysis	O	1611-1619
,	O	1619-1620
and	O	1621-1624
that	O	1625-1629
the	O	1630-1633
higher	O	1634-1640
level	O	1641-1646
of	O	1647-1649
tau	O	1650-1653
reflects	O	1654-1662
the	O	1663-1666
process	O	1667-1674
of	O	1675-1677
neuronal	B	1678-1686
degeneration	I	1687-1699
in	O	1700-1702
ALD	B	1703-1706
.	O	1706-1707

Lorenzos	O	1708-1716
Oil	O	1717-1720
should	O	1721-1727
be	O	1728-1730
given	O	1731-1736
in	O	1737-1739
the	O	1740-1743
early	O	1744-1749
stage	O	1750-1755
.	O	1755-1756
.	O	1755-1756

Two	O	0-3
frequent	O	4-12
missense	O	13-21
mutations	O	22-31
in	O	32-34
Pendred	B	35-42
syndrome	I	43-51
.	O	51-52

Pendred	B	53-60
syndrome	I	61-69
is	O	70-72
an	O	73-75
autosomal	B	76-85
recessive	I	86-95
disorder	I	96-104
characterized	O	105-118
by	O	119-121
early	O	122-127
childhood	O	128-137
deafness	B	138-146
and	O	147-150
goiter	B	151-157
.	O	157-158

A	O	159-160
century	O	161-168
after	O	169-174
its	O	175-178
recognition	O	179-190
as	O	191-193
a	O	194-195
syndrome	O	196-204
by	O	205-207
Vaughan	O	208-215
Pendred	O	216-223
,	O	223-224
the	O	225-228
disease	O	229-236
gene	O	237-241
(	O	242-243
PDS	O	243-246
)	O	246-247
was	O	248-251
mapped	O	252-258
to	O	259-261
chromosome	O	262-272
7q22	O	273-277
-	O	277-278
q31	O	278-281
.	O	281-282

1	O	283-284
and	O	285-288
,	O	288-289
recently	O	290-298
,	O	298-299
found	O	300-305
to	O	306-308
encode	O	309-315
a	O	316-317
putative	O	318-326
sulfate	O	327-334
transporter	O	335-346
.	O	346-347

We	O	348-350
performed	O	351-360
mutation	O	361-369
analysis	O	370-378
of	O	379-381
the	O	382-385
PDS	B	386-389
gene	O	390-394
in	O	395-397
patients	O	398-406
from	O	407-411
14	O	412-414
Pendred	B	415-422
families	O	423-431
originating	O	432-443
from	O	444-448
seven	O	449-454
countries	O	455-464
and	O	465-468
identified	O	469-479
all	O	480-483
mutations	O	484-493
.	O	493-494

The	O	495-498
mutations	O	499-508
include	O	509-516
three	O	517-522
single	O	523-529
base	O	530-534
deletions	O	535-544
,	O	544-545
one	O	546-549
splice	O	550-556
site	O	557-561
mutation	O	562-570
and	O	571-574
10	O	575-577
missense	O	578-586
mutations	O	587-596
.	O	596-597

One	O	598-601
missense	O	602-610
mutation	O	611-619
(	O	620-621
L236P	O	621-626
)	O	626-627
was	O	628-631
found	O	632-637
in	O	638-640
a	O	641-642
homozygous	O	643-653
state	O	654-659
in	O	660-662
two	O	663-666
consanguineous	O	667-681
families	O	682-690
and	O	691-694
in	O	695-697
a	O	698-699
heterozygous	O	700-712
state	O	713-718
in	O	719-721
five	O	722-726
additional	O	727-737
non	O	738-741
-	O	741-742
consanguineous	O	742-756
families	O	757-765
.	O	765-766

Another	O	767-774
missense	O	775-783
mutation	O	784-792
(	O	793-794
T416P	O	794-799
)	O	799-800
was	O	801-804
found	O	805-810
in	O	811-813
a	O	814-815
homozygous	O	816-826
state	O	827-832
in	O	833-835
one	O	836-839
family	O	840-846
and	O	847-850
in	O	851-853
a	O	854-855
heterozygous	O	856-868
state	O	869-874
in	O	875-877
four	O	878-882
families	O	883-891
.	O	891-892

Pendred	B	893-900
patients	O	901-909
in	O	910-912
three	O	913-918
non	O	919-922
-	O	922-923
consanguineous	O	923-937
families	O	938-946
were	O	947-951
shown	O	952-957
to	O	958-960
be	O	961-963
compound	O	964-972
heterozygotes	O	973-986
for	O	987-990
L236P	O	991-996
and	O	997-1000
T416P	O	1001-1006
.	O	1006-1007

In	O	1008-1010
total	O	1011-1016
,	O	1016-1017
one	O	1018-1021
or	O	1022-1024
both	O	1025-1029
of	O	1030-1032
these	O	1033-1038
mutations	O	1039-1048
were	O	1049-1053
found	O	1054-1059
in	O	1060-1062
nine	O	1063-1067
of	O	1068-1070
the	O	1071-1074
14	O	1075-1077
families	O	1078-1086
analyzed	O	1087-1095
.	O	1095-1096

The	O	1097-1100
identification	O	1101-1115
of	O	1116-1118
two	O	1119-1122
frequent	O	1123-1131
PDS	B	1132-1135
mutations	O	1136-1145
will	O	1146-1150
facilitate	O	1151-1161
the	O	1162-1165
molecular	O	1166-1175
diagnosis	O	1176-1185
of	O	1186-1188
Pendred	B	1189-1196
syndrome	I	1197-1205
.	O	1205-1206

Aspartylglucosaminuria	B	0-22
among	O	23-28
Palestinian	O	29-40
Arabs	O	41-46
.	O	46-47

Aspartylglucosaminuria	B	48-70
(	O	71-72
AGU	B	72-75
)	O	75-76
is	O	77-79
a	O	80-81
rare	O	82-86
disorder	B	87-95
of	I	96-98
glycoprotein	I	99-111
metabolism	I	112-122
caused	O	123-129
by	O	130-132
the	O	133-136
deficiency	B	137-147
of	I	148-150
the	I	151-154
lysosomal	I	155-164
enzyme	I	165-171
aspartylglucosaminidase	I	172-195
(	O	196-197
AGA	O	197-200
)	O	200-201
.	O	201-202

AGU	B	203-206
is	O	207-209
inherited	O	210-219
as	O	220-222
an	O	223-225
autosomal	O	226-235
recessive	O	236-245
trait	O	246-251
and	O	252-255
occurs	O	256-262
with	O	263-267
a	O	268-269
high	O	270-274
frequency	O	275-284
in	O	285-287
Finland	O	288-295
because	O	296-303
of	O	304-306
a	O	307-308
founder	O	309-316
effect	O	317-323
.	O	323-324

While	O	325-330
very	O	331-335
few	O	336-339
patients	O	340-348
with	O	349-353
AGU	B	354-357
have	O	358-362
been	O	363-367
reported	O	368-376
from	O	377-381
non	O	382-385
-	O	385-386
Finnish	O	386-393
origin	O	394-400
,	O	400-401
we	O	402-404
diagnosed	O	405-414
the	O	415-418
disorder	O	419-427
in	O	428-430
8	O	431-432
patients	O	433-441
originating	O	442-453
from	O	454-458
3	O	459-460
unrelated	O	461-470
families	O	471-479
,	O	479-480
all	O	481-484
Palestinian	O	485-496
Arabs	O	497-502
from	O	503-507
the	O	508-511
region	O	512-518
of	O	519-521
Jerusalem	O	522-531
.	O	531-532

The	O	533-536
clinical	O	537-545
diagnosis	O	546-555
of	O	556-558
AGU	B	559-562
is	O	563-565
often	O	566-571
difficult	O	572-581
,	O	581-582
in	O	583-585
particular	O	586-596
early	O	597-602
in	O	603-605
the	O	606-609
course	O	610-616
of	O	617-619
the	O	620-623
disease	O	624-631
,	O	631-632
and	O	633-636
most	O	637-641
of	O	642-644
the	O	645-648
patients	O	649-657
are	O	658-661
diagnosed	O	662-671
after	O	672-677
the	O	678-681
age	O	682-685
of	O	686-688
5	O	689-690
years	O	691-696
.	O	696-697

However	O	698-705
,	O	705-706
since	O	707-712
these	O	713-718
patients	O	719-727
excrete	O	728-735
early	O	736-741
large	O	742-747
amounts	O	748-755
of	O	756-758
aspartylglucosamine	O	759-778
in	O	779-781
urine	O	782-787
,	O	787-788
biochemical	O	789-800
screening	O	801-810
is	O	811-813
easy	O	814-818
by	O	819-821
urine	O	822-827
chromatography	O	828-842
.	O	842-843
.	O	842-843

Mutation	O	0-8
spectrum	O	9-17
and	O	18-21
genotype	O	22-30
-	O	30-31
phenotype	O	31-40
analyses	O	41-49
in	O	50-52
Cowden	B	53-59
disease	I	60-67
and	O	68-71
Bannayan	B	72-80
-	I	80-81
Zonana	I	81-87
syndrome	I	88-96
,	O	96-97
two	O	98-101
hamartoma	B	102-111
syndromes	I	112-121
with	O	122-126
germline	O	127-135
PTEN	O	136-140
mutation	O	141-149
.	O	149-150

The	O	151-154
tumour	B	155-161
suppressor	O	162-172
gene	O	173-177
PTEN	O	178-182
,	O	182-183
which	O	184-189
maps	O	190-194
to	O	195-197
10q23	O	198-203
.	O	203-204
3	O	205-206
and	O	207-210
encodes	O	211-218
a	O	219-220
403	O	221-224
amino	O	225-230
acid	O	231-235
dual	O	236-240
specificity	O	241-252
phosphatase	O	253-264
(	O	265-266
protein	O	266-273
tyrosine	O	274-282
phosphatase	O	283-294
;	O	294-295
PTPase	O	296-302
)	O	302-303
,	O	303-304
was	O	305-308
shown	O	309-314
recently	O	315-323
to	O	324-326
play	O	327-331
a	O	332-333
broad	O	334-339
role	O	340-344
in	O	345-347
human	O	348-353
malignancy	B	354-364
.	O	364-365

Somatic	O	366-373
PTEN	O	374-378
deletions	O	379-388
and	O	389-392
mutations	O	393-402
were	O	403-407
observed	O	408-416
in	O	417-419
sporadic	B	420-428
breast	I	429-435
,	I	435-436
brain	I	437-442
,	I	442-443
prostate	I	444-452
and	I	453-456
kidney	I	457-463
cancer	I	464-470
cell	O	471-475
lines	O	476-481
and	O	482-485
in	O	486-488
several	O	489-496
primary	O	497-504
tumours	B	505-512
such	O	513-517
as	O	518-520
endometrial	B	521-532
carcinomas	I	533-543
,	O	543-544
malignant	B	545-554
melanoma	I	555-563
and	O	564-567
thyroid	B	568-575
tumours	I	576-583
.	O	583-584

In	O	585-587
addition	O	588-596
,	O	596-597
PTEN	O	598-602
was	O	603-606
identified	O	607-617
as	O	618-620
the	O	621-624
susceptibility	O	625-639
gene	O	640-644
for	O	645-648
two	O	649-652
hamartoma	B	653-662
syndromes	I	663-672
Cowden	B	674-680
disease	I	681-688
(	O	689-690
CD	B	690-692
;	O	692-693
MIM	O	694-697
158350	O	698-704
)	O	704-705
and	O	706-709
Bannayan	B	710-718
-	I	718-719
Zonana	I	719-725
(	I	726-727
BZS	I	727-730
)	I	730-731
or	I	732-734
Ruvalcaba	I	735-744
-	I	744-745
Riley	I	745-750
-	I	744-745
Smith	I	751-756
syndrome	I	757-765
(	O	766-767
MIM	O	767-770
153480	O	771-777
)	O	777-778
.	O	778-779

Constitutive	O	780-792
DNA	O	793-796
from	O	797-801
37	O	802-804
CD	B	805-807
families	O	808-816
and	O	817-820
seven	O	821-826
BZS	B	827-830
families	O	831-839
was	O	840-843
screened	O	844-852
for	O	853-856
germline	O	857-865
PTEN	O	866-870
mutations	O	871-880
.	O	880-881

PTEN	O	882-886
mutations	O	887-896
were	O	897-901
identified	O	902-912
in	O	913-915
30	O	916-918
of	O	919-921
37	O	922-924
(	O	925-926
81	O	926-928
%	O	928-929
)	O	929-930
CD	B	931-933
families	O	934-942
,	O	942-943
including	O	944-953
missense	O	954-962
and	O	963-966
nonsense	O	967-975
point	O	976-981
mutations	O	982-991
,	O	991-992
deletions	O	993-1002
,	O	1002-1003
insertions	O	1004-1014
,	O	1014-1015
a	O	1016-1017
deletion	O	1018-1026
/	O	1026-1027
insertion	O	1027-1036
and	O	1037-1040
splice	O	1041-1047
site	O	1048-1052
mutations	O	1053-1062
.	O	1062-1063

These	O	1064-1069
mutations	O	1070-1079
were	O	1080-1084
scattered	O	1085-1094
over	O	1095-1099
the	O	1100-1103
entire	O	1104-1110
length	O	1111-1117
of	O	1118-1120
PTEN	O	1121-1125
,	O	1125-1126
with	O	1127-1131
the	O	1132-1135
exception	O	1136-1145
of	O	1146-1148
the	O	1149-1152
first	O	1153-1158
,	O	1158-1159
fourth	O	1160-1166
and	O	1167-1170
last	O	1171-1175
exons	O	1176-1181
.	O	1181-1182

A	O	1183-1184
hot	O	1185-1188
spot	O	1189-1193
for	O	1194-1197
PTEN	O	1198-1202
mutation	O	1203-1211
in	O	1212-1214
CD	B	1215-1217
was	O	1218-1221
identified	O	1222-1232
in	O	1233-1235
exon	O	1236-1240
5	O	1241-1242
that	O	1243-1247
contains	O	1248-1256
the	O	1257-1260
PTPase	O	1261-1267
core	O	1268-1272
motif	O	1273-1278
,	O	1278-1279
with	O	1280-1284
13	O	1285-1287
of	O	1288-1290
30	O	1291-1293
(	O	1294-1295
43	O	1295-1297
%	O	1297-1298
)	O	1298-1299
CD	B	1300-1302
mutations	O	1303-1312
identified	O	1313-1323
in	O	1324-1326
this	O	1327-1331
exon	O	1332-1336
.	O	1336-1337

Seven	O	1338-1343
of	O	1344-1346
30	O	1347-1349
(	O	1350-1351
23	O	1351-1353
%	O	1353-1354
)	O	1354-1355
were	O	1356-1360
within	O	1361-1367
the	O	1368-1371
core	O	1372-1376
motif	O	1377-1382
,	O	1382-1383
the	O	1384-1387
majority	O	1388-1396
(	O	1397-1398
five	O	1398-1402
of	O	1403-1405
seven	O	1406-1411
)	O	1411-1412
of	O	1413-1415
which	O	1416-1421
were	O	1422-1426
missense	O	1427-1435
mutations	O	1436-1445
,	O	1445-1446
possibly	O	1447-1455
pointing	O	1456-1464
to	O	1465-1467
the	O	1468-1471
functional	O	1472-1482
significance	O	1483-1495
of	O	1496-1498
this	O	1499-1503
region	O	1504-1510
.	O	1510-1511

Germline	O	1512-1520
PTEN	O	1521-1525
mutations	O	1526-1535
were	O	1536-1540
identified	O	1541-1551
in	O	1552-1554
four	O	1555-1559
of	O	1560-1562
seven	O	1563-1568
(	O	1569-1570
57	O	1570-1572
%	O	1572-1573
)	O	1573-1574
BZS	B	1575-1578
families	O	1579-1587
studied	O	1588-1595
.	O	1595-1596

Interestingly	O	1597-1610
,	O	1610-1611
none	O	1612-1616
of	O	1617-1619
these	O	1620-1625
mutations	O	1626-1635
was	O	1636-1639
observed	O	1640-1648
in	O	1649-1651
the	O	1652-1655
PTPase	O	1656-1662
core	O	1663-1667
motif	O	1668-1673
.	O	1673-1674

It	O	1675-1677
is	O	1678-1680
also	O	1681-1685
worthy	O	1686-1692
of	O	1693-1695
note	O	1696-1700
that	O	1701-1705
a	O	1706-1707
single	O	1708-1714
nonsense	O	1715-1723
point	O	1724-1729
mutation	O	1730-1738
,	O	1738-1739
R233X	O	1740-1745
,	O	1745-1746
was	O	1747-1750
observed	O	1751-1759
in	O	1760-1762
the	O	1763-1766
germline	O	1767-1775
DNA	O	1776-1779
from	O	1780-1784
two	O	1785-1788
unrelated	O	1789-1798
CD	B	1799-1801
families	O	1802-1810
and	O	1811-1814
one	O	1815-1818
BZS	B	1819-1822
family	O	1823-1829
.	O	1829-1830

Genotype	O	1831-1839
-	O	1839-1840
phenotype	O	1840-1849
studies	O	1850-1857
were	O	1858-1862
not	O	1863-1866
performed	O	1867-1876
on	O	1877-1879
this	O	1880-1884
small	O	1885-1890
group	O	1891-1896
of	O	1897-1899
BZS	B	1900-1903
families	O	1904-1912
.	O	1912-1913

However	O	1914-1921
,	O	1921-1922
genotype	O	1923-1931
-	O	1931-1932
phenotype	O	1932-1941
analysis	O	1942-1950
inthe	O	1951-1956
group	O	1957-1962
of	O	1963-1965
CD	B	1966-1968
families	O	1969-1977
revealed	O	1978-1986
two	O	1987-1990
possible	O	1991-1999
associations	O	2000-2012
worthy	O	2013-2019
of	O	2020-2022
follow	O	2023-2029
-	O	2029-2030
up	O	2030-2032
in	O	2033-2035
independent	O	2036-2047
analyses	O	2048-2056
.	O	2056-2057

The	O	2058-2061
first	O	2062-2067
was	O	2068-2071
an	O	2072-2074
association	O	2075-2086
noted	O	2087-2092
in	O	2093-2095
the	O	2096-2099
group	O	2100-2105
of	O	2106-2108
CD	B	2109-2111
families	O	2112-2120
with	O	2121-2125
breast	B	2126-2132
disease	I	2133-2140
.	O	2140-2141

A	O	2142-2143
correlation	O	2144-2155
was	O	2156-2159
observed	O	2160-2168
between	O	2169-2176
the	O	2177-2180
presence	O	2181-2189
/	O	2189-2190
absence	O	2190-2197
of	O	2198-2200
a	O	2201-2202
PTEN	O	2203-2207
mutation	O	2208-2216
and	O	2217-2220
the	O	2221-2224
type	O	2225-2229
of	O	2230-2232
breast	O	2233-2239
involvement	O	2240-2251
(	O	2252-2253
unaffected	O	2253-2263
versus	O	2264-2270
benign	O	2271-2277
versus	O	2278-2284
malignant	O	2285-2294
)	O	2294-2295
.	O	2295-2296

Specifically	O	2297-2309
and	O	2310-2313
more	O	2314-2318
directly	O	2319-2327
,	O	2327-2328
an	O	2329-2331
association	O	2332-2343
was	O	2344-2347
also	O	2348-2352
observed	O	2353-2361
between	O	2362-2369
the	O	2370-2373
presence	O	2374-2382
of	O	2383-2385
a	O	2386-2387
PTEN	O	2388-2392
mutation	O	2393-2401
and	O	2402-2405
malignant	B	2406-2415
breast	I	2416-2422
disease	I	2423-2430
.	O	2430-2431

Secondly	O	2432-2440
,	O	2440-2441
there	O	2442-2447
appeared	O	2448-2456
to	O	2457-2459
be	O	2460-2462
an	O	2463-2465
interdependent	O	2466-2480
association	O	2481-2492
between	O	2493-2500
mutations	O	2501-2510
upstream	O	2511-2519
and	O	2520-2523
within	O	2524-2530
the	O	2531-2534
PTPase	O	2535-2541
core	O	2542-2546
motif	O	2547-2552
,	O	2552-2553
the	O	2554-2557
core	O	2558-2562
motif	O	2563-2568
containing	O	2569-2579
the	O	2580-2583
majority	O	2584-2592
of	O	2593-2595
missense	O	2596-2604
mutations	O	2605-2614
,	O	2614-2615
and	O	2616-2619
the	O	2620-2623
involvement	O	2624-2635
of	O	2636-2638
all	O	2639-2642
major	O	2643-2648
organ	O	2649-2654
systems	O	2655-2662
(	O	2663-2664
central	O	2664-2671
nervous	O	2672-2679
system	O	2680-2686
,	O	2686-2687
thyroid	O	2688-2695
,	O	2695-2696
breast	O	2697-2703
,	O	2703-2704
skin	O	2705-2709
and	O	2710-2713
gastrointestinal	O	2714-2730
tract	O	2731-2736
)	O	2736-2737
.	O	2737-2738

However	O	2739-2746
,	O	2746-2747
these	O	2748-2753
observations	O	2754-2766
would	O	2767-2772
need	O	2773-2777
to	O	2778-2780
be	O	2781-2783
confirmed	O	2784-2793
by	O	2794-2796
studying	O	2797-2805
a	O	2806-2807
larger	O	2808-2814
number	O	2815-2821
of	O	2822-2824
CD	B	2825-2827
families	O	2828-2836
.	O	2836-2837

I1307K	O	0-6
APC	O	7-10
and	O	11-14
hMLH1	O	15-20
mutations	O	21-30
in	O	31-33
a	O	34-35
non	O	36-39
-	O	39-40
Jewish	O	40-46
family	O	47-53
with	O	54-58
hereditary	B	59-69
non	I	70-73
-	I	73-74
polyposis	I	74-83
colorectal	I	84-94
cancer	I	95-101
.	O	101-102

We	O	103-105
describe	O	106-114
a	O	115-116
French	O	117-123
Canadian	O	124-132
hereditary	B	133-143
non	I	144-147
-	I	147-148
polyposis	I	148-157
colorectal	I	158-168
cancer	I	169-175
(	O	176-177
HNPCC	B	177-182
)	O	182-183
kindred	O	184-191
which	O	192-197
carries	O	198-205
a	O	206-207
novel	O	208-213
truncating	O	214-224
mutation	O	225-233
in	O	234-236
hMLH1	O	237-242
.	O	242-243

Interestingly	O	244-257
,	O	257-258
the	O	259-262
I1307K	O	263-269
APC	O	270-273
polymorphism	O	274-286
,	O	286-287
associated	O	288-298
with	O	299-303
an	O	304-306
increased	O	307-316
risk	O	317-321
of	O	322-324
colorectal	B	325-335
cancer	I	336-342
,	O	342-343
is	O	344-346
also	O	347-351
present	O	352-359
in	O	360-362
this	O	363-367
family	O	368-374
.	O	374-375

The	O	376-379
I1307K	O	380-386
polymorphism	O	387-399
has	O	400-403
previously	O	404-414
only	O	415-419
been	O	420-424
identified	O	425-435
in	O	436-438
individuals	O	439-450
of	O	451-453
self	O	454-458
-	O	458-459
reported	O	459-467
Ashkenazi	O	468-477
Jewish	O	478-484
origins	O	485-492
.	O	492-493

In	O	494-496
addition	O	497-505
,	O	505-506
in	O	507-509
this	O	510-514
family	O	515-521
,	O	521-522
there	O	523-528
appears	O	529-536
to	O	537-539
be	O	540-542
no	O	543-545
relationship	O	546-558
between	O	559-566
the	O	567-570
I1307K	O	571-577
polymorphism	O	578-590
and	O	591-594
the	O	595-598
presence	O	599-607
or	O	608-610
absence	O	611-618
of	O	619-621
cancer	B	622-628
.	O	628-629
.	O	628-629

Wilms	B	0-5
'	I	5-6
tumor	I	7-12
1	O	13-14
and	O	15-18
Dax	O	19-22
-	O	22-23
1	O	23-24
modulate	O	25-33
the	O	34-37
orphan	O	38-44
nuclear	O	45-52
receptor	O	53-61
SF	O	62-64
-	O	64-65
1	O	65-66
in	O	67-69
sex	O	70-73
-	O	73-74
specific	O	74-82
gene	O	83-87
expression	O	88-98
.	O	98-99

Products	O	100-108
of	O	109-111
steroidogenic	O	112-125
factor	O	126-132
1	O	133-134
(	O	135-136
SF	O	136-138
-	O	138-139
1	O	139-140
)	O	140-141
and	O	142-145
Wilms	B	146-151
tumor	I	152-157
1	O	158-159
(	O	160-161
WT1	O	161-164
)	O	164-165
genes	O	166-171
are	O	172-175
essential	O	176-185
for	O	186-189
mammalian	O	190-199
gonadogenesis	O	200-213
prior	O	214-219
to	O	220-222
sexual	O	223-229
differentiation	O	230-245
.	O	245-246

In	O	247-249
males	O	250-255
,	O	255-256
SF	O	257-259
-	O	259-260
1	O	260-261
participates	O	262-274
in	O	275-277
sexual	O	278-284
development	O	285-296
by	O	297-299
regulating	O	300-310
expression	O	311-321
of	O	322-324
the	O	325-328
polypeptide	O	329-340
hormone	O	341-348
Mullerian	O	349-358
inhibiting	O	359-369
substance	O	370-379
(	O	380-381
MIS	O	381-384
)	O	384-385
.	O	385-386

Here	O	387-391
,	O	391-392
we	O	393-395
show	O	396-400
that	O	401-405
WT1	O	406-409
-	O	410-411
KTS	O	411-414
isoforms	O	415-423
associate	O	424-433
and	O	434-437
synergize	O	438-447
with	O	448-452
SF	O	453-455
-	O	455-456
1	O	456-457
to	O	458-460
promote	O	461-468
MIS	O	469-472
expression	O	473-483
.	O	483-484

In	O	485-487
contrast	O	488-496
,	O	496-497
WT1	O	498-501
missense	O	502-510
mutations	O	511-520
,	O	520-521
associated	O	522-532
with	O	533-537
male	B	538-542
pseudohermaphroditism	I	543-564
in	O	565-567
Denys	B	568-573
-	I	573-574
Drash	I	574-579
syndrome	I	580-588
,	O	588-589
fail	O	590-594
to	O	595-597
synergize	O	598-607
with	O	608-612
SF	O	613-615
-	O	615-616
1	O	616-617
.	O	617-618

Additionally	O	619-631
,	O	631-632
the	O	633-636
X	O	637-638
-	O	638-639
linked	O	639-645
,	O	645-646
candidate	O	647-656
dosage	O	657-663
-	O	663-664
sensitive	O	664-673
sex	O	674-677
-	O	677-678
reversal	O	678-686
gene	O	687-691
,	O	691-692
Dax	O	693-696
-	O	696-697
1	O	697-698
,	O	698-699
antagonizes	O	700-711
synergy	O	712-719
between	O	720-727
SF	O	728-730
-	O	730-731
1	O	731-732
and	O	733-736
WT1	O	737-740
,	O	740-741
most	O	742-746
likely	O	747-753
through	O	754-761
a	O	762-763
direct	O	764-770
interaction	O	771-782
with	O	783-787
SF	O	788-790
-	O	790-791
1	O	791-792
.	O	792-793

We	O	794-796
propose	O	797-804
that	O	805-809
WT1	O	810-813
and	O	814-817
Dax	O	818-821
-	O	821-822
1	O	822-823
functionally	O	824-836
oppose	O	837-843
each	O	844-848
other	O	849-854
in	O	855-857
testis	O	858-864
development	O	865-876
by	O	877-879
modulating	O	880-890
SF	O	891-893
-	O	893-894
1	O	894-895
-	O	893-894
mediated	O	896-904
transactivation	O	905-920
.	O	920-921
.	O	920-921

Ethnic	O	0-6
differences	O	7-18
in	O	19-21
the	O	22-25
HFE	O	26-29
codon	O	30-35
282	O	36-39
(	O	40-41
Cys	O	41-44
/	O	44-45
Tyr	O	45-48
)	O	48-49
polymorphism	O	50-62
.	O	62-63

Recent	O	64-70
studies	O	71-78
have	O	79-83
shown	O	84-89
that	O	90-94
hereditary	B	95-105
hemochromatosis	I	106-121
(	O	122-123
HH	B	123-125
)	O	125-126
is	O	127-129
likely	O	130-136
to	O	137-139
be	O	140-142
caused	O	143-149
by	O	150-152
homozygosity	O	153-165
for	O	166-169
a	O	170-171
Cys282Tyr	O	172-181
mutation	O	182-190
in	O	191-193
the	O	194-197
HFE	O	198-201
gene	O	202-206
located	O	207-214
4	O	215-216
.	O	216-217
5	O	218-219
Mb	O	220-222
telomeric	O	223-232
to	O	233-235
HLA	O	236-239
-	O	239-240
A	O	238-239
.	O	241-242

Population	O	243-253
studies	O	254-261
of	O	262-264
this	O	265-269
polymorphism	O	270-282
are	O	283-286
facilitated	O	287-298
by	O	299-301
the	O	302-305
fact	O	306-310
that	O	311-315
the	O	316-319
Cys282Tyr	O	320-329
mutation	O	330-338
creates	O	339-346
a	O	347-348
Rsal	O	349-353
restriction	O	354-365
site	O	366-370
.	O	370-371

We	O	372-374
have	O	375-379
studied	O	380-387
the	O	388-391
codon	O	392-397
282	O	398-401
(	O	402-403
Cys	O	403-406
/	O	406-407
Tyr	O	407-410
)	O	410-411
polymorphism	O	412-424
in	O	425-427
different	O	428-437
ethnic	O	438-444
groups	O	445-451
.	O	451-452

In	O	453-455
agreement	O	456-465
with	O	466-470
previous	O	471-479
observations	O	480-492
the	O	493-496
Tyr	O	497-500
allele	O	501-507
appeared	O	508-516
to	O	517-519
be	O	520-522
rare	O	523-527
or	O	528-530
absent	O	531-537
in	O	538-540
Asiatic	O	541-548
(	O	549-550
Indian	O	550-556
,	O	556-557
Chinese	O	558-565
)	O	565-566
populations	O	567-578
.	O	578-579

The	O	580-583
highest	O	584-591
allele	O	592-598
frequency	O	599-608
(	O	609-610
7	O	610-611
.	O	611-612

5	O	613-614
%	O	614-615
)	O	615-616
was	O	617-620
found	O	621-626
in	O	627-629
Swedes	O	630-636
.	O	636-637

Saamis	O	638-644
(	O	645-646
2	O	646-647
%	O	647-648
)	O	648-649
and	O	650-653
Mordvinians	O	654-665
(	O	666-667
1	O	667-668
.	O	668-669

8	O	670-671
%	O	671-672
)	O	672-673
had	O	674-677
significantly	O	678-691
lower	O	692-697
frequencies	O	698-709
of	O	710-712
the	O	713-716
Tyr	O	717-720
allele	O	721-727
.	O	727-728

Comparisons	O	729-740
with	O	741-745
allele	O	746-752
frequencies	O	753-764
based	O	765-770
on	O	771-773
prevalence	O	774-784
estimates	O	785-794
of	O	795-797
HH	B	798-800
showed	O	801-807
some	O	808-812
disagreements	O	813-826
with	O	827-831
the	O	832-835
RFLP	O	836-840
data	O	841-845
,	O	845-846
particularly	O	847-859
in	O	860-862
Finns	O	863-868
.	O	868-869

The	O	870-873
newly	O	874-879
described	O	880-889
HFE	O	890-893
marker	O	894-900
provides	O	901-909
a	O	910-911
new	O	912-915
approach	O	916-924
to	O	925-927
the	O	928-931
screening	O	932-941
of	O	942-944
HH	B	945-947
as	O	948-950
well	O	951-955
as	O	956-958
studies	O	959-966
of	O	967-969
the	O	970-973
relationship	O	974-986
between	O	987-994
the	O	995-998
HFE	O	999-1002
Tyr	O	1003-1006
allele	O	1007-1013
and	O	1014-1017
different	O	1018-1027
disorders	O	1028-1037
including	O	1038-1047
cancer	B	1048-1054

Risk	O	0-4
reversals	O	5-14
in	O	15-17
predictive	O	18-28
testing	O	29-36
for	O	37-40
Huntington	B	41-51
disease	I	52-59
.	O	59-60

The	O	61-64
first	O	65-70
predictive	O	71-81
testing	O	82-89
for	O	90-93
Huntington	B	94-104
disease	I	105-112
(	O	113-114
HD	B	114-116
)	O	116-117
was	O	118-121
based	O	122-127
on	O	128-130
analysis	O	131-139
of	O	140-142
linked	O	143-149
polymorphic	O	150-161
DNA	O	162-165
markers	O	166-173
to	O	174-176
estimate	O	177-185
the	O	186-189
likelihood	O	190-200
of	O	201-203
inheriting	O	204-214
the	O	215-218
mutation	O	219-227
for	O	228-231
HD	B	232-234
.	O	234-235

Limits	O	236-242
to	O	243-245
accuracy	O	246-254
included	O	255-263
recombination	O	264-277
between	O	278-285
the	O	286-289
DNA	O	290-293
markers	O	294-301
and	O	302-305
the	O	306-309
mutation	O	310-318
,	O	318-319
pedigree	O	320-328
structure	O	329-338
,	O	338-339
and	O	340-343
whether	O	344-351
DNA	O	352-355
samples	O	356-363
were	O	364-368
available	O	369-378
from	O	379-383
family	O	384-390
members	O	391-398
.	O	398-399

With	O	400-404
direct	O	405-411
tests	O	412-417
for	O	418-421
the	O	422-425
HD	B	426-428
mutation	O	429-437
,	O	437-438
we	O	439-441
have	O	442-446
assessed	O	447-455
the	O	456-459
accuracy	O	460-468
of	O	469-471
results	O	472-479
obtained	O	480-488
by	O	489-491
linkage	O	492-499
approaches	O	500-510
when	O	511-515
requested	O	516-525
to	O	526-528
do	O	529-531
so	O	532-534
by	O	535-537
the	O	538-541
test	O	542-546
individuals	O	547-558
.	O	558-559

For	O	560-563
six	O	564-567
such	O	568-572
individuals	O	573-584
,	O	584-585
there	O	586-591
was	O	592-595
significant	O	596-607
disparity	O	608-617
between	O	618-625
the	O	626-629
tests	O	630-635
.	O	635-636

Three	O	637-642
went	O	643-647
from	O	648-652
a	O	653-654
decreased	O	655-664
risk	O	665-669
to	O	670-672
an	O	673-675
increased	O	676-685
risk	O	686-690
,	O	690-691
while	O	692-697
in	O	698-700
another	O	701-708
three	O	709-714
the	O	715-718
risk	O	719-723
was	O	724-727
decreased	O	728-737
.	O	737-738

Knowledge	O	739-748
of	O	749-751
the	O	752-755
potential	O	756-765
reasons	O	766-773
for	O	774-777
these	O	778-783
changes	O	784-791
in	O	792-794
results	O	795-802
and	O	803-806
impact	O	807-813
of	O	814-816
these	O	817-822
risk	O	823-827
reversals	O	828-837
on	O	838-840
both	O	841-845
patients	O	846-854
and	O	855-858
the	O	859-862
counseling	O	863-873
team	O	874-878
can	O	879-882
assist	O	883-889
in	O	890-892
the	O	893-896
development	O	897-908
of	O	909-911
strategies	O	912-922
for	O	923-926
the	O	927-930
prevention	O	931-941
and	O	942-945
,	O	945-946
where	O	947-952
necessary	O	953-962
,	O	962-963
management	O	964-974
of	O	975-977
a	O	978-979
risk	O	980-984
reversal	O	985-993
in	O	994-996
any	O	997-1000
predictive	O	1001-1011
testing	O	1012-1019
program	O	1020-1027
.	O	1027-1028
.	O	1027-1028

Identification	O	0-14
of	O	15-17
three	O	18-23
novel	O	24-29
mutations	O	30-39
and	O	40-43
a	O	44-45
high	O	46-50
frequency	O	51-60
of	O	61-63
the	O	64-67
Arg778Leu	O	68-77
mutation	O	78-86
in	O	87-89
Korean	O	90-96
patients	O	97-105
with	O	106-110
Wilson	B	111-117
disease	I	118-125
.	O	125-126

Four	O	127-131
mutations	O	132-141
-	O	141-142
-	O	141-142
R778L	O	143-148
,	O	148-149
A874V	O	150-155
,	O	155-156
L1083F	O	157-163
,	O	163-164
and	O	165-168
2304delC	O	169-177
-	O	177-178
-	O	177-178
in	O	179-181
the	O	182-185
copper	O	186-192
-	O	192-193
transporting	O	193-205
enzyme	O	206-212
,	O	212-213
P	O	214-215
-	O	215-216
type	O	216-220
ATPase	O	221-227
(	O	228-229
ATP7B	O	229-234
)	O	234-235
,	O	235-236
were	O	237-241
identified	O	242-252
in	O	253-255
Korean	O	256-262
Patients	O	263-271
with	O	272-276
Wilson	B	277-283
disease	I	284-291
.	O	291-292

Arg778Leu	O	293-302
,	O	302-303
the	O	304-307
most	O	308-312
frequently	O	313-323
reported	O	324-332
mutation	O	333-341
of	O	342-344
this	O	345-349
enzyme	O	350-356
,	O	356-357
was	O	358-361
found	O	362-367
in	O	368-370
six	O	371-374
of	O	375-377
eight	O	378-383
unrelated	O	384-393
patients	O	394-402
studied	O	403-410
,	O	410-411
an	O	412-414
allele	O	415-421
frequency	O	422-431
of	O	432-434
37	O	435-437
.	O	437-438
5	O	439-440
%	O	440-441
,	O	441-442
which	O	443-448
is	O	449-451
considerably	O	452-464
higher	O	465-471
than	O	472-476
those	O	477-482
in	O	483-485
other	O	486-491
Asian	O	492-497
populations	O	498-509
.	O	509-510

The	O	511-514
novel	O	515-520
single	O	521-527
nucleotide	O	528-538
deletion	O	539-547
,	O	547-548
2304delC	O	549-557
,	O	557-558
was	O	559-562
found	O	563-568
in	O	569-571
one	O	572-575
patient	O	576-583
.	O	583-584

Since	O	585-590
a	O	591-592
mutation	O	593-601
at	O	602-604
cDNA	O	605-609
nucleotide	O	610-620
2302	O	621-625
(	O	626-627
2302insC	O	627-635
)	O	635-636
had	O	637-640
been	O	641-645
previously	O	646-656
described	O	657-666
,	O	666-667
this	O	668-672
region	O	673-679
of	O	680-682
the	O	683-686
ATP7B	O	687-692
gene	O	693-697
may	O	698-701
be	O	702-704
susceptible	O	705-716
to	O	717-719
gene	O	720-724
rearrangements	O	725-739
causing	O	740-747
Wilson	B	748-754
disease	I	755-762
.	O	762-763

Determination	O	0-13
of	O	14-16
the	O	17-20
genomic	O	21-28
structure	O	29-38
of	O	39-41
the	O	42-45
COL4A4	O	46-52
gene	O	53-57
and	O	58-61
of	O	62-64
novel	O	65-70
mutations	O	71-80
causing	O	81-88
autosomal	B	89-98
recessive	I	99-108
Alport	I	109-115
syndrome	I	116-124
.	O	124-125

Autosomal	B	126-135
recessive	I	136-145
Alport	I	146-152
syndrome	I	153-161
is	O	162-164
a	O	165-166
progressive	O	167-178
hematuric	B	179-188
glomerulonephritis	I	189-207
characterized	O	208-221
by	O	222-224
glomerular	B	225-235
basement	I	236-244
membrane	I	245-253
abnormalities	I	254-267
and	O	268-271
associated	O	272-282
with	O	283-287
mutations	O	288-297
in	O	298-300
either	O	301-307
the	O	308-311
COL4A3	O	312-318
or	O	319-321
the	O	322-325
COL4A4	O	326-332
gene	O	333-337
,	O	337-338
which	O	339-344
encode	O	345-351
the	O	352-355
alpha3	O	356-362
and	O	363-366
alpha4	O	367-373
type	O	374-378
IV	O	379-381
collagen	O	382-390
chains	O	391-397
,	O	397-398
respectively	O	399-411
.	O	411-412

To	O	413-415
date	O	416-420
,	O	420-421
mutation	O	422-430
screening	O	431-440
in	O	441-443
the	O	444-447
two	O	448-451
genes	O	452-457
has	O	458-461
been	O	462-466
hampered	O	467-475
by	O	476-478
the	O	479-482
lack	O	483-487
of	O	488-490
genomic	O	491-498
structure	O	499-508
information	O	509-520
.	O	520-521

We	O	522-524
report	O	525-531
here	O	532-536
the	O	537-540
complete	O	541-549
characterization	O	550-566
of	O	567-569
the	O	570-573
48	O	574-576
exons	O	577-582
of	O	583-585
the	O	586-589
COL4A4	O	590-596
gene	O	597-601
,	O	601-602
a	O	603-604
comprehensive	O	605-618
gene	O	619-623
screen	O	624-630
,	O	630-631
and	O	632-635
the	O	636-639
subsequent	O	640-650
detection	O	651-660
of	O	661-663
10	O	664-666
novel	O	667-672
mutations	O	673-682
in	O	683-685
eight	O	686-691
patients	O	692-700
diagnosed	O	701-710
with	O	711-715
autosomal	B	716-725
recessive	I	726-735
Alport	I	736-742
syndrome	I	743-751
.	O	751-752

Furthermore	O	753-764
,	O	764-765
we	O	766-768
identified	O	769-779
a	O	780-781
glycine	O	782-789
to	O	790-792
alanine	O	793-800
substitution	O	801-813
in	O	814-816
the	O	817-820
collagenous	O	821-832
domain	O	833-839
that	O	840-844
is	O	845-847
apparently	O	848-858
silent	O	859-865
in	O	866-868
the	O	869-872
heterozygous	O	873-885
carriers	O	886-894
,	O	894-895
in	O	896-898
11	O	899-901
.	O	901-902
5	O	903-904
%	O	904-905
of	O	906-908
all	O	909-912
control	O	913-920
individuals	O	921-932
,	O	932-933
and	O	934-937
in	O	938-940
one	O	941-944
control	O	945-952
individual	O	953-963
homozygous	O	964-974
for	O	975-978
this	O	979-983
glycine	O	984-991
substitution	O	992-1004
.	O	1004-1005

There	O	1006-1011
has	O	1012-1015
been	O	1016-1020
no	O	1021-1023
previous	O	1024-1032
finding	O	1033-1040
of	O	1041-1043
a	O	1044-1045
glycine	O	1046-1053
substitution	O	1054-1066
that	O	1067-1071
is	O	1072-1074
not	O	1075-1078
associated	O	1079-1089
with	O	1090-1094
any	O	1095-1098
obvious	O	1099-1106
phenotype	O	1107-1116
in	O	1117-1119
homozygous	O	1120-1130
individuals	O	1131-1142
.	O	1142-1143

A	O	0-1
gene	O	2-6
encoding	O	7-15
a	O	16-17
transmembrane	O	18-31
protein	O	32-39
is	O	40-42
mutated	O	43-50
in	O	51-53
patients	O	54-62
with	O	63-67
diabetes	B	68-76
mellitus	I	77-85
and	O	86-89
optic	B	90-95
atrophy	I	96-103
(	O	104-105
Wolfram	B	105-112
syndrome	I	113-121
)	O	121-122
.	O	122-123

Wolfram	B	124-131
syndrome	I	132-140
(	O	141-142
WFS	B	142-145
;	O	145-146
OMIM	O	147-151
222300	O	152-158
)	O	158-159
is	O	160-162
an	O	163-165
autosomal	B	166-175
recessive	I	176-185
neurodegenerative	I	186-203
disorder	I	204-212
defined	O	213-220
by	O	221-223
young	O	224-229
-	O	229-230
onset	O	230-235
non	O	236-239
-	O	239-240
immune	O	240-246
insulin	B	247-254
-	I	254-255
dependent	I	255-264
diabetes	I	265-273
mellitus	I	274-282
and	O	283-286
progressive	O	287-298
optic	B	299-304
atrophy	I	305-312
.	O	312-313

Linkage	O	314-321
to	O	322-324
markers	O	325-332
on	O	333-335
chromosome	O	336-346
4p	O	347-349
was	O	350-353
confirmed	O	354-363
in	O	364-366
five	O	367-371
families	O	372-380
.	O	380-381

On	O	382-384
the	O	385-388
basis	O	389-394
of	O	395-397
meiotic	O	398-405
recombinants	O	406-418
and	O	419-422
disease	O	423-430
-	O	430-431
associated	O	431-441
haplotypes	O	442-452
,	O	452-453
the	O	454-457
WFS	B	458-461
gene	O	462-466
was	O	467-470
localized	O	471-480
to	O	481-483
a	O	484-485
BAC	O	486-489
/	O	489-490
P1	O	490-492
contig	O	493-499
of	O	500-502
less	O	503-507
than	O	508-512
250	O	513-516
kb	O	517-519
.	O	519-520

Mutations	O	521-530
in	O	531-533
a	O	534-535
novel	O	536-541
gene	O	542-546
(	O	547-548
WFS1	O	548-552
)	O	552-553
encoding	O	554-562
a	O	563-564
putative	O	565-573
transmembrane	O	574-587
protein	O	588-595
were	O	596-600
found	O	601-606
in	O	607-609
all	O	610-613
affected	O	614-622
individuals	O	623-634
in	O	635-637
six	O	638-641
WFS	B	642-645
families	O	646-654
,	O	654-655
and	O	656-659
these	O	660-665
mutations	O	666-675
were	O	676-680
associated	O	681-691
with	O	692-696
the	O	697-700
disease	O	701-708
phenotype	O	709-718
.	O	718-719

WFS1	O	720-724
appears	O	725-732
to	O	733-735
function	O	736-744
in	O	745-747
survival	O	748-756
of	O	757-759
islet	O	760-765
beta	O	766-770
-	O	770-771
cells	O	771-776
and	O	777-780
neurons	O	781-788
.	O	788-789
.	O	788-789

Molecular	O	0-9
defects	O	10-17
leading	O	18-25
to	O	26-28
human	O	29-34
complement	B	35-45
component	I	46-55
C6	I	56-58
deficiency	I	59-69
in	O	70-72
an	O	73-75
African	O	76-83
-	O	83-84
American	O	84-92
family	O	93-99
.	O	99-100

Complement	B	101-111
component	I	112-121
C6	I	122-124
deficiency	I	125-135
(	O	136-137
C6D	B	137-140
)	O	140-141
was	O	142-145
diagnosed	O	146-155
in	O	156-158
a	O	159-160
16	O	161-163
-	O	163-164
year	O	164-168
-	O	163-164
old	O	169-172
African	O	173-180
-	O	180-181
American	O	181-189
male	O	190-194
with	O	195-199
meningococcal	B	200-213
meningitis	I	214-224
.	O	224-225

The	O	226-229
patients	O	230-238
father	O	239-245
and	O	246-249
two	O	250-253
brothers	O	254-262
also	O	263-267
had	O	268-271
C6D	B	272-275
,	O	275-276
but	O	277-280
gave	O	281-285
no	O	286-288
history	O	289-296
of	O	297-299
meningitis	B	300-310
or	O	311-313
other	O	314-319
neisserial	B	320-330
infection	I	331-340
.	O	340-341

By	O	342-344
using	O	345-350
exon	O	351-355
-	O	355-356
specific	O	356-364
polymerase	O	365-375
chain	O	376-381
reaction	O	382-390
(	O	391-392
PCR	O	392-395
)	O	395-396
/	O	396-397
single	O	397-403
-	O	403-404
strand	O	404-410
conformation	O	411-423
polymorphism	O	424-436
as	O	437-439
a	O	440-441
screening	O	442-451
step	O	452-456
and	O	457-460
nucleotide	O	461-471
sequencing	O	472-482
of	O	483-485
target	O	486-492
exons	O	493-498
,	O	498-499
we	O	500-502
determined	O	503-513
that	O	514-518
the	O	519-522
proband	O	523-530
was	O	531-534
a	O	535-536
compound	O	537-545
heterozygote	O	546-558
for	O	559-562
two	O	563-566
C6	O	567-569
gene	O	570-574
mutations	O	575-584
.	O	584-585

The	O	586-589
first	O	590-595
,	O	595-596
1195delC	O	597-605
located	O	606-613
in	O	614-616
exon	O	617-621
7	O	622-623
,	O	623-624
is	O	625-627
a	O	628-629
novel	O	630-635
mutation	O	636-644
,	O	644-645
while	O	646-651
the	O	652-655
second	O	656-662
,	O	662-663
1936delG	O	664-672
in	O	673-675
exon	O	676-680
12	O	681-683
,	O	683-684
has	O	685-688
been	O	689-693
described	O	694-703
before	O	704-710
to	O	711-713
cause	O	714-719
C6D	B	720-723
in	O	724-726
an	O	727-729
unrelated	O	730-739
African	O	740-747
-	O	747-748
American	O	748-756
individual	O	757-767
.	O	767-768

Both	O	769-773
mutations	O	774-783
result	O	784-790
in	O	791-793
premature	O	794-803
termination	O	804-815
codons	O	816-822
and	O	823-826
C6	O	827-829
null	O	830-834
alleles	O	835-842
.	O	842-843

Allele	O	844-850
-	O	850-851
specific	O	851-859
PCR	O	860-863
indicated	O	864-873
that	O	874-878
the	O	879-882
probands	O	883-891
two	O	892-895
brothers	O	896-904
also	O	905-909
inherited	O	910-919
the	O	920-923
1195delC	O	924-932
mutation	O	933-941
from	O	942-946
their	O	947-952
heterozygous	O	953-965
mother	O	966-972
and	O	973-976
the	O	977-980
1936delG	O	981-989
mutation	O	990-998
from	O	999-1003
their	O	1004-1009
homozygous	O	1010-1020
father	O	1021-1027
.	O	1027-1028
.	O	1027-1028

Sperm	O	0-5
DNA	O	6-9
analysis	O	10-18
in	O	19-21
a	O	22-23
Friedreich	B	24-34
ataxia	I	35-41
premutation	O	42-53
carrier	O	54-61
suggests	O	62-70
both	O	71-75
meiotic	O	76-83
and	O	84-87
mitotic	O	88-95
expansion	O	96-105
in	O	106-108
the	O	109-112
FRDA	B	113-117
gene	O	118-122
.	O	122-123

Friedreich	B	124-134
ataxia	I	135-141
is	O	142-144
usually	O	145-152
caused	O	153-159
by	O	160-162
an	O	163-165
expansion	O	166-175
of	O	176-178
a	O	179-180
GAA	O	181-184
trinucleotide	O	185-198
repeat	O	199-205
in	O	206-208
intron	O	209-215
1	O	216-217
of	O	218-220
the	O	221-224
FRDA	B	225-229
gene	O	230-234
.	O	234-235

Occasionally	O	236-248
,	O	248-249
a	O	250-251
fully	O	252-257
expanded	O	258-266
allele	O	267-273
has	O	274-277
been	O	278-282
found	O	283-288
to	O	289-291
arise	O	292-297
from	O	298-302
a	O	303-304
premutation	O	305-316
of	O	317-319
100	O	320-323
or	O	324-326
less	O	327-331
triplet	O	332-339
repeats	O	340-347
.	O	347-348

We	O	349-351
have	O	352-356
examined	O	357-365
the	O	366-369
sperm	O	370-375
DNA	O	376-379
of	O	380-382
a	O	383-384
premutation	O	385-396
carrier	O	397-404
.	O	404-405

This	O	406-410
mans	O	411-415
leucocyte	O	416-425
DNA	O	426-429
showed	O	430-436
one	O	437-440
normal	O	441-447
allele	O	448-454
and	O	455-458
one	O	459-462
allele	O	463-469
of	O	470-472
approximately	O	473-486
100	O	487-490
repeats	O	491-498
.	O	498-499

His	O	500-503
sperm	O	504-509
showed	O	510-516
an	O	517-519
expanded	O	520-528
allele	O	529-535
in	O	536-538
a	O	539-540
tight	O	541-546
range	O	547-552
centering	O	553-562
on	O	563-565
a	O	566-567
size	O	568-572
of	O	573-575
approximately	O	576-589
320	O	590-593
trinucleotide	O	594-607
repeats	O	608-615
.	O	615-616

His	O	617-620
affected	O	621-629
son	O	630-633
has	O	634-637
repeat	O	638-644
sizes	O	645-650
of	O	651-653
1040	O	654-658
and	O	659-662
540	O	663-666
.	O	666-667

These	O	668-673
data	O	674-678
suggest	O	679-686
that	O	687-691
expansion	O	692-701
occurs	O	702-708
in	O	709-711
two	O	712-715
stages	O	716-722
,	O	722-723
the	O	724-727
first	O	728-733
during	O	734-740
meiosis	O	741-748
followed	O	749-757
by	O	758-760
a	O	761-762
second	O	763-769
mitotic	O	770-777
expansion	O	778-787
.	O	787-788

We	O	789-791
also	O	792-796
show	O	797-801
that	O	802-806
in	O	807-809
all	O	810-813
informative	O	814-825
carrier	O	826-833
father	O	834-840
to	O	841-843
affected	O	844-852
child	O	853-858
transmissions	O	859-872
,	O	872-873
with	O	874-878
the	O	879-882
notable	O	883-890
exception	O	891-900
of	O	901-903
the	O	904-907
premutation	O	908-919
carrier	O	920-927
,	O	927-928
the	O	929-932
expansion	O	933-942
size	O	943-947
decreases	O	948-957
.	O	957-958
.	O	957-958

Eye	B	0-3
movement	I	4-12
abnormalities	I	13-26
correlate	O	27-36
with	O	37-41
genotype	O	42-50
in	O	51-53
autosomal	O	54-63
dominant	O	64-72
cerebellar	B	73-83
ataxia	I	84-90
type	I	91-95
I	I	96-97
.	O	97-98

We	O	99-101
compared	O	102-110
horizontal	O	111-121
eye	O	122-125
movements	O	126-135
(	O	136-137
visually	O	137-145
guided	O	146-152
saccades	O	153-161
,	O	161-162
antisaccades	O	163-175
,	O	175-176
and	O	177-180
smooth	O	181-187
pursuit	O	188-195
)	O	195-196
in	O	197-199
control	O	200-207
subjects	O	208-216
(	O	217-218
n	O	218-219
=	O	220-221
14	O	222-224
)	O	224-225
and	O	226-229
patients	O	230-238
with	O	239-243
three	O	244-249
forms	O	250-255
of	O	256-258
autosomal	O	259-268
dominant	O	269-277
cerebellar	B	278-288
ataxias	I	289-296
type	I	297-301
I	I	302-303
spinocerebellar	B	304-319
ataxias	I	320-327
1	I	328-329
and	I	330-333
2	I	334-335
(	O	336-337
SCA1	B	337-341
,	O	341-342
n	O	343-344
=	O	345-346
11	O	347-349
;	O	349-350
SCA2	B	351-355
,	O	355-356
n	O	357-358
=	O	359-360
10	O	361-363
)	O	363-364
and	O	365-368
SCA3	B	369-373
/	O	373-374
Machado	B	374-381
-	I	381-382
Joseph	I	382-388
disease	I	389-396
(	O	397-398
MJD	B	398-401
)	O	401-402
(	O	403-404
n	O	404-405
=	O	406-407
16	O	408-410
)	O	410-411
.	O	411-412

In	O	413-415
SCA1	B	416-420
,	O	420-421
saccade	O	422-429
amplitude	O	430-439
was	O	440-443
significantly	O	444-457
increased	O	458-467
,	O	467-468
resulting	O	469-478
in	O	479-481
hypermetria	B	482-493
.	O	493-494

The	O	495-498
smooth	O	499-505
pursuit	O	506-513
gain	O	514-518
was	O	519-522
decreased	O	523-532
.	O	532-533

In	O	534-536
SCA2	B	537-541
,	O	541-542
saccade	O	543-550
velocity	O	551-559
was	O	560-563
markedly	O	564-572
decreased	O	573-582
.	O	582-583

The	O	584-587
percentage	O	588-598
of	O	599-601
errors	O	602-608
in	O	609-611
antisaccades	O	612-624
was	O	625-628
greatly	O	629-636
increased	O	637-646
and	O	647-650
was	O	651-654
significantly	O	655-668
correlated	O	669-679
with	O	680-684
age	O	685-688
at	O	689-691
disease	O	692-699
onset	O	700-705
.	O	705-706

In	O	707-709
addition	O	710-718
,	O	718-719
a	O	720-721
correlation	O	722-733
between	O	734-741
smooth	O	742-748
pursuit	O	749-756
gain	O	757-761
and	O	762-765
the	O	766-769
number	O	770-776
of	O	777-779
trinucleotide	O	780-793
repeats	O	794-801
was	O	802-805
found	O	806-811
.	O	811-812

In	O	813-815
SCA3	B	816-820
,	O	820-821
gaze	B	822-826
-	I	826-827
evoked	I	827-833
nystagmus	I	834-843
was	O	844-847
often	O	848-853
present	O	854-861
as	O	862-864
was	O	865-868
saccade	O	869-876
hypometria	O	877-887
and	O	888-891
smooth	O	892-898
pursuit	O	899-906
gain	O	907-911
was	O	912-915
markedly	O	916-924
decreased	O	925-934
.	O	934-935

Three	O	936-941
major	O	942-947
criteria	O	948-956
,	O	956-957
saccade	O	958-965
amplitude	O	966-975
,	O	975-976
saccade	O	977-984
velocity	O	985-993
,	O	993-994
and	O	995-998
presence	O	999-1007
of	O	1008-1010
gaze	B	1011-1015
-	I	1015-1016
evoked	I	1016-1022
nystagmus	I	1023-1032
,	O	1032-1033
permitted	O	1034-1043
the	O	1044-1047
correct	O	1048-1055
assignment	O	1056-1066
of	O	1067-1069
90	O	1070-1072
%	O	1072-1073
of	O	1074-1076
the	O	1077-1080
SCA1	B	1081-1085
,	O	1085-1086
90	O	1087-1089
%	O	1089-1090
of	O	1091-1093
the	O	1094-1097
SCA2	B	1098-1102
,	O	1102-1103
and	O	1104-1107
93	O	1108-1110
%	O	1110-1111
of	O	1112-1114
the	O	1115-1118
patients	O	1119-1127
with	O	1128-1132
SCA3	B	1133-1137
to	O	1138-1140
their	O	1141-1146
genetically	O	1147-1158
confirmed	O	1159-1168
patient	O	1169-1176
group	O	1177-1182
and	O	1183-1186
,	O	1186-1187
therefore	O	1188-1197
,	O	1197-1198
may	O	1199-1202
help	O	1203-1207
orient	O	1208-1214
diagnoses	O	1215-1224
of	O	1225-1227
SCA1	B	1228-1232
,	O	1232-1233
SCA2	B	1234-1238
,	O	1238-1239
and	O	1240-1243
SCA3	B	1244-1248
at	O	1249-1251
early	O	1252-1257
clinical	O	1258-1266
stages	O	1267-1273
of	O	1274-1276
the	O	1277-1280
diseases	O	1281-1289
.	O	1289-1290
.	O	1289-1290

Clustering	O	0-10
of	O	11-13
missense	O	14-22
mutations	O	23-32
in	O	33-35
the	O	36-39
ataxia	B	40-46
-	I	46-47
telangiectasia	I	47-61
gene	O	62-66
in	O	67-69
a	O	70-71
sporadic	B	72-80
T	I	81-82
-	I	82-83
cell	I	83-87
leukaemia	I	88-97
.	O	97-98

Ataxia	B	99-105
-	I	105-106
telangiectasia	I	106-120
(	O	121-122
A	B	122-123
-	I	123-124
T	I	124-125
)	O	125-126
is	O	127-129
a	O	130-131
recessive	B	132-141
multi	I	142-147
-	I	147-148
system	I	148-154
disorder	I	155-163
caused	O	164-170
by	O	171-173
mutations	O	174-183
in	O	184-186
the	O	187-190
ATM	O	191-194
gene	O	195-199
at	O	200-202
11q22	O	203-208
-	O	208-209
q23	O	209-212
(	O	213-214
ref	O	214-217
.	O	217-218

3	O	219-220
)	O	220-221
.	O	221-222

The	O	223-226
risk	O	227-231
of	O	232-234
cancer	B	235-241
,	O	241-242
especially	O	243-253
lymphoid	B	254-262
neoplasias	I	263-273
,	O	273-274
is	O	275-277
substantially	O	278-291
elevated	O	292-300
in	O	301-303
A	B	304-305
-	I	305-306
T	I	306-307
patients	O	308-316
and	O	317-320
has	O	321-324
long	O	325-329
been	O	330-334
associated	O	335-345
with	O	346-350
chromosomal	O	351-362
instability	O	363-374
.	O	374-375

By	O	376-378
analysing	O	379-388
tumour	B	389-395
DNA	O	396-399
from	O	400-404
patients	O	405-413
with	O	414-418
sporadic	B	419-427
T	I	428-429
-	I	429-430
cell	I	430-434
prolymphocytic	I	435-449
leukaemia	I	450-459
(	O	460-461
T	B	461-462
-	I	462-463
PLL	I	463-466
)	O	466-467
,	O	467-468
a	O	469-470
rare	O	471-475
clonal	B	476-482
malignancy	I	483-493
with	O	494-498
similarities	O	499-511
to	O	512-514
a	O	515-516
mature	B	517-523
T	I	524-525
-	I	525-526
cell	I	526-530
leukaemia	I	531-540
seen	O	541-545
in	O	546-548
A	B	549-550
-	I	550-551
T	I	551-552
,	O	552-553
we	O	554-556
demonstrate	O	557-568
a	O	569-570
high	O	571-575
frequency	O	576-585
of	O	586-588
ATM	O	589-592
mutations	O	593-602
in	O	603-605
T	B	606-607
-	I	607-608
PLL	I	608-611
.	O	611-612

In	O	613-615
marked	O	616-622
contrast	O	623-631
to	O	632-634
the	O	635-638
ATM	O	639-642
mutation	O	643-651
pattern	O	652-659
in	O	660-662
A	B	663-664
-	I	664-665
T	I	665-666
,	O	666-667
the	O	668-671
most	O	672-676
frequent	O	677-685
nucleotide	O	686-696
changes	O	697-704
in	O	705-707
this	O	708-712
leukaemia	B	713-722
were	O	723-727
missense	O	728-736
mutations	O	737-746
.	O	746-747

These	O	748-753
clustered	O	754-763
in	O	764-766
the	O	767-770
region	O	771-777
corresponding	O	778-791
to	O	792-794
the	O	795-798
kinase	O	799-805
domain	O	806-812
,	O	812-813
which	O	814-819
is	O	820-822
highly	O	823-829
conserved	O	830-839
in	O	840-842
ATM	O	843-846
-	O	846-847
related	O	847-854
proteins	O	855-863
in	O	864-866
mouse	O	867-872
,	O	872-873
yeast	O	874-879
and	O	880-883
Drosophila	O	884-894
.	O	894-895

The	O	896-899
resulting	O	900-909
amino	O	910-915
-	O	915-916
acid	O	916-920
substitutions	O	921-934
are	O	935-938
predicted	O	939-948
to	O	949-951
interfere	O	952-961
with	O	962-966
ATP	O	967-970
binding	O	971-978
or	O	979-981
substrate	O	982-991
recognition	O	992-1003
.	O	1003-1004

Two	O	1005-1008
of	O	1009-1011
seventeen	O	1012-1021
mutated	O	1022-1029
T	B	1030-1031
-	I	1031-1032
PLL	I	1032-1035
samples	O	1036-1043
had	O	1044-1047
a	O	1048-1049
previously	O	1050-1060
reported	O	1061-1069
A	B	1070-1071
-	I	1071-1072
T	I	1072-1073
allele	O	1074-1080
.	O	1080-1081

In	O	1082-1084
contrast	O	1085-1093
,	O	1093-1094
no	O	1095-1097
mutations	O	1098-1107
were	O	1108-1112
detected	O	1113-1121
in	O	1122-1124
the	O	1125-1128
p53	O	1129-1132
gene	O	1133-1137
,	O	1137-1138
suggesting	O	1139-1149
that	O	1150-1154
this	O	1155-1159
tumour	B	1160-1166
suppressor	O	1167-1177
is	O	1178-1180
not	O	1181-1184
frequently	O	1185-1195
altered	O	1196-1203
in	O	1204-1206
this	O	1207-1211
leukaemia	B	1212-1221
.	O	1221-1222

Occasional	O	1223-1233
missense	O	1234-1242
mutations	O	1243-1252
in	O	1253-1255
ATM	O	1256-1259
were	O	1260-1264
also	O	1265-1269
found	O	1270-1275
in	O	1276-1278
tumour	B	1279-1285
DNA	O	1286-1289
from	O	1290-1294
patients	O	1295-1303
with	O	1304-1308
B	B	1309-1310
-	I	1310-1311
cell	I	1311-1315
non	I	1316-1319
-	I	1319-1320
Hodgkins	I	1320-1328
lymphomas	I	1329-1338
(	O	1339-1340
B	B	1340-1341
-	I	1341-1342
NHL	I	1342-1345
)	O	1345-1346
and	O	1347-1350
a	O	1351-1352
B	B	1353-1354
-	I	1354-1355
NHL	I	1355-1358
cell	O	1359-1363
line	O	1364-1368
.	O	1368-1369

The	O	1370-1373
evidence	O	1374-1382
of	O	1383-1385
a	O	1386-1387
significant	O	1388-1399
proportion	O	1400-1410
of	O	1411-1413
loss	O	1414-1418
-	O	1418-1419
of	O	1419-1421
-	O	1418-1419
function	O	1422-1430
mutations	O	1431-1440
and	O	1441-1444
a	O	1445-1446
complete	O	1447-1455
absence	O	1456-1463
of	O	1464-1466
the	O	1467-1470
normal	O	1471-1477
copy	O	1478-1482
of	O	1483-1485
ATM	O	1486-1489
in	O	1490-1492
the	O	1493-1496
majority	O	1497-1505
of	O	1506-1508
mutated	O	1509-1516
tumours	B	1517-1524
establishes	O	1525-1536
somatic	O	1537-1544
inactivation	O	1545-1557
of	O	1558-1560
this	O	1561-1565
gene	O	1566-1570
in	O	1571-1573
the	O	1574-1577
pathogenesis	O	1578-1590
of	O	1591-1593
sporadic	B	1594-1602
T	I	1603-1604
-	I	1604-1605
PLL	I	1605-1608
and	O	1609-1612
suggests	O	1613-1621
that	O	1622-1626
ATM	O	1627-1630
acts	O	1631-1635
as	O	1636-1638
a	O	1639-1640
tumour	B	1641-1647
suppressor	O	1648-1658
.	O	1658-1659

As	O	1660-1662
constitutional	O	1663-1677
DNA	O	1678-1681
was	O	1682-1685
not	O	1686-1689
available	O	1690-1699
,	O	1699-1700
a	O	1701-1702
putative	O	1703-1711
hereditary	O	1712-1722
predisposition	O	1723-1737
to	O	1738-1740
T	B	1741-1742
-	I	1742-1743
PLL	I	1743-1746
will	O	1747-1751
require	O	1752-1759
further	O	1760-1767
investigation	O	1768-1781
.	O	1781-1782
.	O	1781-1782

Identification	O	0-14
of	O	15-17
a	O	18-19
novel	O	20-25
nonsense	O	26-34
mutation	O	35-43
and	O	44-47
a	O	48-49
missense	O	50-58
substitution	O	59-71
in	O	72-74
the	O	75-78
vasopressin	O	79-90
-	O	90-91
neurophysin	O	91-102
II	O	103-105
gene	O	106-110
in	O	111-113
two	O	114-117
Spanish	O	118-125
kindreds	O	126-134
with	O	135-139
familial	B	140-148
neurohypophyseal	I	149-165
diabetes	I	166-174
insipidus	I	175-184
.	O	184-185

Familial	B	186-194
neurohypophyseal	I	195-211
diabetes	I	212-220
insipidus	I	221-230
(	O	231-232
FNDI	B	232-236
)	O	236-237
is	O	238-240
an	O	241-243
autosomal	B	244-253
dominant	I	254-262
disease	I	263-270
caused	O	271-277
by	O	278-280
deficiency	O	281-291
in	O	292-294
the	O	295-298
antidiuretic	O	299-311
hormone	O	312-319
arginine	O	320-328
vasopressin	O	329-340
(	O	341-342
AVP	O	342-345
)	O	345-346
encoded	O	347-354
by	O	355-357
the	O	358-361
AVP	O	362-365
-	O	365-366
neurophysin	O	366-377
II	O	378-380
(	O	381-382
AVP	O	382-385
-	O	385-386
NPII	O	386-390
)	O	390-391
gene	O	392-396
on	O	397-399
chromosome	O	400-410
20p13	O	411-416
.	O	416-417

In	O	418-420
this	O	421-425
study	O	426-431
,	O	431-432
we	O	433-435
analyzed	O	436-444
two	O	445-448
families	O	449-457
with	O	458-462
FNDI	B	463-467
using	O	468-473
direct	O	474-480
automated	O	481-490
fluorescent	O	491-502
,	O	502-503
solid	O	504-509
phase	O	510-515
,	O	515-516
single	O	517-523
-	O	523-524
stranded	O	524-532
DNA	O	533-536
sequencing	O	537-547
of	O	548-550
PCR	O	551-554
-	O	554-555
amplified	O	555-564
AVP	O	565-568
-	O	568-569
NPII	O	569-573
DNA	O	574-577
.	O	577-578

In	O	579-581
one	O	582-585
of	O	586-588
the	O	589-592
families	O	593-601
,	O	601-602
affected	O	603-611
individuals	O	612-623
presented	O	624-633
a	O	634-635
novel	O	636-641
nonsense	O	642-650
mutation	O	651-659
in	O	660-662
exon	O	663-667
3	O	668-669
of	O	670-672
the	O	673-676
gene	O	677-681
,	O	681-682
consisting	O	683-693
in	O	694-696
a	O	697-698
G	O	699-700
to	O	701-703
T	O	704-705
transition	O	706-716
at	O	717-719
nucleotide	O	720-730
2101	O	731-735
,	O	735-736
which	O	737-742
produces	O	743-751
a	O	752-753
stop	O	754-758
signal	O	759-765
in	O	766-768
codon	O	769-774
82	O	775-777
(	O	778-779
Glu	O	779-782
)	O	782-783
of	O	784-786
NPII	O	787-791
.	O	791-792

The	O	793-796
premature	O	797-806
termination	O	807-818
eliminates	O	819-829
part	O	830-834
of	O	835-837
the	O	838-841
C	O	842-843
-	O	843-844
terminal	O	844-852
domain	O	853-859
of	O	860-862
NPII	O	863-867
,	O	867-868
including	O	869-878
a	O	879-880
cysteine	O	881-889
residue	O	890-897
in	O	898-900
position	O	901-909
85	O	910-912
,	O	912-913
which	O	914-919
could	O	920-925
be	O	926-928
involved	O	929-937
in	O	938-940
the	O	941-944
correct	O	945-952
folding	O	953-960
of	O	961-963
the	O	964-967
prohormone	O	968-978
.	O	978-979

In	O	980-982
the	O	983-986
second	O	987-993
family	O	994-1000
,	O	1000-1001
a	O	1002-1003
G279A	O	1004-1009
substitution	O	1010-1022
at	O	1023-1025
position	O	1026-1034
-	O	1035-1036
1	O	1036-1037
of	O	1038-1040
the	O	1041-1044
signal	O	1045-1051
peptide	O	1052-1059
was	O	1060-1063
observed	O	1064-1072
in	O	1073-1075
all	O	1076-1079
affected	O	1080-1088
individuals	O	1089-1100
.	O	1100-1101

This	O	1102-1106
missense	O	1107-1115
mutation	O	1116-1124
,	O	1124-1125
which	O	1126-1131
replaces	O	1132-1140
Ala	O	1141-1144
with	O	1145-1149
Thr	O	1150-1153
,	O	1153-1154
is	O	1155-1157
frequent	O	1158-1166
among	O	1167-1172
FNDI	B	1173-1177
patients	O	1178-1186
and	O	1187-1190
is	O	1191-1193
thought	O	1194-1201
to	O	1202-1204
reduce	O	1205-1211
the	O	1212-1215
efficiency	O	1216-1226
of	O	1227-1229
cleavage	O	1230-1238
by	O	1239-1241
signal	O	1242-1248
peptidases	O	1249-1259
.	O	1259-1260
.	O	1259-1260

Cloning	O	0-7
of	O	8-10
a	O	11-12
novel	O	13-18
member	O	19-25
of	O	26-28
the	O	29-32
low	O	33-36
-	O	36-37
density	O	37-44
lipoprotein	O	45-56
receptor	O	57-65
family	O	66-72
.	O	72-73

A	O	74-75
gene	O	76-80
encoding	O	81-89
a	O	90-91
novel	O	92-97
transmembrane	O	98-111
protein	O	112-119
was	O	120-123
identified	O	124-134
by	O	135-137
DNA	O	138-141
sequence	O	142-150
analysis	O	151-159
within	O	160-166
the	O	167-170
insulin	B	171-178
-	I	178-179
dependent	I	179-188
diabetes	I	189-197
mellitus	I	198-206
(	O	207-208
IDDM	B	208-212
)	O	212-213
locus	O	214-219
IDDM4	O	220-225
on	O	226-228
chromosome	O	229-239
11q13	O	240-245
.	O	245-246

Based	O	247-252
on	O	253-255
its	O	256-259
chromosomal	O	260-271
position	O	272-280
,	O	280-281
this	O	282-286
gene	O	287-291
is	O	292-294
a	O	295-296
candidate	O	297-306
for	O	307-310
conferring	O	311-321
susceptibility	O	322-336
to	O	337-339
diabetes	B	340-348
.	O	348-349

The	O	350-353
gene	O	354-358
,	O	358-359
termed	O	360-366
low	O	367-370
-	O	370-371
density	O	371-378
lipoprotein	O	379-390
receptor	O	391-399
related	O	400-407
protein	O	408-415
5	O	416-417
(	O	418-419
LRP5	O	419-423
)	O	423-424
,	O	424-425
encodes	O	426-433
a	O	434-435
protein	O	436-443
of	O	444-446
1615	O	447-451
amino	O	452-457
acids	O	458-463
that	O	464-468
contains	O	469-477
conserved	O	478-487
modules	O	488-495
which	O	496-501
are	O	502-505
characteristic	O	506-520
of	O	521-523
the	O	524-527
low	O	528-531
-	O	531-532
density	O	532-539
lipoprotein	O	540-551
(	O	552-553
LDL	O	553-556
)	O	556-557
receptor	O	558-566
family	O	567-573
.	O	573-574

These	O	575-580
modules	O	581-588
include	O	589-596
a	O	597-598
putative	O	599-607
signal	O	608-614
peptide	O	615-622
for	O	623-626
protein	O	627-634
export	O	635-641
,	O	641-642
four	O	643-647
epidermal	O	648-657
growth	O	658-664
factor	O	665-671
(	O	672-673
EGF	O	673-676
)	O	676-677
repeats	O	678-685
with	O	686-690
associated	O	691-701
spacer	O	702-708
domains	O	709-716
,	O	716-717
three	O	718-723
LDL	O	724-727
-	O	727-728
receptor	O	728-736
(	O	737-738
LDLR	O	738-742
)	O	742-743
repeats	O	744-751
,	O	751-752
a	O	753-754
single	O	755-761
transmembrane	O	762-775
spanning	O	776-784
domain	O	785-791
,	O	791-792
and	O	793-796
a	O	797-798
cytoplasmic	O	799-810
domain	O	811-817
.	O	817-818

The	O	819-822
encoded	O	823-830
protein	O	831-838
has	O	839-842
a	O	843-844
unique	O	845-851
organization	O	852-864
of	O	865-867
EGF	O	868-871
and	O	872-875
LDLR	O	876-880
repeats	O	881-888
;	O	888-889
therefore	O	890-899
,	O	899-900
LRP5	O	901-905
likely	O	906-912
represents	O	913-923
a	O	924-925
new	O	926-929
category	O	930-938
of	O	939-941
the	O	942-945
LDLR	O	946-950
family	O	951-957
.	O	957-958

Both	O	959-963
human	O	964-969
and	O	970-973
mouse	O	974-979
LRP5	O	980-984
cDNAs	O	985-990
have	O	991-995
been	O	996-1000
isolated	O	1001-1009
and	O	1010-1013
the	O	1014-1017
encoded	O	1018-1025
mature	O	1026-1032
proteins	O	1033-1041
are	O	1042-1045
95	O	1046-1048
%	O	1048-1049
identical	O	1050-1059
,	O	1059-1060
indicating	O	1061-1071
a	O	1072-1073
high	O	1074-1078
degree	O	1079-1085
of	O	1086-1088
evolutionary	O	1089-1101
conservation	O	1102-1114
.	O	1114-1115
.	O	1114-1115

ATM	O	0-3
germline	O	4-12
mutations	O	13-22
in	O	23-25
classical	O	26-35
ataxia	B	36-42
-	I	42-43
telangiectasia	I	43-57
patients	O	58-66
in	O	67-69
the	O	70-73
Dutch	O	74-79
population	O	80-90
.	O	90-91

Germline	O	92-100
mutations	O	101-110
in	O	111-113
the	O	114-117
ATM	O	118-121
gene	O	122-126
are	O	127-130
responsible	O	131-142
for	O	143-146
the	O	147-150
autosomal	B	151-160
recessive	I	161-170
disorder	I	171-179
ataxia	B	180-186
-	I	186-187
telangiectasia	I	187-201
(	O	202-203
A	B	203-204
-	I	204-205
T	I	205-206
)	O	206-207
.	O	207-208

In	O	209-211
our	O	212-215
study	O	216-221
,	O	221-222
we	O	223-225
have	O	226-230
determined	O	231-241
the	O	242-245
ATM	O	246-249
mutation	O	250-258
spectrum	O	259-267
in	O	268-270
19	O	271-273
classical	O	274-283
A	B	284-285
-	I	285-286
T	I	286-287
patients	O	288-296
,	O	296-297
including	O	298-307
some	O	308-312
immigrant	O	313-322
populations	O	323-334
,	O	334-335
as	O	336-338
well	O	339-343
as	O	344-346
12	O	347-349
of	O	350-352
Dutch	O	353-358
ethnic	O	359-365
origin	O	366-372
.	O	372-373

Both	O	374-378
the	O	379-382
protein	O	383-390
truncation	O	391-401
test	O	402-406
(	O	407-408
PTT	O	408-411
)	O	411-412
and	O	413-416
the	O	417-420
restriction	O	421-432
endonuclease	O	433-445
fingerprinting	O	446-460
(	O	461-462
REF	O	462-465
)	O	465-466
method	O	467-473
were	O	474-478
used	O	479-483
and	O	484-487
compared	O	488-496
for	O	497-500
their	O	501-506
detection	O	507-516
efficiency	O	517-527
,	O	527-528
identifying	O	529-540
76	O	541-543
%	O	543-544
and	O	545-548
60	O	549-551
%	O	551-552
of	O	553-555
the	O	556-559
mutations	O	560-569
,	O	569-570
respectively	O	571-583
.	O	583-584

Most	O	585-589
patients	O	590-598
were	O	599-603
found	O	604-609
to	O	610-612
be	O	613-615
compound	O	616-624
heterozygote	O	625-637
.	O	637-638

Seventeen	O	639-648
mutations	O	649-658
were	O	659-663
distinct	O	664-672
,	O	672-673
of	O	674-676
which	O	677-682
10	O	683-685
were	O	686-690
not	O	691-694
reported	O	695-703
previously	O	704-714
.	O	714-715

Mutations	O	716-725
are	O	726-729
small	O	730-735
deletions	O	736-745
or	O	746-748
point	O	749-754
mutations	O	755-764
frequently	O	765-775
affecting	O	776-785
splice	O	786-792
sites	O	793-798
.	O	798-799

Moreover	O	800-808
,	O	808-809
a	O	810-811
16	O	812-814
.	O	814-815
7	O	816-817
-	O	817-818
kb	O	818-820
genomic	O	821-828
deletion	O	829-837
of	O	838-840
the	O	841-844
3	O	845-846
end	O	847-850
of	O	851-853
the	O	854-857
gene	O	858-862
,	O	862-863
most	O	864-868
likely	O	869-875
a	O	876-877
result	O	878-884
of	O	885-887
recombination	O	888-901
between	O	902-909
two	O	910-913
LINE	O	914-918
elements	O	919-927
,	O	927-928
was	O	929-932
identified	O	933-943
.	O	943-944

The	O	945-948
most	O	949-953
frequently	O	954-964
found	O	965-970
mutation	O	971-979
,	O	979-980
identified	O	981-991
in	O	992-994
three	O	995-1000
unrelated	O	1001-1010
Turkish	O	1011-1018
A	B	1019-1020
-	I	1020-1021
T	I	1021-1022
individuals	O	1023-1034
,	O	1034-1035
was	O	1036-1039
previously	O	1040-1050
described	O	1051-1060
to	O	1061-1063
be	O	1064-1066
a	O	1067-1068
Turkish	O	1069-1076
A	B	1077-1078
-	I	1078-1079
T	I	1079-1080
founder	O	1081-1088
mutation	O	1089-1097
.	O	1097-1098

The	O	1099-1102
presence	O	1103-1111
of	O	1112-1114
a	O	1115-1116
founder	O	1117-1124
mutation	O	1125-1133
among	O	1134-1139
relatively	O	1140-1150
small	O	1151-1156
ethnic	O	1157-1163
population	O	1164-1174
groups	O	1175-1181
in	O	1182-1184
Western	O	1185-1192
Europe	O	1193-1199
could	O	1200-1205
indicate	O	1206-1214
a	O	1215-1216
high	O	1217-1221
carrier	O	1222-1229
frequency	O	1230-1239
in	O	1240-1242
such	O	1243-1247
communities	O	1248-1259
.	O	1259-1260

In	O	1261-1263
patients	O	1264-1272
of	O	1273-1275
Dutch	O	1276-1281
ethnic	O	1282-1288
origin	O	1289-1295
,	O	1295-1296
however	O	1297-1304
,	O	1304-1305
no	O	1306-1308
significant	O	1309-1320
founder	O	1321-1328
effect	O	1329-1335
could	O	1336-1341
be	O	1342-1344
identified	O	1345-1355
.	O	1355-1356

The	O	1357-1360
observed	O	1361-1369
genetic	O	1370-1377
heterogeneity	O	1378-1391
including	O	1392-1401
the	O	1402-1405
relative	O	1406-1414
high	O	1415-1419
percentage	O	1420-1430
of	O	1431-1433
splice	O	1434-1440
-	O	1440-1441
site	O	1441-1445
mutations	O	1446-1455
had	O	1456-1459
no	O	1460-1462
reflection	O	1463-1473
on	O	1474-1476
the	O	1477-1480
phenotype	O	1481-1490
.	O	1490-1491

All	O	1492-1495
patients	O	1496-1504
manifested	O	1505-1515
classical	O	1516-1525
A	B	1526-1527
-	I	1527-1528
T	I	1528-1529
and	O	1530-1533
increased	O	1534-1543
cellular	O	1544-1552
radioresistant	O	1553-1567
DNA	O	1568-1571
synthesis	O	1572-1581
.	O	1581-1582

Diagnosis	O	0-9
of	O	10-12
hemochromatosis	B	13-28
.	O	28-29

If	O	30-32
untreated	O	33-42
,	O	42-43
hemochromatosis	B	44-59
can	O	60-63
cause	O	64-69
serious	O	70-77
illness	O	78-85
and	O	86-89
early	B	90-95
death	I	96-101
,	O	101-102
but	O	103-106
the	O	107-110
disease	O	111-118
is	O	119-121
still	O	122-127
substantially	O	128-141
under	O	142-147
-	O	147-148
diagnosed	O	148-157
.	O	157-158

The	O	159-162
cornerstone	O	163-174
of	O	175-177
screening	O	178-187
and	O	188-191
case	O	192-196
detection	O	197-206
is	O	207-209
the	O	210-213
measurement	O	214-225
of	O	226-228
serum	O	229-234
transferrin	O	235-246
saturation	O	247-257
and	O	258-261
the	O	262-265
serum	O	266-271
ferritin	O	272-280
level	O	281-286
.	O	286-287

Once	O	288-292
the	O	293-296
diagnosis	O	297-306
is	O	307-309
suspected	O	310-319
,	O	319-320
physicians	O	321-331
must	O	332-336
use	O	337-340
serum	O	341-346
ferritin	O	347-355
levels	O	356-362
and	O	363-366
hepatic	O	367-374
iron	O	375-379
stores	O	380-386
on	O	387-389
liver	O	390-395
biopsy	O	396-402
specimens	O	403-412
to	O	413-415
assess	O	416-422
patients	O	423-431
for	O	432-435
the	O	436-439
presence	O	440-448
of	O	449-451
iron	B	452-456
overload	I	457-465
.	O	465-466

Liver	O	467-472
biopsy	O	473-479
is	O	480-482
also	O	483-487
used	O	488-492
to	O	493-495
establish	O	496-505
the	O	506-509
presence	O	510-518
or	O	519-521
absence	O	522-529
of	O	530-532
cirrhosis	B	533-542
,	O	542-543
which	O	544-549
can	O	550-553
affect	O	554-560
prognosis	O	561-570
and	O	571-574
management	O	575-585
.	O	585-586

A	O	587-588
DNA	O	589-592
-	O	592-593
based	O	593-598
test	O	599-603
for	O	604-607
the	O	608-611
HFE	O	612-615
gene	O	616-620
is	O	621-623
commercially	O	624-636
available	O	637-646
,	O	646-647
but	O	648-651
its	O	652-655
place	O	656-661
in	O	662-664
the	O	665-668
diagnosis	O	669-678
of	O	679-681
hemochromatosis	B	682-697
is	O	698-700
still	O	701-706
being	O	707-712
evaluated	O	713-722
.	O	722-723

Currently	O	724-733
,	O	733-734
the	O	735-738
most	O	739-743
useful	O	744-750
role	O	751-755
for	O	756-759
this	O	760-764
test	O	765-769
is	O	770-772
in	O	773-775
the	O	776-779
detection	O	780-789
of	O	790-792
hemochromatosis	B	793-808
in	O	809-811
the	O	812-815
family	O	816-822
members	O	823-830
of	O	831-833
patients	O	834-842
with	O	843-847
a	O	848-849
proven	O	850-856
case	O	857-861
of	O	862-864
the	O	865-868
disease	O	869-876
.	O	876-877

It	O	878-880
is	O	881-883
crucial	O	884-891
to	O	892-894
diagnose	O	895-903
hemochromatosis	B	904-919
before	O	920-926
hepatic	B	927-934
cirrhosis	I	935-944
develops	O	945-953
because	O	954-961
phlebotomy	O	962-972
therapy	O	973-980
can	O	981-984
avert	O	985-990
serious	O	991-998
chronic	O	999-1006
disease	O	1007-1014
and	O	1015-1018
can	O	1019-1022
even	O	1023-1027
lead	O	1028-1032
to	O	1033-1035
normal	O	1036-1042
life	O	1043-1047
expectancy	O	1048-1058
.	O	1058-1059
.	O	1058-1059

PAX6	O	0-4
mutations	O	5-14
reviewed	O	15-23
.	O	23-24

Mutations	O	25-34
in	O	35-37
PAX6	O	38-42
are	O	43-46
responsible	O	47-58
for	O	59-62
human	O	63-68
aniridia	B	69-77
and	O	78-81
have	O	82-86
also	O	87-91
been	O	92-96
found	O	97-102
in	O	103-105
patients	O	106-114
with	O	115-119
Peters	B	120-126
anomaly	I	127-134
,	O	134-135
with	O	136-140
congenital	B	141-151
cataracts	I	152-161
,	O	161-162
with	O	163-167
autosomal	B	168-177
dominant	I	178-186
keratitis	I	187-196
,	O	196-197
and	O	198-201
with	O	202-206
isolated	B	207-215
foveal	I	216-222
hypoplasia	I	223-233
.	O	233-234

No	O	235-237
locus	O	238-243
other	O	244-249
than	O	250-254
chromosome	O	255-265
11p13	O	266-271
has	O	272-275
been	O	276-280
implicated	O	281-291
in	O	292-294
aniridia	B	295-303
,	O	303-304
and	O	305-308
PAX6	O	309-313
is	O	314-316
clearly	O	317-324
the	O	325-328
major	O	329-334
,	O	334-335
if	O	336-338
not	O	339-342
only	O	343-347
,	O	347-348
gene	O	349-353
responsible	O	354-365
.	O	365-366

Twenty	O	367-373
-	O	373-374
eight	O	374-379
percent	O	380-387
of	O	388-390
identified	O	391-401
PAX6	O	402-406
mutations	O	407-416
are	O	417-420
C	O	421-422
-	O	422-423
T	O	423-424
changes	O	425-432
at	O	433-435
CpG	O	436-439
dinucleotides	O	440-453
,	O	453-454
20	O	455-457
%	O	457-458
are	O	459-462
splicing	O	463-471
errors	O	472-478
,	O	478-479
and	O	480-483
more	O	484-488
than	O	489-493
30	O	494-496
%	O	496-497
are	O	498-501
deletion	O	502-510
or	O	511-513
insertion	O	514-523
events	O	524-530
.	O	530-531

There	O	532-537
is	O	538-540
a	O	541-542
noticeably	O	543-553
elevated	O	554-562
level	O	563-568
of	O	569-571
mutation	O	572-580
in	O	581-583
the	O	584-587
paired	O	588-594
domain	O	595-601
compared	O	602-610
with	O	611-615
the	O	616-619
rest	O	620-624
of	O	625-627
the	O	628-631
gene	O	632-636
.	O	636-637

Increased	O	638-647
mutation	O	648-656
in	O	657-659
the	O	660-663
homeodomain	O	664-675
is	O	676-678
accounted	O	679-688
for	O	689-692
by	O	693-695
the	O	696-699
hypermutable	O	700-712
CpG	O	713-716
dinucleotide	O	717-729
in	O	730-732
codon	O	733-738
240	O	739-742
.	O	742-743

Very	O	744-748
nearly	O	749-755
all	O	756-759
mutations	O	760-769
appear	O	770-776
to	O	777-779
cause	O	780-785
loss	O	786-790
of	O	791-793
function	O	794-802
of	O	803-805
the	O	806-809
mutant	O	810-816
allele	O	817-823
,	O	823-824
and	O	825-828
more	O	829-833
than	O	834-838
80	O	839-841
%	O	841-842
of	O	843-845
exonic	O	846-852
substitutions	O	853-866
result	O	867-873
in	O	874-876
nonsense	O	877-885
codons	O	886-892
.	O	892-893

In	O	894-896
a	O	897-898
gene	O	899-903
with	O	904-908
such	O	909-913
extraordinarily	O	914-929
high	O	930-934
sequence	O	935-943
conservation	O	944-956
throughout	O	957-967
evolution	O	968-977
,	O	977-978
there	O	979-984
are	O	985-988
presumed	O	989-997
undiscovered	O	998-1010
missense	O	1011-1019
mutations	O	1020-1029
,	O	1029-1030
these	O	1031-1036
are	O	1037-1040
hypothesized	O	1041-1053
to	O	1054-1056
exist	O	1057-1062
in	O	1063-1065
as	O	1066-1068
-	O	1068-1069
yet	O	1069-1072
unidentified	O	1073-1085
phenotypes	O	1086-1096
.	O	1096-1097
.	O	1096-1097

Schwartz	B	0-8
-	I	8-9
Jampel	I	9-15
syndrome	I	16-24
type	I	25-29
2	I	30-31
and	O	32-35
Stuve	B	36-41
-	I	41-42
Wiedemann	I	42-51
syndrome	I	52-60
:	O	60-61
a	O	62-63
case	O	64-68
for	O	69-72
"	O	73-74
lumping	O	74-81
"	O	73-74
.	O	82-83

Recent	O	84-90
studies	O	91-98
demonstrated	O	99-111
the	O	112-115
existence	O	116-125
of	O	126-128
a	O	129-130
genetically	O	131-142
distinct	O	143-151
,	O	151-152
usually	O	153-160
lethal	O	161-167
form	O	168-172
of	O	173-175
the	O	176-179
Schwartz	B	180-188
-	I	188-189
Jampel	I	189-195
syndrome	I	196-204
(	O	205-206
SJS	B	206-209
)	O	209-210
of	O	211-213
myotonia	B	214-222
and	O	223-226
skeletal	B	227-235
dysplasia	I	236-245
,	O	245-246
which	O	247-252
we	O	253-255
called	O	256-262
SJS	B	263-266
type	I	267-271
2	I	272-273
.	O	273-274
This	O	275-279
disorder	O	280-288
is	O	289-291
reminiscent	O	292-303
of	O	304-306
another	O	307-314
rare	O	315-319
condition	O	320-329
,	O	329-330
the	O	331-334
Stuve	B	335-340
-	I	340-341
Wiedemann	I	341-350
syndrome	I	351-359
(	O	360-361
SWS	B	361-364
)	O	364-365
,	O	365-366
which	O	367-372
comprises	O	373-382
campomelia	B	383-393
at	O	394-396
birth	O	397-402
with	O	403-407
skeletal	B	408-416
dysplasia	I	417-426
,	O	426-427
contractures	B	428-440
,	O	440-441
and	O	442-445
early	B	446-451
death	I	452-457
.	O	457-458

To	O	459-461
test	O	462-466
for	O	467-470
possible	O	471-479
nosologic	O	480-489
identity	O	490-498
between	O	499-506
these	O	507-512
disorders	O	513-522
,	O	522-523
we	O	524-526
reviewed	O	527-535
the	O	536-539
literature	O	540-550
and	O	551-554
obtained	O	555-563
a	O	564-565
follow	O	566-572
-	O	572-573
up	O	573-575
of	O	576-578
the	O	579-582
only	O	583-587
two	O	588-591
surviving	O	592-601
patients	O	602-610
,	O	610-611
one	O	612-615
with	O	616-620
SJS	B	621-624
type	I	625-629
2	I	630-631
at	O	632-634
age	O	635-638
10	O	639-641
years	O	642-647
and	O	648-651
another	O	652-659
with	O	660-664
SWS	B	665-668
at	O	669-671
age	O	672-675
7	O	676-677
years	O	678-683
.	O	683-684

Patients	O	685-693
reported	O	694-702
as	O	703-705
having	O	706-712
either	O	713-719
neonatal	O	720-728
SJS	B	729-732
or	O	733-735
SWS	B	736-739
presented	O	740-749
a	O	750-751
combination	O	752-763
of	O	764-766
a	O	767-768
severe	O	769-775
,	O	775-776
prenatal	O	777-785
-	O	785-786
onset	O	786-791
neuromuscular	B	792-805
disorder	I	806-814
(	O	815-816
with	O	816-820
congenital	B	821-831
joint	I	832-837
contractures	I	838-850
,	O	850-851
respiratory	O	852-863
and	O	864-867
feeding	O	868-875
difficulties	O	876-888
,	O	888-889
tendency	O	890-898
to	O	899-901
hyperthermia	B	902-914
,	O	914-915
and	O	916-919
frequent	O	920-928
death	O	929-934
in	O	935-937
infancy	O	938-945
)	O	945-946
with	O	947-951
a	O	952-953
distinct	O	954-962
campomelic	B	963-973
-	I	973-974
metaphyseal	I	974-985
skeletal	I	986-994
dysplasia	I	995-1004
.	O	1004-1005

The	O	1006-1009
similarity	O	1010-1020
of	O	1021-1023
the	O	1024-1027
clinical	O	1028-1036
and	O	1037-1040
radiographic	O	1041-1053
findings	O	1054-1062
is	O	1063-1065
so	O	1066-1068
extensive	O	1069-1078
that	O	1079-1083
these	O	1084-1089
disorders	O	1090-1099
appear	O	1100-1106
to	O	1107-1109
be	O	1110-1112
a	O	1113-1114
single	O	1115-1121
entity	O	1122-1128
.	O	1128-1129

The	O	1130-1133
follow	O	1134-1140
-	O	1140-1141
up	O	1141-1143
observation	O	1144-1155
of	O	1156-1158
an	O	1159-1161
identical	O	1162-1171
and	O	1172-1175
unique	O	1176-1182
pattern	O	1183-1190
of	O	1191-1193
progressive	O	1194-1205
bone	B	1206-1210
dysplasia	I	1211-1220
in	O	1221-1223
the	O	1224-1227
two	O	1228-1231
patients	O	1232-1240
(	O	1241-1242
one	O	1242-1245
with	O	1246-1250
SJS	B	1251-1254
type	I	1255-1259
2	I	1260-1261
,	O	1261-1262
one	O	1263-1266
with	O	1267-1271
SWS	B	1272-1275
)	O	1275-1276
surviving	O	1277-1286
beyond	O	1287-1293
infancy	O	1294-1301
adds	O	1302-1306
to	O	1307-1309
the	O	1310-1313
evidence	O	1314-1322
in	O	1323-1325
favor	O	1326-1331
of	O	1332-1334
identity	O	1335-1343
.	O	1343-1344

The	O	1345-1348
hypothesis	O	1349-1359
that	O	1360-1364
SWS	B	1365-1368
and	O	1369-1372
SJS	B	1373-1376
type	I	1377-1381
2	I	1382-1383
are	O	1384-1387
the	O	1388-1391
same	O	1392-1396
disorder	O	1397-1405
should	O	1406-1412
be	O	1413-1415
testable	O	1416-1424
by	O	1425-1427
molecular	O	1428-1437
methods	O	1438-1445
.	O	1445-1446
.	O	1445-1446

The	O	0-3
185delAG	O	4-12
BRCA1	O	13-18
mutation	O	19-27
originated	O	28-38
before	O	39-45
the	O	46-49
dispersion	O	50-60
of	O	61-63
Jews	O	64-68
in	O	69-71
the	O	72-75
diaspora	O	76-84
and	O	85-88
is	O	89-91
not	O	92-95
limited	O	96-103
to	O	104-106
Ashkenazim	O	107-117
.	O	117-118

The	O	119-122
185delAG	O	123-131
mutation	O	132-140
in	O	141-143
BRCA1	O	144-149
is	O	150-152
detected	O	153-161
in	O	162-164
Ashkenazi	O	165-174
Jews	O	175-179
both	O	180-184
in	O	185-187
familial	B	188-196
breast	I	197-203
and	I	204-207
ovarian	I	208-215
cancer	I	216-222
and	O	223-226
in	O	227-229
the	O	230-233
general	O	234-241
population	O	242-252
.	O	252-253

All	O	254-257
tested	O	258-264
Ashkenazi	O	265-274
mutation	O	275-283
carriers	O	284-292
share	O	293-298
the	O	299-302
same	O	303-307
allelic	O	308-315
pattern	O	316-323
at	O	324-326
the	O	327-330
BRCA1	O	331-336
locus	O	337-342
.	O	342-343

Our	O	344-347
previous	O	348-356
study	O	357-362
showed	O	363-369
that	O	370-374
this	O	375-379
Ashkenazi	O	380-389
mutation	O	390-398
also	O	399-403
occurs	O	404-410
in	O	411-413
Iraqi	O	414-419
Jews	O	420-424
with	O	425-429
a	O	430-431
similar	O	432-439
allelic	O	440-447
pattern	O	448-455
.	O	455-456

We	O	457-459
extended	O	460-468
our	O	469-472
analysis	O	473-481
to	O	482-484
other	O	485-490
non	O	491-494
-	O	494-495
Ashkenazi	O	495-504
subsets	O	505-512
354	O	514-517
of	O	518-520
Moroccan	O	521-529
origin	O	530-536
,	O	536-537
200	O	538-541
Yemenites	O	542-551
and	O	552-555
150	O	556-559
Iranian	O	560-567
Jews	O	568-572
.	O	572-573

Heteroduplex	O	574-586
analysis	O	587-595
complemented	O	596-608
by	O	609-611
direct	O	612-618
DNA	O	619-622
sequencing	O	623-633
of	O	634-636
abnormally	O	637-647
migrating	O	648-657
bands	O	658-663
were	O	664-668
employed	O	669-677
.	O	677-678

Four	O	679-683
of	O	684-686
Moroccan	O	687-695
origin	O	696-702
(	O	703-704
1	O	704-705
.	O	705-706

1	O	707-708
%	O	708-709
)	O	709-710
and	O	711-714
none	O	715-719
of	O	720-722
the	O	723-726
Yemenites	O	727-736
or	O	737-739
Iranians	O	740-748
was	O	749-752
a	O	753-754
carrier	O	755-762
of	O	763-765
the	O	766-769
185delAG	O	770-778
mutation	O	779-787
.	O	787-788

BRCA1	O	789-794
allelic	O	795-802
patterns	O	803-811
were	O	812-816
determined	O	817-827
for	O	828-831
four	O	832-836
of	O	837-839
these	O	840-845
individuals	O	846-857
and	O	858-861
for	O	862-865
12	O	866-868
additional	O	869-879
non	O	880-883
-	O	883-884
Ashkenazi	O	884-893
185delAG	O	894-902
mutation	O	903-911
carriers	O	912-920
who	O	921-924
had	O	925-928
breast	B	929-935
/	I	935-936
ovarian	I	936-943
cancer	I	944-950
.	O	950-951

Six	O	952-955
non	O	956-959
-	O	959-960
Ashkenazi	O	960-969
individuals	O	970-981
shared	O	982-988
the	O	989-992
common	O	993-999
Ashkenazi	O	1000-1009
haplotype	O	1010-1019
,	O	1019-1020
four	O	1021-1025
had	O	1026-1029
a	O	1030-1031
closely	O	1032-1039
related	O	1040-1047
pattern	O	1048-1055
,	O	1055-1056
and	O	1057-1060
the	O	1061-1064
rest	O	1065-1069
(	O	1070-1071
n	O	1071-1072
=	O	1073-1074
6	O	1075-1076
)	O	1076-1077
displayed	O	1078-1087
a	O	1088-1089
distinct	O	1090-1098
BRCA1	O	1099-1104
allelic	O	1105-1112
pattern	O	1113-1120
.	O	1120-1121

We	O	1122-1124
conclude	O	1125-1133
that	O	1134-1138
the	O	1139-1142
185delAG	O	1143-1151
BRCA1	O	1152-1157
mutation	O	1158-1166
occurs	O	1167-1173
in	O	1174-1176
some	O	1177-1181
non	O	1182-1185
-	O	1185-1186
Ashkenazi	O	1186-1195
populations	O	1196-1207
at	O	1208-1210
rates	O	1211-1216
comparable	O	1217-1227
with	O	1228-1232
that	O	1233-1237
of	O	1238-1240
Ashkenazim	O	1241-1251
.	O	1251-1252

The	O	1253-1256
majority	O	1257-1265
of	O	1266-1268
Jewish	O	1269-1275
185delAG	O	1276-1284
mutation	O	1285-1293
carriers	O	1294-1302
have	O	1303-1307
a	O	1308-1309
common	O	1310-1316
allelic	O	1317-1324
pattern	O	1325-1332
,	O	1332-1333
supporting	O	1334-1344
the	O	1345-1348
founder	O	1349-1356
effect	O	1357-1363
notion	O	1364-1370
,	O	1370-1371
but	O	1372-1375
dating	O	1376-1382
the	O	1383-1386
mutations	O	1387-1396
origin	O	1397-1403
to	O	1404-1406
an	O	1407-1409
earlier	O	1410-1417
date	O	1418-1422
than	O	1423-1427
currently	O	1428-1437
estimated	O	1438-1447
.	O	1447-1448

However	O	1449-1456
,	O	1456-1457
the	O	1458-1461
different	O	1462-1471
allelic	O	1472-1479
pattern	O	1480-1487
at	O	1488-1490
the	O	1491-1494
BRCA1	O	1495-1500
locus	O	1501-1506
even	O	1507-1511
in	O	1512-1514
some	O	1515-1519
Jewish	O	1520-1526
mutation	O	1527-1535
carriers	O	1536-1544
,	O	1544-1545
might	O	1546-1551
suggest	O	1552-1559
that	O	1560-1564
the	O	1565-1568
mutation	O	1569-1577
arose	O	1578-1583
independently	O	1584-1597
.	O	1597-1598
.	O	1597-1598

The	O	0-3
RB1	O	4-7
gene	O	8-12
mutation	O	13-21
in	O	22-24
a	O	25-26
child	O	27-32
with	O	33-37
ectopic	B	38-45
intracranial	I	46-58
retinoblastoma	I	59-73
.	O	73-74

The	O	75-78
RB1	O	79-82
gene	O	83-87
mutation	O	88-96
was	O	97-100
investigated	O	101-113
in	O	114-116
a	O	117-118
child	O	119-124
with	O	125-129
ectopic	B	130-137
intracranial	I	138-150
retinoblastoma	I	151-165
using	O	166-171
DNA	O	172-175
obtained	O	176-184
from	O	185-189
both	O	190-194
the	O	195-198
pineal	B	199-205
and	I	206-209
retinal	I	210-217
tumours	I	218-225
of	O	226-228
the	O	229-232
patient	O	233-240
.	O	240-241

A	O	242-243
nonsense	O	244-252
mutation	O	253-261
in	O	262-264
exon	O	265-269
17	O	270-272
(	O	273-274
codon	O	274-279
556	O	280-283
)	O	283-284
of	O	285-287
the	O	288-291
RB1	O	292-295
gene	O	296-300
was	O	301-304
found	O	305-310
to	O	311-313
be	O	314-316
present	O	317-324
homozygously	O	325-337
in	O	338-340
both	O	341-345
the	O	346-349
retinal	B	350-357
and	I	358-361
the	I	362-365
pineal	I	366-372
tumours	I	373-380
.	O	380-381

The	O	382-385
same	O	386-390
mutation	O	391-399
was	O	400-403
present	O	404-411
heterozygously	O	412-426
in	O	427-429
the	O	430-433
DNA	O	434-437
from	O	438-442
the	O	443-446
constitutional	O	447-461
cells	O	462-467
of	O	468-470
the	O	471-474
patient	O	475-482
,	O	482-483
proving	O	484-491
it	O	492-494
to	O	495-497
be	O	498-500
of	O	501-503
germline	O	504-512
origin	O	513-519
.	O	519-520

The	O	521-524
initial	O	525-532
mutation	O	533-541
was	O	542-545
shown	O	546-551
to	O	552-554
have	O	555-559
occurred	O	560-568
in	O	569-571
the	O	572-575
paternally	O	576-586
derived	O	587-594
RB1	O	595-598
allele	O	599-605
.	O	605-606

The	O	607-610
mutation	O	611-619
is	O	620-622
in	O	623-625
an	O	626-628
area	O	629-633
of	O	634-636
the	O	637-640
gene	O	641-645
that	O	646-650
encodes	O	651-658
the	O	659-662
protein	O	663-670
-	O	670-671
binding	O	671-678
region	O	679-685
known	O	686-691
as	O	692-694
the	O	695-698
pocket	O	699-705
region	O	706-712
and	O	713-716
has	O	717-720
been	O	721-725
detected	O	726-734
in	O	735-737
other	O	738-743
cases	O	744-749
of	O	750-752
retinoblastoma	B	753-767
.	O	767-768
.	O	767-768

Genomic	O	0-7
structure	O	8-17
of	O	18-20
the	O	21-24
human	O	25-30
congenital	B	31-41
chloride	I	42-50
diarrhea	I	51-59
(	O	60-61
CLD	B	61-64
)	O	64-65
gene	O	66-70
.	O	70-71

Congenital	B	72-82
chloride	I	83-91
diarrhea	I	92-100
(	O	101-102
CLD	B	102-105
)	O	105-106
is	O	107-109
caused	O	110-116
by	O	117-119
mutations	O	120-129
in	O	130-132
a	O	133-134
gene	O	135-139
which	O	140-145
encodes	O	146-153
an	O	154-156
intestinal	O	157-167
anion	O	168-173
transporter	O	174-185
.	O	185-186

We	O	187-189
report	O	190-196
here	O	197-201
the	O	202-205
complete	O	206-214
genomic	O	215-222
organization	O	223-235
of	O	236-238
the	O	239-242
human	O	243-248
CLD	B	249-252
gene	O	253-257
which	O	258-263
spans	O	264-269
approximately	O	270-283
39kb	O	284-288
,	O	288-289
and	O	290-293
comprises	O	294-303
21	O	304-306
exons	O	307-312
.	O	312-313

All	O	314-317
exon	O	318-322
/	O	322-323
intron	O	323-329
boundaries	O	330-340
conform	O	341-348
to	O	349-351
the	O	352-355
GT	O	356-358
/	O	358-359
AG	O	359-361
rule	O	362-366
.	O	366-367

An	O	368-370
analysis	O	371-379
of	O	380-382
the	O	383-386
putative	O	387-395
promoter	O	396-404
region	O	405-411
sequence	O	412-420
shows	O	421-426
a	O	427-428
putative	O	429-437
TATA	O	438-442
box	O	443-446
and	O	447-450
predicts	O	451-459
multiple	O	460-468
transcription	O	469-482
factor	O	483-489
binding	O	490-497
sites	O	498-503
.	O	503-504

The	O	505-508
genomic	O	509-516
structure	O	517-526
was	O	527-530
determined	O	531-541
using	O	542-547
DNA	O	548-551
from	O	552-556
several	O	557-564
sources	O	565-572
including	O	573-582
multiple	O	583-591
large	O	592-597
-	O	597-598
insert	O	598-604
libaries	O	605-613
and	O	614-617
genomic	O	618-625
DNA	O	626-629
from	O	630-634
Finnish	O	635-642
CLD	B	643-646
patients	O	647-655
and	O	656-659
controls	O	660-668
.	O	668-669

Exon	O	670-674
-	O	674-675
specific	O	675-683
primers	O	684-691
developed	O	692-701
in	O	702-704
this	O	705-709
study	O	710-715
will	O	716-720
facilitate	O	721-731
mutation	O	732-740
screening	O	741-750
studies	O	751-758
of	O	759-761
patients	O	762-770
with	O	771-775
the	O	776-779
disease	O	780-787
.	O	787-788

Genomic	O	789-796
sequencing	O	797-807
of	O	808-810
a	O	811-812
BAC	O	813-816
clone	O	817-822
H	O	823-824
_	O	824-825
RG364P16	O	825-833
revealed	O	834-842
the	O	843-846
presence	O	847-855
of	O	856-858
another	O	859-866
,	O	866-867
highly	O	868-874
homologous	O	875-885
gene	O	886-890
3	O	891-892
of	O	893-895
the	O	896-899
CLD	B	900-903
gene	O	904-908
,	O	908-909
with	O	910-914
a	O	915-916
similar	O	917-924
genomic	O	925-932
structure	O	933-942
,	O	942-943
recently	O	944-952
identified	O	953-963
as	O	964-966
the	O	967-970
Pendred	B	971-978
syndrome	I	979-987
gene	O	988-992
(	O	993-994
PDS	B	994-997
)	O	997-998
.	O	998-999
.	O	998-999

Mutation	O	0-8
analysis	O	9-17
of	O	18-20
UBE3A	O	21-26
in	O	27-29
Angelman	B	30-38
syndrome	I	39-47
patients	O	48-56
.	O	56-57

Angelman	B	58-66
syndrome	I	67-75
(	O	76-77
AS	B	77-79
)	O	79-80
is	O	81-83
caused	O	84-90
by	O	91-93
chromosome	O	94-104
15q11	O	105-110
-	O	110-111
q13	O	111-114
deletions	O	115-124
of	O	125-127
maternal	O	128-136
origin	O	137-143
,	O	143-144
by	O	145-147
paternal	O	148-156
uniparental	B	157-168
disomy	I	169-175
(	O	176-177
UPD	B	177-180
)	O	180-181
15	O	182-184
,	O	184-185
by	O	186-188
imprinting	O	189-199
defects	O	200-207
,	O	207-208
and	O	209-212
by	O	213-215
mutations	O	216-225
in	O	226-228
the	O	229-232
UBE3A	O	233-238
gene	O	239-243
.	O	243-244

UBE3A	O	245-250
encodes	O	251-258
a	O	259-260
ubiquitin	O	261-270
-	O	270-271
protein	O	271-278
ligase	O	279-285
and	O	286-289
shows	O	290-295
brain	O	296-301
-	O	301-302
specific	O	302-310
imprinting	O	311-321
.	O	321-322

Here	O	323-327
we	O	328-330
describe	O	331-339
UBE3A	O	340-345
coding	O	346-352
-	O	352-353
region	O	353-359
mutations	O	360-369
detected	O	370-378
by	O	379-381
SSCP	O	382-386
analysis	O	387-395
in	O	396-398
13	O	399-401
AS	B	402-404
individuals	O	405-416
or	O	417-419
families	O	420-428
.	O	428-429

Two	O	430-433
identical	O	434-443
de	O	444-446
novo	O	447-451
5	O	452-453
-	O	453-454
bp	O	454-456
duplications	O	457-469
in	O	470-472
exon	O	473-477
16	O	478-480
were	O	481-485
found	O	486-491
.	O	491-492

Among	O	493-498
the	O	499-502
other	O	503-508
11	O	509-511
unique	O	512-518
mutations	O	519-528
,	O	528-529
8	O	530-531
were	O	532-536
small	O	537-542
deletions	O	543-552
or	O	553-555
insertions	O	556-566
predicted	O	567-576
to	O	577-579
cause	O	580-585
frameshifts	O	586-597
,	O	597-598
1	O	599-600
was	O	601-604
a	O	605-606
mutation	O	607-615
to	O	616-618
a	O	619-620
stop	O	621-625
codon	O	626-631
,	O	631-632
1	O	633-634
was	O	635-638
a	O	639-640
missense	O	641-649
mutation	O	650-658
,	O	658-659
and	O	660-663
1	O	664-665
was	O	666-669
predicted	O	670-679
to	O	680-682
cause	O	683-688
insertion	O	689-698
of	O	699-701
an	O	702-704
isoleucine	O	705-715
in	O	716-718
the	O	719-722
hect	O	723-727
domain	O	728-734
of	O	735-737
the	O	738-741
UBE3A	O	742-747
protein	O	748-755
,	O	755-756
which	O	757-762
functions	O	763-772
in	O	773-775
E2	O	776-778
binding	O	779-786
and	O	787-790
ubiquitin	O	791-800
transfer	O	801-809
.	O	809-810

Eight	O	811-816
of	O	817-819
the	O	820-823
cases	O	824-829
were	O	830-834
familial	O	835-843
,	O	843-844
and	O	845-848
five	O	849-853
were	O	854-858
sporadic	O	859-867
.	O	867-868

In	O	869-871
two	O	872-875
familial	O	876-884
cases	O	885-890
and	O	891-894
one	O	895-898
sporadic	O	899-907
case	O	908-912
,	O	912-913
mosaicism	O	914-923
for	O	924-927
UBE3A	O	928-933
mutations	O	934-943
was	O	944-947
detected	O	948-956
in	O	958-960
the	O	961-964
mother	O	965-971
of	O	972-974
three	O	975-980
AS	B	981-983
sons	O	984-988
,	O	988-989
in	O	990-992
the	O	993-996
maternal	O	997-1005
grandfather	O	1006-1017
of	O	1018-1020
two	O	1021-1024
AS	B	1025-1027
first	O	1028-1033
cousins	O	1034-1041
,	O	1041-1042
and	O	1043-1046
in	O	1047-1049
the	O	1050-1053
mother	O	1054-1060
of	O	1061-1063
an	O	1064-1066
AS	B	1067-1069
daughter	O	1070-1078
.	O	1078-1079

The	O	1080-1083
frequencies	O	1084-1095
with	O	1096-1100
which	O	1101-1106
we	O	1107-1109
detected	O	1110-1118
mutations	O	1119-1128
were	O	1129-1133
5	O	1134-1135
(	O	1136-1137
14	O	1137-1139
%	O	1139-1140
)	O	1140-1141
of	O	1142-1144
35	O	1145-1147
in	O	1148-1150
sporadic	O	1151-1159
cases	O	1160-1165
and	O	1166-1169
8	O	1170-1171
(	O	1172-1173
80	O	1173-1175
%	O	1175-1176
)	O	1176-1177
of	O	1178-1180
10	O	1181-1183
in	O	1184-1186
familial	O	1187-1195
cases	O	1196-1201
.	O	1201-1202
.	O	1201-1202

Autosomal	B	0-9
dominant	I	10-18
neurohypophyseal	I	19-35
diabetes	I	36-44
insipidus	I	45-54
associated	O	55-65
with	O	66-70
a	O	71-72
missense	O	73-81
mutation	O	82-90
encoding	O	91-99
Gly23	O	100-105
-	O	105-106
-	O	105-106
>	O	107-108
Val	O	108-111
in	O	112-114
neurophysin	O	115-126
II	O	127-129
.	O	129-130

Autosomal	B	131-140
dominant	I	141-149
neurohypophyseal	I	150-166
diabetes	I	167-175
insipidus	I	176-185
(	O	186-187
ADNDI	B	187-192
)	O	192-193
is	O	194-196
an	O	197-199
inherited	B	200-209
disease	I	210-217
caused	O	218-224
by	O	225-227
progressive	O	228-239
degeneration	O	240-252
of	O	253-255
the	O	256-259
magnocellular	O	260-273
neurons	O	274-281
of	O	282-284
the	O	285-288
hypothalamus	O	289-301
leading	O	302-309
to	O	310-312
decreased	O	313-322
ability	O	323-330
to	O	331-333
produce	O	334-341
the	O	342-345
hormone	O	346-353
arginine	O	354-362
vasopressin	O	363-374
(	O	375-376
AVP	O	376-379
)	O	379-380
.	O	380-381

Affected	O	382-390
individuals	O	391-402
are	O	403-406
not	O	407-410
symptomatic	O	411-422
at	O	423-425
birth	O	426-431
,	O	431-432
but	O	433-436
usually	O	437-444
develop	O	445-452
diabetes	B	453-461
insipidus	I	462-471
at	O	472-474
1	O	475-476
-	O	476-477
6	O	477-478
yr	O	479-481
of	O	482-484
age	O	485-488
.	O	488-489

The	O	490-493
genetic	O	494-501
locus	O	502-507
of	O	508-510
the	O	511-514
disease	O	515-522
is	O	523-525
the	O	526-529
AVP	O	530-533
-	O	533-534
neurophysin	O	534-545
II	O	546-548
(	O	549-550
NPII	O	550-554
)	O	554-555
gene	O	556-560
,	O	560-561
and	O	562-565
mutations	O	566-575
that	O	576-580
cause	O	581-586
ADNDI	B	587-592
have	O	593-597
been	O	598-602
found	O	603-608
in	O	609-611
both	O	612-616
the	O	617-620
signal	O	621-627
peptide	O	628-635
of	O	636-638
the	O	639-642
prepro	O	643-649
-	O	649-650
AVP	O	650-653
-	O	649-650
NPII	O	654-658
precursor	O	659-668
and	O	669-672
within	O	673-679
NPII	O	680-684
itself	O	685-691
.	O	691-692

An	O	693-695
affected	O	696-704
girl	O	705-709
who	O	710-713
presented	O	714-723
at	O	724-726
9	O	727-728
months	O	729-735
of	O	736-738
age	O	739-742
and	O	743-746
her	O	747-750
similarly	O	751-760
affected	O	761-769
younger	O	770-777
brother	O	778-785
and	O	786-789
father	O	790-796
were	O	797-801
all	O	802-805
found	O	806-811
to	O	812-814
have	O	815-819
a	O	820-821
novel	O	822-827
missense	O	828-836
mutation	O	837-845
(	O	846-847
G1758	O	847-852
-	O	852-853
-	O	852-853
>	O	855-856
T	O	857-858
)	O	858-859
encoding	O	860-868
the	O	869-872
amino	O	873-878
acid	O	879-883
substitution	O	884-896
Gly23	O	897-902
-	O	902-903
-	O	902-903
>	O	905-906
Val	O	907-910
within	O	911-917
NPII	O	918-922
.	O	922-923

The	O	924-927
mutation	O	928-936
was	O	937-940
confirmed	O	941-950
by	O	951-953
restriction	O	954-965
endonuclease	O	966-978
analysis	O	979-987
.	O	987-988

A	O	989-990
T1	O	991-993
-	O	993-994
weighted	O	994-1002
magnetic	O	1003-1011
resonance	O	1012-1021
imaging	O	1022-1029
of	O	1030-1032
the	O	1033-1036
fathers	O	1037-1044
pituitary	O	1045-1054
gland	O	1055-1060
demonstrates	O	1061-1073
an	O	1074-1076
attenuated	O	1077-1087
posterior	O	1088-1097
pituitary	O	1098-1107
bright	O	1108-1114
spot	O	1115-1119
.	O	1119-1120

This	O	1121-1125
mutation	O	1126-1134
may	O	1135-1138
be	O	1139-1141
valuable	O	1142-1150
for	O	1151-1154
developing	O	1155-1165
models	O	1166-1172
of	O	1173-1175
dominantly	B	1176-1186
inherited	I	1187-1196
neurodegeneration	I	1197-1214
,	O	1214-1215
as	O	1216-1218
the	O	1219-1222
early	O	1223-1228
age	O	1229-1232
of	O	1233-1235
onset	O	1236-1241
of	O	1242-1244
symptoms	O	1245-1253
suggests	O	1254-1262
that	O	1263-1267
this	O	1268-1272
mutation	O	1273-1281
may	O	1282-1285
be	O	1286-1288
particularly	O	1289-1301
deleterious	O	1302-1313
to	O	1314-1316
the	O	1317-1320
magnocellular	O	1321-1334
neuron	O	1335-1341
.	O	1341-1342
.	O	1341-1342

Reversal	O	0-8
of	O	9-11
severe	O	12-18
hypertrophic	B	19-31
cardiomyopathy	I	32-46
and	O	47-50
excellent	O	51-60
neuropsychologic	O	61-77
outcome	O	78-85
in	O	86-88
very	B	89-93
-	I	93-94
long	I	94-98
-	I	93-94
chain	I	99-104
acyl	I	105-109
-	I	109-110
coenzyme	I	110-118
A	I	119-120
dehydrogenase	I	121-134
deficiency	I	135-145
.	O	145-146

Very	B	147-151
-	I	151-152
long	I	152-156
-	I	151-152
chain	I	157-162
acyl	I	163-167
-	I	167-168
coenzyme	I	168-176
A	I	177-178
dehydrogenase	I	179-192
(	I	193-194
VLCAD	I	194-199
)	I	199-200
deficiency	I	201-211
is	O	212-214
a	O	215-216
disorder	O	217-225
of	O	226-228
fatty	O	229-234
acid	O	235-239
beta	O	240-244
oxidation	O	245-254
that	O	255-259
reportedly	O	260-270
has	O	271-274
high	O	275-279
rates	O	280-285
of	O	286-288
morbidity	O	289-298
and	O	299-302
mortality	O	303-312
.	O	312-313

We	O	314-316
describe	O	317-325
the	O	326-329
outcome	O	330-337
of	O	338-340
a	O	341-342
5	O	343-344
-	O	344-345
year	O	345-349
-	O	344-345
old	O	350-353
girl	O	354-358
with	O	359-363
VLCAD	B	364-369
deficiency	I	370-380
who	O	381-384
was	O	385-388
first	O	389-394
seen	O	395-399
at	O	400-402
5	O	403-404
months	O	405-411
of	O	412-414
age	O	415-418
with	O	419-423
severe	O	424-430
hypertrophic	B	431-443
cardiomyopathy	I	444-458
,	O	458-459
hepatomegaly	B	460-472
,	O	472-473
encephalopathy	B	474-488
,	O	488-489
and	O	490-493
hypotonia	B	494-503
.	O	503-504

Biochemical	O	505-516
studies	O	517-524
indicated	O	525-534
VLCAD	B	535-540
deficiency	I	541-551
caused	O	552-558
by	O	559-561
a	O	562-563
stable	O	564-570
yet	O	571-574
inactive	O	575-583
enzyme	O	584-590
.	O	590-591

Molecular	O	592-601
genetic	O	602-609
analysis	O	610-618
of	O	619-621
her	O	622-625
VLCAD	O	626-631
gene	O	632-636
revealed	O	637-645
a	O	646-647
T1372C	O	648-654
(	O	655-656
F458L	O	656-661
)	O	661-662
missense	O	663-671
mutation	O	672-680
and	O	681-684
a	O	685-686
1668	O	687-691
ACAG	O	692-696
1669	O	697-701
splice	O	702-708
site	O	709-713
mutation	O	714-722
.	O	722-723

After	O	724-729
initial	O	730-737
treatment	O	738-747
with	O	748-752
intravenous	O	753-764
glucose	O	765-772
and	O	773-776
carnitine	O	777-786
,	O	786-787
the	O	788-791
patient	O	792-799
has	O	800-803
thrived	O	804-811
on	O	812-814
a	O	815-816
low	O	817-820
-	O	820-821
fat	O	821-824
diet	O	825-829
supplemented	O	830-842
with	O	843-847
medium	O	848-854
-	O	854-855
chain	O	855-860
triglyceride	O	861-873
oil	O	874-877
and	O	878-881
carnitine	O	882-891
and	O	892-895
avoidance	O	896-905
of	O	906-908
fasting	O	909-916
.	O	916-917

Her	O	918-921
ventricular	O	922-933
hypertrophy	O	934-945
resolved	O	946-954
significantly	O	955-968
over	O	969-973
1	O	974-975
year	O	976-980
,	O	980-981
and	O	982-985
cognitively	O	986-997
,	O	997-998
she	O	999-1002
is	O	1003-1005
in	O	1006-1008
the	O	1009-1012
superior	O	1013-1021
range	O	1022-1027
for	O	1028-1031
age	O	1032-1035
.	O	1035-1036

Clinical	O	1037-1045
recognition	O	1046-1057
of	O	1058-1060
VLCAD	B	1061-1066
deficiency	I	1067-1077
is	O	1078-1080
important	O	1081-1090
because	O	1091-1098
it	O	1099-1101
is	O	1102-1104
one	O	1105-1108
of	O	1109-1111
the	O	1112-1115
few	O	1116-1119
directly	O	1120-1128
treatable	O	1129-1138
causes	O	1139-1145
of	O	1146-1148
cardiomyopathy	B	1149-1163
in	O	1164-1166
children	O	1167-1175
.	O	1175-1176
.	O	1175-1176

Mutations	O	0-9
of	O	10-12
the	O	13-16
ATM	O	17-20
gene	O	21-25
detected	O	26-34
in	O	35-37
Japanese	O	38-46
ataxia	B	47-53
-	I	53-54
telangiectasia	I	54-68
patients	O	69-77
:	O	77-78
possible	O	79-87
preponderance	O	88-101
of	O	102-104
the	O	105-108
two	O	109-112
founder	O	113-120
mutations	O	121-130
4612del165	O	131-141
and	O	142-145
7883del5	O	146-154
.	O	154-155

The	O	156-159
ATM	O	160-163
(	O	164-165
A	O	165-166
-	O	166-167
T	O	167-168
,	O	168-169
mutated	O	170-177
)	O	177-178
gene	O	179-183
on	O	184-186
human	O	187-192
chromosome	O	193-203
11q22	O	204-209
.	O	209-210

3	O	211-212
has	O	213-216
recently	O	217-225
been	O	226-230
identified	O	231-241
as	O	242-244
the	O	245-248
gene	O	249-253
responsible	O	254-265
for	O	266-269
the	O	270-273
human	O	274-279
recessive	B	280-289
disease	I	290-297
ataxia	B	298-304
-	I	304-305
telangiectasia	I	305-319
(	O	320-321
A	B	321-322
-	I	322-323
T	I	323-324
)	O	324-325
.	O	325-326

In	O	327-329
order	O	330-335
to	O	336-338
define	O	339-345
the	O	346-349
types	O	350-355
of	O	356-358
disease	O	359-366
-	O	366-367
causing	O	367-374
ATM	O	375-378
mutations	O	379-388
in	O	389-391
Japanese	O	392-400
A	B	401-402
-	I	402-403
T	I	403-404
patients	O	405-413
as	O	414-416
well	O	417-421
as	O	422-424
to	O	425-427
look	O	428-432
for	O	433-436
possible	O	437-445
mutational	O	446-456
hotspots	O	457-465
,	O	465-466
reverse	O	467-474
-	O	474-475
transcribed	O	475-486
RNA	O	487-490
derived	O	491-498
from	O	499-503
ten	O	504-507
patients	O	508-516
belonging	O	517-526
to	O	527-529
eight	O	530-535
unrelated	O	536-545
Japanese	O	546-554
A	B	555-556
-	I	556-557
T	I	557-558
families	O	559-567
was	O	568-571
analyzed	O	572-580
for	O	581-584
mutations	O	585-594
by	O	595-597
the	O	598-601
restriction	O	602-613
endonuclease	O	614-626
fingerprinting	O	627-641
method	O	642-648
.	O	648-649

As	O	650-652
has	O	653-656
been	O	657-661
reported	O	662-670
by	O	671-673
others	O	674-680
,	O	680-681
mutations	O	682-691
that	O	692-696
lead	O	697-701
to	O	702-704
exon	O	705-709
skipping	O	710-718
or	O	719-721
premature	O	722-731
protein	O	732-739
truncation	O	740-750
were	O	751-755
also	O	756-760
predominant	O	761-772
in	O	773-775
our	O	776-779
mutants	O	780-787
.	O	787-788

Six	O	789-792
different	O	793-802
mutations	O	803-812
were	O	813-817
identified	O	818-828
on	O	829-831
12	O	832-834
of	O	835-837
the	O	838-841
16	O	842-844
alleles	O	845-852
examined	O	853-861
.	O	861-862

Four	O	863-867
were	O	868-872
deletions	O	873-882
involving	O	883-892
a	O	893-894
loss	O	895-899
of	O	900-902
a	O	903-904
single	O	905-911
exon	O	912-916
exon	O	918-922
7	O	923-924
,	O	924-925
exon	O	926-930
16	O	931-933
,	O	933-934
exon	O	935-939
33	O	940-942
or	O	943-945
exon	O	946-950
35	O	951-953
.	O	953-954

The	O	955-958
others	O	959-965
were	O	966-970
minute	O	971-977
deletions	O	978-987
,	O	987-988
4649delA	O	989-997
in	O	998-1000
exon	O	1001-1005
33	O	1006-1008
and	O	1009-1012
7883del5	O	1013-1021
in	O	1022-1024
exon	O	1025-1029
55	O	1030-1032
.	O	1032-1033

The	O	1034-1037
mutations	O	1038-1047
4612del165	O	1048-1058
and	O	1059-1062
7883del5	O	1063-1071
were	O	1072-1076
found	O	1077-1082
in	O	1083-1085
more	O	1086-1090
than	O	1091-1095
two	O	1096-1099
unrelated	O	1100-1109
families	O	1110-1118
;	O	1118-1119
44	O	1120-1122
%	O	1122-1123
(	O	1124-1125
7	O	1125-1126
of	O	1127-1129
16	O	1130-1132
)	O	1132-1133
of	O	1134-1136
the	O	1137-1140
mutant	O	1141-1147
alleles	O	1148-1155
had	O	1156-1159
one	O	1160-1163
of	O	1164-1166
the	O	1167-1170
two	O	1171-1174
mutations	O	1175-1184
.	O	1184-1185

The	O	1186-1189
4612del165	O	1190-1200
mutations	O	1201-1210
in	O	1211-1213
three	O	1214-1219
different	O	1220-1229
families	O	1230-1238
were	O	1239-1243
all	O	1244-1247
ascribed	O	1248-1256
to	O	1257-1259
the	O	1260-1263
same	O	1264-1268
T	O	1269-1270
-	O	1270-1271
-	O	1270-1271
>	O	1273-1274
A	O	1275-1276
substitution	O	1277-1289
at	O	1290-1292
the	O	1293-1296
splice	O	1297-1303
donor	O	1304-1309
site	O	1310-1314
in	O	1315-1317
intron	O	1318-1324
33	O	1325-1327
.	O	1327-1328

Microsatellite	O	1329-1343
genotyping	O	1344-1354
around	O	1355-1361
the	O	1362-1365
ATM	O	1366-1369
locus	O	1370-1375
also	O	1376-1380
indicated	O	1381-1390
that	O	1391-1395
a	O	1396-1397
common	O	1398-1404
haplotype	O	1405-1414
was	O	1415-1418
shared	O	1419-1425
by	O	1426-1428
the	O	1429-1432
mutant	O	1433-1439
alleles	O	1440-1447
in	O	1448-1450
both	O	1451-1455
mutations	O	1456-1465
.	O	1465-1466

This	O	1467-1471
suggests	O	1472-1480
that	O	1481-1485
these	O	1486-1491
two	O	1492-1495
founder	O	1496-1503
mutations	O	1504-1513
may	O	1514-1517
be	O	1518-1520
predominant	O	1521-1532
among	O	1533-1538
Japanese	O	1539-1547
ATM	O	1548-1551
mutant	O	1552-1558
alleles	O	1559-1566
.	O	1566-1567

Down	O	0-4
-	O	4-5
regulation	O	5-15
of	O	16-18
transmembrane	O	19-32
carbonic	O	33-41
anhydrases	O	42-52
in	O	53-55
renal	B	56-61
cell	I	62-66
carcinoma	I	67-76
cell	O	77-81
lines	O	82-87
by	O	88-90
wild	O	91-95
-	O	95-96
type	O	96-100
von	B	101-104
Hippel	I	105-111
-	I	111-112
Lindau	I	112-118
transgenes	O	119-129
.	O	129-130

To	O	131-133
discover	O	134-142
genes	O	143-148
involved	O	149-157
in	O	158-160
von	B	161-164
Hippel	I	165-171
-	I	171-172
Lindau	I	172-178
(	O	179-180
VHL	B	180-183
)	O	183-184
-	O	185-186
mediated	O	186-194
carcinogenesis	O	195-209
,	O	209-210
we	O	211-213
used	O	214-218
renal	B	219-224
cell	I	225-229
carcinoma	I	230-239
cell	O	240-244
lines	O	245-250
stably	O	251-257
transfected	O	258-269
with	O	270-274
wild	O	275-279
-	O	279-280
type	O	280-284
VHL	O	285-288
-	O	288-289
expressing	O	289-299
transgenes	O	300-310
.	O	310-311

Large	O	312-317
-	O	317-318
scale	O	318-323
RNA	O	324-327
differential	O	328-340
display	O	341-348
technology	O	349-359
applied	O	360-367
to	O	368-370
these	O	371-376
cell	O	377-381
lines	O	382-387
identified	O	388-398
several	O	399-406
differentially	O	407-421
expressed	O	422-431
genes	O	432-437
,	O	437-438
including	O	439-448
an	O	449-451
alpha	O	452-457
carbonic	O	458-466
anhydrase	O	467-476
gene	O	477-481
,	O	481-482
termed	O	483-489
CA12	O	490-494
.	O	494-495

The	O	496-499
deduced	O	500-507
protein	O	508-515
sequence	O	516-524
was	O	525-528
classified	O	529-539
as	O	540-542
a	O	543-544
one	O	545-548
-	O	548-549
pass	O	549-553
transmembrane	O	554-567
CA	O	568-570
possessing	O	571-581
an	O	582-584
apparently	O	585-595
intact	O	596-602
catalytic	O	603-612
domain	O	613-619
in	O	620-622
the	O	623-626
extracellular	O	627-640
CA	O	641-643
module	O	644-650
.	O	650-651

Reintroduced	O	652-664
wild	O	665-669
-	O	669-670
type	O	670-674
VHL	B	675-678
strongly	O	679-687
inhibited	O	688-697
the	O	698-701
overexpression	O	702-716
of	O	717-719
the	O	720-723
CA12	O	724-728
gene	O	729-733
in	O	734-736
the	O	737-740
parental	O	741-749
renal	B	750-755
cell	I	756-760
carcinoma	I	761-770
cell	O	771-775
lines	O	776-781
.	O	781-782

Similar	O	783-790
results	O	791-798
were	O	799-803
obtained	O	804-812
with	O	813-817
CA9	O	818-821
,	O	821-822
encoding	O	823-831
another	O	832-839
transmembrane	O	840-853
CA	O	854-856
with	O	857-861
an	O	862-864
intact	O	865-871
catalytic	O	872-881
domain	O	882-888
.	O	888-889

Although	O	890-898
both	O	899-903
domains	O	904-911
of	O	912-914
the	O	915-918
VHL	B	919-922
protein	O	923-930
contribute	O	931-941
to	O	942-944
regulation	O	945-955
of	O	956-958
CA12	O	959-963
expression	O	964-974
,	O	974-975
the	O	976-979
elongin	O	980-987
binding	O	988-995
domain	O	996-1002
alone	O	1003-1008
could	O	1009-1014
effectively	O	1015-1026
regulate	O	1027-1035
CA9	O	1036-1039
expression	O	1040-1050
.	O	1050-1051

We	O	1052-1054
mapped	O	1055-1061
CA12	O	1062-1066
and	O	1067-1070
CA9	O	1071-1074
loci	O	1075-1079
to	O	1080-1082
chromosome	O	1083-1093
bands	O	1094-1099
15q22	O	1100-1105
and	O	1106-1109
17q21	O	1110-1115
.	O	1115-1116
2	O	1117-1118
respectively	O	1119-1131
,	O	1131-1132
regions	O	1133-1140
prone	O	1141-1146
to	O	1147-1149
amplification	O	1150-1163
in	O	1164-1166
some	O	1167-1171
human	O	1172-1177
cancers	B	1178-1185
.	O	1185-1186

Additional	O	1187-1197
experiments	O	1198-1209
are	O	1210-1213
needed	O	1214-1220
to	O	1221-1223
define	O	1224-1230
the	O	1231-1234
role	O	1235-1239
of	O	1240-1242
CA	O	1243-1245
IX	O	1246-1248
and	O	1249-1252
CA	O	1253-1255
XII	O	1256-1259
enzymes	O	1260-1267
in	O	1268-1270
the	O	1271-1274
regulation	O	1275-1285
of	O	1286-1288
pH	O	1289-1291
in	O	1292-1294
the	O	1295-1298
extracellular	O	1299-1312
microenvironment	O	1313-1329
and	O	1330-1333
its	O	1334-1337
potential	O	1338-1347
impact	O	1348-1354
on	O	1355-1357
cancer	B	1358-1364
cell	O	1365-1369
growth	O	1370-1376
.	O	1376-1377

A	O	0-1
novel	O	2-7
common	O	8-14
missense	O	15-23
mutation	O	24-32
G301C	O	33-38
in	O	39-41
the	O	42-45
N	O	46-47
-	O	47-48
acetylgalactosamine	O	48-67
-	O	47-48
6	O	68-69
-	O	47-48
sulfate	O	70-77
sulfatase	O	78-87
gene	O	88-92
in	O	93-95
mucopolysaccharidosis	B	96-117
IVA	I	118-121
.	O	121-122

Mucopolysaccharidosis	B	123-144
IVA	I	145-148
(	O	149-150
MPS	B	150-153
IVA	I	154-157
)	O	157-158
is	O	159-161
an	O	162-164
autosomal	B	165-174
recessive	I	175-184
lysosomal	I	185-194
storage	I	195-202
disorder	I	203-211
caused	O	212-218
by	O	219-221
a	O	222-223
genetic	B	224-231
defect	I	232-238
in	O	239-241
N	O	242-243
-	O	243-244
acetylgalactosamine	O	244-263
-	O	243-244
6	O	264-265
-	O	243-244
sulfate	O	266-273
sulfatase	O	274-283
(	O	284-285
GALNS	O	285-290
)	O	290-291
.	O	291-292

In	O	293-295
previous	O	296-304
studies	O	305-312
,	O	312-313
we	O	314-316
have	O	317-321
found	O	322-327
two	O	328-331
common	O	332-338
mutations	O	339-348
in	O	349-351
Caucasians	O	352-362
and	O	363-366
Japanese	O	367-375
,	O	375-376
respectively	O	377-389
.	O	389-390

To	O	391-393
characterize	O	394-406
the	O	407-410
mutational	O	411-421
spectrum	O	422-430
in	O	431-433
various	O	434-441
ethnic	O	442-448
groups	O	449-455
,	O	455-456
mutations	O	457-466
in	O	467-469
the	O	470-473
GALNS	O	474-479
gene	O	480-484
in	O	485-487
Colombian	O	488-497
MPS	B	498-501
IVA	I	502-505
patients	O	506-514
were	O	515-519
investigated	O	520-532
,	O	532-533
and	O	534-537
genetic	O	538-545
backgrounds	O	546-557
were	O	558-562
extensively	O	563-574
analyzed	O	575-583
to	O	584-586
identify	O	587-595
racial	O	596-602
origin	O	603-609
,	O	609-610
based	O	611-616
on	O	617-619
mitochondrial	O	620-633
DNA	O	634-637
(	O	638-639
mtDNA	O	639-644
)	O	644-645
lineages	O	646-654
.	O	654-655

Three	O	656-661
novel	O	662-667
missense	O	668-676
mutations	O	677-686
never	O	687-692
identified	O	693-703
previously	O	704-714
in	O	715-717
other	O	718-723
populations	O	724-735
and	O	736-739
found	O	740-745
in	O	746-748
16	O	749-751
out	O	752-755
of	O	756-758
19	O	759-761
Colombian	O	762-771
MPS	B	772-775
IVA	I	776-779
unrelated	O	780-789
alleles	O	790-797
account	O	798-805
for	O	806-809
84	O	810-812
.	O	812-813

2	O	814-815
%	O	815-816
of	O	817-819
the	O	820-823
alleles	O	824-831
in	O	832-834
this	O	835-839
study	O	840-845
.	O	845-846

The	O	847-850
G301C	O	851-856
and	O	857-860
S162F	O	861-866
mutations	O	867-876
account	O	877-884
for	O	885-888
68	O	889-891
.	O	891-892

4	O	893-894
%	O	894-895
and	O	896-899
10	O	900-902
.	O	902-903
5	O	904-905
%	O	905-906
of	O	907-909
mutations	O	910-919
,	O	919-920
respectively	O	921-933
,	O	933-934
whereas	O	935-942
the	O	943-946
remaining	O	947-956
F69V	O	957-961
is	O	962-964
limited	O	965-972
to	O	973-975
a	O	976-977
single	O	978-984
allele	O	985-991
.	O	991-992

The	O	993-996
skewed	O	997-1003
prevalence	O	1004-1014
of	O	1015-1017
G301C	O	1018-1023
in	O	1024-1026
only	O	1027-1031
Colombian	O	1032-1041
patients	O	1042-1050
and	O	1051-1054
haplotype	O	1055-1064
analysis	O	1065-1073
by	O	1074-1076
restriction	O	1077-1088
fragment	O	1089-1097
length	O	1098-1104
polymorphisms	O	1105-1118
in	O	1119-1121
the	O	1122-1125
GALNS	O	1126-1131
gene	O	1132-1136
suggest	O	1137-1144
that	O	1145-1149
G301C	O	1150-1155
originated	O	1156-1166
from	O	1167-1171
a	O	1172-1173
common	O	1174-1180
ancestor	O	1181-1189
.	O	1189-1190

Investigation	O	1191-1204
of	O	1205-1207
the	O	1208-1211
genetic	O	1212-1219
background	O	1220-1230
by	O	1231-1233
means	O	1234-1239
of	O	1240-1242
mtDNA	O	1243-1248
lineages	O	1249-1257
indicate	O	1258-1266
that	O	1267-1271
all	O	1272-1275
our	O	1276-1279
patients	O	1280-1288
are	O	1289-1292
probably	O	1293-1301
of	O	1302-1304
native	O	1305-1311
American	O	1312-1320
descent	O	1321-1328

W474C	O	0-5
amino	O	6-11
acid	O	12-16
substitution	O	17-29
affects	O	30-37
early	O	38-43
processing	O	44-54
of	O	55-57
the	O	58-61
alpha	O	62-67
-	O	67-68
subunit	O	68-75
of	O	76-78
beta	O	79-83
-	O	83-84
hexosaminidase	O	84-98
A	O	99-100
and	O	101-104
is	O	105-107
associated	O	108-118
with	O	119-123
subacute	O	124-132
G	B	133-134
(	I	134-135
M2	I	135-137
)	I	137-138
gangliosidosis	I	139-153
.	O	153-154

Mutations	O	155-164
in	O	165-167
the	O	168-171
HEXA	O	172-176
gene	O	177-181
,	O	181-182
encoding	O	183-191
the	O	192-195
alpha	O	196-201
-	O	201-202
subunit	O	202-209
of	O	210-212
beta	O	213-217
-	O	217-218
hexosaminidase	O	218-232
A	O	233-234
(	O	235-236
Hex	O	236-239
A	O	240-241
)	O	241-242
,	O	242-243
that	O	244-248
abolish	O	249-256
Hex	O	257-260
A	O	261-262
enzyme	O	263-269
activity	O	270-278
cause	O	279-284
Tay	B	285-288
-	I	288-289
Sachs	I	289-294
disease	I	295-302
(	O	303-304
TSD	B	304-307
)	O	307-308
,	O	308-309
the	O	310-313
fatal	O	314-319
infantile	B	320-329
form	I	330-334
of	I	335-337
G	I	338-339
(	I	340-341
M2	I	341-343
)	I	343-344
gangliosidosis	I	345-359
,	I	359-360
Type	I	361-365
1	I	366-367
.	O	367-368
Less	O	369-373
severe	O	374-380
,	O	380-381
subacute	O	382-390
(	O	391-392
juvenile	O	392-400
-	O	400-401
onset	O	401-406
)	O	406-407
and	O	408-411
chronic	O	412-419
(	O	420-421
adult	O	421-426
-	O	426-427
onset	O	427-432
)	O	432-433
variants	O	434-442
are	O	443-446
characterized	O	447-460
by	O	461-463
a	O	464-465
broad	O	466-471
spectrum	O	472-480
of	O	481-483
clinical	O	484-492
manifestations	O	493-507
and	O	508-511
are	O	512-515
associated	O	516-526
with	O	527-531
residual	O	532-540
levels	O	541-547
of	O	548-550
Hex	O	551-554
A	O	555-556
enzyme	O	557-563
activity	O	564-572
.	O	572-573

We	O	574-576
identified	O	577-587
a	O	588-589
1422	O	590-594
G	O	595-596
-	O	596-597
-	O	596-597
>	O	599-600
C	O	601-602
(	O	603-604
amino	O	604-609
acid	O	610-614
W474C	O	615-620
)	O	620-621
substitution	O	622-634
in	O	635-637
the	O	638-641
first	O	642-647
position	O	648-656
of	O	657-659
exon	O	660-664
13	O	665-667
of	O	668-670
HEXA	O	671-675
of	O	676-678
a	O	679-680
non	O	681-684
-	O	684-685
Jewish	O	685-691
proband	O	692-699
who	O	700-703
manifested	O	704-714
a	O	715-716
subacute	O	717-725
variant	O	726-733
of	O	734-736
G	B	737-738
(	I	739-740
M2	I	740-742
)	I	742-743
gangliosidosis	I	744-758
.	O	758-759

On	O	760-762
the	O	763-766
second	O	767-773
maternally	O	774-784
inherited	O	785-794
allele	O	795-801
,	O	801-802
we	O	803-805
identified	O	806-816
the	O	817-820
common	O	821-827
infantile	O	828-837
disease	O	838-845
-	O	845-846
causing	O	846-853
4	O	854-855
-	O	855-856
bp	O	856-858
insertion	O	859-868
,	O	868-869
+	O	870-871
TATC	O	872-876
1278	O	877-881
,	O	881-882
in	O	883-885
exon	O	886-890
11	O	891-893
.	O	893-894

Pulse	O	895-900
-	O	900-901
chase	O	901-906
analysis	O	907-915
using	O	916-921
proband	O	922-929
fibroblasts	O	930-941
revealed	O	942-950
that	O	951-955
the	O	956-959
W474C	O	960-965
-	O	965-966
containing	O	966-976
alpha	O	977-982
-	O	982-983
subunit	O	983-990
precursor	O	991-1000
was	O	1001-1004
normally	O	1005-1013
synthesized	O	1014-1025
,	O	1025-1026
but	O	1027-1030
not	O	1031-1034
phosphorylated	O	1035-1049
or	O	1050-1052
secreted	O	1053-1061
,	O	1061-1062
and	O	1063-1066
the	O	1067-1070
mature	O	1071-1077
lysosomal	O	1078-1087
alpha	O	1088-1093
-	O	1093-1094
subunit	O	1094-1101
was	O	1102-1105
not	O	1106-1109
detected	O	1110-1118
.	O	1118-1119

When	O	1120-1124
the	O	1125-1128
W474C	O	1129-1134
-	O	1134-1135
containing	O	1135-1145
alpha	O	1146-1151
-	O	1151-1152
subunit	O	1152-1159
was	O	1160-1163
transiently	O	1164-1175
co	O	1176-1178
-	O	1178-1179
expressed	O	1179-1188
with	O	1189-1193
the	O	1194-1197
beta	O	1198-1202
-	O	1202-1203
subunit	O	1203-1210
to	O	1211-1213
produce	O	1214-1221
Hex	O	1222-1225
A	O	1226-1227
(	O	1228-1229
alphabeta	O	1229-1238
)	O	1238-1239
in	O	1240-1242
COS	O	1243-1246
-	O	1246-1247
7	O	1247-1248
cells	O	1249-1254
,	O	1254-1255
the	O	1256-1259
mature	O	1260-1266
alpha	O	1267-1272
-	O	1272-1273
subunit	O	1273-1280
was	O	1281-1284
present	O	1285-1292
,	O	1292-1293
but	O	1294-1297
its	O	1298-1301
level	O	1302-1307
was	O	1308-1311
much	O	1312-1316
lower	O	1317-1322
than	O	1323-1327
that	O	1328-1332
from	O	1333-1337
normal	O	1338-1344
alpha	O	1345-1350
-	O	1350-1351
subunit	O	1351-1358
transfections	O	1359-1372
,	O	1372-1373
although	O	1374-1382
higher	O	1383-1389
than	O	1390-1394
in	O	1395-1397
those	O	1398-1403
cells	O	1404-1409
transfected	O	1410-1421
with	O	1422-1426
an	O	1427-1429
alpha	O	1430-1435
-	O	1435-1436
subunit	O	1436-1443
associated	O	1444-1454
with	O	1455-1459
infantile	O	1460-1469
TSD	B	1470-1473
.	O	1473-1474

Furthermore	O	1475-1486
,	O	1486-1487
the	O	1488-1491
precursor	O	1492-1501
level	O	1502-1507
of	O	1508-1510
the	O	1511-1514
W474C	O	1515-1520
alpha	O	1521-1526
-	O	1526-1527
subunit	O	1527-1534
was	O	1535-1538
found	O	1539-1544
to	O	1545-1547
accumulate	O	1548-1558
in	O	1559-1561
comparison	O	1562-1572
to	O	1573-1575
the	O	1576-1579
normal	O	1580-1586
alpha	O	1587-1592
-	O	1592-1593
subunit	O	1593-1600
precursor	O	1601-1610
levels	O	1611-1617
.	O	1617-1618

We	O	1619-1621
conclude	O	1622-1630
that	O	1631-1635
the	O	1636-1639
1422	O	1640-1644
G	O	1645-1646
-	O	1646-1647
-	O	1646-1647
>	O	1649-1650
C	O	1651-1652
mutation	O	1653-1661
is	O	1662-1664
the	O	1665-1668
cause	O	1669-1674
of	O	1675-1677
Hex	B	1678-1681
A	I	1682-1683
enzyme	I	1684-1690
deficiency	I	1691-1701
in	O	1702-1704
the	O	1705-1708
proband	O	1709-1716
.	O	1716-1717

The	O	1718-1721
resulting	O	1722-1731
W474C	O	1732-1737
substitution	O	1738-1750
clearly	O	1751-1758
interferes	O	1759-1769
with	O	1770-1774
alpha	O	1775-1780
-	O	1780-1781
subunit	O	1781-1788
processing	O	1789-1799
,	O	1799-1800
but	O	1801-1804
because	O	1805-1812
the	O	1813-1816
base	O	1817-1821
substitution	O	1822-1834
falls	O	1835-1840
at	O	1841-1843
the	O	1844-1847
first	O	1848-1853
position	O	1854-1862
of	O	1863-1865
exon	O	1866-1870
13	O	1871-1873
,	O	1873-1874
aberrant	O	1875-1883
splicing	O	1884-1892
may	O	1893-1896
also	O	1897-1901
contribute	O	1902-1912
to	O	1913-1915
Hex	B	1916-1919
A	I	1920-1921
deficiency	I	1922-1932
in	O	1933-1935
this	O	1936-1940
proband	O	1941-1948
.	O	1948-1949
.	O	1948-1949

Myotonic	B	0-8
dystrophy	I	9-18
protein	O	19-26
kinase	O	27-33
is	O	34-36
involved	O	37-45
in	O	46-48
the	O	49-52
modulation	O	53-63
of	O	64-66
the	O	67-70
Ca2	O	71-74
+	O	74-75
homeostasis	O	76-87
in	O	88-90
skeletal	O	91-99
muscle	O	100-106
cells	O	107-112
.	O	112-113

Myotonic	B	114-122
dystrophy	I	123-132
(	O	133-134
DM	B	134-136
)	O	136-137
,	O	137-138
the	O	139-142
most	O	143-147
prevalent	O	148-157
muscular	B	158-166
disorder	I	167-175
in	O	176-178
adults	O	179-185
,	O	185-186
is	O	187-189
caused	O	190-196
by	O	197-199
(	O	200-201
CTG	O	201-204
)	O	204-205
n	O	206-207
-	O	207-208
repeat	O	208-214
expansion	O	215-224
in	O	225-227
a	O	228-229
gene	O	230-234
encoding	O	235-243
a	O	244-245
protein	O	246-253
kinase	O	254-260
(	O	261-262
DM	B	262-264
protein	O	265-272
kinase	O	273-279
;	O	279-280
DMPK	O	281-285
)	O	285-286
and	O	287-290
involves	O	291-299
changes	O	300-307
in	O	308-310
cytoarchitecture	O	311-327
and	O	328-331
ion	O	332-335
homeostasis	O	336-347
.	O	347-348

To	O	349-351
obtain	O	352-358
clues	O	359-364
to	O	365-367
the	O	368-371
normal	O	372-378
biological	O	379-389
role	O	390-394
of	O	395-397
DMPK	O	398-402
in	O	403-405
cellular	O	406-414
ion	O	415-418
homeostasis	O	419-430
,	O	430-431
we	O	432-434
have	O	435-439
compared	O	440-448
the	O	449-452
resting	O	453-460
[	O	461-462
Ca2	O	462-465
+	O	466-467
]	O	467-468
i	O	469-470
,	O	470-471
the	O	472-475
amplitude	O	476-485
and	O	486-489
shape	O	490-495
of	O	496-498
depolarization	O	499-513
-	O	513-514
induced	O	514-521
Ca2	O	522-525
+	O	526-527
transients	O	528-538
,	O	538-539
and	O	540-543
the	O	544-547
content	O	548-555
of	O	556-558
ATP	O	559-562
-	O	562-563
driven	O	563-569
ion	O	570-573
pumps	O	574-579
in	O	580-582
cultured	O	583-591
skeletal	O	592-600
muscle	O	601-607
cells	O	608-613
of	O	614-616
wild	O	617-621
-	O	621-622
type	O	622-626
and	O	627-630
DMPK	O	631-635
[	O	636-637
-	O	637-638
/	O	638-639
-	O	637-638
]	O	640-641
knockout	O	642-650
mice	O	651-655
.	O	655-656

In	O	657-659
vitro	O	660-665
-	O	665-666
differentiated	O	666-680
DMPK	O	681-685
[	O	686-687
-	O	687-688
/	O	688-689
-	O	687-688
]	O	690-691
myotubes	O	692-700
exhibit	O	701-708
a	O	709-710
higher	O	711-717
resting	O	718-725
[	O	726-727
Ca2	O	727-730
+	O	731-732
]	O	732-733
i	O	734-735
than	O	736-740
do	O	741-743
wild	O	744-748
-	O	748-749
type	O	749-753
myotubes	O	754-762
because	O	763-770
of	O	771-773
an	O	774-776
altered	O	777-784
open	O	785-789
probability	O	790-801
of	O	802-804
voltage	O	805-812
-	O	812-813
dependent	O	813-822
l	O	823-824
-	O	824-825
type	O	825-829
Ca2	O	830-833
+	O	834-835
and	O	836-839
Na	O	840-842
+	O	843-844
channels	O	845-853
.	O	853-854

The	O	855-858
mutant	O	859-865
myotubes	O	866-874
exhibit	O	875-882
smaller	O	883-890
and	O	891-894
slower	O	895-901
Ca2	O	902-905
+	O	906-907
responses	O	908-917
upon	O	918-922
triggering	O	923-933
by	O	934-936
acetylcholine	O	937-950
or	O	951-953
high	O	954-958
external	O	959-967
K	O	968-969
+	O	970-971
.	O	971-972

In	O	973-975
addition	O	976-984
,	O	984-985
we	O	986-988
observed	O	989-997
that	O	998-1002
these	O	1003-1008
Ca2	O	1009-1012
+	O	1013-1014
transients	O	1015-1025
partially	O	1026-1035
result	O	1036-1042
from	O	1043-1047
an	O	1048-1050
influx	O	1051-1057
of	O	1058-1060
extracellular	O	1061-1074
Ca2	O	1075-1078
+	O	1079-1080
through	O	1081-1088
the	O	1089-1092
l	O	1093-1094
-	O	1094-1095
type	O	1095-1099
Ca2	O	1100-1103
+	O	1104-1105
channel	O	1106-1113
.	O	1113-1114

Neither	O	1115-1122
the	O	1123-1126
content	O	1127-1134
nor	O	1135-1138
the	O	1139-1142
activity	O	1143-1151
of	O	1152-1154
Na	O	1155-1157
+	O	1158-1159
/	O	1159-1160
K	O	1160-1161
+	O	1162-1163
ATPase	O	1164-1170
and	O	1171-1174
sarcoplasmic	O	1175-1187
reticulum	O	1188-1197
Ca2	O	1198-1201
+	O	1202-1203
-	O	1204-1205
ATPase	O	1205-1211
are	O	1212-1215
affected	O	1216-1224
by	O	1225-1227
DMPK	O	1228-1232
absence	O	1233-1240
.	O	1240-1241

In	O	1242-1244
conclusion	O	1245-1255
,	O	1255-1256
our	O	1257-1260
data	O	1261-1265
suggest	O	1266-1273
that	O	1274-1278
DMPK	O	1279-1283
is	O	1284-1286
involved	O	1287-1295
in	O	1296-1298
modulating	O	1299-1309
the	O	1310-1313
initial	O	1314-1321
events	O	1322-1328
of	O	1329-1331
excitation	O	1332-1342
-	O	1342-1343
contraction	O	1343-1354
coupling	O	1355-1363
in	O	1364-1366
skeletal	O	1367-1375
muscle	O	1376-1382
.	O	1382-1383
.	O	1382-1383

Insertional	O	0-11
mutation	O	12-20
by	O	21-23
transposable	O	24-36
element	O	37-44
,	O	44-45
L1	O	46-48
,	O	48-49
in	O	50-52
the	O	53-56
DMD	B	57-60
gene	O	61-65
results	O	66-73
in	O	74-76
X	B	77-78
-	I	78-79
linked	I	79-85
dilated	I	86-93
cardiomyopathy	I	94-108
.	O	108-109

X	B	110-111
-	I	111-112
linked	I	112-118
dilated	I	119-126
cardiomyopathy	I	127-141
(	O	142-143
XLDCM	B	143-148
)	O	148-149
is	O	150-152
a	O	153-154
clinical	O	155-163
phenotype	O	164-173
of	O	174-176
dystrophinopathy	B	177-193
which	O	194-199
is	O	200-202
characterized	O	203-216
by	O	217-219
preferential	O	220-232
myocardial	B	233-243
involvement	I	244-255
without	O	256-263
any	O	264-267
overt	O	268-273
clinical	O	274-282
signs	O	283-288
of	O	289-291
skeletal	B	292-300
myopathy	I	301-309
.	O	309-310

To	O	311-313
date	O	314-318
,	O	318-319
several	O	320-327
mutations	O	328-337
in	O	338-340
the	O	341-344
Duchenne	B	345-353
muscular	I	354-362
dystrophy	I	363-372
gene	O	373-377
,	O	377-378
DMD	O	379-382
,	O	382-383
have	O	384-388
been	O	389-393
identified	O	394-404
in	O	405-407
patients	O	408-416
with	O	417-421
XLDCM	B	422-427
,	O	427-428
but	O	429-432
a	O	433-434
pathogenic	O	435-445
correlation	O	446-457
of	O	458-460
these	O	461-466
cardiospecific	O	467-481
mutations	O	482-491
in	O	492-494
DMD	O	495-498
with	O	499-503
the	O	504-507
XLDCM	B	508-513
phenotype	O	514-523
has	O	524-527
remained	O	528-536
to	O	537-539
be	O	540-542
elucidated	O	543-553
.	O	553-554

We	O	555-557
report	O	558-564
here	O	565-569
the	O	570-573
identification	O	574-588
of	O	589-591
a	O	592-593
unique	O	594-600
de	O	601-603
novo	O	604-608
L1	O	609-611
insertion	O	612-621
in	O	622-624
the	O	625-628
muscle	O	629-635
exon	O	636-640
1	O	641-642
in	O	643-645
DMD	O	646-649
in	O	650-652
three	O	653-658
XLDCM	B	659-664
patients	O	665-673
from	O	674-678
two	O	679-682
unrelated	O	683-692
Japanese	O	693-701
families	O	702-710
.	O	710-711

The	O	712-715
insertion	O	716-725
was	O	726-729
a	O	730-731
5	O	732-733
-	O	733-734
truncated	O	734-743
form	O	744-748
of	O	749-751
human	O	752-757
L1	O	758-760
inversely	O	761-770
integrated	O	771-781
in	O	782-784
the	O	785-788
5	O	789-790
-	O	790-791
untranslated	O	791-803
region	O	804-810
in	O	811-813
the	O	814-817
muscle	O	818-824
exon	O	825-829
1	O	830-831
,	O	831-832
which	O	833-838
affected	O	839-847
the	O	848-851
transcription	O	852-865
or	O	866-868
the	O	869-872
stability	O	873-882
of	O	883-885
the	O	886-889
muscle	O	890-896
form	O	897-901
of	O	902-904
dystrophin	O	905-915
transcripts	O	916-927
but	O	928-931
not	O	932-935
that	O	936-940
of	O	941-943
the	O	944-947
brain	O	948-953
or	O	954-956
Purkinje	O	957-965
cell	O	966-970
form	O	971-975
,	O	975-976
probably	O	977-985
due	O	986-989
to	O	990-992
its	O	993-996
unique	O	997-1003
site	O	1004-1008
of	O	1009-1011
integration	O	1012-1023
.	O	1023-1024

We	O	1025-1027
speculate	O	1028-1037
that	O	1038-1042
this	O	1043-1047
insertion	O	1048-1057
of	O	1058-1060
an	O	1061-1063
L1	O	1064-1066
sequence	O	1067-1075
in	O	1076-1078
DMD	O	1079-1082
is	O	1083-1085
responsible	O	1086-1097
for	O	1098-1101
some	O	1102-1106
of	O	1107-1109
the	O	1110-1113
population	O	1114-1124
of	O	1125-1127
Japanese	O	1128-1136
patients	O	1137-1145
with	O	1146-1150
XLDCM	B	1151-1156
.	O	1156-1157
.	O	1156-1157

Genetic	O	0-7
heterogeneity	O	8-21
of	O	22-24
Saethre	B	25-32
-	I	32-33
Chotzen	I	33-40
syndrome	I	41-49
,	O	49-50
due	O	51-54
to	O	55-57
TWIST	O	58-63
and	O	64-67
FGFR	O	68-72
mutations	O	73-82
.	O	82-83

Thirty	O	84-90
-	O	90-91
two	O	91-94
unrelated	O	95-104
patients	O	105-113
with	O	114-118
features	O	119-127
of	O	128-130
Saethre	B	131-138
-	I	138-139
Chotzen	I	139-146
syndrome	I	147-155
,	O	155-156
a	O	157-158
common	O	159-165
autosomal	B	166-175
dominant	I	176-184
condition	I	185-194
of	O	195-197
craniosynostosis	B	198-214
and	O	215-218
limb	B	219-223
anomalies	I	224-233
,	O	233-234
were	O	235-239
screened	O	240-248
for	O	249-252
mutations	O	253-262
in	O	263-265
TWIST	O	266-271
,	O	271-272
FGFR2	O	273-278
,	O	278-279
and	O	280-283
FGFR3	O	284-289
.	O	289-290

Nine	O	291-295
novel	O	296-301
and	O	302-305
three	O	306-311
recurrent	O	312-321
TWIST	O	322-327
mutations	O	328-337
were	O	338-342
found	O	343-348
in	O	349-351
12	O	352-354
families	O	355-363
.	O	363-364

Seven	O	365-370
families	O	371-379
were	O	380-384
found	O	385-390
to	O	391-393
have	O	394-398
the	O	399-402
FGFR3	O	403-408
P250R	O	409-414
mutation	O	415-423
,	O	423-424
and	O	425-428
one	O	429-432
individual	O	433-443
was	O	444-447
found	O	448-453
to	O	454-456
have	O	457-461
an	O	462-464
FGFR2	O	465-470
VV269	O	471-476
-	O	476-477
270	O	477-480
deletion	O	481-489
.	O	489-490

To	O	491-493
date	O	494-498
,	O	498-499
our	O	500-503
detection	O	504-513
rate	O	514-518
for	O	519-522
TWIST	O	523-528
or	O	529-531
FGFR	O	532-536
mutations	O	537-546
is	O	547-549
68	O	550-552
%	O	552-553
in	O	554-556
our	O	557-560
Saethre	B	561-568
-	I	568-569
Chotzen	I	569-576
syndrome	I	577-585
patients	O	586-594
,	O	594-595
including	O	596-605
our	O	606-609
five	O	610-614
patients	O	615-623
elsewhere	O	624-633
reported	O	634-642
with	O	643-647
TWIST	O	648-653
mutations	O	654-663
.	O	663-664

More	O	665-669
than	O	670-674
35	O	675-677
different	O	678-687
TWIST	O	688-693
mutations	O	694-703
are	O	704-707
now	O	708-711
known	O	712-717
in	O	718-720
the	O	721-724
literature	O	725-735
.	O	735-736

The	O	737-740
most	O	741-745
common	O	746-752
phenotypic	O	753-763
features	O	764-772
,	O	772-773
present	O	774-781
in	O	782-784
more	O	785-789
than	O	790-794
a	O	795-796
third	O	797-802
of	O	803-805
our	O	806-809
patients	O	810-818
with	O	819-823
TWIST	O	824-829
mutations	O	830-839
,	O	839-840
are	O	841-844
coronal	B	845-852
synostosis	I	853-863
,	O	863-864
brachycephaly	B	865-878
,	O	878-879
low	B	880-883
frontal	I	884-891
hairline	I	892-900
,	O	900-901
facial	B	902-908
asymmetry	I	909-918
,	O	918-919
ptosis	B	920-926
,	O	926-927
hypertelorism	B	928-941
,	O	941-942
broad	B	943-948
great	I	949-954
toes	I	955-959
,	O	959-960
and	O	961-964
clinodactyly	B	965-977
.	O	977-978

Significant	O	979-990
intra	O	991-996
-	O	996-997
and	O	998-1001
interfamilial	O	1002-1015
phenotypic	O	1016-1026
variability	O	1027-1038
is	O	1039-1041
present	O	1042-1049
for	O	1050-1053
either	O	1054-1060
TWIST	O	1061-1066
mutations	O	1067-1076
or	O	1077-1079
FGFR	O	1080-1084
mutations	O	1085-1094
.	O	1094-1095

The	O	1096-1099
overlap	O	1100-1107
in	O	1108-1110
clinical	O	1111-1119
features	O	1120-1128
and	O	1129-1132
the	O	1133-1136
presence	O	1137-1145
,	O	1145-1146
in	O	1147-1149
the	O	1150-1153
same	O	1154-1158
genes	O	1159-1164
,	O	1164-1165
of	O	1166-1168
mutations	O	1169-1178
for	O	1179-1182
more	O	1183-1187
than	O	1188-1192
one	O	1193-1196
craniosynostotic	B	1197-1213
condition	I	1214-1223
-	O	1223-1224
such	O	1224-1228
as	O	1229-1231
Saethre	B	1232-1239
-	I	1239-1240
Chotzen	I	1240-1247
,	I	1247-1248
Crouzon	I	1249-1256
,	I	1256-1257
and	I	1258-1261
Pfeiffer	I	1262-1270
syndromes	I	1271-1280
-	O	1280-1281
support	O	1281-1288
the	O	1289-1292
hypothesis	O	1293-1303
that	O	1304-1308
TWIST	O	1309-1314
and	O	1315-1318
FGFRs	O	1319-1324
are	O	1325-1328
components	O	1329-1339
of	O	1340-1342
the	O	1343-1346
same	O	1347-1351
molecular	O	1352-1361
pathway	O	1362-1369
involved	O	1370-1378
in	O	1379-1381
the	O	1382-1385
modulation	O	1386-1396
of	O	1397-1399
craniofacial	O	1400-1412
and	O	1413-1416
limb	O	1417-1421
development	O	1422-1433
in	O	1434-1436
humans	O	1437-1443
.	O	1443-1444
.	O	1443-1444

Frequent	O	0-8
inactivation	O	9-21
of	O	22-24
PTEN	O	25-29
/	O	29-30
MMAC1	O	30-35
in	O	36-38
primary	O	39-46
prostate	B	47-55
cancer	I	56-62
.	O	62-63

Sporadic	B	64-72
prostate	I	73-81
carcinoma	I	82-91
is	O	92-94
the	O	95-98
most	O	99-103
common	O	104-110
male	B	111-115
cancer	I	116-122
in	O	123-125
the	O	126-129
Western	O	130-137
world	O	138-143
,	O	143-144
yet	O	145-148
many	O	149-153
of	O	154-156
the	O	157-160
major	O	161-166
genetic	O	167-174
events	O	175-181
involved	O	182-190
in	O	191-193
the	O	194-197
progression	O	198-209
of	O	210-212
this	O	213-217
often	O	218-223
fatal	O	224-229
cancer	B	230-236
remain	O	237-243
to	O	244-246
be	O	247-249
elucidated	O	250-260
.	O	260-261

Numerous	O	262-270
cytogenetic	O	271-282
and	O	283-286
allelotype	O	287-297
studies	O	298-305
have	O	306-310
reported	O	311-319
frequent	O	320-328
loss	O	329-333
of	O	334-336
heterozygosity	O	337-351
on	O	352-354
chromosomal	O	355-366
arm	O	367-370
10q	O	371-374
in	O	375-377
sporadic	B	378-386
prostate	I	387-395
cancer	I	396-402
.	O	402-403

Deletion	O	404-412
mapping	O	413-420
studies	O	421-428
have	O	429-433
unambiguously	O	434-447
identified	O	448-458
a	O	459-460
region	O	461-467
of	O	468-470
chromosome	O	471-481
10q23	O	482-487
to	O	488-490
be	O	491-493
the	O	494-497
minimal	O	498-505
area	O	506-510
of	O	511-513
loss	O	514-518
.	O	518-519

A	O	520-521
new	O	522-525
tumor	B	526-531
suppressor	O	532-542
gene	O	543-547
,	O	547-548
PTEN	O	549-553
/	O	553-554
MMAC1	O	554-559
,	O	559-560
was	O	561-564
isolated	O	565-573
recently	O	574-582
at	O	583-585
this	O	586-590
region	O	591-597
of	O	598-600
chromosome	O	601-611
10q23	O	612-617
and	O	618-621
found	O	622-627
to	O	628-630
be	O	631-633
inactivated	O	634-645
by	O	646-648
mutation	O	649-657
in	O	658-660
three	O	661-666
prostate	B	667-675
cancer	I	676-682
cell	O	683-687
lines	O	688-693
.	O	693-694

We	O	695-697
screened	O	698-706
80	O	707-709
prostate	B	710-718
tumors	I	719-725
by	O	726-728
microsatellite	O	729-743
analysis	O	744-752
and	O	753-756
found	O	757-762
chromosome	O	763-773
10q23	O	774-779
to	O	780-782
be	O	783-785
deleted	O	786-793
in	O	794-796
23	O	797-799
cases	O	800-805
.	O	805-806

We	O	807-809
then	O	810-814
proceeded	O	815-824
with	O	825-829
sequence	O	830-838
analysis	O	839-847
of	O	848-850
the	O	851-854
entire	O	855-861
PTEN	O	862-866
/	O	866-867
MMAC1	O	867-872
coding	O	873-879
region	O	880-886
and	O	887-890
tested	O	891-897
for	O	898-901
homozygous	O	902-912
deletion	O	913-921
with	O	922-926
new	O	927-930
intragenic	O	931-941
markers	O	942-949
in	O	950-952
these	O	953-958
23	O	959-961
cases	O	962-967
with	O	968-972
10q23	O	973-978
loss	O	979-983
of	O	984-986
heterozygosity	O	987-1001
.	O	1001-1002

The	O	1003-1006
identification	O	1007-1021
of	O	1022-1024
the	O	1025-1028
second	O	1029-1035
mutational	O	1036-1046
event	O	1047-1052
in	O	1053-1055
10	O	1056-1058
(	O	1059-1060
43	O	1060-1062
%	O	1062-1063
)	O	1063-1064
tumors	B	1065-1071
establishes	O	1072-1083
PTEN	O	1084-1088
/	O	1088-1089
MMAC1	O	1089-1094
as	O	1095-1097
a	O	1098-1099
main	O	1100-1104
inactivation	O	1105-1117
target	O	1118-1124
of	O	1125-1127
10q	O	1128-1131
loss	O	1132-1136
in	O	1137-1139
sporadic	B	1140-1148
prostate	I	1149-1157
cancer	I	1158-1164
.	O	1164-1165
.	O	1164-1165

Molecular	O	0-9
heterogeneity	O	10-23
in	O	24-26
mucopolysaccharidosis	B	27-48
IVA	I	49-52
in	O	53-55
Australia	O	56-65
and	O	66-69
Northern	O	70-78
Ireland	O	79-86
:	O	86-87
nine	O	88-92
novel	O	93-98
mutations	O	99-108
including	O	109-118
T312S	O	119-124
,	O	124-125
a	O	126-127
common	O	128-134
allele	O	135-141
that	O	142-146
confers	O	147-154
a	O	155-156
mild	O	157-161
phenotype	O	162-171
.	O	171-172

Mucopolysaccharidosis	B	173-194
IVA	I	195-198
(	O	199-200
MPS	B	200-203
IVA	I	204-207
)	O	207-208
is	O	209-211
an	O	212-214
autosomal	B	215-224
recessive	I	225-234
lysosomal	I	235-244
storage	I	245-252
disorder	I	253-261
caused	O	262-268
by	O	269-271
a	O	272-273
genetic	B	274-281
defect	I	282-288
in	O	289-291
N	O	292-293
-	O	293-294
acetylgalactosamine	O	294-313
-	O	293-294
6	O	314-315
-	O	293-294
sulfate	O	316-323
sulfatase	O	324-333
(	O	334-335
GALNS	O	335-340
)	O	340-341
.	O	341-342

Previous	O	343-351
studies	O	352-359
of	O	360-362
patients	O	363-371
from	O	372-376
a	O	377-378
British	O	379-386
-	O	386-387
Irish	O	387-392
population	O	393-403
showed	O	404-410
that	O	411-415
the	O	416-419
I113F	O	420-425
mutation	O	426-434
is	O	435-437
the	O	438-441
most	O	442-446
common	O	447-453
single	O	454-460
mutation	O	461-469
among	O	470-475
MPS	B	476-479
IVA	I	480-483
patients	O	484-492
and	O	493-496
produces	O	497-505
a	O	506-507
severe	O	508-514
clinical	O	515-523
phenotype	O	524-533
.	O	533-534

We	O	535-537
studied	O	538-545
mutations	O	546-555
in	O	556-558
the	O	559-562
GALNS	O	563-568
gene	O	569-573
from	O	574-578
23	O	579-581
additional	O	582-592
MPS	B	593-596
IVA	I	597-600
patients	O	601-609
(	O	610-611
15	O	611-613
from	O	614-618
Australia	O	619-628
,	O	628-629
8	O	630-631
from	O	632-636
Northern	O	637-645
Ireland	O	646-653
)	O	653-654
,	O	654-655
with	O	656-660
various	O	661-668
clinical	O	669-677
phenotypes	O	678-688
(	O	689-690
severe	O	690-696
,	O	696-697
16	O	698-700
cases	O	701-706
;	O	706-707
intermediate	O	708-720
,	O	720-721
4	O	722-723
cases	O	724-729
;	O	729-730
mild	O	731-735
,	O	735-736
3	O	737-738
cases	O	739-744
)	O	744-745
.	O	745-746

We	O	747-749
found	O	750-755
two	O	756-759
common	O	760-766
mutations	O	767-776
that	O	777-781
together	O	782-790
accounted	O	791-800
for	O	801-804
32	O	805-807
%	O	807-808
of	O	809-811
the	O	812-815
44	O	816-818
unrelated	O	819-828
alleles	O	829-836
in	O	837-839
these	O	840-845
patients	O	846-854
.	O	854-855

One	O	856-859
is	O	860-862
the	O	863-866
T312S	O	867-872
mutation	O	873-881
,	O	881-882
a	O	883-884
novel	O	885-890
mutation	O	891-899
found	O	900-905
exclusively	O	906-917
in	O	918-920
milder	O	921-927
patients	O	928-936
.	O	936-937

The	O	938-941
other	O	942-947
is	O	948-950
the	O	951-954
previously	O	955-965
described	O	966-975
I113F	O	976-981
that	O	982-986
produces	O	987-995
a	O	996-997
severe	O	998-1004
phenotype	O	1005-1014
.	O	1014-1015

The	O	1016-1019
I113F	O	1020-1025
and	O	1026-1029
T312S	O	1030-1035
mutations	O	1036-1045
accounted	O	1046-1055
for	O	1056-1059
8	O	1060-1061
(	O	1062-1063
18	O	1063-1065
%	O	1065-1066
)	O	1066-1067
and	O	1068-1071
6	O	1072-1073
(	O	1074-1075
14	O	1075-1077
%	O	1077-1078
)	O	1078-1079
of	O	1080-1082
44	O	1083-1085
unrelated	O	1086-1095
alleles	O	1096-1103
,	O	1103-1104
respectively	O	1105-1117
.	O	1117-1118

The	O	1119-1122
relatively	O	1123-1133
high	O	1134-1138
residual	O	1139-1147
GALNS	O	1148-1153
activity	O	1154-1162
seen	O	1163-1167
when	O	1168-1172
the	O	1173-1176
T312S	O	1177-1182
mutant	O	1183-1189
cDNA	O	1190-1194
is	O	1195-1197
overexpressed	O	1198-1211
in	O	1212-1214
mutant	O	1215-1221
cells	O	1222-1227
provides	O	1228-1236
an	O	1237-1239
explanation	O	1240-1251
for	O	1252-1255
the	O	1256-1259
mild	O	1260-1264
phenotype	O	1265-1274
in	O	1275-1277
patients	O	1278-1286
with	O	1287-1291
this	O	1292-1296
mutation	O	1297-1305
.	O	1305-1306

The	O	1307-1310
distribution	O	1311-1323
and	O	1324-1327
relative	O	1328-1336
frequencies	O	1337-1348
of	O	1349-1351
the	O	1352-1355
I113F	O	1356-1361
and	O	1362-1365
T312S	O	1366-1371
mutations	O	1372-1381
in	O	1382-1384
Australia	O	1385-1394
corresponded	O	1395-1407
to	O	1408-1410
those	O	1411-1416
observed	O	1417-1425
in	O	1426-1428
Northern	O	1429-1437
Ireland	O	1438-1445
and	O	1446-1449
are	O	1450-1453
unique	O	1454-1460
to	O	1461-1463
these	O	1464-1469
two	O	1470-1473
populations	O	1474-1485
,	O	1485-1486
suggesting	O	1487-1497
that	O	1498-1502
both	O	1503-1507
mutations	O	1508-1517
were	O	1518-1522
probably	O	1523-1531
introduced	O	1532-1542
to	O	1543-1545
Australia	O	1546-1555
by	O	1556-1558
Irish	O	1559-1564
migrants	O	1565-1573
during	O	1574-1580
the	O	1581-1584
19th	O	1585-1589
century	O	1590-1597
.	O	1597-1598

Haplotype	O	1599-1608
analysis	O	1609-1617
using	O	1618-1623
6	O	1624-1625
RFLPs	O	1626-1631
provides	O	1632-1640
additional	O	1641-1651
data	O	1652-1656
that	O	1657-1661
the	O	1662-1665
I113F	O	1666-1671
mutation	O	1672-1680
originated	O	1681-1691
from	O	1692-1696
a	O	1697-1698
common	O	1699-1705
ancestor	O	1706-1714
.	O	1714-1715

The	O	1716-1719
other	O	1720-1725
9	O	1726-1727
novel	O	1728-1733
mutations	O	1734-1743
identified	O	1744-1754
in	O	1755-1757
these	O	1758-1763
23	O	1764-1766
patients	O	1767-1775
were	O	1776-1780
each	O	1781-1785
limited	O	1786-1793
to	O	1794-1796
a	O	1797-1798
single	O	1799-1805
family	O	1806-1812
.	O	1812-1813

These	O	1814-1819
data	O	1820-1824
provide	O	1825-1832
further	O	1833-1840
evidence	O	1841-1849
for	O	1850-1853
extensive	O	1854-1863
allelic	O	1864-1871
heterogeneity	O	1872-1885
in	O	1886-1888
MPS	B	1889-1892
IVA	I	1893-1896
in	O	1897-1899
British	O	1900-1907
-	O	1907-1908
Irish	O	1908-1913
patients	O	1914-1922
and	O	1923-1926
provide	O	1927-1934
evidence	O	1935-1943
for	O	1944-1947
their	O	1948-1953
transmission	O	1954-1966
to	O	1967-1969
Australia	O	1970-1979
by	O	1980-1982
British	O	1983-1990
-	O	1990-1991
Irish	O	1991-1996
migrants	O	1997-2005
.	O	2005-2006
.	O	2005-2006

Further	O	0-7
evidence	O	8-16
for	O	17-20
a	O	21-22
major	O	23-28
ancient	O	29-36
mutation	O	37-45
underlying	O	46-56
myotonic	B	57-65
dystrophy	I	66-75
from	O	76-80
linkage	O	81-88
disequilibrium	O	89-103
studies	O	104-111
in	O	112-114
the	O	115-118
Japanese	O	119-127
population	O	128-138
.	O	138-139

The	O	140-143
myotonic	B	144-152
dystrophy	I	153-162
(	O	163-164
DM	B	164-166
)	O	166-167
mutation	O	168-176
is	O	177-179
an	O	180-182
unstable	O	183-191
(	O	192-193
CTG	O	193-196
)	O	196-197
n	O	198-199
repeat	O	200-206
,	O	206-207
present	O	208-215
at	O	216-218
a	O	219-220
copy	O	221-225
number	O	226-232
of	O	233-235
5	O	236-237
-	O	237-238
37	O	238-240
repeats	O	241-248
on	O	249-251
normal	O	252-258
chromosomes	O	259-270
but	O	271-274
amplified	O	275-284
to	O	285-287
50	O	288-290
-	O	290-291
3000	O	291-295
copies	O	296-302
on	O	303-305
DM	B	306-308
chromosomes	O	309-320
.	O	320-321

Previous	O	322-330
findings	O	331-339
in	O	340-342
Caucasian	O	343-352
populations	O	353-364
of	O	365-367
a	O	368-369
DM	B	370-372
founder	O	373-380
chromosome	O	381-391
raise	O	392-397
a	O	398-399
question	O	400-408
about	O	409-414
the	O	415-418
molecular	O	419-428
events	O	429-435
involved	O	436-444
in	O	445-447
the	O	448-451
expansion	O	452-461
mutation	O	462-470
.	O	470-471

To	O	472-474
investigate	O	475-486
whether	O	487-494
a	O	495-496
founder	O	497-504
chromosome	O	505-515
for	O	516-519
the	O	520-523
DM	B	524-526
mutation	O	527-535
exists	O	536-542
in	O	543-545
the	O	546-549
Japanese	O	550-558
population	O	559-569
,	O	569-570
we	O	571-573
genotyped	O	574-583
families	O	584-592
using	O	593-598
polymorphic	O	599-610
markers	O	611-618
near	O	619-623
the	O	624-627
(	O	628-629
CTG	O	629-632
)	O	632-633
n	O	634-635
repeat	O	636-642
region	O	643-649
and	O	650-653
constructed	O	654-665
haplotypes	O	666-676
.	O	676-677

Six	O	678-681
different	O	682-691
haplotypes	O	692-702
were	O	703-707
found	O	708-713
and	O	714-717
DM	B	718-720
alleles	O	721-728
were	O	729-733
always	O	734-740
haplotype	O	741-750
A	O	751-752
.	O	752-753
To	O	754-756
find	O	757-761
an	O	762-764
origin	O	765-771
of	O	772-774
the	O	775-778
(	O	779-780
CTG	O	780-783
)	O	783-784
n	O	785-786
repeat	O	787-793
mutation	O	794-802
and	O	803-806
to	O	807-809
investigate	O	810-821
the	O	822-825
mechanism	O	826-835
of	O	836-838
the	O	839-842
expansion	O	843-852
mutation	O	853-861
in	O	862-864
the	O	865-868
Japanese	O	869-877
population	O	878-888
we	O	889-891
have	O	892-896
studied	O	897-904
90	O	905-907
Japanese	O	908-916
DM	B	917-919
families	O	920-928
comprising	O	929-939
190	O	940-943
affected	O	944-952
and	O	953-956
130	O	957-960
unaffected	O	961-971
members	O	972-979
.	O	979-980

The	O	981-984
results	O	985-992
suggest	O	993-1000
that	O	1001-1005
a	O	1006-1007
few	O	1008-1011
common	O	1012-1018
ancestral	O	1019-1028
mutations	O	1029-1038
in	O	1039-1041
both	O	1042-1046
Caucasian	O	1047-1056
and	O	1057-1060
Japanese	O	1061-1069
populations	O	1070-1081
have	O	1082-1086
originated	O	1087-1097
by	O	1098-1100
expansion	O	1101-1110
of	O	1111-1113
an	O	1114-1116
ancestral	O	1117-1126
n	O	1127-1128
=	O	1129-1130
5	O	1131-1132
repeat	O	1133-1139
to	O	1140-1142
n	O	1143-1144
=	O	1145-1146
19	O	1147-1149
-	O	1149-1150
37	O	1150-1152
copies	O	1153-1159
.	O	1159-1160

These	O	1161-1166
data	O	1167-1171
support	O	1172-1179
multistep	O	1180-1189
models	O	1190-1196
of	O	1197-1199
triplet	O	1200-1207
repeat	O	1208-1214
expansion	O	1215-1224
that	O	1225-1229
have	O	1230-1234
been	O	1235-1239
proposed	O	1240-1248
for	O	1249-1252
both	O	1253-1257
DM	B	1258-1260
and	O	1261-1264
Friedreichs	B	1265-1276
ataxia	I	1277-1283
.	O	1283-1284
.	O	1283-1284

Prevalence	O	0-10
of	O	11-13
p16	O	14-17
and	O	18-21
CDK4	O	22-26
germline	O	27-35
mutations	O	36-45
in	O	46-48
48	O	49-51
melanoma	B	52-60
-	O	60-61
prone	O	61-66
families	O	67-75
in	O	76-78
France	O	79-85
.	O	85-86

The	O	87-90
French	O	91-97
Familial	B	98-106
Melanoma	I	107-115
Study	O	116-121
Group	O	122-127
.	O	127-128

Germline	O	129-137
mutations	O	138-147
in	O	148-150
the	O	151-154
p16	O	155-158
and	O	159-162
CDK4	O	163-167
genes	O	168-173
have	O	174-178
been	O	179-183
reported	O	184-192
in	O	193-195
a	O	196-197
subset	O	198-204
of	O	205-207
melanoma	B	208-216
pedigrees	O	217-226
,	O	226-227
but	O	228-231
their	O	232-237
prevalence	O	238-248
is	O	249-251
not	O	252-255
well	O	256-260
known	O	261-266
.	O	266-267

We	O	268-270
searched	O	271-279
for	O	280-283
such	O	284-288
germline	O	289-297
mutations	O	298-307
in	O	308-310
48	O	311-313
French	O	314-320
melanoma	B	321-329
-	O	329-330
prone	O	330-335
families	O	336-344
selected	O	345-353
according	O	354-363
to	O	364-366
two	O	367-370
major	O	371-376
criteria	O	377-385
families	O	387-395
with	O	396-400
at	O	401-403
least	O	404-409
three	O	410-415
affected	O	416-424
members	O	425-432
(	O	433-434
n	O	434-435
=	O	436-437
20	O	438-440
)	O	440-441
or	O	442-444
families	O	445-453
with	O	454-458
two	O	459-462
affected	O	463-471
members	O	472-479
,	O	479-480
one	O	481-484
of	O	485-487
them	O	488-492
affected	O	493-501
before	O	502-508
the	O	509-512
age	O	513-516
of	O	517-519
50	O	520-522
(	O	523-524
n	O	524-525
=	O	526-527
28	O	528-530
)	O	530-531
,	O	531-532
and	O	533-536
one	O	537-540
additional	O	541-551
minor	O	552-557
criterion	O	558-567
.	O	567-568

Sixteen	O	569-576
different	O	577-586
p16	O	587-590
germline	O	591-599
mutations	O	600-609
were	O	610-614
found	O	615-620
in	O	621-623
21	O	624-626
families	O	627-635
,	O	635-636
while	O	637-642
one	O	643-646
germline	O	647-655
mutation	O	656-664
,	O	664-665
Arg24His	O	666-674
,	O	674-675
was	O	676-679
detected	O	680-688
in	O	689-691
the	O	692-695
CDK4	O	696-700
gene	O	701-705
.	O	705-706

The	O	707-710
frequency	O	711-720
of	O	721-723
p16	O	724-727
gene	O	728-732
mutation	O	733-741
in	O	742-744
our	O	745-748
sample	O	749-755
(	O	756-757
44	O	757-759
%	O	759-760
)	O	760-761
is	O	762-764
among	O	765-770
the	O	771-774
highest	O	775-782
rates	O	783-788
yet	O	789-792
reported	O	793-801
and	O	802-805
the	O	806-809
CDK4	O	810-814
mutation	O	815-823
is	O	824-826
the	O	827-830
second	O	831-837
mutation	O	838-846
detected	O	847-855
in	O	856-858
this	O	859-863
gene	O	864-868
worldwide	O	869-878
.	O	878-879

In	O	880-882
summary	O	883-890
,	O	890-891
our	O	892-895
results	O	896-903
show	O	904-908
frequent	O	909-917
involvement	O	918-929
of	O	930-932
the	O	933-936
p16	O	937-940
gene	O	941-945
in	O	946-948
familial	B	949-957
melanoma	I	958-966
and	O	967-970
confirm	O	971-978
the	O	979-982
role	O	983-987
of	O	988-990
the	O	991-994
CDK4	O	995-999
gene	O	1000-1004
as	O	1005-1007
a	O	1008-1009
melanoma	B	1010-1018
-	O	1018-1019
predisposing	O	1019-1031
gene	O	1032-1036
.	O	1036-1037
.	O	1036-1037

Systematic	O	0-10
analysis	O	11-19
of	O	20-22
coproporphyrinogen	O	23-41
oxidase	O	42-49
gene	O	50-54
defects	O	55-62
in	O	63-65
hereditary	B	66-76
coproporphyria	I	77-91
and	O	92-95
mutation	O	96-104
update	O	105-111
.	O	111-112

Hereditary	B	113-123
coproporphyria	I	124-138
(	O	139-140
HC	B	140-142
)	O	142-143
is	O	144-146
an	O	147-149
acute	O	150-155
hepatic	B	156-163
porphyria	I	164-173
with	O	174-178
autosomal	O	179-188
dominant	O	189-197
inheritance	O	198-209
caused	O	210-216
by	O	217-219
deficient	B	220-229
activity	I	230-238
of	I	239-241
coproporphyrinogen	I	242-260
III	I	261-264
oxidase	I	265-272
(	O	273-274
CPO	O	274-277
)	O	277-278
.	O	278-279

Clinical	O	280-288
manifestations	O	289-303
of	O	304-306
the	O	307-310
disease	O	311-318
are	O	319-322
characterized	O	323-336
by	O	337-339
acute	O	340-345
attacks	O	346-353
of	O	354-356
neurological	B	357-369
dysfunction	I	370-381
often	O	382-387
precipitated	O	388-400
by	O	401-403
drugs	O	404-409
,	O	409-410
fasting	O	411-418
,	O	418-419
cyclical	O	420-428
hormonal	O	429-437
changes	O	438-445
,	O	445-446
or	O	447-449
infectious	B	450-460
diseases	I	461-469
.	O	469-470

Skin	O	471-475
photosensitivity	O	476-492
may	O	493-496
also	O	497-501
be	O	502-504
present	O	505-512
.	O	512-513

The	O	514-517
seven	O	518-523
exons	O	524-529
,	O	529-530
the	O	531-534
exon	O	535-539
/	O	539-540
intron	O	540-546
boundaries	O	547-557
and	O	558-561
part	O	562-566
of	O	567-569
3	O	570-571
noncoding	O	572-581
sequence	O	582-590
of	O	591-593
the	O	594-597
CPO	O	598-601
gene	O	602-606
were	O	607-611
systematically	O	612-626
analyzed	O	627-635
by	O	636-638
an	O	639-641
exon	O	642-646
-	O	646-647
by	O	647-649
-	O	646-647
exon	O	642-646
denaturing	O	655-665
gradient	O	666-674
gel	O	675-678
electrophoresis	O	679-694
(	O	695-696
DGGE	O	696-700
)	O	700-701
strategy	O	702-710
followed	O	711-719
by	O	720-722
direct	O	723-729
sequencing	O	730-740
in	O	741-743
seven	O	744-749
unrelated	O	750-759
heterozygous	O	760-772
HC	B	773-775
patients	O	776-784
from	O	785-789
France	O	790-796
,	O	796-797
Holland	O	798-805
,	O	805-806
and	O	807-810
Czech	O	811-816
Republic	O	817-825
.	O	825-826

Seven	O	827-832
novel	O	833-838
mutations	O	839-848
and	O	849-852
two	O	853-856
new	O	857-860
polymorphisms	O	861-874
were	O	875-879
detected	O	880-888
.	O	888-889

Among	O	890-895
these	O	896-901
mutations	O	902-911
two	O	913-916
are	O	917-920
missense	O	921-929
(	O	930-931
G197W	O	931-936
,	O	936-937
W427R	O	938-943
)	O	943-944
,	O	944-945
two	O	946-949
are	O	950-953
nonsense	O	954-962
(	O	963-964
Q306X	O	964-969
,	O	969-970
Q385X	O	971-976
)	O	976-977
,	O	977-978
two	O	979-982
are	O	983-986
small	O	987-992
deletions	O	993-1002
(	O	1003-1004
662de14bp	O	1004-1013
;	O	1013-1014
1168del3bp	O	1015-1025
removing	O	1026-1034
a	O	1035-1036
glycine	O	1037-1044
at	O	1045-1047
position	O	1048-1056
390	O	1057-1060
)	O	1060-1061
,	O	1061-1062
and	O	1063-1066
one	O	1067-1070
is	O	1071-1073
a	O	1074-1075
splicing	O	1076-1084
mutation	O	1085-1093
(	O	1094-1095
IVS1	O	1095-1099
-	O	1099-1100
15c	O	1100-1103
-	O	1099-1100
-	O	1099-1100
>	O	1106-1107
g	O	1108-1109
)	O	1109-1110
which	O	1111-1116
creates	O	1117-1124
a	O	1125-1126
new	O	1127-1130
acceptor	O	1131-1139
splice	O	1140-1146
site	O	1147-1151
.	O	1151-1152

The	O	1153-1156
pathological	O	1157-1169
significance	O	1170-1182
of	O	1183-1185
the	O	1186-1189
point	O	1190-1195
mutations	O	1196-1205
G197W	O	1206-1211
,	O	1211-1212
W427R	O	1213-1218
,	O	1218-1219
and	O	1220-1223
the	O	1224-1227
in	O	1228-1230
-	O	1230-1231
frame	O	1231-1236
deletion	O	1237-1245
390delGly	O	1246-1255
were	O	1256-1260
assessed	O	1261-1269
by	O	1270-1272
their	O	1273-1278
respective	O	1279-1289
expression	O	1290-1300
in	O	1301-1303
a	O	1304-1305
prokaryotic	O	1306-1317
system	O	1318-1324
using	O	1325-1330
site	O	1331-1335
-	O	1335-1336
directed	O	1336-1344
mutagenesis	O	1345-1356
.	O	1356-1357

These	O	1358-1363
mutations	O	1364-1373
resulted	O	1374-1382
in	O	1383-1385
the	O	1386-1389
absence	O	1390-1397
or	O	1398-1400
a	O	1401-1402
dramatic	O	1403-1411
decrease	O	1412-1420
of	O	1421-1423
CPO	O	1424-1427
activity	O	1428-1436
.	O	1436-1437

The	O	1438-1441
two	O	1442-1445
polymorphisms	O	1446-1459
were	O	1460-1464
localized	O	1465-1474
in	O	1475-1477
noncoding	O	1478-1487
part	O	1488-1492
of	O	1493-1495
the	O	1496-1499
gene	O	1500-1504
1	O	1506-1507
)	O	1507-1508
a	O	1509-1510
C	O	1511-1512
/	O	1512-1513
G	O	1513-1514
polymorphism	O	1515-1527
in	O	1528-1530
the	O	1531-1534
promotor	O	1535-1543
region	O	1544-1550
,	O	1550-1551
142	O	1552-1555
bp	O	1556-1558
upstream	O	1559-1567
from	O	1568-1572
the	O	1573-1576
transcriptional	O	1577-1592
initiation	O	1593-1603
site	O	1604-1608
(	O	1609-1610
-	O	1610-1611
142C	O	1611-1615
/	O	1615-1616
G	O	1616-1617
)	O	1617-1618
,	O	1618-1619
and	O	1620-1623
2	O	1624-1625
)	O	1625-1626
a	O	1627-1628
6	O	1629-1630
bp	O	1631-1633
deletion	O	1634-1642
polymorphism	O	1643-1655
in	O	1656-1658
the	O	1659-1662
3	O	1663-1664
noncoding	O	1665-1674
part	O	1675-1679
of	O	1680-1682
the	O	1683-1686
CPO	O	1687-1690
gene	O	1691-1695
,	O	1695-1696
574	O	1697-1700
bp	O	1701-1703
downstream	O	1704-1714
of	O	1715-1717
the	O	1718-1721
last	O	1722-1726
base	O	1727-1731
of	O	1732-1734
the	O	1735-1738
normal	O	1739-1745
termination	O	1746-1757
codon	O	1758-1763
(	O	1764-1765
+	O	1765-1766
574	O	1767-1770
delATTCTT	O	1771-1780
)	O	1780-1781
.	O	1781-1782

Five	O	1783-1787
intragenic	O	1788-1798
dimorphisms	O	1799-1810
are	O	1811-1814
now	O	1815-1818
well	O	1819-1823
characterized	O	1824-1837
and	O	1838-1841
the	O	1842-1845
high	O	1846-1850
degree	O	1851-1857
of	O	1858-1860
allelic	O	1861-1868
heterogeneity	O	1869-1882
in	O	1883-1885
HC	B	1886-1888
is	O	1889-1891
demonstrated	O	1892-1904
with	O	1905-1909
seven	O	1910-1915
new	O	1916-1919
different	O	1920-1929
mutations	O	1930-1939
making	O	1940-1946
a	O	1947-1948
total	O	1949-1954
of	O	1955-1957
nineteen	O	1958-1966
CPO	O	1967-1970
gene	B	1971-1975
defects	I	1976-1983
reported	O	1984-1992
so	O	1993-1995
far	O	1996-1999
.	O	1999-2000
.	O	1999-2000

The	O	0-3
haptoglobin	O	4-15
-	O	15-16
gene	O	16-20
deletion	O	21-29
responsible	O	30-41
for	O	42-45
anhaptoglobinemia	B	46-63
.	O	63-64

We	O	65-67
have	O	68-72
found	O	73-78
an	O	79-81
allelic	O	82-89
deletion	O	90-98
of	O	99-101
the	O	102-105
haptoglobin	O	106-117
(	O	118-119
Hp	O	119-121
)	O	121-122
gene	O	123-127
from	O	128-132
an	O	133-135
individual	O	136-146
with	O	147-151
anhaptoglobinemia	B	152-169
.	O	169-170

The	O	171-174
Hp	O	175-177
gene	O	178-182
cluster	O	183-190
consists	O	191-199
of	O	200-202
coding	O	203-209
regions	O	210-217
of	O	218-220
the	O	221-224
alpha	O	225-230
chain	O	231-236
and	O	237-240
beta	O	241-245
chain	O	246-251
of	O	252-254
the	O	255-258
haptoglobin	O	259-270
gene	O	271-275
(	O	276-277
Hp	O	277-279
)	O	279-280
and	O	281-284
of	O	285-287
the	O	288-291
alpha	O	292-297
chain	O	298-303
and	O	304-307
beta	O	308-312
chain	O	313-318
of	O	319-321
the	O	322-325
haptoglobin	O	326-337
-	O	337-338
related	O	338-345
gene	O	346-350
(	O	351-352
Hpr	O	352-355
)	O	355-356
,	O	356-357
in	O	358-360
tandem	O	361-367
from	O	368-372
the	O	373-376
5	O	377-378
side	O	379-383
.	O	383-384

Southern	O	385-393
blot	O	394-398
and	O	399-402
PCR	O	403-406
analyses	O	407-415
have	O	416-420
indicated	O	421-430
that	O	431-435
the	O	436-439
individual	O	440-450
with	O	451-455
anhaptoglobinemia	B	456-473
was	O	474-477
homozygous	O	478-488
for	O	489-492
the	O	493-496
gene	O	497-501
deletion	O	502-510
and	O	511-514
that	O	515-519
the	O	520-523
gene	O	524-528
deletion	O	529-537
was	O	538-541
included	O	542-550
at	O	551-553
least	O	554-559
from	O	560-564
the	O	565-568
promoter	O	569-577
region	O	578-584
of	O	585-587
Hp	O	588-590
to	O	591-593
Hpr	O	594-597
alpha	O	598-603
but	O	604-607
not	O	608-611
to	O	612-614
Hpr	O	615-618
beta	O	619-623
(	O	624-625
Hpdel	O	625-630
)	O	630-631
.	O	631-632

In	O	633-635
addition	O	636-644
,	O	644-645
we	O	646-648
found	O	649-654
seven	O	655-660
individuals	O	661-672
with	O	673-677
hypohaptoglobinemia	B	678-697
in	O	698-700
three	O	701-706
families	O	707-715
,	O	715-716
and	O	717-720
the	O	721-724
genotypes	O	725-734
of	O	735-737
six	O	738-741
of	O	742-744
the	O	745-748
seven	O	749-754
individuals	O	755-766
were	O	767-771
found	O	772-777
to	O	778-780
be	O	781-783
Hp2	O	784-787
/	O	787-788
Hpdel	O	788-793
.	O	793-794

The	O	795-798
phenotypes	O	799-809
and	O	810-813
genotypes	O	814-823
in	O	824-826
one	O	827-830
of	O	831-833
these	O	834-839
three	O	840-845
families	O	846-854
showed	O	855-861
the	O	862-865
father	O	866-872
to	O	873-875
be	O	876-878
hypohaptoglobinemic	B	879-898
(	O	899-900
Hp2	O	900-903
)	O	903-904
and	O	905-908
Hp2	O	909-912
/	O	912-913
Hpdel	O	913-918
,	O	918-919
the	O	920-923
mother	O	924-930
to	O	931-933
be	O	934-936
Hp2	O	937-940
-	O	940-941
1	O	941-942
and	O	943-946
Hp1	O	947-950
/	O	950-951
Hp2	O	951-954
,	O	954-955
one	O	956-959
of	O	960-962
the	O	963-966
two	O	967-970
children	O	971-979
to	O	980-982
be	O	983-985
hypohaptoglobinemic	B	986-1005
(	O	1006-1007
Hp2	O	1007-1010
)	O	1010-1011
and	O	1012-1015
Hp2	O	1016-1019
/	O	1019-1020
Hpdel	O	1020-1025
,	O	1025-1026
and	O	1027-1030
the	O	1031-1034
other	O	1035-1040
child	O	1041-1046
to	O	1047-1049
be	O	1050-1052
Hp1	O	1053-1056
and	O	1057-1060
Hp1	O	1061-1064
/	O	1064-1065
Hpdel	O	1065-1070
,	O	1070-1071
showing	O	1072-1079
an	O	1080-1082
anomalous	O	1083-1092
inheritance	O	1093-1104
of	O	1105-1107
Hp	O	1108-1110
phenotypes	O	1111-1121
in	O	1122-1124
the	O	1125-1128
child	O	1129-1134
with	O	1135-1139
Hp1	O	1140-1143
.	O	1143-1144

The	O	1145-1148
Hp2	O	1149-1152
/	O	1152-1153
Hpdel	O	1153-1158
individuals	O	1159-1170
had	O	1171-1174
an	O	1175-1177
extremely	O	1178-1187
low	O	1188-1191
level	O	1192-1197
of	O	1198-1200
Hp	O	1201-1203
(	O	1204-1205
mean	O	1205-1209
+	O	1210-1211
/	O	1211-1212
-	O	1212-1213
SD	O	1213-1215
=	O	1216-1217
0	O	1218-1219
.	O	1219-1220
049	O	1221-1224
+	O	1225-1226
/	O	1226-1227
-	O	1227-1228
0	O	1228-1229
.	O	1229-1230

043	O	1231-1234
mg	O	1235-1237
/	O	1237-1238
ml	O	1238-1240
;	O	1240-1241
n	O	1242-1243
=	O	1244-1245
6	O	1246-1247
)	O	1247-1248
,	O	1248-1249
compared	O	1250-1258
with	O	1259-1263
the	O	1264-1267
level	O	1268-1273
(	O	1274-1275
1	O	1275-1276
.	O	1276-1277

64	O	1278-1280
+	O	1281-1282
/	O	1282-1283
-	O	1283-1284
1	O	1284-1285
.	O	1285-1286

07	O	1287-1289
mg	O	1290-1292
/	O	1292-1293
ml	O	1293-1295
)	O	1295-1296
obtained	O	1297-1305
from	O	1306-1310
52	O	1311-1313
healthy	O	1314-1321
volunteers	O	1322-1332
having	O	1333-1339
phenotype	O	1340-1349
Hp2	O	1350-1353
,	O	1353-1354
whereas	O	1355-1362
the	O	1363-1366
serum	O	1367-1372
Hp	O	1373-1375
level	O	1376-1381
of	O	1382-1384
an	O	1385-1387
individual	O	1388-1398
with	O	1399-1403
Hp1	O	1404-1407
/	O	1407-1408
Hpdel	O	1408-1413
was	O	1414-1417
0	O	1418-1419
.	O	1419-1420
50	O	1421-1423
mg	O	1424-1426
/	O	1426-1427
ml	O	1427-1429
,	O	1429-1430
which	O	1431-1436
was	O	1437-1440
approximately	O	1441-1454
half	O	1455-1459
the	O	1460-1463
level	O	1464-1469
of	O	1470-1472
Hp	O	1473-1475
in	O	1476-1478
control	O	1479-1486
sera	O	1487-1491
from	O	1492-1496
the	O	1497-1500
Hp1	O	1501-1504
phenotype	O	1505-1514
(	O	1515-1516
1	O	1516-1517
.	O	1517-1518
26	O	1519-1521
+	O	1522-1523
/	O	1523-1524
-	O	1524-1525
0	O	1525-1526
.	O	1526-1527

33	O	1528-1530
mg	O	1531-1533
/	O	1533-1534
ml	O	1534-1536
;	O	1536-1537
n	O	1538-1539
=	O	1540-1541
9	O	1542-1543
)	O	1543-1544
,	O	1544-1545
showing	O	1546-1553
a	O	1554-1555
gene	O	1556-1560
-	O	1560-1561
dosage	O	1561-1567
effect	O	1568-1574
.	O	1574-1575

The	O	1576-1579
other	O	1580-1585
allele	O	1586-1592
(	O	1593-1594
Hp2	O	1594-1597
)	O	1597-1598
of	O	1599-1601
individuals	O	1602-1613
with	O	1614-1618
Hp2	O	1619-1622
/	O	1622-1623
Hpdel	O	1623-1628
was	O	1629-1632
found	O	1633-1638
to	O	1639-1641
have	O	1642-1646
,	O	1646-1647
in	O	1648-1650
all	O	1651-1654
exons	O	1655-1660
,	O	1660-1661
no	O	1662-1664
mutation	O	1665-1673
,	O	1673-1674
by	O	1675-1677
DNA	O	1678-1681
sequencing	O	1682-1692
.	O	1692-1693

On	O	1694-1696
the	O	1697-1700
basis	O	1701-1706
of	O	1707-1709
the	O	1710-1713
present	O	1714-1721
study	O	1722-1727
,	O	1727-1728
the	O	1729-1732
mechanism	O	1733-1742
of	O	1743-1745
anhaptoglobinemia	B	1746-1763
and	O	1764-1767
the	O	1768-1771
mechanism	O	1772-1781
of	O	1782-1784
anomalous	O	1785-1794
inheritance	O	1795-1806
of	O	1807-1809
Hp	O	1810-1812
phenotypes	O	1813-1823
were	O	1824-1828
well	O	1829-1833
explained	O	1834-1843
.	O	1843-1844

However	O	1845-1852
,	O	1852-1853
the	O	1854-1857
mechanism	O	1858-1867
of	O	1868-1870
hypohaptoglobinemia	B	1871-1890
remains	O	1891-1898
unknown	O	1899-1906

Genotype	O	0-8
-	O	8-9
phenotype	O	9-18
correlations	O	19-31
in	O	32-34
attenuated	B	35-45
adenomatous	I	46-57
polyposis	I	58-67
coli	I	68-72
.	O	72-73

Germ	O	74-78
-	O	78-79
line	O	79-83
mutations	O	84-93
of	O	94-96
the	O	97-100
tumor	B	101-106
suppressor	O	107-117
APC	O	118-121
are	O	122-125
implicated	O	126-136
in	O	137-139
attenuated	B	140-150
adenomatous	I	151-162
polyposis	I	163-172
coli	I	173-177
(	O	178-179
AAPC	B	179-183
)	O	183-184
,	O	184-185
a	O	186-187
variant	O	188-195
of	O	196-198
familial	B	199-207
adenomatous	I	208-219
polyposis	I	220-229
(	O	230-231
FAP	B	231-234
)	O	234-235
.	O	235-236

AAPC	B	237-241
is	O	242-244
recognized	O	245-255
by	O	256-258
the	O	259-262
occurrence	O	263-273
of	O	274-276
<	O	277-278
100	O	279-282
colonic	B	283-290
adenomas	I	291-299
and	O	300-303
a	O	304-305
later	O	306-311
onset	O	312-317
of	O	318-320
colorectal	B	321-331
cancer	I	332-338
(	O	339-340
age	O	340-343
>	O	344-345
40	O	346-348
years	O	349-354
)	O	354-355
.	O	355-356

The	O	357-360
aim	O	361-364
of	O	365-367
this	O	368-372
study	O	373-378
was	O	379-382
to	O	383-385
assess	O	386-392
genotype	O	393-401
-	O	401-402
phenotype	O	402-411
correlations	O	412-424
in	O	425-427
AAPC	B	428-432
families	O	433-441
.	O	441-442

By	O	443-445
protein	O	446-453
-	O	453-454
truncation	O	454-464
test	O	465-469
(	O	470-471
PTT	O	471-474
)	O	474-475
assay	O	476-481
,	O	481-482
the	O	483-486
entire	O	487-493
coding	O	494-500
region	O	501-507
of	O	508-510
the	O	511-514
APC	B	515-518
gene	O	519-523
was	O	524-527
screened	O	528-536
in	O	537-539
affected	O	540-548
individuals	O	549-560
from	O	561-565
11	O	566-568
AAPC	B	569-573
kindreds	O	574-582
,	O	582-583
and	O	584-587
their	O	588-593
phenotypic	O	594-604
differences	O	605-616
were	O	617-621
examined	O	622-630
.	O	630-631

Five	O	632-636
novel	O	637-642
germ	O	643-647
-	O	647-648
line	O	648-652
APC	B	653-656
mutations	O	657-666
were	O	667-671
identified	O	672-682
in	O	683-685
seven	O	686-691
kindreds	O	692-700
.	O	700-701

Mutations	O	702-711
were	O	712-716
located	O	717-724
in	O	725-727
three	O	728-733
different	O	734-743
regions	O	744-751
of	O	752-754
the	O	755-758
APC	B	759-762
gene	O	763-767
(	O	769-770
1	O	770-771
)	O	771-772
at	O	773-775
the	O	776-779
5	O	780-781
end	O	782-785
spanning	O	786-794
exons	O	795-800
4	O	801-802
and	O	803-806
5	O	807-808
,	O	808-809
(	O	810-811
2	O	811-812
)	O	812-813
within	O	814-820
exon	O	821-825
9	O	826-827
,	O	827-828
and	O	829-832
(	O	833-834
3	O	834-835
)	O	835-836
at	O	837-839
the	O	840-843
3	O	844-845
distal	O	846-852
end	O	853-856
of	O	857-859
the	O	860-863
gene	O	864-868
.	O	868-869

Variability	O	870-881
in	O	882-884
the	O	885-888
number	O	889-895
of	O	896-898
colorectal	B	899-909
adenomas	I	910-918
was	O	919-922
most	O	923-927
apparent	O	928-936
in	O	937-939
individuals	O	940-951
with	O	952-956
mutations	O	957-966
in	O	967-969
region	O	970-976
1	O	977-978
,	O	978-979
and	O	980-983
upper	O	984-989
-	O	989-990
gastrointestinal	O	990-1006
manifestations	O	1007-1021
were	O	1022-1026
more	O	1027-1031
severe	O	1032-1038
in	O	1039-1041
them	O	1042-1046
.	O	1046-1047

In	O	1048-1050
individuals	O	1051-1062
with	O	1063-1067
mutations	O	1068-1077
in	O	1078-1080
either	O	1081-1087
region	O	1088-1094
2	O	1095-1096
or	O	1097-1099
region	O	1100-1106
3	O	1107-1108
,	O	1108-1109
the	O	1110-1113
average	O	1114-1121
number	O	1122-1128
of	O	1129-1131
adenomas	B	1132-1140
tended	O	1141-1147
to	O	1148-1150
be	O	1151-1153
lower	O	1154-1159
than	O	1160-1164
those	O	1165-1170
in	O	1171-1173
individuals	O	1174-1185
with	O	1186-1190
mutations	O	1191-1200
in	O	1201-1203
region	O	1204-1210
1	O	1211-1212
,	O	1212-1213
although	O	1214-1222
age	O	1223-1226
at	O	1227-1229
diagnosis	O	1230-1239
was	O	1240-1243
similar	O	1244-1251
.	O	1251-1252

In	O	1253-1255
all	O	1256-1259
AAPC	B	1260-1264
kindreds	O	1265-1273
,	O	1273-1274
a	O	1275-1276
predominance	O	1277-1289
of	O	1290-1292
right	O	1293-1298
-	O	1298-1299
sided	O	1299-1304
colorectal	B	1305-1315
adenomas	I	1316-1324
and	O	1325-1328
rectal	B	1329-1335
polyp	I	1336-1341
sparing	O	1342-1349
was	O	1350-1353
observed	O	1354-1362
.	O	1362-1363

No	O	1364-1366
desmoid	B	1367-1374
tumors	I	1375-1381
were	O	1382-1386
found	O	1387-1392
in	O	1393-1395
these	O	1396-1401
kindreds	O	1402-1410
.	O	1410-1411

Our	O	1412-1415
data	O	1416-1420
suggest	O	1421-1428
that	O	1429-1433
,	O	1433-1434
in	O	1435-1437
AAPC	B	1438-1442
families	O	1443-1451
,	O	1451-1452
the	O	1453-1456
location	O	1457-1465
of	O	1466-1468
the	O	1469-1472
APC	B	1473-1476
mutation	O	1477-1485
may	O	1486-1489
partially	O	1490-1499
predict	O	1500-1507
specific	O	1508-1516
phenotypic	O	1517-1527
expression	O	1528-1538
.	O	1538-1539

This	O	1540-1544
should	O	1545-1551
help	O	1552-1556
in	O	1557-1559
the	O	1560-1563
design	O	1564-1570
of	O	1571-1573
tailored	O	1574-1582
clinical	O	1583-1591
-	O	1591-1592
management	O	1592-1602
protocols	O	1603-1612
in	O	1613-1615
this	O	1616-1620
subset	O	1621-1627
of	O	1628-1630
FAP	B	1631-1634
patients	O	1635-1643
.	O	1643-1644
.	O	1643-1644

The	O	0-3
APC	B	4-7
variants	O	8-16
I1307K	O	17-23
and	O	24-27
E1317Q	O	28-34
are	O	35-38
associated	O	39-49
with	O	50-54
colorectal	B	55-65
tumors	I	66-72
,	O	72-73
but	O	74-77
not	O	78-81
always	O	82-88
with	O	89-93
a	O	94-95
family	O	96-102
history	O	103-110
.	O	110-111

Classical	O	112-121
familial	B	122-130
adenomatous	I	131-142
polyposis	I	143-152
(	O	153-154
FAP	B	154-157
)	O	157-158
is	O	159-161
a	O	162-163
high	O	164-168
-	O	168-169
penetrance	O	169-179
autosomal	B	180-189
dominant	I	190-198
disease	I	199-206
that	O	207-211
predisposes	O	212-223
to	O	224-226
hundreds	O	227-235
or	O	236-238
thousands	O	239-248
of	O	249-251
colorectal	B	252-262
adenomas	I	263-271
and	I	272-275
carcinoma	I	276-285
and	O	286-289
that	O	290-294
results	O	295-302
from	O	303-307
truncating	O	308-318
mutations	O	319-328
in	O	329-331
the	O	332-335
APC	B	336-339
gene	O	340-344
.	O	344-345

A	O	346-347
variant	O	348-355
of	O	356-358
FAP	B	359-362
is	O	363-365
attenuated	B	366-376
adenomatous	I	377-388
polyposis	I	389-398
coli	I	399-403
,	O	403-404
which	O	405-410
results	O	411-418
from	O	419-423
germ	O	424-428
-	O	428-429
line	O	429-433
mutations	O	434-443
in	O	444-446
the	O	447-450
5	O	451-452
and	O	453-456
3	O	457-458
regions	O	459-466
of	O	467-469
the	O	470-473
APC	B	474-477
gene	O	478-482
.	O	482-483

Attenuated	B	484-494
adenomatous	I	495-506
polyposis	I	507-516
coli	I	517-521
patients	O	522-530
have	O	531-535
"	O	536-537
multiple	O	538-546
"	O	547-548
colorectal	B	549-559
adenomas	I	560-568
(	O	569-570
typically	O	570-579
fewer	O	580-585
than	O	586-590
100	O	591-594
)	O	594-595
without	O	596-603
the	O	604-607
florid	O	608-614
phenotype	O	615-624
of	O	625-627
classical	O	628-637
FAP	B	638-641
.	O	641-642

Another	O	643-650
group	O	651-656
of	O	657-659
patients	O	660-668
with	O	669-673
multiple	O	674-682
adenomas	B	683-691
has	O	692-695
no	O	696-698
mutations	O	699-708
in	O	709-711
the	O	712-715
APC	B	716-719
gene	O	720-724
,	O	724-725
and	O	726-729
their	O	730-735
phenotype	O	736-745
probably	O	746-754
results	O	755-762
from	O	763-767
variation	O	768-777
at	O	778-780
a	O	781-782
locus	O	783-788
,	O	788-789
or	O	790-792
loci	O	793-797
,	O	797-798
elsewhere	O	799-808
in	O	809-811
the	O	812-815
genome	O	816-822
.	O	822-823

Recently	O	824-832
,	O	832-833
however	O	834-841
,	O	841-842
a	O	843-844
missense	O	845-853
variant	O	854-861
of	O	862-864
APC	B	865-868
(	O	869-870
I1307K	O	870-876
)	O	876-877
was	O	878-881
described	O	882-891
that	O	892-896
confers	O	897-904
an	O	905-907
increased	O	908-917
risk	O	918-922
of	O	923-925
colorectal	B	926-936
tumors	I	937-943
,	O	943-944
including	O	945-954
multiple	O	955-963
adenomas	B	964-972
,	O	972-973
in	O	974-976
Ashkenazim	O	977-987
.	O	987-988

We	O	989-991
have	O	992-996
studied	O	997-1004
a	O	1005-1006
set	O	1007-1010
of	O	1011-1013
164	O	1014-1017
patients	O	1018-1026
with	O	1027-1031
multiple	O	1032-1040
colorectal	B	1041-1051
adenomas	I	1052-1060
and	I	1061-1064
/	I	1064-1065
or	I	1065-1067
carcinoma	I	1068-1077
and	O	1078-1081
analyzed	O	1082-1090
codons	O	1091-1097
1263	O	1098-1102
-	O	1102-1103
1377	O	1103-1107
(	O	1108-1109
exon	O	1109-1113
15G	O	1114-1117
)	O	1117-1118
of	O	1119-1121
the	O	1122-1125
APC	B	1126-1129
gene	O	1130-1134
for	O	1135-1138
germ	O	1139-1143
-	O	1143-1144
line	O	1144-1148
variants	O	1149-1157
.	O	1157-1158

Three	O	1159-1164
patients	O	1165-1173
with	O	1174-1178
the	O	1179-1182
I1307K	O	1183-1189
allele	O	1190-1196
were	O	1197-1201
detected	O	1202-1210
,	O	1210-1211
each	O	1212-1216
of	O	1217-1219
Ashkenazi	O	1220-1229
descent	O	1230-1237
.	O	1237-1238

Four	O	1239-1243
patients	O	1244-1252
had	O	1253-1256
a	O	1257-1258
germ	O	1259-1263
-	O	1263-1264
line	O	1264-1268
E1317Q	O	1269-1275
missense	O	1276-1284
variant	O	1285-1292
of	O	1293-1295
APC	O	1296-1299
that	O	1300-1304
was	O	1305-1308
not	O	1309-1312
present	O	1313-1320
in	O	1321-1323
controls	O	1324-1332
;	O	1332-1333
one	O	1334-1337
of	O	1338-1340
these	O	1341-1346
individuals	O	1347-1358
had	O	1359-1362
an	O	1363-1365
unusually	O	1366-1375
large	O	1376-1381
number	O	1382-1388
of	O	1389-1391
metaplastic	B	1392-1403
polyps	I	1404-1410
of	I	1411-1413
the	I	1414-1417
colorectum	I	1418-1428
.	O	1428-1429

There	O	1430-1435
is	O	1436-1438
increasing	O	1439-1449
evidence	O	1450-1458
that	O	1459-1463
there	O	1464-1469
exist	O	1470-1475
germ	O	1476-1480
-	O	1480-1481
line	O	1481-1485
variants	O	1486-1494
of	O	1495-1497
the	O	1498-1501
APC	B	1502-1505
gene	O	1506-1510
that	O	1511-1515
predispose	O	1516-1526
to	O	1527-1529
the	O	1530-1533
development	O	1534-1545
of	O	1546-1548
multiple	O	1549-1557
colorectal	B	1558-1568
adenomas	I	1569-1577
and	I	1578-1581
carcinoma	I	1582-1591
,	O	1591-1592
but	O	1593-1596
without	O	1597-1604
the	O	1605-1608
florid	O	1609-1615
phenotype	O	1616-1625
of	O	1626-1628
classical	O	1629-1638
FAP	B	1639-1642
,	O	1642-1643
and	O	1644-1647
possibly	O	1648-1656
with	O	1657-1661
importance	O	1662-1672
for	O	1673-1676
colorectal	B	1677-1687
cancer	I	1688-1694
risk	O	1695-1699
in	O	1700-1702
the	O	1703-1706
general	O	1707-1714
population	O	1715-1725
.	O	1725-1726
.	O	1725-1726

The	O	0-3
hemochromatosis	B	4-19
845	O	20-23
G	O	24-25
-	O	25-26
-	O	25-26
>	O	27-28
A	O	28-29
and	O	30-33
187	O	34-37
C	O	38-39
-	O	39-40
-	O	39-40
>	O	41-42
G	O	42-43
mutations	O	44-53
:	O	53-54
prevalence	O	55-65
in	O	66-68
non	O	69-72
-	O	72-73
Caucasian	O	73-82
populations	O	83-94
.	O	94-95

Hemochromatosis	B	96-111
,	O	111-112
the	O	113-116
inherited	B	117-126
disorder	I	127-135
of	I	136-138
iron	I	139-143
metabolism	I	144-154
,	O	154-155
leads	O	156-161
,	O	161-162
if	O	163-165
untreated	O	166-175
,	O	175-176
to	O	177-179
progressive	O	180-191
iron	B	192-196
overload	I	197-205
and	O	206-209
premature	B	210-219
death	I	220-225
.	O	225-226

The	O	227-230
hemochromatosis	B	231-246
gene	O	247-251
,	O	251-252
HFE	O	253-256
,	O	256-257
recently	O	258-266
has	O	267-270
been	O	271-275
identified	O	276-286
,	O	286-287
and	O	288-291
characterization	O	292-308
of	O	309-311
this	O	312-316
gene	O	317-321
has	O	322-325
shown	O	326-331
that	O	332-336
it	O	337-339
contains	O	340-348
two	O	349-352
mutations	O	353-362
that	O	363-367
result	O	368-374
in	O	375-377
amino	O	378-383
acid	O	384-388
substitutions	O	389-402
-	O	402-403
cDNA	O	403-407
nucleotides	O	408-419
845	O	420-423
G	O	424-425
-	O	425-426
-	O	425-426
>	O	428-429
A	O	430-431
(	O	432-433
C282Y	O	433-438
)	O	438-439
and	O	440-443
187	O	444-447
C	O	448-449
-	O	449-450
-	O	449-450
>	O	452-453
G	O	454-455
(	O	456-457
H63D	O	457-461
)	O	461-462
.	O	462-463

Although	O	464-472
hemochromatosis	B	473-488
is	O	489-491
common	O	492-498
in	O	499-501
Caucasians	O	502-512
,	O	512-513
affecting	O	514-523
>	O	524-525
=	O	526-527
1	O	528-529
/	O	529-530
300	O	530-533
individuals	O	534-545
of	O	546-548
northern	O	549-557
European	O	558-566
origin	O	567-573
,	O	573-574
it	O	575-577
has	O	578-581
not	O	582-585
been	O	586-590
recognized	O	591-601
in	O	602-604
other	O	605-610
populations	O	611-622
.	O	622-623

The	O	624-627
present	O	628-635
study	O	636-641
used	O	642-646
PCR	O	647-650
and	O	651-654
restriction	O	655-666
-	O	666-667
enzyme	O	667-673
digestion	O	674-683
to	O	684-686
analyze	O	687-694
the	O	695-698
frequency	O	699-708
of	O	709-711
the	O	712-715
845	O	716-719
G	O	720-721
-	O	721-722
-	O	721-722
>	O	724-725
A	O	726-727
and	O	728-731
187	O	732-735
C	O	736-737
-	O	737-738
-	O	737-738
>	O	740-741
G	O	742-743
mutations	O	744-753
in	O	754-756
HLA	O	757-760
-	O	760-761
typed	O	761-766
samples	O	767-774
from	O	775-779
non	O	780-783
-	O	783-784
Caucasian	O	784-793
populations	O	794-805
,	O	805-806
comprising	O	807-817
Australian	O	818-828
Aboriginal	O	829-839
,	O	839-840
Chinese	O	841-848
,	O	848-849
and	O	850-853
Pacific	O	854-861
Islanders	O	862-871
.	O	871-872

Results	O	873-880
showed	O	881-887
that	O	888-892
the	O	893-896
845	O	897-900
G	O	901-902
-	O	902-903
-	O	902-903
>	O	905-906
A	O	907-908
mutation	O	909-917
was	O	918-921
present	O	922-929
in	O	930-932
these	O	933-938
populations	O	939-950
(	O	951-952
allele	O	952-958
frequency	O	959-968
0	O	969-970
.	O	970-971
32	O	972-974
%	O	974-975
)	O	975-976
,	O	976-977
and	O	978-981
,	O	981-982
furthermore	O	983-994
,	O	994-995
it	O	996-998
was	O	999-1002
always	O	1003-1009
seen	O	1010-1014
in	O	1015-1017
conjunction	O	1018-1029
with	O	1030-1034
HLA	O	1035-1038
haplotypes	O	1039-1049
common	O	1050-1056
in	O	1057-1059
Caucasians	O	1060-1070
,	O	1070-1071
suggesting	O	1072-1082
that	O	1083-1087
845	O	1088-1091
G	O	1092-1093
-	O	1093-1094
-	O	1093-1094
>	O	1096-1097
A	O	1098-1099
may	O	1100-1103
have	O	1104-1108
been	O	1109-1113
introduced	O	1114-1124
into	O	1125-1129
these	O	1130-1135
populations	O	1136-1147
by	O	1148-1150
Caucasian	O	1151-1160
admixture	O	1161-1170
.	O	1170-1171

187	O	1172-1175
C	O	1176-1177
-	O	1177-1178
-	O	1177-1178
>	O	1180-1181
G	O	1182-1183
was	O	1184-1187
present	O	1188-1195
at	O	1196-1198
an	O	1199-1201
allele	O	1202-1208
frequency	O	1209-1218
of	O	1219-1221
2	O	1222-1223
.	O	1223-1224
68	O	1225-1227
%	O	1227-1228
in	O	1229-1231
the	O	1232-1235
two	O	1236-1239
populations	O	1240-1251
analyzed	O	1252-1260
(	O	1261-1262
Australian	O	1262-1272
Aboriginal	O	1273-1283
and	O	1284-1287
Chinese	O	1288-1295
)	O	1295-1296
.	O	1296-1297

In	O	1298-1300
the	O	1301-1304
Australian	O	1305-1315
Aboriginal	O	1316-1326
samples	O	1327-1334
,	O	1334-1335
187	O	1336-1339
C	O	1340-1341
-	O	1341-1342
-	O	1341-1342
>	O	1344-1345
G	O	1346-1347
was	O	1348-1351
found	O	1352-1357
to	O	1358-1360
be	O	1361-1363
associated	O	1364-1374
with	O	1375-1379
HLA	O	1380-1383
haplotypes	O	1384-1394
common	O	1395-1401
in	O	1402-1404
Caucasians	O	1405-1415
,	O	1415-1416
suggesting	O	1417-1427
that	O	1428-1432
it	O	1433-1435
was	O	1436-1439
introduced	O	1440-1450
by	O	1451-1453
recent	O	1454-1460
admixture	O	1461-1470
.	O	1470-1471

In	O	1472-1474
the	O	1475-1478
Chinese	O	1479-1486
samples	O	1487-1494
analyzed	O	1495-1503
,	O	1503-1504
187	O	1505-1508
C	O	1509-1510
-	O	1510-1511
-	O	1510-1511
>	O	1513-1514
G	O	1515-1516
was	O	1517-1520
present	O	1521-1528
in	O	1529-1531
association	O	1532-1543
with	O	1544-1548
a	O	1549-1550
wide	O	1551-1555
variety	O	1556-1563
of	O	1564-1566
HLA	O	1567-1570
haplotypes	O	1571-1581
,	O	1581-1582
showing	O	1583-1590
this	O	1591-1595
mutation	O	1596-1604
to	O	1605-1607
be	O	1608-1610
widespread	O	1611-1621
and	O	1622-1625
likely	O	1626-1632
to	O	1633-1635
predate	O	1636-1643
the	O	1644-1647
more	O	1648-1652
genetically	O	1653-1664
restricted	O	1665-1675
845	O	1676-1679
G	O	1680-1681
-	O	1681-1682
-	O	1681-1682
>	O	1684-1685
A	O	1686-1687
mutation	O	1688-1696
.	O	1696-1697

BRCA1	O	0-5
required	O	6-14
for	O	15-18
transcription	O	19-32
-	O	32-33
coupled	O	33-40
repair	O	41-47
of	O	48-50
oxidative	O	51-60
DNA	O	61-64
damage	O	65-71
.	O	71-72

The	O	73-76
breast	B	77-83
and	I	84-87
ovarian	I	88-95
cancer	I	96-102
susceptibility	O	103-117
gene	O	118-122
BRCA1	O	123-128
encodes	O	129-136
a	O	137-138
zinc	O	139-143
finger	O	144-150
protein	O	151-158
of	O	159-161
unknown	O	162-169
function	O	170-178
.	O	178-179

Association	O	180-191
of	O	192-194
the	O	195-198
BRCA1	O	199-204
protein	O	205-212
with	O	213-217
the	O	218-221
DNA	O	222-225
repair	O	226-232
protein	O	233-240
Rad51	O	241-246
and	O	247-250
changes	O	251-258
in	O	259-261
the	O	262-265
phosphorylation	O	266-281
and	O	282-285
cellular	O	286-294
localization	O	295-307
of	O	308-310
the	O	311-314
protein	O	315-322
after	O	323-328
exposure	O	329-337
to	O	338-340
DNA	O	341-344
-	O	344-345
damaging	O	345-353
agents	O	354-360
are	O	361-364
consistent	O	365-375
with	O	376-380
a	O	381-382
role	O	383-387
for	O	388-391
BRCA1	O	392-397
in	O	398-400
DNA	O	401-404
repair	O	405-411
.	O	411-412

Here	O	413-417
,	O	417-418
it	O	419-421
is	O	422-424
shown	O	425-430
that	O	431-435
mouse	O	436-441
embryonic	O	442-451
stem	O	452-456
cells	O	457-462
deficient	B	463-472
in	I	473-475
BRCA1	I	476-481
are	O	482-485
defective	O	486-495
in	O	496-498
the	O	499-502
ability	O	503-510
to	O	511-513
carry	O	514-519
out	O	520-523
transcription	O	524-537
-	O	537-538
coupled	O	538-545
repair	O	546-552
of	O	553-555
oxidative	O	556-565
DNA	O	566-569
damage	O	570-576
,	O	576-577
and	O	578-581
are	O	582-585
hypersensitive	O	586-600
to	O	601-603
ionizing	O	604-612
radiation	O	613-622
and	O	623-626
hydrogen	O	627-635
peroxide	O	636-644
.	O	644-645

These	O	646-651
results	O	652-659
suggest	O	660-667
that	O	668-672
BRCA1	O	673-678
participates	O	679-691
,	O	691-692
directly	O	693-701
or	O	702-704
indirectly	O	705-715
,	O	715-716
in	O	717-719
transcription	O	720-733
-	O	733-734
coupled	O	734-741
repair	O	742-748
of	O	749-751
oxidative	O	752-761
DNA	O	762-765
damage	O	766-772
.	O	772-773
.	O	772-773

A	O	0-1
mouse	O	2-7
model	O	8-13
of	O	14-16
severe	O	17-23
von	B	24-27
Willebrand	I	28-38
disease	I	39-46
:	O	46-47
defects	O	48-55
in	O	56-58
hemostasis	O	59-69
and	O	70-73
thrombosis	B	74-84
.	O	84-85

von	B	86-89
Willebrand	I	90-100
factor	I	101-107
(	I	108-109
vWf	I	109-112
)	I	112-113
deficiency	I	114-124
causes	O	125-131
severe	O	132-138
von	B	139-142
Willebrand	I	143-153
disease	I	154-161
in	O	162-164
humans	O	165-171
.	O	171-172

We	O	173-175
generated	O	176-185
a	O	186-187
mouse	O	188-193
model	O	194-199
for	O	200-203
this	O	204-208
disease	O	209-216
by	O	217-219
using	O	220-225
gene	O	226-230
targeting	O	231-240
.	O	240-241

vWf	B	242-245
-	I	245-246
deficient	I	246-255
mice	O	256-260
appeared	O	261-269
normal	O	270-276
at	O	277-279
birth	O	280-285
;	O	285-286
they	O	287-291
were	O	292-296
viable	O	297-303
and	O	304-307
fertile	O	308-315
.	O	315-316

Neither	O	317-324
vWf	O	325-328
nor	O	329-332
vWf	O	333-336
propolypeptide	O	337-351
(	O	352-353
von	B	353-356
Willebrand	I	357-367
antigen	O	368-375
II	O	376-378
)	O	378-379
were	O	380-384
detectable	O	385-395
in	O	396-398
plasma	O	399-405
,	O	405-406
platelets	O	407-416
,	O	416-417
or	O	418-420
endothelial	O	421-432
cells	O	433-438
of	O	439-441
the	O	442-445
homozygous	O	446-456
mutant	O	457-463
mice	O	464-468
.	O	468-469

The	O	470-473
mutant	O	474-480
mice	O	481-485
exhibited	O	486-495
defects	O	496-503
in	O	504-506
hemostasis	O	507-517
with	O	518-522
a	O	523-524
highly	O	525-531
prolonged	O	532-541
bleeding	O	542-550
time	O	551-555
and	O	556-559
spontaneous	O	560-571
bleeding	O	572-580
events	O	581-587
in	O	588-590
approximately	O	591-604
10	O	605-607
%	O	607-608
of	O	609-611
neonates	O	612-620
.	O	620-621

As	O	622-624
in	O	625-627
the	O	628-631
human	O	632-637
disease	O	638-645
,	O	645-646
the	O	647-650
factor	O	651-657
VIII	O	658-662
level	O	663-668
in	O	669-671
these	O	672-677
mice	O	678-682
was	O	683-686
reduced	O	687-694
strongly	O	695-703
as	O	704-706
a	O	707-708
result	O	709-715
of	O	716-718
the	O	719-722
lack	O	723-727
of	O	728-730
protection	O	731-741
provided	O	742-750
by	O	751-753
vWf	O	754-757
.	O	757-758

Defective	O	759-768
thrombosis	B	769-779
in	O	780-782
mutant	O	783-789
mice	O	790-794
was	O	795-798
also	O	799-803
evident	O	804-811
in	O	812-814
an	O	815-817
in	O	818-820
vivo	O	821-825
model	O	826-831
of	O	832-834
vascular	B	835-843
injury	I	844-850
.	O	850-851

In	O	852-854
this	O	855-859
model	O	860-865
,	O	865-866
the	O	867-870
exteriorized	O	871-883
mesentery	O	884-893
was	O	894-897
superfused	O	898-908
with	O	909-913
ferric	O	914-920
chloride	O	921-929
and	O	930-933
the	O	934-937
accumulation	O	938-950
of	O	951-953
fluorescently	O	954-967
labeled	O	968-975
platelets	O	976-985
was	O	986-989
observed	O	990-998
by	O	999-1001
intravital	O	1002-1012
microscopy	O	1013-1023
.	O	1023-1024

We	O	1025-1027
conclude	O	1028-1036
that	O	1037-1041
these	O	1042-1047
mice	O	1048-1052
very	O	1053-1057
closely	O	1058-1065
mimic	O	1066-1071
severe	O	1072-1078
human	O	1079-1084
von	B	1085-1088
Willebrand	I	1089-1099
disease	I	1100-1107
and	O	1108-1111
will	O	1112-1116
be	O	1117-1119
very	O	1120-1124
useful	O	1125-1131
for	O	1132-1135
investigating	O	1136-1149
the	O	1150-1153
role	O	1154-1158
of	O	1159-1161
vWf	O	1162-1165
in	O	1166-1168
normal	O	1169-1175
physiology	O	1176-1186
and	O	1187-1190
in	O	1191-1193
disease	O	1194-1201
models	O	1202-1208
.	O	1208-1209
.	O	1208-1209

The	O	0-3
von	B	4-7
Hippel	I	8-14
-	I	14-15
Lindau	I	15-21
tumor	I	22-27
suppressor	O	28-38
gene	O	39-43
is	O	44-46
required	O	47-55
for	O	56-59
cell	O	60-64
cycle	O	65-70
exit	O	71-75
upon	O	76-80
serum	O	81-86
withdrawal	O	87-97
.	O	97-98

The	O	99-102
inactivation	O	103-115
of	O	116-118
the	O	119-122
von	B	123-126
Hippel	I	127-133
-	I	133-134
Lindau	I	134-140
(	I	141-142
VHL	I	142-145
)	I	145-146
tumor	I	147-152
suppressor	O	153-163
gene	O	164-168
predisposes	O	169-180
affected	O	181-189
individuals	O	190-201
to	O	202-204
the	O	205-208
human	O	209-214
VHL	B	215-218
cancer	I	219-225
syndrome	I	226-234
and	O	235-238
is	O	239-241
associated	O	242-252
with	O	253-257
sporadic	B	258-266
renal	I	267-272
cell	I	273-277
carcinomas	I	278-288
(	O	289-290
RCC	B	290-293
)	O	293-294
and	O	295-298
brain	B	299-304
hemangioblastomas	I	305-322
.	O	322-323

VHL	O	324-327
-	O	327-328
negative	O	328-336
786	O	337-340
-	O	340-341
0	O	341-342
RCC	B	343-346
cells	O	347-352
are	O	353-356
tumorigenic	O	357-368
in	O	369-371
nude	O	372-376
mice	O	377-381
which	O	382-387
is	O	388-390
suppressed	O	391-401
by	O	402-404
the	O	405-408
reintroduction	O	409-423
of	O	424-426
VHL	B	427-430
.	O	430-431

Remarkably	O	432-442
,	O	442-443
this	O	444-448
occurs	O	449-455
without	O	456-463
affecting	O	464-473
the	O	474-477
growth	O	478-484
rate	O	485-489
and	O	490-493
cell	O	494-498
cycle	O	499-504
profile	O	505-512
of	O	513-515
these	O	516-521
cells	O	522-527
in	O	528-530
culture	O	531-538
.	O	538-539

The	O	540-543
786	O	544-547
-	O	547-548
0	O	548-549
cell	O	550-554
line	O	555-559
,	O	559-560
like	O	561-565
many	O	566-570
cancer	B	571-577
cells	O	578-583
,	O	583-584
fails	O	585-590
to	O	591-593
exit	O	594-598
the	O	599-602
cell	O	603-607
cycle	O	608-613
upon	O	614-618
serum	O	619-624
withdrawal	O	625-635
.	O	635-636

Here	O	637-641
,	O	641-642
it	O	643-645
is	O	646-648
shown	O	649-654
that	O	655-659
reintroduction	O	660-674
of	O	675-677
the	O	678-681
wild	O	682-686
-	O	686-687
type	O	687-691
VHL	B	692-695
gene	O	696-700
restores	O	701-709
the	O	710-713
ability	O	714-721
of	O	722-724
VHL	O	725-728
-	O	728-729
negative	O	729-737
RCC	B	738-741
cancer	I	742-748
cells	O	749-754
to	O	755-757
exit	O	758-762
the	O	763-766
cell	O	767-771
cycle	O	772-777
and	O	778-781
enter	O	782-787
G0	O	788-790
/	O	790-791
quiescence	O	791-801
in	O	802-804
low	O	805-808
serum	O	809-814
.	O	814-815

Both	O	816-820
VHL	O	821-824
-	O	824-825
positive	O	825-833
and	O	834-837
VHL	O	838-841
-	O	841-842
negative	O	842-850
RCC	B	851-854
cells	O	855-860
exit	O	861-865
the	O	866-869
cell	O	870-874
cycle	O	875-880
by	O	881-883
contact	O	884-891
inhibition	O	892-902
.	O	902-903

The	O	904-907
cyclin	O	908-914
-	O	914-915
dependent	O	915-924
kinase	O	925-931
inhibitor	O	932-941
,	O	941-942
p27	O	943-946
,	O	946-947
accumulates	O	948-959
upon	O	960-964
serum	O	965-970
withdrawal	O	971-981
,	O	981-982
only	O	983-987
in	O	988-990
the	O	991-994
presence	O	995-1003
of	O	1004-1006
VHL	B	1007-1010
,	O	1010-1011
as	O	1012-1014
a	O	1015-1016
result	O	1017-1023
of	O	1024-1026
the	O	1027-1030
stabilization	O	1031-1044
of	O	1045-1047
the	O	1048-1051
protein	O	1052-1059
.	O	1059-1060

We	O	1061-1063
propose	O	1064-1071
that	O	1072-1076
the	O	1077-1080
loss	O	1081-1085
of	O	1086-1088
wild	O	1089-1093
-	O	1093-1094
type	O	1094-1098
VHL	B	1099-1102
gene	O	1103-1107
results	O	1108-1115
in	O	1116-1118
a	O	1119-1120
specific	O	1121-1129
cellular	O	1130-1138
defect	O	1139-1145
in	O	1146-1148
serum	O	1149-1154
-	O	1154-1155
dependent	O	1155-1164
growth	O	1165-1171
control	O	1172-1179
,	O	1179-1180
which	O	1181-1186
may	O	1187-1190
initiate	O	1191-1199
tumor	B	1200-1205
formation	O	1206-1215
.	O	1215-1216

This	O	1217-1221
is	O	1222-1224
corrected	O	1225-1234
by	O	1235-1237
the	O	1238-1241
reintroduction	O	1242-1256
of	O	1257-1259
wild	O	1260-1264
-	O	1264-1265
type	O	1265-1269
VHL	B	1270-1273
,	O	1273-1274
implicating	O	1275-1286
VHL	B	1287-1290
as	O	1291-1293
the	O	1294-1297
first	O	1298-1303
tumor	B	1304-1309
suppressor	O	1310-1320
involved	O	1321-1329
in	O	1330-1332
the	O	1333-1336
regulation	O	1337-1347
of	O	1348-1350
cell	O	1351-1355
cycle	O	1356-1361
exit	O	1362-1366
,	O	1366-1367
which	O	1368-1373
is	O	1374-1376
consistent	O	1377-1387
with	O	1388-1392
its	O	1393-1396
gatekeeper	O	1397-1407
function	O	1408-1416
in	O	1417-1419
the	O	1420-1423
kidney	O	1424-1430
.	O	1430-1431
.	O	1430-1431

Nonsense	O	0-8
mutation	O	9-17
in	O	18-20
exon	O	21-25
4	O	26-27
of	O	28-30
human	O	31-36
complement	O	37-47
C9	O	48-50
gene	O	51-55
is	O	56-58
the	O	59-62
major	O	63-68
cause	O	69-74
of	O	75-77
Japanese	O	78-86
complement	B	87-97
C9	I	98-100
deficiency	I	101-111
.	O	111-112

Deficiency	B	113-123
of	I	124-126
the	I	127-130
ninth	I	131-136
component	I	137-146
of	I	147-149
human	I	150-155
complement	I	156-166
(	O	167-168
C9	O	168-170
)	O	170-171
is	O	172-174
the	O	175-178
most	O	179-183
common	O	184-190
complement	B	191-201
deficiency	I	202-212
in	O	213-215
Japan	O	216-221
but	O	222-225
is	O	226-228
rare	O	229-233
in	O	234-236
other	O	237-242
countries	O	243-252
.	O	252-253

We	O	254-256
studied	O	257-264
the	O	265-268
molecular	O	269-278
basis	O	279-284
of	O	285-287
C9	B	288-290
deficiency	I	291-301
in	O	302-304
four	O	305-309
Japanese	O	310-318
C9	B	319-321
-	I	321-322
deficient	I	322-331
patients	O	332-340
who	O	341-344
had	O	345-348
suffered	O	349-357
from	O	358-362
meningococcal	B	363-376
meningitis	I	377-387
.	O	387-388

Direct	O	389-395
sequencing	O	396-406
of	O	407-409
amplified	O	410-419
C9	O	420-422
cDNA	O	423-427
and	O	428-431
DNA	O	432-435
revealed	O	436-444
a	O	445-446
nonsense	O	447-455
substitution	O	456-468
(	O	469-470
CGA	O	470-473
-	O	473-474
-	O	473-474
>	O	476-477
TGA	O	478-481
)	O	481-482
at	O	483-485
codon	O	486-491
95	O	492-494
in	O	495-497
exon	O	498-502
4	O	503-504
in	O	505-507
the	O	508-511
four	O	512-516
C9	B	517-519
-	I	519-520
deficient	I	520-529
individuals	O	530-541
.	O	541-542

An	O	543-545
allele	O	546-552
-	O	552-553
specific	O	553-561
polymerase	O	562-572
chain	O	573-578
reaction	O	579-587
system	O	588-594
designed	O	595-603
to	O	604-606
detect	O	607-613
exclusively	O	614-625
only	O	626-630
one	O	631-634
of	O	635-637
the	O	638-641
normal	O	642-648
and	O	649-652
mutant	O	653-659
alleles	O	660-667
indicated	O	668-677
that	O	678-682
all	O	683-686
the	O	687-690
four	O	691-695
patients	O	696-704
were	O	705-709
homozygous	O	710-720
for	O	721-724
the	O	725-728
mutation	O	729-737
in	O	738-740
exon	O	741-745
4	O	746-747
and	O	748-751
that	O	752-756
the	O	757-760
parents	O	761-768
of	O	769-771
patient	O	772-779
2	O	780-781
were	O	782-786
heterozygous	O	787-799
.	O	799-800

The	O	801-804
common	O	805-811
mutation	O	812-820
at	O	821-823
codon	O	824-829
95	O	830-832
in	O	833-835
exon	O	836-840
4	O	841-842
might	O	843-848
be	O	849-851
responsible	O	852-863
for	O	864-867
most	O	868-872
Japanese	O	873-881
C9	B	882-884
deficiency	I	885-895
.	O	895-896
.	O	895-896

Human	B	0-5
complement	I	6-16
factor	I	17-23
H	I	24-25
deficiency	I	26-36
associated	O	37-47
with	O	48-52
hemolytic	B	53-62
uremic	I	63-69
syndrome	I	70-78
.	O	78-79

This	O	80-84
study	O	85-90
reports	O	91-98
on	O	99-101
six	O	102-105
cases	O	106-111
of	O	112-114
deficiency	B	115-125
in	I	126-128
the	I	129-132
human	I	133-138
complement	I	139-149
regulatory	I	150-160
protein	I	161-168
Factor	I	169-175
H	I	176-177
(	O	178-179
FH	O	179-181
)	O	181-182
in	O	183-185
the	O	186-189
context	O	190-197
of	O	198-200
an	O	201-203
acute	B	204-209
renal	I	210-215
disease	I	216-223
.	O	223-224

Five	O	225-229
of	O	230-232
the	O	233-236
cases	O	237-242
were	O	243-247
observed	O	248-256
in	O	257-259
children	O	260-268
presenting	O	269-279
with	O	280-284
idiopathic	O	285-295
hemolytic	B	296-305
uremic	I	306-312
syndrome	I	313-321
(	O	322-323
HUS	B	323-326
)	O	326-327
.	O	327-328

Two	O	329-332
of	O	333-335
the	O	336-339
children	O	340-348
exhibited	O	349-358
a	O	359-360
homozygous	O	361-371
deficiency	O	372-382
characterized	O	383-396
by	O	397-399
the	O	400-403
absence	O	404-411
of	O	412-414
the	O	415-418
150	O	419-422
-	O	422-423
kD	O	423-425
form	O	426-430
of	O	431-433
Factor	O	434-440
H	O	441-442
and	O	443-446
the	O	447-450
presence	O	451-459
,	O	459-460
upon	O	461-465
immunoblotting	O	466-480
,	O	480-481
of	O	482-484
the	O	485-488
42	O	489-491
-	O	491-492
kD	O	492-494
Factor	O	495-501
H	O	502-503
-	O	503-504
like	O	504-508
protein	O	509-516
1	O	517-518
(	O	519-520
FHL	O	520-523
-	O	523-524
1	O	524-525
)	O	525-526
and	O	527-530
other	O	531-536
FH	O	537-539
-	O	539-540
related	O	540-547
protein	O	548-555
(	O	556-557
FHR	O	557-560
)	O	560-561
bands	O	562-567
.	O	567-568

Southern	O	569-577
blot	O	578-582
and	O	583-586
PCR	O	587-590
analysis	O	591-599
of	O	600-602
DNA	O	603-606
of	O	607-609
one	O	610-613
patient	O	614-621
with	O	622-626
homozygous	O	627-637
deficiency	O	638-648
ruled	O	649-654
out	O	655-658
the	O	659-662
presence	O	663-671
of	O	672-674
a	O	675-676
large	O	677-682
deletion	O	683-691
of	O	692-694
the	O	695-698
FH	O	699-701
gene	O	702-706
as	O	707-709
the	O	710-713
underlying	O	714-724
defect	O	725-731
for	O	732-735
the	O	736-739
deficiency	O	740-750
.	O	750-751

The	O	752-755
other	O	756-761
four	O	762-766
children	O	767-775
presented	O	776-785
with	O	786-790
heterozygous	O	791-803
deficiency	O	804-814
and	O	815-818
exhibited	O	819-828
a	O	829-830
normal	O	831-837
immunoblotting	O	838-852
pattern	O	853-860
of	O	861-863
proteins	O	864-872
of	O	873-875
the	O	876-879
FH	O	880-882
family	O	883-889
.	O	889-890

Factor	B	891-897
H	I	898-899
deficiency	I	900-910
is	O	911-913
the	O	914-917
only	O	918-922
complement	B	923-933
deficiency	I	934-944
associated	O	945-955
with	O	956-960
HUS	B	961-964
.	O	964-965

These	O	966-971
observations	O	972-984
suggest	O	985-992
a	O	993-994
role	O	995-999
for	O	1000-1003
FH	O	1004-1006
and	O	1007-1010
/	O	1010-1011
or	O	1011-1013
FH	O	1014-1016
receptors	O	1017-1026
in	O	1027-1029
the	O	1030-1033
pathogenesis	O	1034-1046
of	O	1047-1049
idiopathic	O	1050-1060
HUS	B	1061-1064
.	O	1064-1065
.	O	1064-1065

Cell	O	0-4
cycle	O	5-10
-	O	10-11
dependent	O	11-20
colocalization	O	21-35
of	O	36-38
BARD1	O	39-44
and	O	45-48
BRCA1	O	49-54
proteins	O	55-63
in	O	64-66
discrete	O	67-75
nuclear	O	76-83
domains	O	84-91
.	O	91-92

Germ	O	93-97
-	O	97-98
line	O	98-102
mutations	O	103-112
of	O	113-115
the	O	116-119
BRCA1	O	120-125
gene	O	126-130
predispose	O	131-141
women	O	142-147
to	O	148-150
early	O	151-156
-	O	156-157
onset	O	157-162
breast	B	163-169
and	I	170-173
ovarian	I	174-181
cancer	I	182-188
by	O	189-191
compromising	O	192-204
the	O	205-208
genes	O	209-214
presumptive	O	215-226
function	O	227-235
as	O	236-238
a	O	239-240
tumor	B	241-246
suppressor	O	247-257
.	O	257-258

Although	O	259-267
the	O	268-271
biochemical	O	272-283
properties	O	284-294
of	O	295-297
BRCA1	O	298-303
polypeptides	O	304-316
are	O	317-320
not	O	321-324
understood	O	325-335
,	O	335-336
their	O	337-342
expression	O	343-353
pattern	O	354-361
and	O	362-365
subcellular	O	366-377
localization	O	378-390
suggest	O	391-398
a	O	399-400
role	O	401-405
in	O	406-408
cell	O	409-413
-	O	413-414
cycle	O	414-419
regulation	O	420-430
.	O	430-431

When	O	432-436
resting	O	437-444
cells	O	445-450
are	O	451-454
induced	O	455-462
to	O	463-465
proliferate	O	466-477
,	O	477-478
the	O	479-482
steady	O	483-489
-	O	489-490
state	O	490-495
levels	O	496-502
of	O	503-505
BRCA1	O	506-511
increase	O	512-520
in	O	521-523
late	O	524-528
G1	O	529-531
and	O	532-535
reach	O	536-541
a	O	542-543
maximum	O	544-551
during	O	552-558
S	O	559-560
phase	O	561-566
.	O	566-567

Moreover	O	568-576
,	O	576-577
in	O	578-580
S	O	581-582
phase	O	583-588
cells	O	589-594
,	O	594-595
BRCA1	O	596-601
polypeptides	O	602-614
are	O	615-618
hyperphosphorylated	O	619-638
and	O	639-642
accumulate	O	643-653
into	O	654-658
discrete	O	659-667
subnuclear	O	668-678
foci	O	679-683
termed	O	684-690
"	O	691-692
BRCA1	O	693-698
nuclear	O	699-706
dots	O	707-711
.	O	711-712

"	O	713-714
BRCA1	O	715-720
associates	O	721-731
in	O	732-734
vivo	O	735-739
with	O	740-744
a	O	745-746
structurally	O	747-759
related	O	760-767
protein	O	768-775
termed	O	776-782
BARD1	O	783-788
.	O	788-789

Here	O	790-794
we	O	795-797
show	O	798-802
that	O	803-807
the	O	808-811
steady	O	812-818
-	O	818-819
state	O	819-824
levels	O	825-831
of	O	832-834
BARD1	O	835-840
,	O	840-841
unlike	O	842-848
those	O	849-854
of	O	855-857
BRCA1	O	858-863
,	O	863-864
remain	O	865-871
relatively	O	872-882
constant	O	883-891
during	O	892-898
cell	O	899-903
cycle	O	904-909
progression	O	910-921
.	O	921-922

However	O	923-930
,	O	930-931
immunostaining	O	932-946
revealed	O	947-955
that	O	956-960
BARD1	O	961-966
resides	O	967-974
within	O	975-981
BRCA1	O	982-987
nuclear	O	988-995
dots	O	996-1000
during	O	1001-1007
S	O	1008-1009
phase	O	1010-1015
of	O	1016-1018
the	O	1019-1022
cell	O	1023-1027
cycle	O	1028-1033
,	O	1033-1034
but	O	1035-1038
not	O	1039-1042
during	O	1043-1049
the	O	1050-1053
G1	O	1054-1056
phase	O	1057-1062
.	O	1062-1063

Nevertheless	O	1064-1076
,	O	1076-1077
BARD1	O	1078-1083
polypeptides	O	1084-1096
are	O	1097-1100
found	O	1101-1106
exclusively	O	1107-1118
in	O	1119-1121
the	O	1122-1125
nuclear	O	1126-1133
fractions	O	1134-1143
of	O	1144-1146
both	O	1147-1151
G1	O	1152-1154
-	O	1154-1155
and	O	1156-1159
S	O	1160-1161
-	O	1161-1162
phase	O	1162-1167
cells	O	1168-1173
.	O	1173-1174

Therefore	O	1175-1184
,	O	1184-1185
progression	O	1186-1197
to	O	1198-1200
S	O	1201-1202
phase	O	1203-1208
is	O	1209-1211
accompanied	O	1212-1223
by	O	1224-1226
the	O	1227-1230
aggregation	O	1231-1242
of	O	1243-1245
nuclear	O	1246-1253
BARD1	O	1254-1259
polypeptides	O	1260-1272
into	O	1273-1277
BRCA1	O	1278-1283
nuclear	O	1284-1291
dots	O	1292-1296
.	O	1296-1297

This	O	1298-1302
cell	O	1303-1307
cycle	O	1308-1313
-	O	1313-1314
dependent	O	1314-1323
colocalization	O	1324-1338
of	O	1339-1341
BARD1	O	1342-1347
and	O	1348-1351
BRCA1	O	1352-1357
indicates	O	1358-1367
a	O	1368-1369
role	O	1370-1374
for	O	1375-1378
BARD1	O	1379-1384
in	O	1385-1387
BRCA1	O	1388-1393
-	O	1393-1394
mediated	O	1394-1402
tumor	B	1403-1408
suppression	O	1409-1420
.	O	1420-1421

Genetic	O	0-7
basis	O	8-13
and	O	14-17
molecular	O	18-27
mechanism	O	28-37
for	O	38-41
idiopathic	B	42-52
ventricular	I	53-64
fibrillation	I	65-77
.	O	77-78

Ventricular	B	79-90
fibrillation	I	91-103
causes	O	104-110
more	O	111-115
than	O	116-120
300	O	121-124
,	O	124-125
000	O	126-129
sudden	O	130-136
deaths	O	137-143
each	O	144-148
year	O	149-153
in	O	154-156
the	O	157-160
USA	O	161-164
alone	O	165-170
.	O	170-171

In	O	172-174
approximately	O	175-188
5	O	189-190
-	O	190-191
12	O	191-193
%	O	193-194
of	O	195-197
these	O	198-203
cases	O	204-209
,	O	209-210
there	O	211-216
are	O	217-220
no	O	221-223
demonstrable	O	224-236
cardiac	O	237-244
or	O	245-247
non	O	248-251
-	O	251-252
cardiac	O	252-259
causes	O	260-266
to	O	267-269
account	O	270-277
for	O	278-281
the	O	282-285
episode	O	286-293
,	O	293-294
which	O	295-300
is	O	301-303
therefore	O	304-313
classified	O	314-324
as	O	325-327
idiopathic	B	328-338
ventricular	I	339-350
fibrillation	I	351-363
(	O	364-365
IVF	B	365-368
)	O	368-369
.	O	369-370

A	O	371-372
distinct	O	373-381
group	O	382-387
of	O	388-390
IVF	B	391-394
patients	O	395-403
has	O	404-407
been	O	408-412
found	O	413-418
to	O	419-421
present	O	422-429
with	O	430-434
a	O	435-436
characteristic	O	437-451
electrocardiographic	O	452-472
pattern	O	473-480
.	O	480-481

Because	O	482-489
of	O	490-492
the	O	493-496
small	O	497-502
size	O	503-507
of	O	508-510
most	O	511-515
pedigrees	O	516-525
and	O	526-529
the	O	530-533
high	O	534-538
incidence	O	539-548
of	O	549-551
sudden	B	552-558
death	I	559-564
,	O	564-565
however	O	566-573
,	O	573-574
molecular	O	575-584
genetic	O	585-592
studies	O	593-600
of	O	601-603
IVF	B	604-607
have	O	608-612
not	O	613-616
yet	O	617-620
been	O	621-625
done	O	626-630
.	O	630-631

Because	O	632-639
IVF	B	640-643
causes	O	644-650
cardiac	O	651-658
rhythm	O	659-665
disturbance	O	666-677
,	O	677-678
we	O	679-681
investigated	O	682-694
whether	O	695-702
malfunction	O	703-714
of	O	715-717
ion	O	718-721
channels	O	722-730
could	O	731-736
cause	O	737-742
the	O	743-746
disorder	O	747-755
by	O	756-758
studying	O	759-767
mutations	O	768-777
in	O	778-780
the	O	781-784
cardiac	O	785-792
sodium	O	793-799
channel	O	800-807
gene	O	808-812
SCN5A	O	813-818
.	O	818-819

We	O	820-822
have	O	823-827
now	O	828-831
identified	O	832-842
a	O	843-844
missense	O	845-853
mutation	O	854-862
,	O	862-863
a	O	864-865
splice	O	866-872
-	O	872-873
donor	O	873-878
mutation	O	879-887
,	O	887-888
and	O	889-892
a	O	893-894
frameshift	O	895-905
mutation	O	906-914
in	O	915-917
the	O	918-921
coding	O	922-928
region	O	929-935
of	O	936-938
SCN5A	O	939-944
in	O	945-947
three	O	948-953
IVF	B	954-957
families	O	958-966
.	O	966-967

We	O	968-970
show	O	971-975
that	O	976-980
sodium	O	981-987
channels	O	988-996
with	O	997-1001
the	O	1002-1005
missense	O	1006-1014
mutation	O	1015-1023
recover	O	1024-1031
from	O	1032-1036
inactivation	O	1037-1049
more	O	1050-1054
rapidly	O	1055-1062
than	O	1063-1067
normal	O	1068-1074
and	O	1075-1078
that	O	1079-1083
the	O	1084-1087
frameshift	O	1088-1098
mutation	O	1099-1107
causes	O	1108-1114
the	O	1115-1118
sodium	O	1119-1125
channel	O	1126-1133
to	O	1134-1136
be	O	1137-1139
non	O	1140-1143
-	O	1143-1144
functional	O	1144-1154
.	O	1154-1155

Our	O	1156-1159
results	O	1160-1167
indicate	O	1168-1176
that	O	1177-1181
mutations	O	1182-1191
in	O	1192-1194
cardiac	O	1195-1202
ion	O	1203-1206
-	O	1206-1207
channel	O	1207-1214
genes	O	1215-1220
contribute	O	1221-1231
to	O	1232-1234
the	O	1235-1238
risk	O	1239-1243
of	O	1244-1246
developing	O	1247-1257
IVF	B	1258-1261
.	O	1261-1262
.	O	1261-1262

Prevalence	O	0-10
of	O	11-13
the	O	14-17
I1307K	O	18-24
APC	B	25-28
gene	O	29-33
variant	O	34-41
in	O	42-44
Israeli	O	45-52
Jews	O	53-57
of	O	58-60
differing	O	61-70
ethnic	O	71-77
origin	O	78-84
and	O	85-88
risk	O	89-93
for	O	94-97
colorectal	B	98-108
cancer	I	109-115
.	O	115-116

BACKGROUND	O	117-127
&	O	128-129
AIMS	O	130-134
Israeli	O	136-143
Jews	O	144-148
of	O	149-151
European	O	152-160
birth	O	161-166
,	O	166-167
i	O	168-169
.	O	169-170
e	O	171-172
.	O	172-173
,	O	173-174
Ashkenazim	O	175-185
,	O	185-186
have	O	187-191
the	O	192-195
highest	O	196-203
colorectal	B	204-214
cancer	I	215-221
incidence	O	222-231
of	O	232-234
any	O	235-238
Israeli	O	239-246
ethnic	O	247-253
group	O	254-259
.	O	259-260

The	O	261-264
I1307K	O	265-271
APC	B	272-275
gene	O	276-280
variant	O	281-288
was	O	289-292
found	O	293-298
in	O	299-301
6	O	302-303
.	O	303-304
1	O	305-306
%	O	306-307
of	O	308-310
American	O	311-319
Jews	O	320-324
,	O	324-325
28	O	326-328
%	O	328-329
of	O	330-332
their	O	333-338
familial	O	339-347
colorectal	B	348-358
cancer	I	359-365
cases	O	366-371
,	O	371-372
but	O	373-376
not	O	377-380
in	O	381-383
non	O	384-387
-	O	387-388
Jews	O	388-392
.	O	392-393

We	O	394-396
assessed	O	397-405
the	O	406-409
I1307K	O	410-416
prevalence	O	417-427
in	O	428-430
Israeli	O	431-438
Jews	O	439-443
of	O	444-446
differing	O	447-456
ethnic	O	457-463
origin	O	464-470
and	O	471-474
risk	O	475-479
for	O	480-483
colorectal	B	484-494
cancer	I	495-501
.	O	501-502

METHODS	O	503-510
DNA	O	512-515
samples	O	516-523
from	O	524-528
500	O	529-532
unrelated	O	533-542
Jews	O	543-547
of	O	548-550
European	O	551-559
or	O	560-562
non	O	563-566
-	O	566-567
European	O	567-575
origin	O	576-582
,	O	582-583
with	O	584-588
or	O	589-591
without	O	592-599
a	O	600-601
personal	O	602-610
and	O	611-614
/	O	614-615
or	O	615-617
family	O	618-624
history	O	625-632
of	O	633-635
neoplasia	B	636-645
,	O	645-646
were	O	647-651
examined	O	652-660
for	O	661-664
the	O	665-668
I1307K	O	669-675
variant	O	676-683
by	O	684-686
the	O	687-690
allele	O	691-697
-	O	697-698
specific	O	698-706
oligonucleotide	O	707-722
(	O	723-724
ASO	O	724-727
)	O	727-728
method	O	729-735
.	O	735-736

RESULTS	O	737-744
In	O	746-748
persons	O	749-756
at	O	757-759
average	O	760-767
risk	O	768-772
for	O	773-776
colorectal	B	777-787
cancer	I	788-794
,	O	794-795
I1307K	O	796-802
was	O	803-806
found	O	807-812
in	O	813-815
5	O	816-817
.	O	817-818
0	O	819-820
%	O	820-821
of	O	822-824
120	O	825-828
European	O	829-837
and	O	838-841
1	O	842-843
.	O	843-844
6	O	845-846
%	O	846-847
of	O	848-850
188	O	851-854
non	O	855-858
-	O	858-859
European	O	859-867
Jews	O	868-872
(	O	873-874
P	O	874-875
=	O	876-877
0	O	878-879
.	O	879-880
08	O	881-883
)	O	883-884
.	O	884-885

It	O	886-888
occurred	O	889-897
in	O	898-900
15	O	901-903
.	O	903-904
4	O	905-906
%	O	906-907
of	O	908-910
52	O	911-913
Ashkenazi	O	914-923
Israelis	O	924-932
with	O	933-937
familial	O	938-946
cancer	B	947-953
(	O	954-955
P	O	955-956
=	O	957-958
0	O	959-960
.	O	960-961
02	O	962-964
)	O	964-965
and	O	966-969
was	O	970-973
not	O	974-977
detected	O	978-986
in	O	987-989
51	O	990-992
non	O	993-996
-	O	996-997
European	O	997-1005
Jews	O	1006-1010
at	O	1011-1013
increased	O	1014-1023
cancer	B	1024-1030
risk	O	1031-1035
.	O	1035-1036

Colorectal	B	1037-1047
neoplasia	I	1048-1057
occurred	O	1058-1066
personally	O	1067-1077
or	O	1078-1080
in	O	1081-1083
the	O	1084-1087
families	O	1088-1096
of	O	1097-1099
13	O	1100-1102
of	O	1103-1105
20	O	1106-1108
Ashkenazi	O	1109-1118
I1307K	O	1119-1125
carriers	O	1126-1134
,	O	1134-1135
8	O	1136-1137
of	O	1138-1140
whom	O	1141-1145
also	O	1146-1150
had	O	1151-1154
a	O	1155-1156
personal	O	1157-1165
or	O	1166-1168
family	O	1169-1175
history	O	1176-1183
of	O	1184-1186
noncolonic	O	1187-1197
neoplasia	B	1198-1207
.	O	1207-1208

CONCLUSIONS	O	1209-1220
The	O	1222-1225
I1307K	O	1226-1232
APC	O	1233-1236
variant	O	1237-1244
may	O	1245-1248
represent	O	1249-1258
a	O	1259-1260
susceptibility	O	1261-1275
gene	O	1276-1280
for	O	1281-1284
colorectal	B	1285-1295
,	I	1295-1296
or	I	1297-1299
other	I	1300-1305
,	I	1305-1306
cancers	I	1307-1314
in	O	1315-1317
Ashkenazi	O	1318-1327
Jews	O	1328-1332
,	O	1332-1333
and	O	1334-1337
partially	O	1338-1347
explains	O	1348-1356
the	O	1357-1360
higher	O	1361-1367
incidence	O	1368-1377
of	O	1378-1380
colorectal	B	1381-1391
cancer	I	1392-1398
in	O	1399-1401
European	O	1402-1410
Israelis	O	1411-1419
.	O	1419-1420

Susceptibility	O	0-14
to	O	15-17
ankylosing	B	18-28
spondylitis	I	29-40
in	O	41-43
twins	O	44-49
:	O	49-50
the	O	51-54
role	O	55-59
of	O	60-62
genes	O	63-68
,	O	68-69
HLA	O	70-73
,	O	73-74
and	O	75-78
the	O	79-82
environment	O	83-94
.	O	94-95

OBJECTIVE	O	96-105
To	O	107-109
determine	O	110-119
the	O	120-123
relative	O	124-132
effects	O	133-140
of	O	141-143
genetic	O	144-151
and	O	152-155
environmental	O	156-169
factors	O	170-177
in	O	178-180
susceptibility	O	181-195
to	O	196-198
ankylosing	B	199-209
spondylitis	I	210-221
(	O	222-223
AS	B	223-225
)	O	225-226
.	O	226-227

METHODS	O	228-235
Twins	O	237-242
with	O	243-247
AS	B	248-250
were	O	251-255
identified	O	256-266
from	O	267-271
the	O	272-275
Royal	O	276-281
National	O	282-290
Hospital	O	291-299
for	O	300-303
Rheumatic	B	304-313
Diseases	I	314-322
database	O	323-331
.	O	331-332

Clinical	O	333-341
and	O	342-345
radiographic	O	346-358
examinations	O	359-371
were	O	372-376
performed	O	377-386
to	O	387-389
establish	O	390-399
diagnoses	O	400-409
,	O	409-410
and	O	411-414
disease	O	415-422
severity	O	423-431
was	O	432-435
assessed	O	436-444
using	O	445-450
a	O	451-452
combination	O	453-464
of	O	465-467
validated	O	468-477
scoring	O	478-485
systems	O	486-493
.	O	493-494

HLA	O	495-498
typing	O	499-505
for	O	506-509
HLA	O	510-513
-	O	513-514
B27	O	514-517
,	O	517-518
HLA	O	519-522
-	O	522-523
B60	O	523-526
,	O	526-527
and	O	528-531
HLA	O	532-535
-	O	535-536
DR1	O	536-539
was	O	540-543
performed	O	544-553
by	O	554-556
polymerase	O	557-567
chain	O	568-573
reaction	O	574-582
with	O	583-587
sequence	O	588-596
-	O	596-597
specific	O	597-605
primers	O	606-613
,	O	613-614
and	O	615-618
zygosity	O	619-627
was	O	628-631
assessed	O	632-640
using	O	641-646
microsatellite	O	647-661
markers	O	662-669
.	O	669-670

Genetic	O	671-678
and	O	679-682
environmental	O	683-696
variance	O	697-705
components	O	706-716
were	O	717-721
assessed	O	722-730
with	O	731-735
the	O	736-739
program	O	740-747
Mx	O	748-750
,	O	750-751
using	O	752-757
data	O	758-762
from	O	763-767
this	O	768-772
and	O	773-776
previous	O	777-785
studies	O	786-793
of	O	794-796
twins	O	797-802
with	O	803-807
AS	B	808-810
.	O	810-811
RESULTS	O	812-819
Six	O	821-824
of	O	825-827
8	O	828-829
monozygotic	O	830-841
(	O	842-843
MZ	O	843-845
)	O	845-846
twin	O	847-851
pairs	O	852-857
were	O	858-862
disease	O	863-870
concordant	O	871-881
,	O	881-882
compared	O	883-891
with	O	892-896
4	O	897-898
of	O	899-901
15	O	902-904
B27	O	905-908
-	O	908-909
positive	O	909-917
dizygotic	O	918-927
(	O	928-929
DZ	O	929-931
)	O	931-932
twin	O	933-937
pairs	O	938-943
(	O	944-945
27	O	945-947
%	O	947-948
)	O	948-949
and	O	950-953
4	O	954-955
of	O	956-958
32	O	959-961
DZ	O	962-964
twin	O	965-969
pairs	O	970-975
overall	O	976-983
(	O	984-985
12	O	985-987
.	O	987-988

5	O	989-990
%	O	990-991
)	O	991-992
.	O	992-993

Nonsignificant	O	994-1008
increases	O	1009-1018
in	O	1019-1021
similarity	O	1022-1032
with	O	1033-1037
regard	O	1038-1044
to	O	1045-1047
age	O	1048-1051
at	O	1052-1054
disease	O	1055-1062
onset	O	1063-1068
and	O	1069-1072
all	O	1073-1076
of	O	1077-1079
the	O	1080-1083
disease	O	1084-1091
severity	O	1092-1100
scores	O	1101-1107
assessed	O	1108-1116
were	O	1117-1121
noted	O	1122-1127
in	O	1128-1130
disease	O	1131-1138
-	O	1138-1139
concordant	O	1139-1149
MZ	O	1150-1152
twins	O	1153-1158
compared	O	1159-1167
with	O	1168-1172
concordant	O	1173-1183
DZ	O	1184-1186
twins	O	1187-1192
.	O	1192-1193

HLA	O	1194-1197
-	O	1197-1198
B27	O	1198-1201
and	O	1202-1205
B60	O	1206-1209
were	O	1210-1214
associated	O	1215-1225
with	O	1226-1230
the	O	1231-1234
disease	O	1235-1242
in	O	1243-1245
probands	O	1246-1254
,	O	1254-1255
and	O	1256-1259
the	O	1260-1263
rate	O	1264-1268
of	O	1269-1271
disease	O	1272-1279
concordance	O	1280-1291
was	O	1292-1295
significantly	O	1296-1309
increased	O	1310-1319
among	O	1320-1325
DZ	O	1326-1328
twin	O	1329-1333
pairs	O	1334-1339
in	O	1340-1342
which	O	1343-1348
the	O	1349-1352
co	O	1353-1355
-	O	1355-1356
twin	O	1356-1360
was	O	1361-1364
positive	O	1365-1373
for	O	1374-1377
both	O	1378-1382
B27	O	1383-1386
and	O	1387-1390
DR1	O	1391-1394
.	O	1394-1395

Additive	O	1396-1404
genetic	O	1405-1412
effects	O	1413-1420
were	O	1421-1425
estimated	O	1426-1435
to	O	1436-1438
contribute	O	1439-1449
97	O	1450-1452
%	O	1452-1453
of	O	1454-1456
the	O	1457-1460
population	O	1461-1471
variance	O	1472-1480
.	O	1480-1481

CONCLUSION	O	1482-1492
Susceptibility	O	1494-1508
to	O	1509-1511
AS	B	1512-1514
is	O	1515-1517
largely	O	1518-1525
genetically	O	1526-1537
determined	O	1538-1548
,	O	1548-1549
and	O	1550-1553
the	O	1554-1557
environmental	O	1558-1571
trigger	O	1572-1579
for	O	1580-1583
the	O	1584-1587
disease	O	1588-1595
is	O	1596-1598
probably	O	1599-1607
ubiquitous	O	1608-1618
.	O	1618-1619

HLA	O	1620-1623
-	O	1623-1624
B27	O	1624-1627
accounts	O	1628-1636
for	O	1637-1640
a	O	1641-1642
minority	O	1643-1651
of	O	1652-1654
the	O	1655-1658
overall	O	1659-1666
genetic	O	1667-1674
susceptibility	O	1675-1689
to	O	1690-1692
AS	B	1693-1695
.	O	1695-1696

The	O	0-3
APCI1307K	O	4-13
allele	O	14-20
and	O	21-24
cancer	B	25-31
risk	O	32-36
in	O	37-39
a	O	40-41
community	O	42-51
-	O	51-52
based	O	52-57
study	O	58-63
of	O	64-66
Ashkenazi	O	67-76
Jews	O	77-81
.	O	81-82

Mutations	O	83-92
in	O	93-95
APC	O	96-99
are	O	100-103
classically	O	104-115
associated	O	116-126
with	O	127-131
familial	B	132-140
adenomatous	I	141-152
polyposis	I	153-162
(	O	163-164
FAP	B	164-167
)	O	167-168
,	O	168-169
a	O	170-171
highly	O	172-178
penetrant	O	179-188
autosomal	B	189-198
dominant	I	199-207
disorder	I	208-216
characterized	O	217-230
by	O	231-233
multiple	O	234-242
intestinal	O	243-253
polyps	B	254-260
and	O	261-264
,	O	264-265
without	O	266-273
surgical	O	274-282
intervention	O	283-295
,	O	295-296
the	O	297-300
development	O	301-312
of	O	313-315
colorectal	B	316-326
cancer	I	327-333
(	O	334-335
CRC	B	335-338
)	O	338-339
.	O	339-340

APC	B	341-344
is	O	345-347
a	O	348-349
tumour	O	350-356
-	O	356-357
suppressor	O	357-367
gene	O	368-372
,	O	372-373
and	O	374-377
somatic	O	378-385
loss	O	386-390
occurs	O	391-397
in	O	398-400
tumours	B	401-408
.	O	408-409

The	O	410-413
germline	O	414-422
T	O	423-424
-	O	424-425
to	O	425-427
-	O	424-425
A	O	428-429
transversion	O	430-442
responsible	O	443-454
for	O	455-458
the	O	459-462
APC	O	463-466
I1307K	O	467-473
allele	O	474-480
converts	O	481-489
the	O	490-493
wild	O	494-498
-	O	498-499
type	O	499-503
sequence	O	504-512
to	O	513-515
a	O	516-517
homopolymer	O	518-529
tract	O	530-535
(	O	536-537
A8	O	537-539
)	O	539-540
that	O	541-545
is	O	546-548
genetically	O	549-560
unstable	O	561-569
and	O	570-573
prone	O	574-579
to	O	580-582
somatic	O	583-590
mutation	O	591-599
.	O	599-600

The	O	601-604
I1307K	O	605-611
allele	O	612-618
was	O	619-622
found	O	623-628
in	O	629-631
6	O	632-633
.	O	633-634
1	O	635-636
%	O	636-637
of	O	638-640
unselected	O	641-651
Ashkenazi	O	652-661
Jews	O	662-666
and	O	667-670
higher	O	671-677
proportions	O	678-689
of	O	690-692
Ashkenazim	O	693-703
with	O	704-708
family	O	709-715
or	O	716-718
personal	O	719-727
histories	O	728-737
of	O	738-740
CRC	B	741-744
(	O	745-746
ref	O	746-749
.	O	749-750

2	O	751-752
)	O	752-753
.	O	753-754

To	O	755-757
evaluate	O	758-766
the	O	767-770
role	O	771-775
of	O	776-778
I1307K	O	779-785
in	O	786-788
cancer	B	789-795
,	O	795-796
we	O	797-799
genotyped	O	800-809
5	O	810-811
,	O	811-812
081	O	813-816
Ashkenazi	O	817-826
volunteers	O	827-837
in	O	838-840
a	O	841-842
community	O	843-852
survey	O	853-859
.	O	859-860

Risk	O	861-865
of	O	866-868
developing	O	869-879
colorectal	B	880-890
,	I	890-891
breast	I	892-898
and	I	899-902
other	I	903-908
cancers	I	909-916
were	O	917-921
compared	O	922-930
between	O	931-938
genotyped	O	939-948
I1307K	O	949-955
carriers	O	956-964
and	O	965-968
non	O	969-972
-	O	972-973
carriers	O	973-981
and	O	982-985
their	O	986-991
first	O	992-997
-	O	997-998
degree	O	998-1004
relatives	O	1005-1014
.	O	1014-1015

The	O	0-3
hemochromatosis	B	4-19
gene	O	20-24
product	O	25-32
complexes	O	33-42
with	O	43-47
the	O	48-51
transferrin	O	52-63
receptor	O	64-72
and	O	73-76
lowers	O	77-83
its	O	84-87
affinity	O	88-96
for	O	97-100
ligand	O	101-107
binding	O	108-115
.	O	115-116

We	O	117-119
recently	O	120-128
reported	O	129-137
the	O	138-141
positional	O	142-152
cloning	O	153-160
of	O	161-163
a	O	164-165
candidate	O	166-175
gene	O	176-180
for	O	181-184
hereditary	B	185-195
hemochromatosis	I	196-211
called	O	212-218
HFE	O	219-222
.	O	222-223

The	O	224-227
gene	O	228-232
product	O	233-240
,	O	240-241
a	O	242-243
member	O	244-250
of	O	251-253
the	O	254-257
major	O	258-263
histocompatibility	O	264-282
complex	O	283-290
class	O	291-296
I	O	297-298
-	O	298-299
like	O	299-303
family	O	304-310
,	O	310-311
was	O	312-315
found	O	316-321
to	O	322-324
have	O	325-329
a	O	330-331
mutation	O	332-340
,	O	340-341
Cys	O	342-345
-	O	345-346
282	O	346-349
-	O	350-351
-	O	350-351
>	O	353-354
Tyr	O	355-358
(	O	359-360
C282Y	O	360-365
)	O	365-366
,	O	366-367
in	O	368-370
85	O	371-373
%	O	373-374
of	O	375-377
patient	O	378-385
chromosomes	O	386-397
.	O	397-398

This	O	399-403
mutation	O	404-412
eliminates	O	413-423
the	O	424-427
ability	O	428-435
of	O	436-438
HFE	O	439-442
to	O	443-445
associate	O	446-455
with	O	456-460
beta2	O	461-466
-	O	466-467
microglobulin	O	467-480
(	O	481-482
beta2m	O	482-488
)	O	488-489
and	O	490-493
prevents	O	494-502
cell	O	503-507
-	O	507-508
surface	O	508-515
expression	O	516-526
.	O	526-527

A	O	528-529
second	O	530-536
mutation	O	537-545
that	O	546-550
has	O	551-554
no	O	555-557
effect	O	558-564
on	O	565-567
beta2m	O	568-574
association	O	575-586
,	O	586-587
H63D	O	588-592
,	O	592-593
was	O	594-597
found	O	598-603
in	O	604-606
eight	O	607-612
out	O	613-616
of	O	617-619
nine	O	620-624
patients	O	625-633
heterozygous	O	634-646
for	O	647-650
the	O	651-654
C282Y	O	655-660
mutant	O	661-667
.	O	667-668

In	O	669-671
this	O	672-676
report	O	677-683
,	O	683-684
we	O	685-687
demonstrate	O	688-699
in	O	700-702
cultured	O	703-711
293	O	712-715
cells	O	716-721
overexpressing	O	722-736
wild	O	737-741
-	O	741-742
type	O	742-746
or	O	747-749
mutant	O	750-756
HFE	O	757-760
proteins	O	761-769
that	O	770-774
both	O	775-779
the	O	780-783
wild	O	784-788
-	O	788-789
type	O	789-793
and	O	794-797
H63D	O	798-802
HFE	O	803-806
proteins	O	807-815
form	O	816-820
stable	O	821-827
complexes	O	828-837
with	O	838-842
the	O	843-846
transferrin	O	847-858
receptor	O	859-867
(	O	868-869
TfR	O	869-872
)	O	872-873
.	O	873-874

The	O	875-878
C282Y	O	879-884
mutation	O	885-893
nearly	O	894-900
completely	O	901-911
prevents	O	912-920
the	O	921-924
association	O	925-936
of	O	937-939
the	O	940-943
mutant	O	944-950
HFE	O	951-954
protein	O	955-962
with	O	963-967
the	O	968-971
TfR	O	972-975
.	O	975-976

Studies	O	977-984
on	O	985-987
cell	O	988-992
-	O	992-993
associated	O	993-1003
transferrin	O	1004-1015
at	O	1016-1018
37	O	1019-1021
degrees	O	1022-1029
C	O	1030-1031
suggest	O	1032-1039
that	O	1040-1044
the	O	1045-1048
overexpressed	O	1049-1062
wild	O	1063-1067
-	O	1067-1068
type	O	1068-1072
HFE	O	1073-1076
protein	O	1077-1084
decreases	O	1085-1094
the	O	1095-1098
affinity	O	1099-1107
of	O	1108-1110
the	O	1111-1114
TfR	O	1115-1118
for	O	1119-1122
transferrin	O	1123-1134
.	O	1134-1135

The	O	1136-1139
overexpressed	O	1140-1153
H63D	O	1154-1158
protein	O	1159-1166
does	O	1167-1171
not	O	1172-1175
have	O	1176-1180
this	O	1181-1185
effect	O	1186-1192
,	O	1192-1193
providing	O	1194-1203
the	O	1204-1207
first	O	1208-1213
direct	O	1214-1220
evidence	O	1221-1229
for	O	1230-1233
a	O	1234-1235
functional	O	1236-1246
consequence	O	1247-1258
of	O	1259-1261
the	O	1262-1265
H63D	O	1266-1270
mutation	O	1271-1279
.	O	1279-1280

Addition	O	1281-1289
of	O	1290-1292
soluble	O	1293-1300
wild	O	1301-1305
-	O	1305-1306
type	O	1306-1310
HFE	O	1311-1314
/	O	1314-1315
beta2m	O	1315-1321
heterodimers	O	1322-1334
to	O	1335-1337
cultured	O	1338-1346
cells	O	1347-1352
also	O	1353-1357
decreased	O	1358-1367
the	O	1368-1371
apparent	O	1372-1380
affinity	O	1381-1389
of	O	1390-1392
the	O	1393-1396
TfR	O	1397-1400
for	O	1401-1404
its	O	1405-1408
ligand	O	1409-1415
under	O	1416-1421
steady	O	1422-1428
-	O	1428-1429
state	O	1429-1434
conditions	O	1435-1445
,	O	1445-1446
both	O	1447-1451
in	O	1452-1454
293	O	1455-1458
cells	O	1459-1464
and	O	1465-1468
in	O	1469-1471
HeLa	O	1472-1476
cells	O	1477-1482
.	O	1482-1483

Furthermore	O	1484-1495
,	O	1495-1496
at	O	1497-1499
4	O	1500-1501
degrees	O	1502-1509
C	O	1510-1511
,	O	1511-1512
the	O	1513-1516
added	O	1517-1522
soluble	O	1523-1530
complex	O	1531-1538
of	O	1539-1541
HFE	O	1542-1545
/	O	1545-1546
beta2m	O	1546-1552
inhibited	O	1553-1562
binding	O	1563-1570
of	O	1571-1573
transferrin	O	1574-1585
to	O	1586-1588
HeLa	O	1589-1593
cell	O	1594-1598
TfR	O	1599-1602
in	O	1603-1605
a	O	1606-1607
concentration	O	1608-1621
-	O	1621-1622
dependent	O	1622-1631
manner	O	1632-1638
.	O	1638-1639

Scatchard	O	1640-1649
plots	O	1650-1655
of	O	1656-1658
these	O	1659-1664
data	O	1665-1669
indicate	O	1670-1678
that	O	1679-1683
the	O	1684-1687
added	O	1688-1693
heterodimer	O	1694-1705
substantially	O	1706-1719
reduced	O	1720-1727
the	O	1728-1731
affinity	O	1732-1740
of	O	1741-1743
TfR	O	1744-1747
for	O	1748-1751
transferrin	O	1752-1763
.	O	1763-1764

These	O	1765-1770
results	O	1771-1778
establish	O	1779-1788
a	O	1789-1790
molecular	O	1791-1800
link	O	1801-1805
between	O	1806-1813
HFE	O	1814-1817
and	O	1818-1821
a	O	1822-1823
key	O	1824-1827
protein	O	1828-1835
involved	O	1836-1844
in	O	1845-1847
iron	O	1848-1852
transport	O	1853-1862
,	O	1862-1863
the	O	1864-1867
TfR	O	1868-1871
,	O	1871-1872
and	O	1873-1876
raise	O	1877-1882
the	O	1883-1886
possibility	O	1887-1898
that	O	1899-1903
alterations	O	1904-1915
in	O	1916-1918
this	O	1919-1923
regulatory	O	1924-1934
mechanism	O	1935-1944
may	O	1945-1948
play	O	1949-1953
a	O	1954-1955
role	O	1956-1960
in	O	1961-1963
the	O	1964-1967
pathogenesis	O	1968-1980
of	O	1981-1983
hereditary	B	1984-1994
hemochromatosis	I	1995-2010
.	O	2010-2011
.	O	2010-2011

Cycloheximide	O	0-13
facilitates	O	14-25
the	O	26-29
identification	O	30-44
of	O	45-47
aberrant	O	48-56
transcripts	O	57-68
resulting	O	69-78
from	O	79-83
a	O	84-85
novel	O	86-91
splice	O	92-98
-	O	98-99
site	O	99-103
mutation	O	104-112
in	O	113-115
COL17A1	O	116-123
in	O	124-126
a	O	127-128
patient	O	129-136
with	O	137-141
generalized	O	142-153
atrophic	B	154-162
benign	I	163-169
epidermolysis	I	170-183
bullosa	I	184-191
.	O	191-192

Patients	O	193-201
with	O	202-206
generalized	O	207-218
atrophic	B	219-227
benign	I	228-234
epidermolysis	I	235-248
bullosa	I	249-256
often	O	257-262
show	O	263-267
decreased	O	268-277
expression	O	278-288
of	O	289-291
type	O	292-296
XVII	O	297-301
collagen	O	302-310
,	O	310-311
a	O	312-313
transmembrane	O	314-327
hemidesmosomal	O	328-342
protein	O	343-350
encoded	O	351-358
by	O	359-361
COL17A1	O	362-369
.	O	369-370

This	O	371-375
report	O	376-382
documents	O	383-392
a	O	393-394
novel	O	395-400
splice	O	401-407
-	O	407-408
site	O	408-412
mutation	O	413-421
in	O	422-424
COL17A1	O	425-432
in	O	433-435
a	O	436-437
patient	O	438-445
with	O	446-450
generalized	O	451-462
atrophic	B	463-471
benign	I	472-478
epidermolysis	I	479-492
bullosa	I	493-500
,	O	500-501
and	O	502-505
applies	O	506-513
a	O	514-515
new	O	516-519
methodology	O	520-531
to	O	532-534
define	O	535-541
and	O	542-545
characterize	O	546-558
the	O	559-562
resulting	O	563-572
mRNA	O	573-577
splice	O	578-584
variants	O	585-593
.	O	593-594

Mutational	O	595-605
analysis	O	606-614
of	O	615-617
COL17A1	O	618-625
identified	O	626-636
a	O	637-638
maternally	O	639-649
inherited	O	650-659
G	O	660-661
-	O	661-662
to	O	662-664
-	O	661-662
T	O	665-666
transversion	O	667-679
at	O	680-682
the	O	683-686
-	O	687-688
1	O	688-689
position	O	690-698
of	O	699-701
exon	O	702-706
32	O	707-709
.	O	709-710

This	O	711-715
acceptor	O	716-724
splice	O	725-731
-	O	731-732
site	O	732-736
mutation	O	737-745
led	O	746-749
to	O	750-752
the	O	753-756
formation	O	757-766
of	O	767-769
aberrant	O	770-778
transcripts	O	779-790
present	O	791-798
at	O	799-801
extremely	O	802-811
low	O	812-815
levels	O	816-822
.	O	822-823

Based	O	824-829
on	O	830-832
our	O	833-836
recent	O	837-843
finding	O	844-851
that	O	852-856
cycloheximide	O	857-870
stabilized	O	871-881
mutant	O	882-888
COL17A1	O	889-896
transcripts	O	897-908
in	O	909-911
keratinocytes	O	912-925
homozygous	O	926-936
for	O	937-940
a	O	941-942
frameshift	O	943-953
mutation	O	954-962
,	O	962-963
the	O	964-967
effects	O	968-975
of	O	976-978
the	O	979-982
splice	O	983-989
-	O	989-990
site	O	990-994
mutation	O	995-1003
on	O	1004-1006
splicing	O	1007-1015
of	O	1016-1018
COL17A1	O	1019-1026
transcripts	O	1027-1038
were	O	1039-1043
determined	O	1044-1054
using	O	1055-1060
reverse	O	1061-1068
transcriptase	O	1069-1082
polymerase	O	1083-1093
chain	O	1094-1099
reaction	O	1100-1108
of	O	1109-1111
total	O	1112-1117
RNA	O	1118-1121
from	O	1122-1126
keratinocytes	O	1127-1140
incubated	O	1141-1150
for	O	1151-1154
2	O	1155-1156
.	O	1156-1157
5	O	1158-1159
h	O	1160-1161
in	O	1162-1164
the	O	1165-1168
presence	O	1169-1177
or	O	1178-1180
absence	O	1181-1188
of	O	1189-1191
10	O	1192-1194
microg	O	1195-1201
cycloheximide	O	1202-1215
per	O	1216-1219
ml	O	1220-1222
.	O	1222-1223

Using	O	1224-1229
this	O	1230-1234
approach	O	1235-1243
,	O	1243-1244
an	O	1245-1247
abnormally	O	1248-1258
spliced	O	1259-1266
transcript	O	1267-1277
was	O	1278-1281
identified	O	1282-1292
that	O	1293-1297
contains	O	1298-1306
an	O	1307-1309
extra	O	1310-1315
264	O	1316-1319
bases	O	1320-1325
upstream	O	1326-1334
from	O	1335-1339
exon	O	1340-1344
32	O	1345-1347
,	O	1347-1348
resulting	O	1349-1358
in	O	1359-1361
a	O	1362-1363
premature	O	1364-1373
termination	O	1374-1385
codon	O	1386-1391
27	O	1392-1394
bp	O	1395-1397
downstream	O	1398-1408
from	O	1409-1413
the	O	1414-1417
cryptic	O	1418-1425
splice	O	1426-1432
site	O	1433-1437
.	O	1437-1438

Three	O	1439-1444
other	O	1445-1450
splice	O	1451-1457
variants	O	1458-1466
,	O	1466-1467
including	O	1468-1477
one	O	1478-1481
derived	O	1482-1489
from	O	1490-1494
the	O	1495-1498
skipping	O	1499-1507
of	O	1508-1510
exon	O	1511-1515
32	O	1516-1518
,	O	1518-1519
were	O	1520-1524
also	O	1525-1529
identified	O	1530-1540
.	O	1540-1541

These	O	1542-1547
results	O	1548-1555
indicate	O	1556-1564
the	O	1565-1568
usefulness	O	1569-1579
of	O	1580-1582
cycloheximide	O	1583-1596
treatment	O	1597-1606
in	O	1607-1609
evaluating	O	1610-1620
the	O	1621-1624
abnormal	O	1625-1633
processing	O	1634-1644
of	O	1645-1647
mRNA	O	1648-1652
due	O	1653-1656
to	O	1657-1659
splice	O	1660-1666
-	O	1666-1667
site	O	1667-1671
mutations	O	1672-1681
,	O	1681-1682
because	O	1683-1690
(	O	1692-1693
i	O	1693-1694
)	O	1694-1695
aberrant	O	1696-1704
splicing	O	1705-1713
often	O	1714-1719
generates	O	1720-1729
a	O	1730-1731
premature	O	1732-1741
termination	O	1742-1753
codon	O	1754-1759
,	O	1759-1760
(	O	1761-1762
ii	O	1762-1764
)	O	1764-1765
transcripts	O	1766-1777
with	O	1778-1782
premature	O	1783-1792
termination	O	1793-1804
codons	O	1805-1811
can	O	1812-1815
occur	O	1816-1821
at	O	1822-1824
low	O	1825-1828
or	O	1829-1831
undetectable	O	1832-1844
levels	O	1845-1851
due	O	1852-1855
to	O	1856-1858
nonsense	O	1859-1867
-	O	1867-1868
mediated	O	1868-1876
mRNA	O	1877-1881
decay	O	1882-1887
,	O	1887-1888
and	O	1889-1892
(	O	1893-1894
iii	O	1894-1897
)	O	1897-1898
the	O	1899-1902
levels	O	1903-1909
of	O	1910-1912
these	O	1913-1918
transcripts	O	1919-1930
can	O	1931-1934
be	O	1935-1937
increased	O	1938-1947
by	O	1948-1950
cycloheximide	O	1951-1964
.	O	1964-1965

The	O	0-3
DMPK	O	4-8
gene	O	9-13
of	O	14-16
severely	O	17-25
affected	O	26-34
myotonic	B	35-43
dystrophy	I	44-53
patients	O	54-62
is	O	63-65
hypermethylated	O	66-81
proximal	O	82-90
to	O	91-93
the	O	94-97
largely	O	98-105
expanded	O	106-114
CTG	O	115-118
repeat	O	119-125
.	O	125-126

Using	O	127-132
methylation	O	133-144
-	O	144-145
sensitive	O	145-154
restriction	O	155-166
enzymes	O	167-174
,	O	174-175
we	O	176-178
characterized	O	179-192
the	O	193-196
methylation	O	197-208
pattern	O	209-216
on	O	217-219
the	O	220-223
5	O	224-225
side	O	226-230
of	O	231-233
the	O	234-237
CTG	O	238-241
repeat	O	242-248
in	O	249-251
the	O	252-255
DMPK	O	256-260
gene	O	261-265
of	O	266-268
normal	O	269-275
individuals	O	276-287
and	O	288-291
of	O	292-294
patients	O	295-303
affected	O	304-312
with	O	313-317
myotonic	B	318-326
dystrophy	I	327-336
,	O	336-337
showing	O	338-345
expansions	O	346-356
of	O	357-359
the	O	360-363
repetitive	O	364-374
sequence	O	375-383
.	O	383-384

The	O	385-388
gene	O	389-393
segment	O	394-401
analyzed	O	402-410
corresponds	O	411-422
to	O	423-425
the	O	426-429
genomic	O	430-437
SacI	O	438-442
-	O	442-443
HindIII	O	443-450
fragment	O	451-459
carrying	O	460-468
exons	O	469-474
11	O	475-477
-	O	477-478
15	O	478-480
.	O	480-481

There	O	482-487
is	O	488-490
constitutive	O	491-503
methylation	O	504-515
in	O	516-518
intron	O	519-525
12	O	526-528
at	O	529-531
restriction	O	532-543
sites	O	544-549
of	O	550-552
SacII	O	553-558
and	O	559-562
HhaI	O	563-567
,	O	567-568
localized	O	569-578
1	O	579-580
,	O	580-581
159	O	582-585
-	O	585-586
1	O	582-583
,	O	587-588
232	O	589-592
bp	O	593-595
upstream	O	596-604
of	O	605-607
the	O	608-611
CTG	O	612-615
repeat	O	616-622
,	O	622-623
whereas	O	624-631
most	O	632-636
,	O	636-637
if	O	638-640
not	O	641-644
all	O	645-648
,	O	648-649
of	O	650-652
the	O	653-656
other	O	657-662
sites	O	663-668
of	O	669-671
SacII	O	672-677
,	O	677-678
HhaI	O	679-683
,	O	683-684
and	O	685-688
HpaII	O	689-694
in	O	695-697
this	O	698-702
region	O	703-709
are	O	710-713
unmethylated	O	714-726
,	O	726-727
in	O	728-730
normal	O	731-737
individuals	O	738-749
and	O	750-753
most	O	754-758
of	O	759-761
the	O	762-765
patients	O	766-774
.	O	774-775

In	O	776-778
a	O	779-780
number	O	781-787
of	O	788-790
young	O	791-796
and	O	797-800
severely	O	801-809
affected	O	810-818
patients	O	819-827
,	O	827-828
however	O	829-836
,	O	836-837
complete	O	838-846
methylation	O	847-858
of	O	859-861
these	O	862-867
restriction	O	868-879
sites	O	880-885
was	O	886-889
found	O	890-895
in	O	896-898
the	O	899-902
mutated	O	903-910
allele	O	911-917
.	O	917-918

In	O	919-921
most	O	922-926
of	O	927-929
these	O	930-935
patients	O	936-944
,	O	944-945
the	O	946-949
onset	O	950-955
of	O	956-958
the	O	959-962
disease	O	963-970
was	O	971-974
congenital	O	975-985
.	O	985-986

Preliminary	O	987-998
in	O	999-1001
vivo	O	1002-1006
footprinting	O	1007-1019
data	O	1020-1024
gave	O	1025-1029
evidence	O	1030-1038
for	O	1039-1042
protein	O	1043-1050
-	O	1050-1051
DNA	O	1051-1054
contact	O	1055-1062
in	O	1063-1065
normal	O	1066-1072
genes	O	1073-1078
at	O	1079-1081
an	O	1082-1084
Sp1	O	1085-1088
consensus	O	1089-1098
binding	O	1099-1106
site	O	1107-1111
upstream	O	1112-1120
of	O	1121-1123
the	O	1124-1127
CTG	O	1128-1131
repeat	O	1132-1138
and	O	1139-1142
for	O	1143-1146
a	O	1147-1148
significant	O	1149-1160
reduction	O	1161-1170
of	O	1171-1173
this	O	1174-1178
interaction	O	1179-1190
in	O	1191-1193
cells	O	1194-1199
with	O	1200-1204
a	O	1205-1206
hypermethylated	O	1207-1222
DMPK	O	1223-1227
gene	O	1228-1232
.	O	1232-1233
.	O	1232-1233

Progression	O	0-11
of	O	12-14
somatic	O	15-22
CTG	O	23-26
repeat	O	27-33
length	O	34-40
heterogeneity	O	41-54
in	O	55-57
the	O	58-61
blood	O	62-67
cells	O	68-73
of	O	74-76
myotonic	B	77-85
dystrophy	I	86-95
patients	O	96-104
.	O	104-105

The	O	106-109
genetic	O	110-117
basis	O	118-123
of	O	124-126
myotonic	B	127-135
dystrophy	I	136-145
(	O	146-147
DM	B	147-149
)	O	149-150
is	O	151-153
the	O	154-157
expansion	O	158-167
of	O	168-170
an	O	171-173
unstable	O	174-182
CTG	O	183-186
repeat	O	187-193
in	O	194-196
the	O	197-200
34	O	201-203
UTR	O	204-207
of	O	208-210
the	O	211-214
DM	B	215-217
protein	O	218-225
kinase	O	226-232
gene	O	233-237
on	O	238-240
chromosome	O	241-251
19	O	252-254
.	O	254-255

One	O	256-259
of	O	260-262
the	O	263-266
principal	O	267-276
features	O	277-285
of	O	286-288
the	O	289-292
DM	B	293-295
mutation	O	296-304
is	O	305-307
an	O	308-310
extraordinarily	O	311-326
high	O	327-331
level	O	332-337
of	O	338-340
somatic	O	341-348
mosaicism	O	349-358
,	O	358-359
due	O	360-363
to	O	364-366
an	O	367-369
extremely	O	370-379
high	O	380-384
degree	O	385-391
of	O	392-394
somatic	O	395-402
instability	O	403-414
both	O	415-419
within	O	420-426
and	O	427-430
between	O	431-438
different	O	439-448
tissues	O	449-456
.	O	456-457

This	O	458-462
instability	O	463-474
appears	O	475-482
to	O	483-485
be	O	486-488
biased	O	489-495
towards	O	496-503
further	O	504-511
expansion	O	512-521
and	O	522-525
continuous	O	526-536
throughout	O	537-547
the	O	548-551
life	O	552-556
of	O	557-559
an	O	560-562
individual	O	563-573
,	O	573-574
features	O	575-583
that	O	584-588
could	O	589-594
be	O	595-597
associated	O	598-608
with	O	609-613
the	O	614-617
progressive	O	618-629
nature	O	630-636
of	O	637-639
the	O	640-643
disease	O	644-651
.	O	651-652

Although	O	653-661
increasing	O	662-672
measured	O	673-681
allele	O	682-688
size	O	689-693
between	O	694-701
patients	O	702-710
clearly	O	711-718
correlates	O	719-729
with	O	730-734
an	O	735-737
increased	O	738-747
severity	O	748-756
of	O	757-759
symptoms	O	760-768
and	O	769-772
an	O	773-775
earlier	O	776-783
age	O	784-787
of	O	788-790
onset	O	791-796
,	O	796-797
this	O	798-802
correlation	O	803-814
is	O	815-817
not	O	818-821
precise	O	822-829
and	O	830-833
measured	O	834-842
allele	O	843-849
length	O	850-856
cannot	O	857-863
be	O	864-866
used	O	867-871
as	O	872-874
an	O	875-877
accurate	O	878-886
predictor	O	887-896
of	O	897-899
age	O	900-903
of	O	904-906
onset	O	907-912
.	O	912-913

In	O	914-916
order	O	917-922
to	O	923-925
further	O	926-933
characterize	O	934-946
the	O	947-950
dynamics	O	951-959
of	O	960-962
DM	B	963-965
CTG	O	966-969
repeat	O	970-976
somatic	O	977-984
instability	O	985-996
,	O	996-997
we	O	998-1000
have	O	1001-1005
studied	O	1006-1013
repeat	O	1014-1020
length	O	1021-1027
changes	O	1028-1035
over	O	1036-1040
time	O	1041-1045
in	O	1046-1048
111	O	1049-1052
myotonic	B	1053-1061
dystrophy	I	1062-1071
patients	O	1072-1080
with	O	1081-1085
varying	O	1086-1093
clinical	O	1094-1102
severity	O	1103-1111
and	O	1112-1115
CTG	O	1116-1119
repeat	O	1120-1126
size	O	1127-1131
over	O	1132-1136
time	O	1137-1141
intervals	O	1142-1151
of	O	1152-1154
1	O	1155-1156
-	O	1156-1157
7	O	1157-1158
years	O	1159-1164
.	O	1164-1165

We	O	1166-1168
have	O	1169-1173
found	O	1174-1179
a	O	1180-1181
direct	O	1182-1188
progression	O	1189-1200
of	O	1201-1203
the	O	1204-1207
size	O	1208-1212
heterogeneity	O	1213-1226
over	O	1227-1231
time	O	1232-1236
related	O	1237-1244
to	O	1245-1247
initial	O	1248-1255
CTG	O	1256-1259
repeat	O	1260-1266
size	O	1267-1271
and	O	1272-1275
the	O	1276-1279
time	O	1280-1284
interval	O	1285-1293
and	O	1294-1297
always	O	1298-1304
biased	O	1305-1311
towards	O	1312-1319
further	O	1320-1327
expansion	O	1328-1337
.	O	1337-1338

Attempts	O	1339-1347
to	O	1348-1350
mathematically	O	1351-1365
model	O	1366-1371
the	O	1372-1375
dynamics	O	1376-1384
have	O	1385-1389
proved	O	1390-1396
only	O	1397-1401
partially	O	1402-1411
successful	O	1412-1422
suggesting	O	1423-1433
that	O	1434-1438
individual	O	1439-1449
specific	O	1450-1458
genetic	O	1459-1466
and	O	1467-1470
/	O	1470-1471
or	O	1471-1473
environmental	O	1474-1487
factors	O	1488-1495
also	O	1496-1500
play	O	1501-1505
a	O	1506-1507
role	O	1508-1512
in	O	1513-1515
somatic	O	1516-1523
mosaicism	O	1524-1533
.	O	1533-1534
.	O	1533-1534

Inherited	B	0-9
colorectal	I	10-20
polyposis	I	21-30
and	O	31-34
cancer	B	35-41
risk	O	42-46
of	O	47-49
the	O	50-53
APC	O	54-57
I1307K	O	58-64
polymorphism	O	65-77
.	O	77-78

Germ	O	79-83
-	O	83-84
line	O	84-88
and	O	89-92
somatic	O	93-100
truncating	O	101-111
mutations	O	112-121
of	O	122-124
the	O	125-128
APC	B	129-132
gene	O	133-137
are	O	138-141
thought	O	142-149
to	O	150-152
initiate	O	153-161
colorectal	B	162-172
tumor	I	173-178
formation	O	179-188
in	O	189-191
familial	B	192-200
adenomatous	I	201-212
polyposis	I	213-222
syndrome	I	223-231
and	O	232-235
sporadic	O	236-244
colorectal	O	245-255
carcinogenesis	O	256-270
,	O	270-271
respectively	O	272-284
.	O	284-285

Recently	O	286-294
,	O	294-295
an	O	296-298
isoleucine	O	299-309
-	O	309-310
-	O	309-310
>	O	312-313
lysine	O	314-320
polymorphism	O	321-333
at	O	334-336
codon	O	337-342
1307	O	343-347
(	O	348-349
I1307K	O	349-355
)	O	355-356
of	O	357-359
the	O	360-363
APC	B	364-367
gene	O	368-372
has	O	373-376
been	O	377-381
identified	O	382-392
in	O	393-395
6	O	396-397
%	O	397-398
-	O	399-400
7	O	400-401
%	O	401-402
of	O	403-405
the	O	406-409
Ashkenazi	O	410-419
Jewish	O	420-426
population	O	427-437
.	O	437-438

To	O	439-441
assess	O	442-448
the	O	449-452
risk	O	453-457
of	O	458-460
this	O	461-465
common	O	466-472
APC	B	473-476
allelic	O	477-484
variant	O	485-492
in	O	493-495
colorectal	O	496-506
carcinogenesis	O	507-521
,	O	521-522
we	O	523-525
have	O	526-530
analyzed	O	531-539
a	O	540-541
large	O	542-547
cohort	O	548-554
of	O	555-557
unselected	O	558-568
Ashkenazi	O	569-578
Jewish	O	579-585
subjects	O	586-594
with	O	595-599
adenomatous	B	600-611
polyps	I	612-618
and	O	619-622
.	O	622-623

or	O	624-626
colorectal	B	627-637
cancer	I	638-644
,	I	644-645
for	O	646-649
the	O	650-653
APC	O	654-657
I1307K	O	658-664
polymorphism	O	665-677
.	O	677-678

The	O	679-682
APC	O	683-686
I1307K	O	687-693
allele	O	694-700
was	O	701-704
identified	O	705-715
in	O	716-718
48	O	719-721
(	O	722-723
10	O	723-725
.	O	725-726

1	O	727-728
%	O	728-729
)	O	729-730
of	O	731-733
476	O	734-737
patients	O	738-746
.	O	746-747

Compared	O	748-756
with	O	757-761
the	O	762-765
frequency	O	766-775
in	O	776-778
two	O	779-782
separate	O	783-791
population	O	792-802
control	O	803-810
groups	O	811-817
,	O	817-818
the	O	819-822
APC	O	823-826
I1307K	O	827-833
allele	O	834-840
is	O	841-843
associated	O	844-854
with	O	855-859
an	O	860-862
estimated	O	863-872
relative	O	873-881
risk	O	882-886
of	O	887-889
1	O	890-891
.	O	891-892
5	O	893-894
-	O	894-895
1	O	895-896
.	O	896-897
7	O	898-899
for	O	900-903
colorectal	B	904-914
neoplasia	I	915-924
(	O	925-926
both	O	926-930
P	O	931-932
=	O	933-934
.	O	934-935
01	O	936-938
)	O	938-939
.	O	939-940

Furthermore	O	941-952
,	O	952-953
compared	O	954-962
with	O	963-967
noncarriers	O	968-979
,	O	979-980
APC	O	981-984
I1307K	O	985-991
carriers	O	992-1000
had	O	1001-1004
increased	O	1005-1014
numbers	O	1015-1022
of	O	1023-1025
adenomas	B	1026-1034
and	O	1035-1038
colorectal	B	1039-1049
cancers	I	1050-1057
per	O	1058-1061
patient	O	1062-1069
(	O	1070-1071
P	O	1071-1072
=	O	1073-1074
.	O	1074-1075
03	O	1076-1078
)	O	1078-1079
,	O	1079-1080
as	O	1081-1083
well	O	1084-1088
as	O	1089-1091
a	O	1092-1093
younger	O	1094-1101
age	O	1102-1105
at	O	1106-1108
diagnosis	O	1109-1118
.	O	1118-1119

We	O	1120-1122
conclude	O	1123-1131
that	O	1132-1136
the	O	1137-1140
APC	O	1141-1144
I1307K	O	1145-1151
variant	O	1152-1159
leads	O	1160-1165
to	O	1166-1168
increased	O	1169-1178
adenoma	B	1179-1186
formation	O	1187-1196
and	O	1197-1200
directly	O	1201-1209
contributes	O	1210-1221
to	O	1222-1224
3	O	1225-1226
%	O	1226-1227
-	O	1228-1229
4	O	1229-1230
%	O	1230-1231
of	O	1232-1234
all	O	1235-1238
Ashkenazi	O	1239-1248
Jewish	O	1249-1255
colorectal	B	1256-1266
cancer	I	1267-1273
.	O	1273-1274

The	O	1275-1278
estimated	O	1279-1288
relative	O	1289-1297
risk	O	1298-1302
for	O	1303-1306
carriers	O	1307-1315
may	O	1316-1319
justify	O	1320-1327
specific	O	1328-1336
clinical	O	1337-1345
screening	O	1346-1355
for	O	1356-1359
the	O	1360-1363
360	O	1364-1367
,	O	1367-1368
000	O	1369-1372
Americans	O	1373-1382
expected	O	1383-1391
to	O	1392-1394
harbor	O	1395-1401
this	O	1402-1406
allele	O	1407-1413
,	O	1413-1414
and	O	1415-1418
genetic	O	1419-1426
testing	O	1427-1434
in	O	1435-1437
the	O	1438-1441
setting	O	1442-1449
of	O	1450-1452
long	O	1453-1457
-	O	1457-1458
term	O	1458-1462
-	O	1457-1458
outcome	O	1463-1470
studies	O	1471-1478
may	O	1479-1482
impact	O	1483-1489
significantly	O	1490-1503
on	O	1504-1506
colorectal	B	1507-1517
cancer	I	1518-1524
prevention	O	1525-1535
in	O	1536-1538
this	O	1539-1543
population	O	1544-1554
.	O	1554-1555

Human	O	0-5
MLH1	O	6-10
deficiency	O	11-21
predisposes	O	22-33
to	O	34-36
hematological	B	37-50
malignancy	I	51-61
and	O	62-65
neurofibromatosis	B	66-83
type	I	84-88
1	I	89-90
.	O	90-91
Heterozygous	O	92-104
germ	O	105-109
-	O	109-110
line	O	110-114
mutations	O	115-124
in	O	125-127
the	O	128-131
DNA	O	132-135
mismatch	O	136-144
repair	O	145-151
genes	O	152-157
lead	O	158-162
to	O	163-165
hereditary	B	166-176
nonpolyposis	I	177-189
colorectal	I	190-200
cancer	I	201-207
.	O	207-208

The	O	209-212
disease	O	213-220
susceptibility	O	221-235
of	O	236-238
individuals	O	239-250
who	O	251-254
constitutionally	O	255-271
lack	O	272-276
both	O	277-281
wild	O	282-286
-	O	286-287
type	O	287-291
alleles	O	292-299
is	O	300-302
unknown	O	303-310
.	O	310-311

We	O	312-314
have	O	315-319
identified	O	320-330
three	O	331-336
offspring	O	337-346
in	O	347-349
a	O	350-351
hereditary	B	352-362
nonpolyposis	I	363-375
colorectal	I	376-386
cancer	I	387-393
family	O	394-400
who	O	401-404
developed	O	405-414
hematological	B	415-428
malignancy	I	429-439
at	O	440-442
a	O	443-444
very	O	445-449
early	O	450-455
age	O	456-459
,	O	459-460
and	O	461-464
at	O	465-467
least	O	468-473
two	O	474-477
of	O	478-480
them	O	481-485
displayed	O	486-495
signs	O	496-501
of	O	502-504
neurofibromatosis	B	505-522
type	I	523-527
1	I	528-529
(	O	530-531
NF1	B	531-534
)	O	534-535
.	O	535-536

DNA	O	537-540
sequence	O	541-549
analysis	O	550-558
and	O	559-562
allele	O	563-569
-	O	569-570
specific	O	570-578
amplification	O	579-592
in	O	593-595
two	O	596-599
siblings	O	600-608
revealed	O	609-617
a	O	618-619
homozygous	O	620-630
MLH1	O	631-635
mutation	O	636-644
(	O	645-646
C676T	O	646-651
-	O	651-652
-	O	651-652
>	O	654-655
Arg226Stop	O	656-666
)	O	666-667
.	O	667-668

Thus	O	669-673
,	O	673-674
a	O	675-676
homozygous	O	677-687
germ	O	688-692
-	O	692-693
line	O	693-697
MLH1	O	698-702
mutation	O	703-711
and	O	712-715
consequent	O	716-726
mismatch	O	727-735
repair	O	736-742
deficiency	O	743-753
results	O	754-761
in	O	762-764
a	O	765-766
mutator	O	767-774
phenotype	O	775-784
characterized	O	785-798
by	O	799-801
leukemia	B	802-810
and	O	811-814
/	O	814-815
or	O	815-817
lymphoma	B	818-826
associated	O	827-837
with	O	838-842
neurofibromatosis	B	843-860
type	I	861-865
1	I	866-867
.	O	867-868
.	O	867-868

Are	O	0-3
Dp71	O	4-8
and	O	9-12
Dp140	O	13-18
brain	O	19-24
dystrophin	O	25-35
isoforms	O	36-44
related	O	45-52
to	O	53-55
cognitive	B	56-65
impairment	I	66-76
in	O	77-79
Duchenne	B	80-88
muscular	I	89-97
dystrophy	I	98-107
?	O	107-108

Molecular	O	109-118
study	O	119-124
and	O	125-128
neuropsychological	O	129-147
analysis	O	148-156
were	O	157-161
performed	O	162-171
concurrently	O	172-184
on	O	185-187
49	O	188-190
patients	O	191-199
with	O	200-204
Duchenne	B	205-213
muscular	I	214-222
dystrophy	I	223-232
(	O	233-234
DMD	B	234-237
)	O	237-238
in	O	239-241
order	O	242-247
to	O	248-250
find	O	251-255
a	O	256-257
molecular	O	258-267
explanation	O	268-279
for	O	280-283
the	O	284-287
cognitive	B	288-297
impairment	I	298-308
observed	O	309-317
in	O	318-320
most	O	321-325
DMD	B	326-329
patients	O	330-338
.	O	338-339

Complete	O	340-348
analysis	O	349-357
of	O	358-360
the	O	361-364
dystrophin	O	365-375
gene	O	376-380
was	O	381-384
performed	O	385-394
to	O	395-397
define	O	398-404
the	O	405-408
localization	O	409-421
of	O	422-424
deletions	O	425-434
and	O	435-438
duplications	O	439-451
in	O	452-454
relation	O	455-463
to	O	464-466
the	O	467-470
different	O	471-480
DMD	B	481-484
promoters	O	485-494
.	O	494-495

Qualitative	O	496-507
analysis	O	508-516
of	O	517-519
the	O	520-523
Dp71	O	524-528
transcript	O	529-539
and	O	540-543
testing	O	544-551
for	O	552-555
the	O	556-559
specific	O	560-568
first	O	569-574
exon	O	575-579
of	O	580-582
Dp140	O	583-588
were	O	589-593
also	O	594-598
carried	O	599-606
out	O	607-610
.	O	610-611

Neuropsychological	O	612-630
analysis	O	631-639
assessed	O	640-648
verbal	O	649-655
and	O	656-659
visuospatial	O	660-672
intelligence	O	673-685
,	O	685-686
verbal	O	687-693
memory	O	694-700
,	O	700-701
and	O	702-705
reading	O	706-713
skills	O	714-720
.	O	720-721

Comparison	O	722-732
of	O	733-735
molecular	O	736-745
and	O	746-749
psychometric	O	750-762
findings	O	763-771
demonstrated	O	772-784
that	O	785-789
deletions	O	790-799
and	O	800-803
duplications	O	804-816
that	O	817-821
were	O	822-826
localized	O	827-836
in	O	837-839
the	O	840-843
distal	O	844-850
part	O	851-855
of	O	856-858
the	O	859-862
gene	O	863-867
seemed	O	868-874
to	O	875-877
be	O	878-880
preferentially	O	881-895
associated	O	896-906
with	O	907-911
cognitive	B	912-921
impairment	I	922-932
.	O	932-933

Two	O	934-937
altered	O	938-945
Dp71	O	946-950
transcripts	O	951-962
and	O	963-966
two	O	967-970
deleted	O	971-978
Dp140	O	979-984
DNA	O	985-988
sequences	O	989-998
were	O	999-1003
found	O	1004-1009
in	O	1010-1012
four	O	1013-1017
patients	O	1018-1026
with	O	1027-1031
severe	O	1032-1038
cerebral	B	1039-1047
dysfunction	I	1048-1059
.	O	1059-1060

These	O	1061-1066
findings	O	1067-1075
suggest	O	1076-1083
that	O	1084-1088
some	O	1089-1093
sequences	O	1094-1103
located	O	1104-1111
in	O	1112-1114
the	O	1115-1118
distal	O	1119-1125
part	O	1126-1130
of	O	1131-1133
the	O	1134-1137
gene	O	1138-1142
and	O	1143-1146
,	O	1146-1147
in	O	1148-1150
particular	O	1151-1161
,	O	1161-1162
some	O	1163-1167
DMD	B	1168-1171
isoforms	O	1172-1180
expressed	O	1181-1190
in	O	1191-1193
the	O	1194-1197
brain	O	1198-1203
may	O	1204-1207
be	O	1208-1210
related	O	1211-1218
to	O	1219-1221
the	O	1222-1225
cognitive	B	1226-1235
impairment	I	1236-1246
associated	O	1247-1257
with	O	1258-1262
DMD	B	1263-1266
.	O	1266-1267
.	O	1266-1267

A	O	0-1
genome	O	2-8
-	O	8-9
wide	O	9-13
search	O	14-20
for	O	21-24
chromosomal	O	25-36
loci	O	37-41
linked	O	42-48
to	O	49-51
mental	O	52-58
health	O	59-65
wellness	O	66-74
in	O	75-77
relatives	O	78-87
at	O	88-90
high	O	91-95
risk	O	96-100
for	O	101-104
bipolar	B	105-112
affective	I	113-122
disorder	I	123-131
among	O	132-137
the	O	138-141
Old	O	142-145
Order	O	146-151
Amish	O	152-157
.	O	157-158

Bipolar	B	159-166
affective	I	167-176
disorder	I	177-185
(	O	186-187
BPAD	B	187-191
;	O	191-192
manic	B	193-198
-	I	198-199
depressive	I	199-209
illness	I	210-217
)	O	217-218
is	O	219-221
characterized	O	222-235
by	O	236-238
episodes	O	239-247
of	O	248-250
mania	B	251-256
and	O	257-260
/	O	260-261
or	O	261-263
hypomania	B	264-273
interspersed	O	274-286
with	O	287-291
periods	O	292-299
of	O	300-302
depression	B	303-313
.	O	313-314

Compelling	O	315-325
evidence	O	326-334
supports	O	335-343
a	O	344-345
significant	O	346-357
genetic	O	358-365
component	O	366-375
in	O	376-378
the	O	379-382
susceptibility	O	383-397
to	O	398-400
develop	O	401-408
BPAD	B	409-413
.	O	413-414

To	O	415-417
date	O	418-422
,	O	422-423
however	O	424-431
,	O	431-432
linkage	O	433-440
studies	O	441-448
have	O	449-453
attempted	O	454-463
only	O	464-468
to	O	469-471
identify	O	472-480
chromosomal	O	481-492
loci	O	493-497
that	O	498-502
cause	O	503-508
or	O	509-511
increase	O	512-520
the	O	521-524
risk	O	525-529
of	O	530-532
developing	O	533-543
BPAD	B	544-548
.	O	548-549

To	O	550-552
determine	O	553-562
whether	O	563-570
there	O	571-576
could	O	577-582
be	O	583-585
protective	O	586-596
alleles	O	597-604
that	O	605-609
prevent	O	610-617
or	O	618-620
reduce	O	621-627
the	O	628-631
risk	O	632-636
of	O	637-639
developing	O	640-650
BPAD	B	651-655
,	O	655-656
similar	O	657-664
to	O	665-667
what	O	668-672
is	O	673-675
observed	O	676-684
in	O	685-687
other	O	688-693
genetic	B	694-701
disorders	I	702-711
,	O	711-712
we	O	713-715
used	O	716-720
mental	O	721-727
health	O	728-734
wellness	O	735-743
(	O	744-745
absence	O	745-752
of	O	753-755
any	O	756-759
psychiatric	B	760-771
disorder	I	772-780
)	O	780-781
as	O	782-784
the	O	785-788
phenotype	O	789-798
in	O	799-801
our	O	802-805
genome	O	806-812
-	O	812-813
wide	O	813-817
linkage	O	818-825
scan	O	826-830
of	O	831-833
several	O	834-841
large	O	842-847
multigeneration	O	848-863
Old	O	864-867
Order	O	868-873
Amish	O	874-879
pedigrees	O	880-889
exhibiting	O	890-900
an	O	901-903
extremely	O	904-913
high	O	914-918
incidence	O	919-928
of	O	929-931
BPAD	B	932-936
.	O	936-937

We	O	938-940
have	O	941-945
found	O	946-951
strong	O	952-958
evidence	O	959-967
for	O	968-971
a	O	972-973
locus	O	974-979
on	O	980-982
chromosome	O	983-993
4p	O	994-996
at	O	997-999
D4S2949	O	1000-1007
(	O	1008-1009
maximum	O	1009-1016
GENEHUNTER	O	1017-1027
-	O	1027-1028
PLUS	O	1028-1032
nonparametric	O	1033-1046
linkage	O	1047-1054
score	O	1055-1060
=	O	1061-1062
4	O	1063-1064
.	O	1064-1065
05	O	1066-1068
,	O	1068-1069
P	O	1070-1071
=	O	1072-1073
5	O	1074-1075
.	O	1075-1076
22	O	1077-1079
x	O	1080-1081
10	O	1082-1084
(	O	1085-1086
-	O	1086-1087
4	O	1087-1088
)	O	1088-1089
;	O	1089-1090
SIBPAL	O	1091-1097
Pempirical	O	1098-1108
value	O	1109-1114
<	O	1115-1116
3	O	1117-1118
x	O	1119-1120
10	O	1121-1123
(	O	1124-1125
-	O	1125-1126
5	O	1126-1127
)	O	1127-1128
)	O	1127-1128
and	O	1130-1133
suggestive	O	1134-1144
evidence	O	1145-1153
for	O	1154-1157
a	O	1158-1159
locus	O	1160-1165
on	O	1166-1168
chromosome	O	1169-1179
4q	O	1180-1182
at	O	1183-1185
D4S397	O	1186-1192
(	O	1193-1194
maximum	O	1194-1201
GENEHUNTER	O	1202-1212
-	O	1212-1213
PLUS	O	1213-1217
nonparametric	O	1218-1231
linkage	O	1232-1239
score	O	1240-1245
=	O	1246-1247
3	O	1248-1249
.	O	1249-1250
29	O	1251-1253
,	O	1253-1254
P	O	1255-1256
=	O	1257-1258
2	O	1259-1260
.	O	1260-1261
57	O	1262-1264
x	O	1265-1266
10	O	1267-1269
(	O	1270-1271
-	O	1271-1272
3	O	1272-1273
)	O	1273-1274
;	O	1274-1275
SIBPAL	O	1276-1282
Pempirical	O	1283-1293
value	O	1294-1299
<	O	1300-1301
1	O	1302-1303
x	O	1304-1305
10	O	1306-1308
(	O	1309-1310
-	O	1310-1311
3	O	1311-1312
)	O	1312-1313
)	O	1312-1313
that	O	1315-1319
are	O	1320-1323
linked	O	1324-1330
to	O	1331-1333
mental	O	1334-1340
health	O	1341-1347
wellness	O	1348-1356
.	O	1356-1357

These	O	1358-1363
findings	O	1364-1372
are	O	1373-1376
consistent	O	1377-1387
with	O	1388-1392
the	O	1393-1396
hypothesis	O	1397-1407
that	O	1408-1412
certain	O	1413-1420
alleles	O	1421-1428
could	O	1429-1434
prevent	O	1435-1442
or	O	1443-1445
modify	O	1446-1452
the	O	1453-1456
clinical	O	1457-1465
manifestations	O	1466-1480
of	O	1481-1483
BPAD	B	1484-1488
and	O	1489-1492
perhaps	O	1493-1500
other	O	1501-1506
related	O	1507-1514
affective	B	1515-1524
disorders	I	1525-1534
.	O	1534-1535

Hereditary	B	0-10
deficiency	I	11-21
of	I	22-24
the	I	25-28
fifth	I	29-34
component	I	35-44
of	I	45-47
complement	I	48-58
in	O	59-61
man	O	62-65
.	O	65-66

I	O	67-68
.	O	68-69
Clinical	O	70-78
,	O	78-79
immunochemical	O	80-94
,	O	94-95
and	O	96-99
family	O	100-106
studies	O	107-114
.	O	114-115

The	O	116-119
first	O	120-125
recognized	O	126-136
human	O	137-142
kindred	O	143-150
with	O	151-155
hereditary	B	156-166
deficiency	I	167-177
of	I	178-180
the	I	181-184
fifth	I	185-190
component	I	191-200
of	I	201-203
complement	I	204-214
(	O	215-216
C5	O	216-218
)	O	218-219
is	O	220-222
described	O	223-232
.	O	232-233

The	O	234-237
proband	O	238-245
,	O	245-246
a	O	247-248
20	O	249-251
-	O	251-252
year	O	252-256
-	O	251-252
old	O	257-260
black	O	261-266
female	O	267-273
with	O	274-278
systemic	B	279-287
lupus	I	288-293
erythematosus	I	294-307
since	O	308-313
age	O	314-317
11	O	318-320
,	O	320-321
lacked	O	322-328
serum	O	329-334
hemolytic	O	335-344
complement	O	345-355
activity	O	356-364
,	O	364-365
even	O	366-370
during	O	371-377
remission	O	378-387
.	O	387-388

C5	O	389-391
was	O	392-395
undetectable	O	396-408
in	O	409-411
her	O	412-415
serum	O	416-421
by	O	422-424
both	O	425-429
immunodiffusion	O	430-445
and	O	446-449
hemolytic	O	450-459
assays	O	460-466
.	O	466-467

Other	O	468-473
complement	O	474-484
components	O	485-495
were	O	496-500
normal	O	501-507
during	O	508-514
remission	O	515-524
of	O	525-527
lupus	O	528-533
,	O	533-534
but	O	535-538
C1	O	539-541
,	O	541-542
C4	O	543-545
,	O	545-546
C2	O	547-549
,	O	549-550
and	O	551-554
C3	O	555-557
levels	O	558-564
fell	O	565-569
during	O	570-576
exacerbations	O	577-590
.	O	590-591

A	O	592-593
younger	O	594-601
half	O	602-606
-	O	606-607
sister	O	607-613
,	O	613-614
who	O	615-618
had	O	619-622
no	O	623-625
underlying	O	626-636
disease	O	637-644
,	O	644-645
was	O	646-649
also	O	650-654
found	O	655-660
to	O	661-663
lack	O	664-668
immunochemically	O	669-685
detectable	O	686-696
C5	O	697-699
.	O	699-700

By	O	701-703
hemolytic	O	704-713
assay	O	714-719
,	O	719-720
she	O	721-724
exhibited	O	725-734
1	O	735-736
-	O	736-737
2	O	737-738
%	O	738-739
of	O	740-742
the	O	743-746
normal	O	747-753
serum	O	754-759
C5	O	760-762
level	O	763-768
and	O	769-772
normal	O	773-779
concentrations	O	780-794
of	O	795-797
other	O	798-803
complement	O	804-814
components	O	815-825
.	O	825-826

C5	O	827-829
levels	O	830-836
of	O	837-839
other	O	840-845
family	O	846-852
members	O	853-860
were	O	861-865
either	O	866-872
normal	O	873-879
or	O	880-882
approximately	O	883-896
half	O	897-901
-	O	901-902
normal	O	902-908
,	O	908-909
consistent	O	910-920
with	O	921-925
autosomal	O	926-935
codominant	O	936-946
inheritance	O	947-958
of	O	959-961
the	O	962-965
gene	O	966-970
determining	O	971-982
C5	B	983-985
deficiency	I	986-996
.	O	996-997

Normal	O	998-1004
hemolytic	O	1005-1014
titers	O	1015-1021
were	O	1022-1026
restored	O	1027-1035
to	O	1036-1038
both	O	1039-1043
homozygous	O	1044-1054
C5	B	1055-1057
-	I	1057-1058
deficient	I	1058-1067
(	O	1068-1069
C5D	B	1069-1072
)	O	1072-1073
sera	O	1074-1078
by	O	1079-1081
addition	O	1082-1090
of	O	1091-1093
highly	O	1094-1100
purified	O	1101-1109
human	O	1110-1115
C5	O	1116-1118
.	O	1118-1119

In	O	1120-1122
specific	O	1123-1131
C5	O	1132-1134
titrations	O	1135-1145
,	O	1145-1146
however	O	1147-1154
,	O	1154-1155
it	O	1156-1158
was	O	1159-1162
noted	O	1163-1168
that	O	1169-1173
when	O	1174-1178
limited	O	1179-1186
amounts	O	1187-1194
of	O	1195-1197
C5	O	1198-1200
were	O	1201-1205
assayed	O	1206-1213
in	O	1214-1216
the	O	1217-1220
presence	O	1221-1229
of	O	1230-1232
low	O	1233-1236
dilutions	O	1237-1246
of	O	1247-1249
either	O	1250-1256
C5D	B	1257-1260
serum	O	1261-1266
,	O	1266-1267
curving	O	1268-1275
rather	O	1276-1282
than	O	1283-1287
linear	O	1288-1294
dose	O	1295-1299
-	O	1299-1300
response	O	1300-1308
plots	O	1309-1314
were	O	1315-1319
consistently	O	1320-1332
obtained	O	1333-1341
,	O	1341-1342
suggesting	O	1343-1353
some	O	1354-1358
inhibitory	O	1359-1369
effect	O	1370-1376
.	O	1376-1377

Further	O	1378-1385
studies	O	1386-1393
suggested	O	1394-1403
that	O	1404-1408
low	O	1409-1412
dilutions	O	1413-1422
of	O	1423-1425
C5D	B	1426-1429
serum	O	1430-1435
contain	O	1436-1443
a	O	1444-1445
factor	O	1446-1452
(	O	1453-1454
or	O	1454-1456
factors	O	1457-1464
)	O	1464-1465
interfering	O	1466-1477
at	O	1478-1480
some	O	1481-1485
step	O	1486-1490
in	O	1491-1493
the	O	1494-1497
hemolytic	O	1498-1507
assay	O	1508-1513
of	O	1514-1516
C5	O	1517-1519
,	O	1519-1520
rather	O	1521-1527
than	O	1528-1532
a	O	1533-1534
true	O	1535-1539
C5	O	1540-1542
inhibitor	O	1543-1552
or	O	1553-1555
inactivator	O	1556-1567
.	O	1567-1568

Of	O	1569-1571
clinical	O	1572-1580
interest	O	1581-1589
are	O	1590-1593
(	O	1594-1595
a	O	1595-1596
)	O	1596-1597
the	O	1598-1601
documentation	O	1602-1615
of	O	1616-1618
membranous	O	1619-1629
glomerulonephritis	B	1630-1648
,	O	1648-1649
vasculitis	B	1650-1660
,	O	1660-1661
and	O	1662-1665
arthritis	B	1666-1675
in	O	1676-1678
an	O	1679-1681
individual	O	1682-1692
lacking	O	1693-1700
C5	O	1701-1703
(	O	1704-1705
and	O	1705-1708
its	O	1709-1712
biologic	O	1713-1721
functions	O	1722-1731
)	O	1731-1732
,	O	1732-1733
and	O	1734-1737
(	O	1738-1739
b	O	1739-1740
)	O	1740-1741
a	O	1742-1743
remarkable	O	1744-1754
propensity	O	1755-1765
to	O	1766-1768
bacterial	B	1769-1778
infections	I	1779-1789
in	O	1790-1792
the	O	1793-1796
proband	O	1797-1804
,	O	1804-1805
even	O	1806-1810
during	O	1811-1817
periods	O	1818-1825
of	O	1826-1828
low	O	1829-1832
-	O	1832-1833
dose	O	1833-1837
or	O	1838-1840
alternate	O	1841-1850
-	O	1850-1851
day	O	1851-1854
corticosteroid	O	1855-1869
therapy	O	1870-1877
.	O	1877-1878

Other	O	1879-1884
observations	O	1885-1897
indicate	O	1898-1906
that	O	1907-1911
the	O	1912-1915
C5D	B	1916-1919
state	O	1920-1925
is	O	1926-1928
compatible	O	1929-1939
with	O	1940-1944
normal	O	1945-1951
coagulation	O	1952-1963
function	O	1964-1972
and	O	1973-1976
the	O	1977-1980
capacity	O	1981-1989
to	O	1990-1992
mount	O	1993-1998
a	O	1999-2000
neutrophilic	O	2001-2013
leukocytosis	O	2014-2026
during	O	2027-2033
pyogenic	B	2034-2042
infection	I	2043-2052
.	O	2052-2053
.	O	2052-2053

Detection	O	0-9
of	O	10-12
heterozygous	O	13-25
carriers	O	26-34
of	O	35-37
the	O	38-41
ataxia	B	42-48
-	I	48-49
telangiectasia	I	49-63
(	O	64-65
ATM	O	65-68
)	O	68-69
gene	O	70-74
by	O	75-77
G2	O	78-80
phase	O	81-86
chromosomal	O	87-98
radiosensitivity	O	99-115
of	O	116-118
peripheral	O	119-129
blood	O	130-135
lymphocytes	O	136-147
.	O	147-148

In	O	149-151
ataxia	B	152-158
-	I	158-159
telangiectasia	I	159-173
(	O	174-175
A	B	175-176
-	I	176-177
T	I	177-178
)	O	178-179
patients	O	180-188
,	O	188-189
mutations	O	190-199
in	O	200-202
a	O	203-204
single	O	205-211
gene	O	212-216
,	O	216-217
ATM	O	218-221
,	O	221-222
result	O	223-229
in	O	230-232
an	O	233-235
autosomal	B	236-245
recessive	I	246-255
syndrome	I	256-264
that	O	265-269
embraces	O	270-278
a	O	279-280
variety	O	281-288
of	O	289-291
clinical	O	292-300
features	O	301-309
and	O	310-313
manifests	O	314-323
extreme	O	324-331
radiosensitivity	O	332-348
and	O	349-352
a	O	353-354
strong	O	355-361
pre	O	362-365
-	O	365-366
disposition	O	366-377
to	O	378-380
malignancy	B	381-391
.	O	391-392

Heterozygotes	O	393-406
for	O	407-410
the	O	411-414
ATM	O	415-418
gene	O	419-423
have	O	424-428
no	O	429-431
clinical	O	432-440
expression	O	441-451
of	O	452-454
A	B	455-456
-	I	456-457
T	I	457-458
but	O	459-462
may	O	463-466
be	O	467-469
cancer	B	470-476
prone	O	477-482
with	O	483-487
a	O	488-489
moderate	O	490-498
increase	O	499-507
in	O	508-510
in	O	511-513
vitro	O	514-519
radiosensitivity	O	520-536
.	O	536-537

We	O	538-540
performed	O	541-550
a	O	551-552
blind	O	553-558
chromosomal	O	559-570
analysis	O	571-579
on	O	580-582
G2	O	583-585
-	O	585-586
phase	O	586-591
lymphocytes	O	592-603
from	O	604-608
7	O	609-610
unrelated	O	611-620
A	B	621-622
-	I	622-623
T	I	623-624
patients	O	625-633
,	O	633-634
13	O	635-637
obligate	O	638-646
A	B	647-648
-	I	648-649
T	I	649-650
heterozygotes	O	651-664
(	O	665-666
parents	O	666-673
of	O	674-676
the	O	677-680
patients	O	681-689
)	O	689-690
,	O	690-691
and	O	692-695
14	O	696-698
normal	O	699-705
controls	O	706-714
following	O	715-724
X	O	725-726
-	O	726-727
irradiation	O	727-738
with	O	739-743
1	O	744-745
Gy	O	746-748
in	O	749-751
order	O	752-757
to	O	758-760
evaluate	O	761-769
this	O	770-774
cytogenetic	O	775-786
method	O	787-793
as	O	794-796
a	O	797-798
tool	O	799-803
for	O	804-807
detection	O	808-817
of	O	818-820
ATM	O	821-824
carriers	O	825-833
.	O	833-834

Both	O	835-839
A	B	840-841
-	I	841-842
T	I	842-843
homozygotes	O	844-855
and	O	856-859
heterozygotes	O	860-873
showed	O	874-880
significantly	O	881-894
increased	O	895-904
levels	O	905-911
of	O	912-914
radiation	O	915-924
-	O	924-925
induced	O	925-932
chromatid	O	933-942
damage	O	943-949
relative	O	950-958
to	O	959-961
that	O	962-966
of	O	967-969
normal	O	970-976
controls	O	977-985
.	O	985-986

These	O	987-992
results	O	993-1000
show	O	1001-1005
that	O	1006-1010
the	O	1011-1014
G2	O	1015-1017
-	O	1017-1018
phase	O	1018-1023
chromosomal	O	1024-1035
radiosensitivity	O	1036-1052
assay	O	1053-1058
can	O	1059-1062
be	O	1063-1065
used	O	1066-1070
for	O	1071-1074
the	O	1075-1078
detection	O	1079-1088
of	O	1089-1091
A	B	1092-1093
-	I	1093-1094
T	I	1094-1095
heterozygotes	O	1096-1109
.	O	1109-1110

In	O	1111-1113
combination	O	1114-1125
with	O	1126-1130
molecular	O	1131-1140
genetic	O	1141-1148
analyses	O	1149-1157
,	O	1157-1158
this	O	1159-1163
test	O	1164-1168
may	O	1169-1172
be	O	1173-1175
of	O	1176-1178
value	O	1179-1184
in	O	1185-1187
studies	O	1188-1195
of	O	1196-1198
familial	B	1199-1207
and	I	1208-1211
sporadic	I	1212-1220
cancers	I	1221-1228
aimed	O	1229-1234
at	O	1235-1237
determination	O	1238-1251
of	O	1252-1254
the	O	1255-1258
potential	O	1259-1268
involvement	O	1269-1280
of	O	1281-1283
ATM	O	1284-1287
mutations	O	1288-1297
in	O	1298-1300
tumor	B	1301-1306
risk	O	1307-1311
or	O	1312-1314
development	O	1315-1326
.	O	1326-1327
.	O	1326-1327

The	O	0-3
molecular	O	4-13
basis	O	14-19
of	O	20-22
C6	B	23-25
deficiency	I	26-36
in	O	37-39
the	O	40-43
western	O	44-51
Cape	O	52-56
,	O	56-57
South	O	58-63
Africa	O	64-70
.	O	70-71

Deficiency	B	72-82
of	I	83-85
the	I	86-89
sixth	I	90-95
component	I	96-105
of	I	106-108
human	I	109-114
complement	I	115-125
(	O	126-127
C6	O	127-129
)	O	129-130
has	O	131-134
been	O	135-139
reported	O	140-148
in	O	149-151
a	O	152-153
number	O	154-160
of	O	161-163
families	O	164-172
from	O	173-177
the	O	178-181
western	O	182-189
Cape	O	190-194
,	O	194-195
South	O	196-201
Africa	O	202-208
.	O	208-209

Meningococcal	B	210-223
disease	I	224-231
is	O	232-234
endemic	O	235-242
in	O	243-245
the	O	246-249
Cape	O	250-254
and	O	255-258
almost	O	259-265
all	O	266-269
pedigrees	O	270-279
of	O	280-282
total	O	283-288
C6	B	289-291
deficiency	I	292-302
(	O	303-304
C6Q0	O	304-308
)	O	308-309
have	O	310-314
been	O	315-319
ascertained	O	320-331
because	O	332-339
of	O	340-342
recurrent	O	343-352
disease	O	353-360
.	O	360-361

We	O	362-364
have	O	365-369
sequenced	O	370-379
the	O	380-383
expressed	O	384-393
exons	O	394-399
of	O	400-402
the	O	403-406
C6	O	407-409
gene	O	410-414
from	O	415-419
selected	O	420-428
cases	O	429-434
and	O	435-438
have	O	439-443
found	O	444-449
three	O	450-455
molecular	O	456-465
defects	O	466-473
leading	O	474-481
to	O	482-484
total	O	485-490
deficiency	O	491-501
879delG	O	503-510
,	O	510-511
which	O	512-517
is	O	518-520
the	O	521-524
common	O	525-531
defect	O	532-538
in	O	539-541
the	O	542-545
Cape	O	546-550
and	O	551-554
hitherto	O	555-563
unreported	O	564-574
,	O	574-575
and	O	576-579
1195delC	O	580-588
and	O	589-592
1936delG	O	593-601
,	O	601-602
which	O	603-608
have	O	609-613
been	O	614-618
previously	O	619-629
reported	O	630-638
in	O	639-641
African	O	642-649
-	O	649-650
Americans	O	650-659
.	O	659-660

We	O	661-663
also	O	664-668
show	O	669-673
that	O	674-678
the	O	679-682
879delG	O	683-690
and	O	691-694
1195delC	O	695-703
defects	O	704-711
are	O	712-715
associated	O	716-726
with	O	727-731
characteristic	O	732-746
C6	O	747-749
/	O	749-750
C7	O	750-752
region	O	753-759
DNA	O	760-763
marker	O	764-770
haplotypes	O	771-781
,	O	781-782
although	O	783-791
small	O	792-797
variations	O	798-808
were	O	809-813
observed	O	814-822
.	O	822-823

The	O	824-827
1936delG	O	828-836
defect	O	837-843
was	O	844-847
observed	O	848-856
only	O	857-861
once	O	862-866
in	O	867-869
the	O	870-873
Cape	O	874-878
,	O	878-879
but	O	880-883
its	O	884-887
associated	O	888-898
haplotype	O	899-908
could	O	909-914
be	O	915-917
deduced	O	918-925
.	O	925-926

The	O	927-930
data	O	931-935
from	O	936-940
the	O	941-944
haplotypes	O	945-955
indicate	O	956-964
that	O	965-969
these	O	970-975
three	O	976-981
molecular	O	982-991
defects	O	992-999
account	O	1000-1007
for	O	1008-1011
the	O	1012-1015
defects	O	1016-1023
in	O	1024-1026
all	O	1027-1030
the	O	1031-1034
38	O	1035-1037
unrelated	O	1038-1047
C6Q0	O	1048-1052
individuals	O	1053-1064
we	O	1065-1067
have	O	1068-1072
studied	O	1073-1080
from	O	1081-1085
the	O	1086-1089
Cape	O	1090-1094
.	O	1094-1095

We	O	1096-1098
have	O	1099-1103
also	O	1104-1108
observed	O	1109-1117
the	O	1118-1121
879delG	O	1122-1129
defect	O	1130-1136
in	O	1137-1139
two	O	1140-1143
Dutch	O	1144-1149
C6	B	1150-1152
-	I	1152-1153
deficient	I	1153-1162
kindreds	O	1163-1171
,	O	1171-1172
but	O	1173-1176
the	O	1177-1180
879delG	O	1181-1188
defect	O	1189-1195
in	O	1196-1198
the	O	1199-1202
Cape	O	1203-1207
probably	O	1208-1216
did	O	1217-1220
not	O	1221-1224
come	O	1225-1229
from	O	1230-1234
The	O	1235-1238
Netherlands	O	1239-1250
.	O	1250-1251
.	O	1250-1251

The	O	0-3
R496H	O	4-9
mutation	O	10-18
of	O	19-21
arylsulfatase	O	22-35
A	O	36-37
does	O	38-42
not	O	43-46
cause	O	47-52
metachromatic	B	53-66
leukodystrophy	I	67-81
.	O	81-82

Deficiency	B	83-93
of	I	94-96
arylsulfatase	I	97-110
A	I	111-112
(	O	113-114
ARSA	O	114-118
)	O	118-119
enzyme	O	120-126
activity	O	127-135
causes	O	136-142
metachromatic	B	143-156
leukodystrophy	I	157-171
(	O	172-173
MLD	B	173-176
)	O	176-177
.	O	177-178

A	O	179-180
number	O	181-187
of	O	188-190
ARSA	O	191-195
gene	O	196-200
mutations	O	201-210
responsible	O	211-222
for	O	223-226
MLD	B	227-230
have	O	231-235
been	O	236-240
identified	O	241-251
.	O	251-252

Recently	O	253-261
,	O	261-262
the	O	263-266
R496H	O	267-272
mutation	O	273-281
of	O	282-284
ARSA	O	285-289
was	O	290-293
proposed	O	294-302
to	O	303-305
be	O	306-308
a	O	309-310
cause	O	311-316
of	O	317-319
MLD	B	320-323
(	O	324-325
Draghia	O	325-332
et	O	333-335
al	O	336-338
.	O	338-339
,	O	339-340
1997	O	341-345
)	O	345-346
.	O	346-347

We	O	348-350
have	O	351-355
investigated	O	356-368
the	O	369-372
R496H	O	373-378
mutation	O	379-387
and	O	388-391
found	O	392-397
this	O	398-402
mutation	O	403-411
at	O	412-414
a	O	415-416
relatively	O	417-427
high	O	428-432
frequency	O	433-442
in	O	443-445
an	O	446-448
African	O	449-456
American	O	457-465
population	O	466-476
(	O	477-478
f	O	478-479
=	O	480-481
0	O	482-483
.	O	483-484
09	O	485-487
,	O	487-488
n	O	489-490
=	O	491-492
61	O	493-495
subjects	O	496-504
)	O	504-505
.	O	505-506

The	O	507-510
ARSA	O	511-515
enzyme	O	516-522
activity	O	523-531
in	O	532-534
subjects	O	535-543
with	O	544-548
and	O	549-552
without	O	553-560
the	O	561-564
R496H	O	565-570
mutation	O	571-579
was	O	580-583
determined	O	584-594
and	O	595-598
found	O	599-604
to	O	605-607
be	O	608-610
normal	O	611-617
.	O	617-618

It	O	619-621
is	O	622-624
therefore	O	625-634
concluded	O	635-644
that	O	645-649
the	O	650-653
R496H	O	654-659
mutation	O	660-668
of	O	669-671
ARSA	O	672-676
does	O	677-681
not	O	682-685
negatively	O	686-696
influence	O	697-706
the	O	707-710
activity	O	711-719
of	O	720-722
ARSA	O	723-727
and	O	728-731
is	O	732-734
not	O	735-738
a	O	739-740
cause	O	741-746
of	O	747-749
MLD	B	750-753

Piebaldism	B	0-10
with	O	11-15
deafness	B	16-24
:	O	24-25
molecular	O	26-35
evidence	O	36-44
for	O	45-48
an	O	49-51
expanded	O	52-60
syndrome	O	61-69
.	O	69-70

In	O	71-73
a	O	74-75
South	O	76-81
African	O	82-89
girl	O	90-94
of	O	95-97
Xhosa	O	98-103
stock	O	104-109
with	O	110-114
severe	O	115-121
piebaldism	B	122-132
and	O	133-136
profound	O	137-145
congenital	O	146-156
sensorineural	B	157-170
deafness	I	171-179
we	O	180-182
identified	O	183-193
a	O	194-195
novel	O	196-201
missense	O	202-210
substitution	O	211-223
at	O	224-226
a	O	227-228
highly	O	229-235
conserved	O	236-245
residue	O	246-253
in	O	254-256
the	O	257-260
intracellular	O	261-274
kinase	O	275-281
domain	O	282-288
of	O	289-291
the	O	292-295
KIT	O	296-299
proto	O	300-305
-	O	305-306
oncogene	O	306-314
,	O	314-315
R796G	O	316-321
.	O	321-322

Though	O	323-329
auditory	B	330-338
anomalies	I	339-348
have	O	349-353
been	O	354-358
observed	O	359-367
in	O	368-370
mice	O	371-375
with	O	376-380
dominant	O	381-389
white	O	390-395
spotting	O	396-404
(	O	405-406
W	O	406-407
)	O	407-408
due	O	409-412
to	O	413-415
KIT	O	416-419
mutations	O	420-429
,	O	429-430
deafness	B	431-439
is	O	440-442
not	O	443-446
typical	O	447-454
in	O	455-457
human	O	458-463
piebaldism	B	464-474
.	O	474-475

Thus	O	476-480
,	O	480-481
the	O	482-485
occurrence	O	486-496
of	O	497-499
sensorineural	B	500-513
deafness	I	514-522
in	O	523-525
this	O	526-530
patient	O	531-538
extends	O	539-546
considerably	O	547-559
the	O	560-563
phenotypic	O	564-574
range	O	575-580
of	O	581-583
piebaldism	B	584-594
due	O	595-598
to	O	599-601
KIT	O	602-605
gene	O	606-610
mutation	O	611-619
in	O	620-622
humans	O	623-629
and	O	630-633
tightens	O	634-642
the	O	643-646
clinical	O	647-655
similarity	O	656-666
between	O	667-674
piebaldism	B	675-685
and	O	686-689
the	O	690-693
various	O	694-701
forms	O	702-707
of	O	708-710
Waardenburg	B	711-722
syndrome	I	723-731
.	O	731-732
.	O	731-732

Genetic	O	0-7
heterogeneity	O	8-21
and	O	22-25
penetrance	O	26-36
analysis	O	37-45
of	O	46-48
the	O	49-52
BRCA1	O	53-58
and	O	59-62
BRCA2	O	63-68
genes	O	69-74
in	O	75-77
breast	B	78-84
cancer	I	85-91
families	O	92-100
.	O	100-101

The	O	102-105
Breast	B	106-112
Cancer	I	113-119
Linkage	O	120-127
Consortium	O	128-138
.	O	138-139

The	O	140-143
contribution	O	144-156
of	O	157-159
BRCA1	O	160-165
and	O	166-169
BRCA2	O	170-175
to	O	176-178
inherited	B	179-188
breast	I	189-195
cancer	I	196-202
was	O	203-206
assessed	O	207-215
by	O	216-218
linkage	O	219-226
and	O	227-230
mutation	O	231-239
analysis	O	240-248
in	O	249-251
237	O	252-255
families	O	256-264
,	O	264-265
each	O	266-270
with	O	271-275
at	O	276-278
least	O	279-284
four	O	285-289
cases	O	290-295
of	O	296-298
breast	B	299-305
cancer	I	306-312
,	O	312-313
collected	O	314-323
by	O	324-326
the	O	327-330
Breast	B	331-337
Cancer	I	338-344
Linkage	O	345-352
Consortium	O	353-363
.	O	363-364

Families	O	365-373
were	O	374-378
included	O	379-387
without	O	388-395
regard	O	396-402
to	O	403-405
the	O	406-409
occurrence	O	410-420
of	O	421-423
ovarian	B	424-431
or	I	432-434
other	I	435-440
cancers	I	441-448
.	O	448-449

Overall	O	450-457
,	O	457-458
disease	O	459-466
was	O	467-470
linked	O	471-477
to	O	478-480
BRCA1	O	481-486
in	O	487-489
an	O	490-492
estimated	O	493-502
52	O	503-505
%	O	505-506
of	O	507-509
families	O	510-518
,	O	518-519
to	O	520-522
BRCA2	O	523-528
in	O	529-531
32	O	532-534
%	O	534-535
of	O	536-538
families	O	539-547
,	O	547-548
and	O	549-552
to	O	553-555
neither	O	556-563
gene	O	564-568
in	O	569-571
16	O	572-574
%	O	574-575
(	O	576-577
95	O	577-579
%	O	579-580
confidence	O	581-591
interval	O	592-600
[	O	601-602
CI	O	602-604
]	O	604-605
6	O	606-607
%	O	607-608
-	O	609-610
28	O	610-612
%	O	612-613
)	O	613-614
,	O	614-615
suggesting	O	616-626
other	O	627-632
predisposition	O	633-647
genes	O	648-653
.	O	653-654

The	O	655-658
majority	O	659-667
(	O	668-669
81	O	669-671
%	O	671-672
)	O	672-673
of	O	674-676
the	O	677-680
breast	B	681-687
-	I	687-688
ovarian	I	688-695
cancer	I	696-702
families	O	703-711
were	O	712-716
due	O	717-720
to	O	721-723
BRCA1	O	724-729
,	O	729-730
with	O	731-735
most	O	736-740
others	O	741-747
(	O	748-749
14	O	749-751
%	O	751-752
)	O	752-753
due	O	754-757
to	O	758-760
BRCA2	O	761-766
.	O	766-767

Conversely	O	768-778
,	O	778-779
the	O	780-783
majority	O	784-792
of	O	793-795
families	O	796-804
with	O	805-809
male	B	810-814
and	I	815-818
female	I	819-825
breast	I	826-832
cancer	I	833-839
were	O	840-844
due	O	845-848
to	O	849-851
BRCA2	O	852-857
(	O	858-859
76	O	859-861
%	O	861-862
)	O	862-863
.	O	863-864

The	O	865-868
largest	O	869-876
proportion	O	877-887
(	O	888-889
67	O	889-891
%	O	891-892
)	O	892-893
of	O	894-896
families	O	897-905
due	O	906-909
to	O	910-912
other	O	913-918
genes	O	919-924
was	O	925-928
found	O	929-934
in	O	935-937
families	O	938-946
with	O	947-951
four	O	952-956
or	O	957-959
five	O	960-964
cases	O	965-970
of	O	971-973
female	O	974-980
breast	B	981-987
cancer	I	988-994
only	O	995-999
.	O	999-1000

These	O	1001-1006
estimates	O	1007-1016
were	O	1017-1021
not	O	1022-1025
substantially	O	1026-1039
affected	O	1040-1048
either	O	1049-1055
by	O	1056-1058
changing	O	1059-1067
the	O	1068-1071
assumed	O	1072-1079
penetrance	O	1080-1090
model	O	1091-1096
for	O	1097-1100
BRCA1	O	1101-1106
or	O	1107-1109
by	O	1110-1112
including	O	1113-1122
or	O	1123-1125
excluding	O	1126-1135
BRCA1	O	1136-1141
mutation	O	1142-1150
data	O	1151-1155
.	O	1155-1156

Among	O	1157-1162
those	O	1163-1168
families	O	1169-1177
with	O	1178-1182
disease	O	1183-1190
due	O	1191-1194
to	O	1195-1197
BRCA1	O	1198-1203
that	O	1204-1208
were	O	1209-1213
tested	O	1214-1220
by	O	1221-1223
one	O	1224-1227
of	O	1228-1230
the	O	1231-1234
standard	O	1235-1243
screening	O	1244-1253
methods	O	1254-1261
,	O	1261-1262
mutations	O	1263-1272
were	O	1273-1277
detected	O	1278-1286
in	O	1287-1289
the	O	1290-1293
coding	O	1294-1300
sequence	O	1301-1309
or	O	1310-1312
splice	O	1313-1319
sites	O	1320-1325
in	O	1326-1328
an	O	1329-1331
estimated	O	1332-1341
63	O	1342-1344
%	O	1344-1345
(	O	1346-1347
95	O	1347-1349
%	O	1349-1350
CI	O	1351-1353
51	O	1354-1356
%	O	1356-1357
-	O	1358-1359
77	O	1359-1361
%	O	1361-1362
)	O	1362-1363
.	O	1363-1364

The	O	1365-1368
estimated	O	1369-1378
sensitivity	O	1379-1390
was	O	1391-1394
identical	O	1395-1404
for	O	1405-1408
direct	O	1409-1415
sequencing	O	1416-1426
and	O	1427-1430
other	O	1431-1436
techniques	O	1437-1447
.	O	1447-1448

The	O	1449-1452
penetrance	O	1453-1463
of	O	1464-1466
BRCA2	O	1467-1472
was	O	1473-1476
estimated	O	1477-1486
by	O	1487-1489
maximizing	O	1490-1500
the	O	1501-1504
LOD	O	1505-1508
score	O	1509-1514
in	O	1515-1517
BRCA2	O	1518-1523
-	O	1523-1524
mutation	O	1524-1532
families	O	1533-1541
,	O	1541-1542
over	O	1543-1547
all	O	1548-1551
possible	O	1552-1560
penetrance	O	1561-1571
functions	O	1572-1581
.	O	1581-1582

The	O	1583-1586
estimated	O	1587-1596
cumulative	O	1597-1607
risk	O	1608-1612
of	O	1613-1615
breast	B	1616-1622
cancer	I	1623-1629
reached	O	1630-1637
28	O	1638-1640
%	O	1640-1641
(	O	1642-1643
95	O	1643-1645
%	O	1645-1646
CI	O	1647-1649
9	O	1650-1651
%	O	1651-1652
-	O	1653-1654
44	O	1654-1656
%	O	1656-1657
)	O	1657-1658
by	O	1659-1661
age	O	1662-1665
50	O	1666-1668
years	O	1669-1674
and	O	1675-1678
84	O	1679-1681
%	O	1681-1682
(	O	1683-1684
95	O	1684-1686
%	O	1686-1687
CI	O	1688-1690
43	O	1691-1693
%	O	1693-1694
-	O	1695-1696
95	O	1696-1698
%	O	1698-1699
)	O	1699-1700
by	O	1701-1703
age	O	1704-1707
70	O	1708-1710
years	O	1711-1716
.	O	1716-1717

The	O	1718-1721
corresponding	O	1722-1735
ovarian	B	1736-1743
cancer	I	1744-1750
risks	O	1751-1756
were	O	1757-1761
0	O	1762-1763
.	O	1763-1764
4	O	1765-1766
%	O	1766-1767
(	O	1768-1769
95	O	1769-1771
%	O	1771-1772
CI	O	1773-1775
0	O	1776-1777
%	O	1777-1778
-	O	1779-1780
1	O	1780-1781
%	O	1781-1782
)	O	1782-1783
by	O	1784-1786
age	O	1787-1790
50	O	1791-1793
years	O	1794-1799
and	O	1800-1803
27	O	1804-1806
%	O	1806-1807
(	O	1808-1809
95	O	1809-1811
%	O	1811-1812
CI	O	1813-1815
0	O	1816-1817
%	O	1817-1818
-	O	1819-1820
47	O	1820-1822
%	O	1822-1823
)	O	1823-1824
by	O	1825-1827
age	O	1828-1831
70	O	1832-1834
years	O	1835-1840
.	O	1840-1841

The	O	1842-1845
lifetime	O	1846-1854
risk	O	1855-1859
of	O	1860-1862
breast	B	1863-1869
cancer	I	1870-1876
appears	O	1877-1884
similar	O	1885-1892
to	O	1893-1895
the	O	1896-1899
risk	O	1900-1904
in	O	1905-1907
BRCA1	O	1908-1913
carriers	O	1914-1922
,	O	1922-1923
but	O	1924-1927
there	O	1928-1933
was	O	1934-1937
some	O	1938-1942
suggestion	O	1943-1953
of	O	1954-1956
a	O	1957-1958
lower	O	1959-1964
risk	O	1965-1969
in	O	1970-1972
BRCA2	O	1973-1978
carriers	O	1979-1987
<	O	1988-1989
50	O	1990-1992
years	O	1993-1998
of	O	1999-2001
age	O	2002-2005
.	O	2005-2006

Severe	O	0-6
early	O	7-12
-	O	12-13
onset	O	13-18
obesity	B	19-26
,	O	26-27
adrenal	B	28-35
insufficiency	I	36-49
and	O	50-53
red	O	54-57
hair	O	58-62
pigmentation	O	63-75
caused	O	76-82
by	O	83-85
POMC	O	86-90
mutations	O	91-100
in	O	101-103
humans	O	104-110
.	O	110-111

Sequential	O	112-122
cleavage	O	123-131
of	O	132-134
the	O	135-138
precursor	O	139-148
protein	O	149-156
pre	O	157-160
-	O	160-161
pro	O	161-164
-	O	160-161
opiomelanocortin	O	165-181
(	O	182-183
POMC	O	183-187
)	O	187-188
generates	O	189-198
the	O	199-202
melanocortin	O	203-215
peptides	O	216-224
adrenocorticotrophin	O	225-245
(	O	246-247
ACTH	O	247-251
)	O	251-252
,	O	252-253
melanocyte	O	254-264
-	O	264-265
stimulating	O	265-276
hormones	O	277-285
(	O	286-287
MSH	O	287-290
)	O	290-291
alpha	O	292-297
,	O	297-298
beta	O	299-303
and	O	304-307
gamma	O	308-313
as	O	314-316
well	O	317-321
as	O	322-324
the	O	325-328
opioid	O	329-335
-	O	335-336
receptor	O	336-344
ligand	O	345-351
beta	O	352-356
-	O	356-357
endorphin	O	357-366
.	O	366-367

While	O	368-373
a	O	374-375
few	O	376-379
cases	O	380-385
of	O	386-388
isolated	O	389-397
ACTH	B	398-402
deficiency	I	403-413
have	O	414-418
been	O	419-423
reported	O	424-432
(	O	433-434
OMIM	O	434-438
201400	O	439-445
)	O	445-446
,	O	446-447
an	O	448-450
inherited	O	451-460
POMC	O	461-465
defect	O	466-472
has	O	473-476
not	O	477-480
been	O	481-485
described	O	486-495
so	O	496-498
far	O	499-502
.	O	502-503

Recent	O	504-510
studies	O	511-518
in	O	519-521
animal	O	522-528
models	O	529-535
elucidated	O	536-546
a	O	547-548
central	O	549-556
role	O	557-561
of	O	562-564
alpha	O	565-570
-	O	570-571
MSH	O	571-574
in	O	575-577
the	O	578-581
regulation	O	582-592
of	O	593-595
food	O	596-600
intake	O	601-607
by	O	608-610
activation	O	611-621
of	O	622-624
the	O	625-628
brain	O	629-634
melanocortin	O	635-647
-	O	647-648
4	O	648-649
-	O	647-648
receptor	O	650-658
(	O	659-660
MC4	O	660-663
-	O	663-664
R	O	664-665
;	O	665-666
refs	O	667-671
3	O	672-673
-	O	673-674
5	O	674-675
)	O	675-676
and	O	677-680
the	O	681-684
linkage	O	685-692
of	O	693-695
human	O	696-701
obesity	B	702-709
to	O	710-712
chromosome	O	713-723
2	O	724-725
in	O	726-728
close	O	729-734
proximity	O	735-744
to	O	745-747
the	O	748-751
POMC	O	752-756
locus	O	757-762
,	O	762-763
led	O	764-767
to	O	768-770
the	O	771-774
proposal	O	775-783
of	O	784-786
an	O	787-789
association	O	790-801
of	O	802-804
POMC	O	805-809
with	O	810-814
human	O	815-820
obesity	B	821-828
.	O	828-829

The	O	830-833
dual	O	834-838
role	O	839-843
of	O	844-846
alpha	O	847-852
-	O	852-853
MSH	O	853-856
in	O	857-859
regulating	O	860-870
food	O	871-875
intake	O	876-882
and	O	883-886
influencing	O	887-898
hair	O	899-903
pigmentation	O	904-916
predicts	O	917-925
that	O	926-930
the	O	931-934
phenotype	O	935-944
associated	O	945-955
with	O	956-960
a	O	961-962
defect	O	963-969
in	O	970-972
POMC	O	973-977
function	O	978-986
would	O	987-992
include	O	993-1000
obesity	B	1001-1008
,	O	1008-1009
alteration	O	1010-1020
in	O	1021-1023
pigmentation	O	1024-1036
and	O	1037-1040
ACTH	B	1041-1045
deficiency	I	1046-1056
.	O	1056-1057

The	O	1058-1061
observation	O	1062-1073
of	O	1074-1076
these	O	1077-1082
symptoms	O	1083-1091
in	O	1092-1094
two	O	1095-1098
probands	O	1099-1107
prompted	O	1108-1116
us	O	1117-1119
to	O	1120-1122
search	O	1123-1129
for	O	1130-1133
mutations	O	1134-1143
within	O	1144-1150
their	O	1151-1156
POMC	O	1157-1161
genes	O	1162-1167
.	O	1167-1168

Patient	O	1169-1176
1	O	1177-1178
was	O	1179-1182
found	O	1183-1188
to	O	1189-1191
be	O	1192-1194
a	O	1195-1196
compound	O	1197-1205
heterozygote	O	1206-1218
for	O	1219-1222
two	O	1223-1226
mutations	O	1227-1236
in	O	1237-1239
exon	O	1240-1244
3	O	1245-1246
(	O	1247-1248
G7013T	O	1248-1254
,	O	1254-1255
C7133delta	O	1256-1266
)	O	1266-1267
which	O	1268-1273
interfere	O	1274-1283
with	O	1284-1288
appropriate	O	1289-1300
synthesis	O	1301-1310
of	O	1311-1313
ACTH	O	1314-1318
and	O	1319-1322
alpha	O	1323-1328
-	O	1328-1329
MSH	O	1329-1332
.	O	1332-1333

Patient	O	1334-1341
2	O	1342-1343
was	O	1344-1347
homozygous	O	1348-1358
for	O	1359-1362
a	O	1363-1364
mutation	O	1365-1373
in	O	1374-1376
exon	O	1377-1381
2	O	1382-1383
(	O	1384-1385
C3804A	O	1385-1391
)	O	1391-1392
which	O	1393-1398
abolishes	O	1399-1408
POMC	O	1409-1413
translation	O	1414-1425
.	O	1425-1426

These	O	1427-1432
findings	O	1433-1441
represent	O	1442-1451
the	O	1452-1455
first	O	1456-1461
examples	O	1462-1470
of	O	1471-1473
a	O	1474-1475
genetic	B	1476-1483
defect	I	1484-1490
within	O	1491-1497
the	O	1498-1501
POMC	O	1502-1506
gene	O	1507-1511
and	O	1512-1515
define	O	1516-1522
a	O	1523-1524
new	O	1525-1528
monogenic	B	1529-1538
endocrine	I	1539-1548
disorder	I	1549-1557
resulting	O	1558-1567
in	O	1568-1570
early	O	1571-1576
-	O	1576-1577
onset	O	1577-1582
obesity	B	1583-1590
,	O	1590-1591
adrenal	B	1592-1599
insufficiency	I	1600-1613
and	O	1614-1617
red	O	1618-1621
hair	O	1622-1626
pigmentation	O	1627-1639
.	O	1639-1640
.	O	1639-1640

The	O	0-3
tumor	B	4-9
suppressor	O	10-20
gene	O	21-25
Smad4	O	26-31
/	O	31-32
Dpc4	O	32-36
is	O	37-39
required	O	40-48
for	O	49-52
gastrulation	O	53-65
and	O	66-69
later	O	70-75
for	O	76-79
anterior	O	80-88
development	O	89-100
of	O	101-103
the	O	104-107
mouse	O	108-113
embryo	O	114-120
.	O	120-121

Mutations	O	122-131
in	O	132-134
the	O	135-138
SMAD4	O	139-144
/	O	144-145
DPC4	O	145-149
tumor	B	150-155
suppressor	O	156-166
gene	O	167-171
,	O	171-172
a	O	173-174
key	O	175-178
signal	O	179-185
transducer	O	186-196
in	O	197-199
most	O	200-204
TGFbeta	O	205-212
-	O	212-213
related	O	213-220
pathways	O	221-229
,	O	229-230
are	O	231-234
involved	O	235-243
in	O	244-246
50	O	247-249
%	O	249-250
of	O	251-253
pancreatic	B	254-264
cancers	I	265-272
.	O	272-273

Homozygous	O	274-284
Smad4	O	285-290
mutant	O	291-297
mice	O	298-302
die	O	303-306
before	O	307-313
day	O	314-317
7	O	318-319
.	O	319-320
5	O	321-322
of	O	323-325
embryogenesis	O	326-339
.	O	339-340

Mutant	O	341-347
embryos	O	348-355
have	O	356-360
reduced	O	361-368
size	O	369-373
,	O	373-374
fail	O	375-379
to	O	380-382
gastrulate	O	383-393
or	O	394-396
express	O	397-404
a	O	405-406
mesodermal	O	407-417
marker	O	418-424
,	O	424-425
and	O	426-429
show	O	430-434
abnormal	O	435-443
visceral	O	444-452
endoderm	O	453-461
development	O	462-473
.	O	473-474

Growth	B	475-481
retardation	I	482-493
of	O	494-496
the	O	497-500
Smad4	O	501-506
-	O	506-507
deficient	O	507-516
embryos	O	517-524
results	O	525-532
from	O	533-537
reduced	O	538-545
cell	O	546-550
proliferation	O	551-564
rather	O	565-571
than	O	572-576
increased	O	577-586
apoptosis	O	587-596
.	O	596-597

Aggregation	O	598-609
of	O	610-612
mutant	O	613-619
Smad4	O	620-625
ES	O	626-628
cells	O	629-634
with	O	635-639
wild	O	640-644
-	O	644-645
type	O	645-649
tetraploid	O	650-660
morulae	O	661-668
rescues	O	669-676
the	O	677-680
gastrulation	B	681-693
defect	I	694-700
.	O	700-701

These	O	702-707
results	O	708-715
indicate	O	716-724
that	O	725-729
Smad4	O	730-735
is	O	736-738
initially	O	739-748
required	O	749-757
for	O	758-761
the	O	762-765
differentiation	O	766-781
of	O	782-784
the	O	785-788
visceral	O	789-797
endoderm	O	798-806
and	O	807-810
that	O	811-815
the	O	816-819
gastrulation	B	820-832
defect	I	833-839
in	O	840-842
the	O	843-846
epiblast	O	847-855
is	O	856-858
secondary	O	859-868
and	O	869-872
non	O	873-876
-	O	876-877
cell	O	877-881
autonomous	O	882-892
.	O	892-893

Rescued	O	894-901
embryos	O	902-909
show	O	910-914
severe	O	915-921
anterior	O	922-930
truncations	O	931-942
,	O	942-943
indicating	O	944-954
a	O	955-956
second	O	957-963
important	O	964-973
role	O	974-978
for	O	979-982
Smad4	O	983-988
in	O	989-991
anterior	O	992-1000
patterning	O	1001-1011
during	O	1012-1018
embryogenesis	O	1019-1032
.	O	1032-1033

Coincidence	O	0-11
of	O	12-14
two	O	15-18
novel	O	19-24
arylsulfatase	O	25-38
A	O	39-40
alleles	O	41-48
and	O	49-52
mutation	O	53-61
459	O	62-65
+	O	65-66
1G	O	66-68
>	O	68-69
A	O	69-70
within	O	71-77
a	O	78-79
family	O	80-86
with	O	87-91
metachromatic	B	92-105
leukodystrophy	I	106-120
:	O	120-121
molecular	O	122-131
basis	O	132-137
of	O	138-140
phenotypic	O	141-151
heterogeneity	O	152-165
.	O	165-166

In	O	167-169
a	O	170-171
family	O	172-178
with	O	179-183
three	O	184-189
siblings	O	190-198
,	O	198-199
one	O	200-203
developed	O	204-213
classical	O	214-223
late	O	224-228
infantile	O	229-238
metachromatic	B	239-252
leukodystrophy	I	253-267
(	O	268-269
MLD	B	269-272
)	O	272-273
,	O	273-274
fatal	O	275-280
at	O	281-283
age	O	284-287
5	O	288-289
years	O	290-295
,	O	295-296
with	O	297-301
deficient	O	302-311
arylsulfatase	O	312-325
A	O	326-327
(	O	328-329
ARSA	O	329-333
)	O	333-334
activity	O	335-343
and	O	344-347
increased	O	348-357
galactosylsulfatide	O	358-377
(	O	378-379
GS	O	379-381
)	O	381-382
excretion	O	383-392
.	O	392-393

The	O	394-397
two	O	398-401
other	O	402-407
siblings	O	408-416
,	O	416-417
apparently	O	418-428
healthy	O	429-436
at	O	437-439
12	O	440-442
(	O	443-444
1	O	444-445
/	O	445-446
2	O	446-447
)	O	447-448
and	O	449-452
15	O	453-455
years	O	456-461
,	O	461-462
respectively	O	463-475
,	O	475-476
and	O	477-480
their	O	481-486
father	O	487-493
,	O	493-494
apparently	O	495-505
healthy	O	506-513
as	O	514-516
well	O	517-521
,	O	521-522
presented	O	523-532
ARSA	O	533-537
and	O	538-541
GS	O	542-544
values	O	545-551
within	O	552-558
the	O	559-562
range	O	563-568
of	O	569-571
MLD	B	572-575
patients	O	576-584
.	O	584-585

Mutation	O	586-594
screening	O	595-604
and	O	605-608
sequence	O	609-617
analysis	O	618-626
disclosed	O	627-636
the	O	637-640
involvement	O	641-652
of	O	653-655
three	O	656-661
different	O	662-671
ARSA	O	672-676
mutations	O	677-686
being	O	687-692
the	O	693-696
molecular	O	697-706
basis	O	707-712
of	O	713-715
intrafamilial	O	716-729
phenotypic	O	730-740
heterogeneity	O	741-754
.	O	754-755

The	O	756-759
late	O	760-764
infantile	O	765-774
patient	O	775-782
inherited	O	783-792
from	O	793-797
his	O	798-801
mother	O	802-808
the	O	809-812
frequent	O	813-821
0	O	822-823
-	O	823-824
type	O	824-828
mutation	O	829-837
459	O	838-841
+	O	842-843
1G	O	844-846
>	O	847-848
A	O	849-850
,	O	850-851
and	O	852-855
from	O	856-860
his	O	861-864
father	O	865-871
a	O	872-873
novel	O	874-879
,	O	879-880
single	O	881-887
basepair	O	888-896
microdeletion	O	897-910
of	O	911-913
guanine	O	914-921
at	O	922-924
nucleotide	O	925-935
7	O	936-937
in	O	938-940
exon	O	941-945
1	O	946-947
(	O	948-949
7delG	O	949-954
)	O	954-955
.	O	955-956

The	O	957-960
two	O	961-964
clinically	O	965-975
unaffected	O	976-986
siblings	O	987-995
carried	O	996-1003
the	O	1004-1007
maternal	O	1008-1016
mutation	O	1017-1025
459	O	1026-1029
+	O	1030-1031
1G	O	1032-1034
>	O	1035-1036
A	O	1037-1038
and	O	1039-1042
,	O	1042-1043
on	O	1044-1046
their	O	1047-1052
paternal	O	1053-1061
allele	O	1062-1068
,	O	1068-1069
a	O	1070-1071
novel	O	1072-1077
cytosine	O	1078-1086
to	O	1087-1089
thymidine	O	1090-1099
transition	O	1100-1110
at	O	1111-1113
nucleotide	O	1114-1124
2435	O	1125-1129
in	O	1130-1132
exon	O	1133-1137
8	O	1138-1139
,	O	1139-1140
resulting	O	1141-1150
in	O	1151-1153
substitution	O	1154-1166
of	O	1167-1169
alanine	O	1170-1177
464	O	1178-1181
by	O	1182-1184
valine	O	1185-1191
(	O	1192-1193
A464V	O	1193-1198
)	O	1198-1199
.	O	1199-1200

The	O	1201-1204
fathers	O	1205-1212
genotype	O	1213-1221
thus	O	1222-1226
was	O	1227-1230
7delG	O	1231-1236
/	O	1236-1237
A464V	O	1237-1242
.	O	1242-1243

Mutation	O	1244-1252
A464V	O	1253-1258
was	O	1259-1262
not	O	1263-1266
found	O	1267-1272
in	O	1273-1275
18	O	1276-1278
unrelated	O	1279-1288
MLD	B	1289-1292
patients	O	1293-1301
and	O	1302-1305
50	O	1306-1308
controls	O	1309-1317
.	O	1317-1318

A464V	O	1319-1324
,	O	1324-1325
although	O	1326-1334
clearly	O	1335-1342
modifying	O	1343-1352
ARSA	O	1353-1357
and	O	1358-1361
GS	O	1362-1364
levels	O	1365-1371
,	O	1371-1372
apparently	O	1373-1383
bears	O	1384-1389
little	O	1390-1396
significance	O	1397-1409
for	O	1410-1413
clinical	O	1414-1422
manifestation	O	1423-1436
of	O	1437-1439
MLD	B	1440-1443
,	O	1443-1444
mimicking	O	1445-1454
the	O	1455-1458
frequent	O	1459-1467
ARSA	O	1468-1472
pseudodeficiency	O	1473-1489
allele	O	1490-1496
.	O	1496-1497

Our	O	1498-1501
results	O	1502-1509
demonstrate	O	1510-1521
that	O	1522-1526
in	O	1527-1529
certain	O	1530-1537
genetic	O	1538-1545
conditions	O	1546-1556
MLD	B	1557-1560
-	O	1560-1561
like	O	1561-1565
ARSA	O	1566-1570
and	O	1571-1574
GS	O	1575-1577
values	O	1578-1584
need	O	1585-1589
not	O	1590-1593
be	O	1594-1596
paralleled	O	1597-1607
by	O	1608-1610
clinical	O	1611-1619
disease	O	1620-1627
,	O	1627-1628
a	O	1629-1630
finding	O	1631-1638
with	O	1639-1643
serious	O	1644-1651
diagnostic	O	1652-1662
and	O	1663-1666
prognostic	O	1667-1677
implications	O	1678-1690
.	O	1690-1691

Moreover	O	1692-1700
,	O	1700-1701
further	O	1702-1709
ARSA	O	1710-1714
alleles	O	1715-1722
functionally	O	1723-1735
similar	O	1736-1743
to	O	1744-1746
A464V	O	1747-1752
might	O	1753-1758
exist	O	1759-1764
which	O	1765-1770
,	O	1770-1771
together	O	1772-1780
with	O	1781-1785
0	O	1786-1787
-	O	1787-1788
type	O	1788-1792
mutations	O	1793-1802
,	O	1802-1803
may	O	1804-1807
cause	O	1808-1813
pathological	O	1814-1826
ARSA	O	1827-1831
and	O	1832-1835
GS	O	1836-1838
levels	O	1839-1845
,	O	1845-1846
but	O	1847-1850
not	O	1851-1854
clinical	O	1855-1863
outbreak	O	1864-1872
of	O	1873-1875
the	O	1876-1879
disease	O	1880-1887
.	O	1887-1888
.	O	1887-1888

Low	O	0-3
levels	O	4-10
of	O	11-13
beta	O	14-18
hexosaminidase	O	19-33
A	O	34-35
in	O	36-38
healthy	O	39-46
individuals	O	47-58
with	O	59-63
apparent	O	64-72
deficiency	O	73-83
of	O	84-86
this	O	87-91
enzyme	O	92-98
.	O	98-99

Appreciable	O	100-111
beta	O	112-116
hexosaminidase	O	117-131
A	O	132-133
(	O	134-135
hex	O	135-138
A	O	139-140
)	O	140-141
activity	O	142-150
has	O	151-154
been	O	155-159
detected	O	160-168
in	O	169-171
cultured	O	172-180
skin	O	181-185
fibroblasts	O	186-197
and	O	198-201
melanoma	B	202-210
tissue	O	211-217
from	O	218-222
healthy	O	223-230
individuals	O	231-242
previously	O	243-253
reported	O	254-262
as	O	263-265
having	O	266-272
deficiency	B	273-283
of	I	284-286
hex	I	287-290
A	I	291-292
activity	O	293-301
indistinguishable	O	302-319
from	O	320-324
that	O	325-329
of	O	330-332
patients	O	333-341
with	O	342-346
Tay	B	347-350
-	I	350-351
Sachs	I	351-356
disease	I	357-364
(	O	365-366
TSD	B	366-369
)	O	369-370
.	O	370-371

Identification	O	372-386
and	O	387-390
quantitation	O	391-403
of	O	404-406
hex	O	407-410
A	O	411-412
,	O	412-413
amounting	O	414-423
to	O	424-426
3	O	427-428
.	O	428-429
5	O	430-431
%	O	431-432
-	O	433-434
6	O	434-435
.	O	435-436

9	O	437-438
%	O	438-439
of	O	440-442
total	O	443-448
beta	O	449-453
hexosaminidase	O	454-468
activity	O	469-477
,	O	477-478
has	O	479-482
been	O	483-487
obtained	O	488-496
by	O	497-499
cellulose	O	500-509
acetate	O	510-517
gel	O	518-521
electrophoresis	O	522-537
,	O	537-538
DEAE	O	539-543
-	O	543-544
cellulose	O	544-553
ion	O	554-557
-	O	557-558
exchange	O	558-566
chromatography	O	567-581
,	O	581-582
radial	O	583-589
immunodiffusion	O	590-605
,	O	605-606
and	O	607-610
radioimmunoassay	O	611-627
.	O	627-628

Previous	O	629-637
family	O	638-644
studies	O	645-652
suggested	O	653-662
that	O	663-667
these	O	668-673
individuals	O	674-685
may	O	686-689
be	O	690-692
compound	O	693-701
heterozygotes	O	702-715
for	O	716-719
the	O	720-723
common	O	724-730
mutant	O	731-737
TSD	B	738-741
gene	O	742-746
and	O	747-750
a	O	751-752
rare	O	753-757
(	O	758-759
allelic	O	759-766
)	O	766-767
mutant	O	768-774
gene	O	775-779
.	O	779-780

Thus	O	781-785
,	O	785-786
the	O	787-790
postulated	O	791-801
rate	O	802-806
mutant	O	807-813
gene	O	814-818
appears	O	819-826
to	O	827-829
code	O	830-834
for	O	835-838
the	O	839-842
expression	O	843-853
of	O	854-856
low	O	857-860
amounts	O	861-868
of	O	869-871
hex	O	872-875
A	O	876-877
.	O	877-878
Heterozygotes	O	879-892
for	O	893-896
the	O	897-900
rare	O	901-905
mutant	O	906-912
may	O	913-916
be	O	917-919
indistinguishable	O	920-937
from	O	938-942
heterozygotes	O	943-956
for	O	957-960
the	O	961-964
common	O	965-971
TSD	B	972-975
mutant	O	976-982
.	O	982-983

However	O	984-991
,	O	991-992
direct	O	993-999
visualization	O	1000-1013
and	O	1014-1017
quantitation	O	1018-1030
of	O	1031-1033
hex	O	1034-1037
A	O	1038-1039
by	O	1040-1042
the	O	1043-1046
methods	O	1047-1054
described	O	1055-1064
may	O	1065-1068
prevent	O	1069-1076
false	O	1077-1082
-	O	1082-1083
positive	O	1083-1091
prenatal	O	1092-1100
diagnosis	O	1101-1110
of	O	1111-1113
TSD	B	1114-1117
in	O	1118-1120
fetuses	O	1121-1128
having	O	1129-1135
the	O	1136-1139
incomplete	O	1140-1150
hex	B	1151-1154
A	I	1155-1156
deficiency	I	1157-1167
of	O	1168-1170
the	O	1171-1174
type	O	1175-1179
described	O	1180-1189
in	O	1190-1192
the	O	1193-1196
four	O	1197-1201
healthy	O	1202-1209
individuals	O	1210-1221

A	O	0-1
mouse	O	2-7
model	O	8-13
for	O	14-17
Prader	B	18-24
-	I	24-25
Willi	I	25-30
syndrome	I	31-39
imprinting	O	40-50
-	O	50-51
centre	O	51-57
mutations	O	58-67
.	O	67-68

Imprinting	O	69-79
in	O	80-82
the	O	83-86
15q11	O	87-92
-	O	92-93
q13	O	93-96
region	O	97-103
involves	O	104-112
an	O	113-115
imprinting	O	116-126
centre	O	127-133
(	O	134-135
IC	O	135-137
)	O	137-138
,	O	138-139
mapping	O	140-147
in	O	148-150
part	O	151-155
to	O	156-158
the	O	159-162
promoter	O	163-171
and	O	172-175
first	O	176-181
exon	O	182-186
of	O	187-189
SNRPN	O	190-195
.	O	195-196

Deletion	O	197-205
of	O	206-208
this	O	209-213
IC	O	214-216
abolishes	O	217-226
local	O	227-232
paternally	O	233-243
derived	O	244-251
gene	O	252-256
expression	O	257-267
and	O	268-271
results	O	272-279
in	O	280-282
Prader	B	283-289
-	I	289-290
Willi	I	290-295
syndrome	I	296-304
(	O	305-306
PWS	B	306-309
)	O	309-310
.	O	310-311

We	O	312-314
have	O	315-319
created	O	320-327
two	O	328-331
deletion	O	332-340
mutations	O	341-350
in	O	351-353
mice	O	354-358
to	O	359-361
understand	O	362-372
PWS	B	373-376
and	O	377-380
the	O	381-384
mechanism	O	385-394
of	O	395-397
this	O	398-402
IC	O	403-405
.	O	405-406

Mice	O	407-411
harbouring	O	412-422
an	O	423-425
intragenic	O	426-436
deletion	O	437-445
in	O	446-448
Snrpn	O	449-454
are	O	455-458
phenotypically	O	459-473
normal	O	474-480
,	O	480-481
suggesting	O	482-492
that	O	493-497
mutations	O	498-507
of	O	508-510
SNRPN	O	511-516
are	O	517-520
not	O	521-524
sufficient	O	525-535
to	O	536-538
induce	O	539-545
PWS	B	546-549
.	O	549-550

Mice	O	551-555
with	O	556-560
a	O	561-562
larger	O	563-569
deletion	O	570-578
involving	O	579-588
both	O	589-593
Snrpn	O	594-599
and	O	600-603
the	O	604-607
putative	O	608-616
PWS	O	617-620
-	O	620-621
IC	O	621-623
lack	O	624-628
expression	O	629-639
of	O	640-642
the	O	643-646
imprinted	O	647-656
genes	O	657-662
Zfp127	O	663-669
(	O	670-671
mouse	O	671-676
homologue	O	677-686
of	O	687-689
ZNF127	O	690-696
)	O	696-697
,	O	697-698
Ndn	O	699-702
and	O	703-706
Ipw	O	707-710
,	O	710-711
and	O	712-715
manifest	O	716-724
several	O	725-732
phenotypes	O	733-743
common	O	744-750
to	O	751-753
PWS	B	754-757
infants	O	758-765
.	O	765-766

These	O	767-772
data	O	773-777
demonstrate	O	778-789
that	O	790-794
both	O	795-799
the	O	800-803
position	O	804-812
of	O	813-815
the	O	816-819
IC	O	820-822
and	O	823-826
its	O	827-830
role	O	831-835
in	O	836-838
the	O	839-842
coordinate	O	843-853
expression	O	854-864
of	O	865-867
genes	O	868-873
is	O	874-876
conserved	O	877-886
between	O	887-894
mouse	O	895-900
and	O	901-904
human	O	905-910
,	O	910-911
and	O	912-915
indicate	O	916-924
that	O	925-929
the	O	930-933
mouse	O	934-939
is	O	940-942
a	O	943-944
suitable	O	945-953
model	O	954-959
system	O	960-966
in	O	967-969
which	O	970-975
to	O	976-978
investigate	O	979-990
the	O	991-994
molecular	O	995-1004
mechanisms	O	1005-1015
of	O	1016-1018
imprinting	O	1019-1029
in	O	1030-1032
this	O	1033-1037
region	O	1038-1044
of	O	1045-1047
the	O	1048-1051
genome	O	1052-1058
.	O	1058-1059
.	O	1058-1059

A	O	0-1
deletion	O	2-10
mutation	O	11-19
in	O	20-22
COL17A1	O	23-30
in	O	31-33
five	O	34-38
Austrian	O	39-47
families	O	48-56
with	O	57-61
generalized	O	62-73
atrophic	B	74-82
benign	I	83-89
epidermolysis	I	90-103
bullosa	I	104-111
represents	O	112-122
propagation	O	123-134
of	O	135-137
an	O	138-140
ancestral	O	141-150
allele	O	151-157
.	O	157-158

Patients	O	159-167
with	O	168-172
generalized	O	173-184
atrophic	B	185-193
benign	I	194-200
epidermolysis	I	201-214
bullosa	I	215-222
,	O	222-223
a	O	224-225
usually	O	226-233
nonlethal	O	234-243
form	O	244-248
of	O	249-251
junctional	B	252-262
epidermolysis	I	263-276
bullosa	I	277-284
,	O	284-285
have	O	286-290
generalized	O	291-302
blistering	B	303-313
,	O	313-314
nail	B	315-319
dystrophy	I	320-329
,	O	329-330
patchy	B	331-337
alopecia	I	338-346
,	O	346-347
and	O	348-351
dental	B	352-358
abnormalities	I	359-372
.	O	372-373

Skin	B	374-378
fragility	I	379-388
in	O	389-391
most	O	392-396
cases	O	397-402
is	O	403-405
due	O	406-409
to	O	410-412
mutations	O	413-422
in	O	423-425
the	O	426-429
gene	O	430-434
encoding	O	435-443
type	O	444-448
XVII	O	449-453
collagen	O	454-462
(	O	463-464
COL17A1	O	464-471
)	O	471-472
.	O	472-473

Recently	O	474-482
,	O	482-483
we	O	484-486
reported	O	487-495
five	O	496-500
Austrian	O	501-509
families	O	510-518
with	O	519-523
generalized	O	524-535
atrophic	B	536-544
benign	I	545-551
epidermolysis	I	552-565
bullosa	I	566-573
who	O	574-577
share	O	578-583
the	O	584-587
same	O	588-592
COL17A1	O	593-600
mutation	O	601-609
.	O	609-610

Affected	O	611-619
individuals	O	620-631
in	O	632-634
three	O	635-640
families	O	641-649
are	O	650-653
homozygous	O	654-664
for	O	665-668
4003delTC	O	669-678
,	O	678-679
whereas	O	680-687
those	O	688-693
in	O	694-696
two	O	697-700
others	O	701-707
are	O	708-711
compound	O	712-720
heterozygotes	O	721-734
.	O	734-735

To	O	736-738
determine	O	739-748
if	O	749-751
the	O	752-755
occurrence	O	756-766
of	O	767-769
4003delTC	O	770-779
in	O	780-782
these	O	783-788
unrelated	O	789-798
families	O	799-807
signifies	O	808-817
propagation	O	818-829
of	O	830-832
an	O	833-835
ancestral	O	836-845
allele	O	846-852
or	O	853-855
a	O	856-857
mutational	O	858-868
hot	O	869-872
spot	O	873-877
,	O	877-878
haplotypes	O	879-889
were	O	890-894
determined	O	895-905
for	O	906-909
polymorphisms	O	910-923
both	O	924-928
within	O	929-935
and	O	936-939
flanking	O	940-948
COL17A1	O	949-956
.	O	956-957

Five	O	958-962
intragenic	O	963-973
polymorphisms	O	974-987
were	O	988-992
chosen	O	993-999
based	O	1000-1005
on	O	1006-1008
their	O	1009-1014
informativeness	O	1015-1030
.	O	1030-1031

One	O	1032-1035
of	O	1036-1038
these	O	1039-1044
,	O	1044-1045
not	O	1046-1049
previously	O	1050-1060
reported	O	1061-1069
,	O	1069-1070
was	O	1071-1074
2988	O	1075-1079
A	O	1080-1081
or	O	1082-1084
C	O	1085-1086
that	O	1087-1091
introduces	O	1092-1102
a	O	1103-1104
new	O	1105-1108
restriction	O	1109-1120
site	O	1121-1125
for	O	1126-1129
Eco0109	O	1130-1137
I	O	1138-1139
.	O	1139-1140

All	O	1141-1144
the	O	1145-1148
4003delTC	O	1149-1158
alleles	O	1159-1166
showed	O	1167-1173
the	O	1174-1177
same	O	1178-1182
haplotype	O	1183-1192
for	O	1193-1196
these	O	1197-1202
five	O	1203-1207
polymorphic	O	1208-1219
markers	O	1220-1227
.	O	1227-1228

Fourteen	O	1229-1237
microsatellite	O	1238-1252
polymorphisms	O	1253-1266
were	O	1267-1271
selected	O	1272-1280
based	O	1281-1286
on	O	1287-1289
their	O	1290-1295
high	O	1296-1300
heterozygosity	O	1301-1315
and	O	1316-1319
their	O	1320-1325
location	O	1326-1334
within	O	1335-1341
10q23	O	1342-1347
-	O	1347-1348
q25	O	1348-1351
near	O	1352-1356
COL17A1	O	1357-1364
.	O	1364-1365

Three	O	1366-1371
families	O	1372-1380
shared	O	1381-1387
microsatellite	O	1388-1402
polymorphisms	O	1403-1416
covering	O	1417-1425
at	O	1426-1428
most	O	1429-1433
19	O	1434-1436
cM	O	1437-1439
,	O	1439-1440
whereas	O	1441-1448
the	O	1449-1452
others	O	1453-1459
shared	O	1460-1466
smaller	O	1467-1474
regions	O	1475-1482
consistent	O	1483-1493
with	O	1494-1498
cross	O	1499-1504
-	O	1504-1505
over	O	1505-1509
events	O	1510-1516
during	O	1517-1523
passage	O	1524-1531
of	O	1532-1534
this	O	1535-1539
mutation	O	1540-1548
through	O	1549-1556
several	O	1557-1564
generations	O	1565-1576
.	O	1576-1577

These	O	1578-1583
results	O	1584-1591
indicate	O	1592-1600
that	O	1601-1605
4003delTC	O	1606-1615
occurs	O	1616-1622
on	O	1623-1625
a	O	1626-1627
single	O	1628-1634
ancestral	O	1635-1644
allele	O	1645-1651
.	O	1651-1652
.	O	1651-1652

Identification	O	0-14
of	O	15-17
a	O	18-19
novel	O	20-25
mutation	O	26-34
of	O	35-37
the	O	38-41
CPO	O	42-45
gene	O	46-50
in	O	51-53
a	O	54-55
Japanese	O	56-64
hereditary	B	65-75
coproporphyria	I	76-90
family	O	91-97
.	O	97-98

Hereditary	B	99-109
coproporphyria	I	110-124
(	O	125-126
HCP	B	126-129
)	O	129-130
is	O	131-133
an	O	134-136
autosomal	B	137-146
dominant	I	147-155
disease	I	156-163
characterized	O	164-177
by	O	178-180
a	O	181-182
deficiency	B	183-193
of	I	194-196
coproporphyrinogen	I	197-215
oxidase	I	216-223
(	O	224-225
CPO	O	225-228
)	O	228-229
caused	O	230-236
by	O	237-239
a	O	240-241
mutation	O	242-250
in	O	251-253
the	O	254-257
CPO	O	258-261
gene	O	262-266
.	O	266-267

Only	O	268-272
11	O	273-275
mutations	O	276-285
of	O	286-288
the	O	289-292
gene	O	293-297
have	O	298-302
been	O	303-307
reported	O	308-316
in	O	317-319
HCP	B	320-323
patients	O	324-332
.	O	332-333

We	O	334-336
report	O	337-343
another	O	344-351
mutation	O	352-360
in	O	361-363
a	O	364-365
Japanese	O	366-374
family	O	375-381
.	O	381-382

Polymerase	O	383-393
chain	O	394-399
reaction	O	400-408
-	O	408-409
single	O	409-415
strand	O	416-422
conformational	O	423-437
polymorphism	O	438-450
and	O	451-454
direct	O	455-461
sequence	O	462-470
analyses	O	471-479
demonstrated	O	480-492
a	O	493-494
C	O	495-496
to	O	497-499
T	O	500-501
substitution	O	502-514
in	O	515-517
exon	O	518-522
1	O	523-524
of	O	525-527
the	O	528-531
CPO	O	532-535
gene	O	536-540
at	O	541-543
nucleotide	O	544-554
position	O	555-563
85	O	564-566
,	O	566-567
which	O	568-573
lies	O	574-578
in	O	579-581
the	O	582-585
putative	O	586-594
presequence	O	595-606
for	O	607-610
targeting	O	611-620
to	O	621-623
mitochondria	O	624-636
.	O	636-637

This	O	638-642
mutation	O	643-651
changes	O	652-659
the	O	660-663
codon	O	664-669
for	O	670-673
glutamine	O	674-683
to	O	684-686
a	O	687-688
termination	O	689-700
codon	O	701-706
at	O	707-709
amino	O	710-715
acid	O	716-720
position	O	721-729
29	O	730-732
.	O	732-733

MaeI	O	734-738
restriction	O	739-750
analysis	O	751-759
showed	O	760-766
two	O	767-770
other	O	771-776
carriers	O	777-785
in	O	786-788
the	O	789-792
family	O	793-799
.	O	799-800

The	O	801-804
C	O	805-806
-	O	806-807
T	O	807-808
mutation	O	809-817
is	O	818-820
located	O	821-828
within	O	829-835
a	O	836-837
recently	O	838-846
proposed	O	847-855
putative	O	856-864
alternative	O	865-876
translation	O	877-888
initiation	O	889-899
codon	O	900-905
(	O	906-907
TIC	O	907-910
-	O	910-911
1	O	911-912
)	O	912-913
,	O	913-914
supporting	O	915-925
that	O	926-930
TIC	O	931-934
-	O	934-935
1	O	935-936
is	O	937-939
the	O	940-943
real	O	944-948
TIC	O	949-952
rather	O	953-959
than	O	960-964
TIC	O	965-968
-	O	968-969
2	O	969-970
.	O	970-971
.	O	970-971

The	O	0-3
chromosomal	O	4-15
order	O	16-21
of	O	22-24
genes	O	25-30
controlling	O	31-42
the	O	43-46
major	O	47-52
histocompatibility	O	53-71
complex	O	72-79
,	O	79-80
properdin	O	81-90
factor	O	91-97
B	O	98-99
,	O	99-100
and	O	101-104
deficiency	B	105-115
of	I	116-118
the	I	119-122
second	I	123-129
component	I	130-139
of	I	140-142
complement	I	143-153
.	O	153-154

The	O	155-158
relationship	O	159-171
of	O	172-174
the	O	175-178
genes	O	179-184
coding	O	185-191
for	O	192-195
HLA	O	196-199
to	O	200-202
those	O	203-208
coding	O	209-215
for	O	216-219
properdin	O	220-229
Factor	O	230-236
B	O	237-238
allotypes	O	239-248
and	O	249-252
for	O	253-256
deficiency	B	257-267
of	I	268-270
the	I	271-274
second	I	275-281
component	I	282-291
of	I	292-294
complement	I	295-305
(	O	306-307
C2	O	307-309
)	O	309-310
was	O	311-314
studied	O	315-322
in	O	323-325
families	O	326-334
of	O	335-337
patients	O	338-346
with	O	347-351
connective	O	352-362
tissue	O	363-369
disorders	O	370-379
.	O	379-380

Patients	O	381-389
were	O	390-394
selected	O	395-403
because	O	404-411
they	O	412-416
were	O	417-421
heterozygous	O	422-434
or	O	435-437
homozygous	O	438-448
for	O	449-452
C2	B	453-455
deficiency	I	456-466
.	O	466-467

12	O	468-470
families	O	471-479
with	O	480-484
15	O	485-487
matings	O	488-495
informative	O	496-507
for	O	508-511
C2	B	512-514
deficiency	I	515-525
were	O	526-530
found	O	531-536
.	O	536-537

Of	O	538-540
57	O	541-543
informative	O	544-555
meioses	O	556-563
,	O	563-564
two	O	565-568
crossovers	O	569-579
were	O	580-584
noted	O	585-590
between	O	591-598
the	O	599-602
C2	B	603-605
deficiency	I	606-616
gene	O	617-621
and	O	622-625
the	O	626-629
HLA	O	630-633
-	O	633-634
B	O	634-635
gene	O	636-640
,	O	640-641
with	O	642-646
a	O	647-648
recombinant	O	649-660
fraction	O	661-669
of	O	670-672
0	O	673-674
.	O	674-675
035	O	676-679
.	O	679-680

A	O	681-682
lod	O	683-686
score	O	687-692
of	O	693-695
13	O	696-698
was	O	699-702
calculated	O	703-713
for	O	714-717
linkage	O	718-725
between	O	726-733
C2	B	734-736
deficiency	I	737-747
and	O	748-751
HLA	O	752-755
-	O	755-756
B	O	756-757
at	O	758-760
a	O	761-762
maximum	O	763-770
likelihood	O	771-781
value	O	782-787
of	O	788-790
the	O	791-794
recombinant	O	795-806
fraction	O	807-815
of	O	816-818
0	O	819-820
.	O	820-821
04	O	822-824
.	O	824-825

18	O	826-828
families	O	829-837
with	O	838-842
21	O	843-845
informative	O	846-857
matings	O	858-865
for	O	866-869
both	O	870-874
properdin	O	875-884
Factor	O	885-891
B	O	892-893
allotype	O	894-902
and	O	903-906
HLA	O	907-910
-	O	910-911
B	O	911-912
were	O	913-917
found	O	918-923
.	O	923-924

Of	O	925-927
72	O	928-930
informative	O	931-942
meioses	O	943-950
,	O	950-951
three	O	952-957
recombinants	O	958-970
were	O	971-975
found	O	976-981
,	O	981-982
giving	O	983-989
a	O	990-991
recombinant	O	992-1003
fraction	O	1004-1012
of	O	1013-1015
0	O	1016-1017
.	O	1017-1018
042	O	1019-1022
.	O	1022-1023

A	O	1024-1025
lod	O	1026-1029
score	O	1030-1035
of	O	1036-1038
16	O	1039-1041
between	O	1042-1049
HLA	O	1050-1053
-	O	1053-1054
B	O	1054-1055
and	O	1056-1059
Factor	O	1060-1066
B	O	1067-1068
allotypes	O	1069-1078
was	O	1079-1082
calculated	O	1083-1093
at	O	1094-1096
a	O	1097-1098
maximum	O	1099-1106
likelihood	O	1107-1117
value	O	1118-1123
of	O	1124-1126
the	O	1127-1130
recombinant	O	1131-1142
fraction	O	1143-1151
of	O	1152-1154
0	O	1155-1156
.	O	1156-1157
04	O	1158-1160
.	O	1160-1161

A	O	1162-1163
crossover	O	1164-1173
was	O	1174-1177
shown	O	1178-1183
to	O	1184-1186
have	O	1187-1191
occurred	O	1192-1200
between	O	1201-1208
genes	O	1209-1214
for	O	1215-1218
Factor	O	1219-1225
B	O	1226-1227
and	O	1228-1231
HLA	O	1232-1235
-	O	1235-1236
D	O	1236-1237
,	O	1237-1238
in	O	1239-1241
which	O	1242-1247
HLA	O	1248-1251
-	O	1251-1252
D	O	1252-1253
segregared	O	1254-1264
with	O	1265-1269
HLA	O	1270-1273
-	O	1273-1274
A	O	1272-1273
and	O	1276-1279
B	O	1280-1281
.	O	1281-1282
These	O	1283-1288
studies	O	1289-1296
suggest	O	1297-1304
that	O	1305-1309
the	O	1310-1313
genes	O	1314-1319
for	O	1320-1323
Factor	O	1324-1330
B	O	1331-1332
and	O	1333-1336
C2	B	1337-1339
deficiency	I	1340-1350
are	O	1351-1354
located	O	1355-1362
outside	O	1363-1370
those	O	1371-1376
for	O	1377-1380
HLA	O	1381-1384
,	O	1384-1385
that	O	1386-1390
the	O	1391-1394
order	O	1395-1400
of	O	1401-1403
genese	O	1404-1410
is	O	1411-1413
HLA	O	1414-1417
-	O	1417-1418
A	O	1416-1417
,	O	1419-1420
-	O	1421-1422
B	O	1422-1423
,	O	1423-1424
-	O	1425-1426
D	O	1426-1427
,	O	1427-1428
Factor	O	1429-1435
B	O	1436-1437
allotype	O	1438-1446
,	O	1446-1447
C2	B	1448-1450
deficiency	I	1451-1461
,	O	1461-1462
that	O	1463-1467
the	O	1468-1471
genes	O	1472-1477
coding	O	1478-1484
for	O	1485-1488
C2	B	1489-1491
deficiency	I	1492-1502
and	O	1503-1506
Factor	O	1507-1513
B	O	1514-1515
allotypes	O	1516-1525
are	O	1526-1529
approximately	O	1530-1543
3	O	1544-1545
-	O	1545-1546
-	O	1545-1546
5	O	1547-1548
centimorgans	O	1549-1561
from	O	1562-1566
the	O	1567-1570
HLA	O	1571-1574
-	O	1574-1575
A	O	1573-1574
and	O	1577-1580
HLA	O	1581-1584
-	O	1584-1585
B	O	1585-1586
loci	O	1587-1591
,	O	1591-1592
and	O	1593-1596
that	O	1597-1601
the	O	1602-1605
apparent	O	1606-1614
lack	O	1615-1619
of	O	1620-1622
recombinants	O	1623-1635
between	O	1636-1643
the	O	1644-1647
Factor	O	1648-1654
B	O	1655-1656
gene	O	1657-1661
and	O	1662-1665
C2	B	1666-1668
deficiency	I	1669-1679
gene	O	1680-1684
suggests	O	1685-1693
that	O	1694-1698
these	O	1699-1704
two	O	1705-1708
genes	O	1709-1714
lie	O	1715-1718
in	O	1719-1721
close	O	1722-1727
proximity	O	1728-1737
to	O	1738-1740
one	O	1741-1744
another	O	1745-1752
.	O	1752-1753

A	O	0-1
novel	O	2-7
missense	O	8-16
mutation	O	17-25
in	O	26-28
patients	O	29-37
from	O	38-42
a	O	43-44
retinoblastoma	B	45-59
pedigree	O	60-68
showing	O	69-76
only	O	77-81
mild	O	82-86
expression	O	87-97
of	O	98-100
the	O	101-104
tumor	B	105-110
phenotype	O	111-120
.	O	120-121

We	O	122-124
have	O	125-129
used	O	130-134
single	O	135-141
strand	O	142-148
conformation	O	149-161
polymorphism	O	162-174
analysis	O	175-183
to	O	184-186
study	O	187-192
the	O	193-196
27	O	197-199
exons	O	200-205
of	O	206-208
the	O	209-212
RB1	O	213-216
gene	O	217-221
in	O	222-224
individuals	O	225-236
from	O	237-241
a	O	242-243
family	O	244-250
showing	O	251-258
mild	O	259-263
expression	O	264-274
of	O	275-277
the	O	278-281
retinoblastoma	B	282-296
phenotype	O	297-306
.	O	306-307

In	O	308-310
this	O	311-315
family	O	316-322
affected	O	323-331
individuals	O	332-343
developed	O	344-353
unilateral	B	354-364
tumors	I	365-371
and	O	372-375
,	O	375-376
as	O	377-379
a	O	380-381
result	O	382-388
of	O	389-391
linkage	O	392-399
analysis	O	400-408
,	O	408-409
unaffected	O	410-420
mutation	O	421-429
carriers	O	430-438
were	O	439-443
also	O	444-448
identified	O	449-459
within	O	460-466
the	O	467-470
pedigree	O	471-479
.	O	479-480

A	O	481-482
single	O	483-489
band	O	490-494
shift	O	495-500
using	O	501-506
SSCP	O	507-511
was	O	512-515
identified	O	516-526
in	O	527-529
exon	O	530-534
21	O	535-537
which	O	538-543
resulted	O	544-552
in	O	553-555
a	O	556-557
missense	O	558-566
mutation	O	567-575
converting	O	576-586
a	O	587-588
cys	O	589-592
-	O	592-593
-	O	592-593
>	O	595-596
arg	O	597-600
at	O	601-603
nucleotide	O	604-614
position	O	615-623
28	O	624-626
in	O	627-629
the	O	630-633
exon	O	634-638
.	O	638-639

The	O	640-643
mutation	O	644-652
destroyed	O	653-662
an	O	663-665
NdeI	O	666-670
restriction	O	671-682
enzyme	O	683-689
site	O	690-694
.	O	694-695

Analysis	O	696-704
of	O	705-707
all	O	708-711
family	O	712-718
members	O	719-726
demonstrated	O	727-739
that	O	740-744
the	O	745-748
missense	O	749-757
mutation	O	758-766
co	O	767-769
-	O	769-770
segregated	O	770-780
with	O	781-785
patients	O	786-794
with	O	795-799
tumors	B	800-806
or	O	807-809
who	O	810-813
,	O	813-814
as	O	815-817
a	O	818-819
result	O	820-826
of	O	827-829
linkage	O	830-837
analysis	O	838-846
had	O	847-850
been	O	851-855
predicted	O	856-865
to	O	866-868
carry	O	869-874
the	O	875-878
predisposing	O	879-891
mutation	O	892-900
.	O	900-901

These	O	902-907
observations	O	908-920
point	O	921-926
to	O	927-929
another	O	930-937
region	O	938-944
of	O	945-947
the	O	948-951
RB1	O	952-955
gene	O	956-960
where	O	961-966
mutations	O	967-976
only	O	977-981
modify	O	982-988
the	O	989-992
function	O	993-1001
of	O	1002-1004
the	O	1005-1008
gene	O	1009-1013
and	O	1014-1017
raise	O	1018-1023
important	O	1024-1033
questions	O	1034-1043
for	O	1044-1047
genetic	O	1048-1055
counseling	O	1056-1066
in	O	1067-1069
families	O	1070-1078
with	O	1079-1083
these	O	1084-1089
distinctive	O	1090-1101
phenotypes	O	1102-1112
.	O	1112-1113
.	O	1112-1113

Complement	B	0-10
C7	I	11-13
deficiency	I	14-24
:	O	24-25
seven	O	26-31
further	O	32-39
molecular	O	40-49
defects	O	50-57
and	O	58-61
their	O	62-67
associated	O	68-78
marker	O	79-85
haplotypes	O	86-96
.	O	96-97

Seven	O	98-103
further	O	104-111
molecular	O	112-121
bases	O	122-127
of	O	128-130
C7	B	131-133
deficiency	I	134-144
are	O	145-148
described	O	149-158
.	O	158-159

All	O	160-163
these	O	164-169
new	O	170-173
molecular	O	174-183
defects	O	184-191
involve	O	192-199
single	O	200-206
-	O	206-207
nucleotide	O	207-217
events	O	218-224
,	O	224-225
deletions	O	226-235
and	O	236-239
substitutions	O	240-253
,	O	253-254
some	O	255-259
of	O	260-262
which	O	263-268
alter	O	269-274
splice	O	275-281
sites	O	282-287
,	O	287-288
and	O	289-292
others	O	293-299
codons	O	300-306
.	O	306-307

They	O	308-312
are	O	313-316
distributed	O	317-328
along	O	329-334
the	O	335-338
C7	O	339-341
gene	O	342-346
,	O	346-347
but	O	348-351
predominantly	O	352-365
towards	O	366-373
the	O	374-377
3	O	378-379
end	O	380-383
.	O	383-384

All	O	385-388
were	O	389-393
found	O	394-399
in	O	400-402
compound	O	403-411
heterozygous	O	412-424
individuals	O	425-436
.	O	436-437

The	O	438-441
C6	O	442-444
/	O	444-445
C7	O	445-447
marker	O	448-454
haplotypes	O	455-465
associated	O	466-476
with	O	477-481
most	O	482-486
C7	B	487-489
defects	I	490-497
are	O	498-501
tabulated	O	502-511
.	O	511-512
.	O	511-512

Identification	O	0-14
of	O	15-17
constitutional	O	18-32
WT1	O	33-36
mutations	O	37-46
,	O	46-47
in	O	48-50
patients	O	51-59
with	O	60-64
isolated	O	65-73
diffuse	B	74-81
mesangial	I	82-91
sclerosis	I	92-101
,	O	101-102
and	O	103-106
analysis	O	107-115
of	O	116-118
genotype	O	119-127
/	O	127-128
phenotype	O	128-137
correlations	O	138-150
by	O	151-153
use	O	154-157
of	O	158-160
a	O	161-162
computerized	O	163-175
mutation	O	176-184
database	O	185-193
.	O	193-194

Constitutional	O	195-209
mutations	O	210-219
of	O	220-222
the	O	223-226
WT1	O	227-230
gene	O	231-235
,	O	235-236
encoding	O	237-245
a	O	246-247
zinc	O	248-252
-	O	252-253
finger	O	253-259
transcription	O	260-273
factor	O	274-280
involved	O	281-289
in	O	290-292
renal	O	293-298
and	O	299-302
gonadal	O	303-310
development	O	311-322
,	O	322-323
are	O	324-327
found	O	328-333
in	O	334-336
most	O	337-341
patients	O	342-350
with	O	351-355
Denys	B	356-361
-	I	361-362
Drash	I	362-367
syndrome	I	368-376
(	O	377-378
DDS	B	378-381
)	O	381-382
,	O	382-383
or	O	384-386
diffuse	B	387-394
mesangial	I	395-404
sclerosis	I	405-414
(	O	415-416
DMS	B	416-419
)	O	419-420
associated	O	421-431
with	O	432-436
pseudohermaphroditism	B	437-458
and	O	459-462
/	O	462-463
or	O	463-465
Wilms	B	466-471
tumor	I	472-477
(	O	478-479
WT	B	479-481
)	O	481-482
.	O	482-483

Most	O	484-488
mutations	O	489-498
in	O	499-501
DDS	B	502-505
patients	O	506-514
lie	O	515-518
in	O	519-521
exon	O	522-526
8	O	527-528
or	O	529-531
exon	O	532-536
9	O	537-538
,	O	538-539
encoding	O	540-548
zinc	O	549-553
finger	O	554-560
2	O	561-562
or	O	563-565
zinc	O	566-570
finger	O	571-577
3	O	578-579
,	O	579-580
respectively	O	581-593
,	O	593-594
with	O	595-599
a	O	600-601
hot	O	602-605
spot	O	606-610
(	O	611-612
R394W	O	612-617
)	O	617-618
in	O	619-621
exon	O	622-626
9	O	627-628
.	O	628-629
We	O	630-632
analyzed	O	633-641
a	O	642-643
series	O	644-650
of	O	651-653
24	O	654-656
patients	O	657-665
,	O	665-666
10	O	667-669
with	O	670-674
isolated	B	675-683
DMS	I	684-687
(	O	688-689
IDMS	B	689-693
)	O	693-694
,	O	694-695
10	O	696-698
with	O	699-703
DDS	B	704-707
,	O	707-708
and	O	709-712
4	O	713-714
with	O	715-719
urogenital	B	720-730
abnormalities	I	731-744
and	O	745-748
/	O	748-749
or	O	749-751
WT	B	752-754
.	O	754-755

We	O	756-758
report	O	759-765
WT1	O	766-769
heterozygous	O	770-782
mutations	O	783-792
in	O	793-795
16	O	796-798
patients	O	799-807
,	O	807-808
4	O	809-810
of	O	811-813
whom	O	814-818
presented	O	819-828
with	O	829-833
IDMS	B	834-838
.	O	838-839

One	O	840-843
male	O	844-848
and	O	849-852
two	O	853-856
female	O	857-863
IDMS	B	864-868
patients	O	869-877
with	O	878-882
WT1	O	883-886
mutations	O	887-896
underwent	O	897-906
normal	O	907-913
puberty	O	914-921
.	O	921-922

Two	O	923-926
mutations	O	927-936
associated	O	937-947
with	O	948-952
IDMS	B	953-957
are	O	958-961
different	O	962-971
from	O	972-976
those	O	977-982
described	O	983-992
in	O	993-995
DDS	B	996-999
patients	O	1000-1008
.	O	1008-1009

No	O	1010-1012
WT1	O	1013-1016
mutations	O	1017-1026
were	O	1027-1031
detected	O	1032-1040
in	O	1041-1043
the	O	1044-1047
six	O	1048-1051
other	O	1052-1057
IDMS	B	1058-1062
patients	O	1063-1071
,	O	1071-1072
suggesting	O	1073-1083
genetic	O	1084-1091
heterogeneity	O	1092-1105
of	O	1106-1108
this	O	1109-1113
disease	O	1114-1121
.	O	1121-1122

We	O	1123-1125
analyzed	O	1126-1134
genotype	O	1135-1143
/	O	1143-1144
phenotype	O	1144-1153
correlations	O	1154-1166
,	O	1166-1167
on	O	1168-1170
the	O	1171-1174
basis	O	1175-1180
of	O	1181-1183
the	O	1184-1187
constitution	O	1188-1200
of	O	1201-1203
a	O	1204-1205
WT1	O	1206-1209
mutation	O	1210-1218
database	O	1219-1227
of	O	1228-1230
84	O	1231-1233
germ	O	1234-1238
-	O	1238-1239
line	O	1239-1243
mutations	O	1244-1253
,	O	1253-1254
to	O	1255-1257
compare	O	1258-1265
the	O	1266-1269
distribution	O	1270-1282
and	O	1283-1286
type	O	1287-1291
of	O	1292-1294
mutations	O	1295-1304
,	O	1304-1305
according	O	1306-1315
to	O	1316-1318
the	O	1319-1322
different	O	1323-1332
symptoms	O	1333-1341
.	O	1341-1342

This	O	1343-1347
demonstrated	O	1348-1360
(	O	1361-1362
1	O	1362-1363
)	O	1363-1364
the	O	1365-1368
association	O	1369-1380
between	O	1381-1388
mutations	O	1389-1398
in	O	1399-1401
exons	O	1402-1407
8	O	1408-1409
and	O	1410-1413
9	O	1414-1415
and	O	1416-1419
DMS	B	1420-1423
;	O	1423-1424
(	O	1425-1426
2	O	1426-1427
)	O	1427-1428
among	O	1429-1434
patients	O	1435-1443
with	O	1444-1448
DMS	B	1449-1452
,	O	1452-1453
a	O	1454-1455
higher	O	1456-1462
frequency	O	1463-1472
of	O	1473-1475
exon	O	1476-1480
8	O	1481-1482
mutations	O	1483-1492
among	O	1493-1498
46	O	1499-1501
,	O	1501-1502
XY	O	1503-1505
patients	O	1506-1514
with	O	1515-1519
female	O	1520-1526
phenotype	O	1527-1536
than	O	1537-1541
among	O	1542-1547
46	O	1548-1550
,	O	1550-1551
XY	O	1552-1554
patients	O	1555-1563
with	O	1564-1568
sexual	O	1569-1575
ambiguity	O	1576-1585
or	O	1586-1588
male	O	1589-1593
phenotype	O	1594-1603
;	O	1603-1604
and	O	1605-1608
(	O	1609-1610
3	O	1610-1611
)	O	1611-1612
statistically	O	1613-1626
significant	O	1627-1638
evidence	O	1639-1647
that	O	1648-1652
mutations	O	1653-1662
in	O	1663-1665
exons	O	1666-1671
8	O	1672-1673
and	O	1674-1677
9	O	1678-1679
preferentially	O	1680-1694
affect	O	1695-1701
amino	O	1702-1707
acids	O	1708-1713
with	O	1714-1718
different	O	1719-1728
functions	O	1729-1738
.	O	1738-1739
.	O	1738-1739

Paternal	O	0-8
transmission	O	9-21
of	O	22-24
congenital	B	25-35
myotonic	I	36-44
dystrophy	I	45-54
.	O	54-55

We	O	56-58
report	O	59-65
a	O	66-67
rare	O	68-72
case	O	73-77
of	O	78-80
paternally	O	81-91
transmitted	O	92-103
congenital	B	104-114
myotonic	I	115-123
dystrophy	I	124-133
(	O	134-135
DM	B	135-137
)	O	137-138
.	O	138-139

The	O	140-143
proband	O	144-151
is	O	152-154
a	O	155-156
23	O	157-159
year	O	160-164
old	O	165-168
,	O	168-169
mentally	B	170-178
retarded	I	179-187
male	O	188-192
who	O	193-196
suffers	O	197-204
severe	O	205-211
muscular	B	212-220
weakness	I	221-229
.	O	229-230

He	O	231-233
presented	O	234-243
with	O	244-248
respiratory	O	249-260
and	O	261-264
feeding	O	265-272
difficulties	O	273-285
at	O	286-288
birth	O	289-294
.	O	294-295

His	O	296-299
two	O	300-303
sibs	O	304-308
suffer	O	309-315
from	O	316-320
childhood	O	321-330
onset	O	331-336
DM	B	337-339
.	O	339-340

Their	O	341-346
late	O	347-351
father	O	352-358
had	O	359-362
the	O	363-366
adult	O	367-372
type	O	373-377
of	O	378-380
DM	B	381-383
,	O	383-384
with	O	385-389
onset	O	390-395
around	O	396-402
30	O	403-405
years	O	406-411
.	O	411-412

Only	O	413-417
six	O	418-421
other	O	422-427
cases	O	428-433
of	O	434-436
paternal	O	437-445
transmission	O	446-458
of	O	459-461
congenital	B	462-472
DM	I	473-475
have	O	476-480
been	O	481-485
reported	O	486-494
recently	O	495-503
.	O	503-504

We	O	505-507
review	O	508-514
the	O	515-518
sex	O	519-522
related	O	523-530
effects	O	531-538
on	O	539-541
transmission	O	542-554
of	O	555-557
congenital	B	558-568
DM	I	569-571
.	O	571-572

Decreased	O	573-582
fertility	O	583-592
of	O	593-595
males	O	596-601
with	O	602-606
adult	O	607-612
onset	O	613-618
DM	B	619-621
and	O	622-625
contraction	O	626-637
of	O	638-640
the	O	641-644
repeat	O	645-651
upon	O	652-656
male	O	657-661
transmission	O	662-674
contribute	O	675-685
to	O	686-688
the	O	689-692
almost	O	693-699
absent	O	700-706
occurrence	O	707-717
of	O	718-720
paternal	O	721-729
transmission	O	730-742
of	O	743-745
congenital	B	746-756
DM	I	757-759
.	O	759-760

Also	O	761-765
the	O	766-769
fathers	O	770-777
of	O	778-780
the	O	781-784
reported	O	785-793
congenitally	O	794-806
affected	O	807-815
children	O	816-824
showed	O	825-831
,	O	831-832
on	O	833-835
average	O	836-843
,	O	843-844
shorter	O	845-852
CTG	O	853-856
repeat	O	857-863
lengths	O	864-871
and	O	872-875
hence	O	876-881
less	O	882-886
severe	O	887-893
clinical	O	894-902
symptoms	O	903-911
than	O	912-916
the	O	917-920
mothers	O	921-928
of	O	929-931
children	O	932-940
with	O	941-945
congenital	B	946-956
DM	I	957-959
.	O	959-960

We	O	961-963
conclude	O	964-972
that	O	973-977
paternal	O	978-986
transmission	O	987-999
of	O	1000-1002
congenital	B	1003-1013
DM	I	1014-1016
is	O	1017-1019
rare	O	1020-1024
and	O	1025-1028
preferentially	O	1029-1043
occurs	O	1044-1050
with	O	1051-1055
onset	O	1056-1061
of	O	1062-1064
DM	B	1065-1067
past	O	1068-1072
30	O	1073-1075
years	O	1076-1081
in	O	1082-1084
the	O	1085-1088
father	O	1089-1095
.	O	1095-1096
.	O	1095-1096

Genomic	O	0-7
organization	O	8-20
of	O	21-23
the	O	24-27
UBE3A	O	28-33
/	O	33-34
E6	O	34-36
-	O	36-37
AP	O	37-39
gene	O	40-44
and	O	45-48
related	O	49-56
pseudogenes	O	57-68
.	O	68-69

The	O	70-73
UBE3A	O	74-79
gene	O	80-84
encodes	O	85-92
the	O	93-96
E6	O	97-99
-	O	99-100
AP	O	100-102
ubiquitin	O	103-112
-	O	112-113
protein	O	113-120
ligase	O	121-127
and	O	128-131
has	O	132-135
recently	O	136-144
been	O	145-149
shown	O	150-155
to	O	156-158
be	O	159-161
mutated	O	162-169
in	O	170-172
Angelman	B	173-181
syndrome	I	182-190
patients	O	191-199
who	O	200-203
lack	O	204-208
15q11	O	209-214
-	O	214-215
q13	O	215-218
deletions	O	219-228
or	O	229-231
chromosome	O	232-242
15	O	243-245
paternal	O	246-254
uniparental	B	255-266
disomy	I	267-273
.	O	273-274

Previous	O	275-283
UBE3A	O	284-289
cDNA	O	290-294
analysis	O	295-303
has	O	304-307
shown	O	308-313
a	O	314-315
coding	O	316-322
region	O	323-329
of	O	330-332
approximately	O	333-346
2	O	347-348
.	O	348-349
6	O	350-351
kb	O	352-354
and	O	355-358
a	O	359-360
3	O	361-362
-	O	362-363
untranslated	O	363-375
region	O	376-382
(	O	383-384
UTR	O	384-387
)	O	387-388
of	O	389-391
<	O	392-393
50	O	394-396
bp	O	397-399
,	O	399-400
whereas	O	401-408
Northern	O	409-417
analysis	O	418-426
has	O	427-430
indicated	O	431-440
mRNA	O	441-445
sizes	O	446-451
of	O	452-454
5	O	455-456
-	O	456-457
8	O	457-458
kb	O	459-461
.	O	461-462

We	O	463-465
have	O	466-470
analyzed	O	471-479
additional	O	480-490
cDNA	O	491-495
clones	O	496-502
and	O	503-506
provide	O	507-514
evidence	O	515-523
for	O	524-527
an	O	528-530
additional	O	531-541
0	O	542-543
.	O	543-544
5	O	545-546
kb	O	547-549
of	O	550-552
5	O	553-554
-	O	554-555
UTR	O	555-558
and	O	559-562
>	O	563-564
2	O	565-566
kb	O	567-569
of	O	570-572
3	O	573-574
-	O	574-575
UTR	O	575-578
.	O	578-579

We	O	580-582
have	O	583-587
established	O	588-599
the	O	600-603
genomic	O	604-611
organization	O	612-624
of	O	625-627
UBE3A	O	628-633
and	O	634-637
the	O	638-641
sequence	O	642-650
of	O	651-653
intron	O	654-660
-	O	660-661
exon	O	661-665
borders	O	666-673
.	O	673-674

We	O	675-677
have	O	678-682
also	O	683-687
mapped	O	688-694
two	O	695-698
highly	O	699-705
homologous	O	706-716
processed	O	717-726
pseudogenes	O	727-738
,	O	738-739
UBE3AP1	O	740-747
and	O	748-751
UBE3AP2	O	752-759
,	O	759-760
to	O	761-763
chromosomes	O	764-775
2	O	776-777
and	O	778-781
21	O	782-784
,	O	784-785
respectively	O	786-798
,	O	798-799
and	O	800-803
determined	O	804-814
their	O	815-820
genomic	O	821-828
organization	O	829-841
.	O	841-842

These	O	843-848
results	O	849-856
will	O	857-861
form	O	862-866
the	O	867-870
basis	O	871-876
for	O	877-880
studies	O	881-888
of	O	889-891
mutation	O	892-900
and	O	901-904
imprinting	O	905-915
of	O	916-918
UBE3A	O	919-924
.	O	924-925

Distribution	O	0-12
of	O	13-15
emerin	O	16-22
and	O	23-26
lamins	O	27-33
in	O	34-36
the	O	37-40
heart	O	41-46
and	O	47-50
implications	O	51-63
for	O	64-67
Emery	B	68-73
-	I	73-74
Dreifuss	I	74-82
muscular	I	83-91
dystrophy	I	92-101
.	O	101-102

Emerin	O	103-109
is	O	110-112
a	O	113-114
nuclear	O	115-122
membrane	O	123-131
protein	O	132-139
which	O	140-145
is	O	146-148
missing	O	149-156
or	O	157-159
defective	O	160-169
in	O	170-172
Emery	B	173-178
-	I	178-179
Dreifuss	I	179-187
muscular	I	188-196
dystrophy	I	197-206
(	O	207-208
EDMD	B	208-212
)	O	212-213
.	O	213-214

It	O	215-217
is	O	218-220
one	O	221-224
member	O	225-231
of	O	232-234
a	O	235-236
family	O	237-243
of	O	244-246
lamina	O	247-253
-	O	253-254
associated	O	254-264
proteins	O	265-273
which	O	274-279
includes	O	280-288
LAP1	O	289-293
,	O	293-294
LAP2	O	295-299
and	O	300-303
lamin	O	304-309
B	O	310-311
receptor	O	312-320
(	O	321-322
LBR	O	322-325
)	O	325-326
.	O	326-327

A	O	328-329
panel	O	330-335
of	O	336-338
16	O	339-341
monoclonal	O	342-352
antibodies	O	353-363
(	O	364-365
mAbs	O	365-369
)	O	369-370
has	O	371-374
been	O	375-379
mapped	O	380-386
to	O	387-389
six	O	390-393
specific	O	394-402
sites	O	403-408
throughout	O	409-419
the	O	420-423
emerin	O	424-430
molecule	O	431-439
using	O	440-445
phage	O	446-451
-	O	451-452
displayed	O	452-461
peptide	O	462-469
libraries	O	470-479
and	O	480-483
has	O	484-487
been	O	488-492
used	O	493-497
to	O	498-500
localize	O	501-509
emerin	O	510-516
in	O	517-519
human	O	520-525
and	O	526-529
rabbit	O	530-536
heart	O	537-542
.	O	542-543

Several	O	544-551
mAbs	O	552-556
against	O	557-564
different	O	565-574
emerin	O	575-581
epitopes	O	582-590
did	O	591-594
not	O	595-598
recognize	O	599-608
intercalated	O	609-621
discs	O	622-627
in	O	628-630
the	O	631-634
heart	O	635-640
,	O	640-641
though	O	642-648
they	O	649-653
recognized	O	654-664
cardiomyocyte	O	665-678
nuclei	O	679-685
strongly	O	686-694
,	O	694-695
both	O	696-700
at	O	701-703
the	O	704-707
rim	O	708-711
and	O	712-715
in	O	716-718
intranuclear	O	719-731
spots	O	732-737
or	O	738-740
channels	O	741-749
.	O	749-750

A	O	751-752
polyclonal	O	753-763
rabbit	O	764-770
antiserum	O	771-780
against	O	781-788
emerin	O	789-795
did	O	796-799
recognize	O	800-809
both	O	810-814
nuclear	O	815-822
membrane	O	823-831
and	O	832-835
intercalated	O	836-848
discs	O	849-854
but	O	855-858
,	O	858-859
after	O	860-865
affinity	O	866-874
purification	O	875-887
against	O	888-895
a	O	896-897
pure	O	898-902
-	O	902-903
emerin	O	903-909
band	O	910-914
on	O	915-917
a	O	918-919
western	O	920-927
blot	O	928-932
,	O	932-933
it	O	934-936
stained	O	937-944
only	O	945-949
the	O	950-953
nuclear	O	954-961
membrane	O	962-970
.	O	970-971

These	O	972-977
results	O	978-985
would	O	986-991
not	O	992-995
be	O	996-998
expected	O	999-1007
if	O	1008-1010
immunostaining	O	1011-1025
at	O	1026-1028
intercalated	O	1029-1041
discs	O	1042-1047
were	O	1048-1052
due	O	1053-1056
to	O	1057-1059
a	O	1060-1061
product	O	1062-1069
of	O	1070-1072
the	O	1073-1076
emerin	O	1077-1083
gene	O	1084-1088
and	O	1089-1092
,	O	1092-1093
therefore	O	1094-1103
,	O	1103-1104
cast	O	1105-1109
some	O	1110-1114
doubt	O	1115-1120
upon	O	1121-1125
the	O	1126-1129
hypothesis	O	1130-1140
that	O	1141-1145
cardiac	B	1146-1153
defects	I	1154-1161
in	O	1162-1164
EDMD	B	1165-1169
are	O	1170-1173
caused	O	1174-1180
by	O	1181-1183
absence	O	1184-1191
of	O	1192-1194
emerin	O	1195-1201
from	O	1202-1206
intercalated	O	1207-1219
discs	O	1220-1225
.	O	1225-1226

Although	O	1227-1235
emerin	O	1236-1242
was	O	1243-1246
abundant	O	1247-1255
in	O	1256-1258
the	O	1259-1262
membranes	O	1263-1272
of	O	1273-1275
cardiomyocyte	O	1276-1289
nuclei	O	1290-1296
,	O	1296-1297
it	O	1298-1300
was	O	1301-1304
absent	O	1305-1311
from	O	1312-1316
many	O	1317-1321
non	O	1322-1325
-	O	1325-1326
myocyte	O	1326-1333
cells	O	1334-1339
in	O	1340-1342
the	O	1343-1346
heart	O	1347-1352
.	O	1352-1353

This	O	1354-1358
distribution	O	1359-1371
of	O	1372-1374
emerin	O	1375-1381
was	O	1382-1385
similar	O	1386-1393
to	O	1394-1396
that	O	1397-1401
of	O	1402-1404
lamin	O	1405-1410
A	O	1411-1412
,	O	1412-1413
a	O	1414-1415
candidate	O	1416-1425
gene	O	1426-1430
for	O	1431-1434
an	O	1435-1437
autosomal	O	1438-1447
form	O	1448-1452
of	O	1453-1455
EDMD	B	1456-1460
.	O	1460-1461

In	O	1462-1464
contrast	O	1465-1473
,	O	1473-1474
lamin	O	1475-1480
B1	O	1481-1483
was	O	1484-1487
absent	O	1488-1494
from	O	1495-1499
cardiomyocyte	O	1500-1513
nuclei	O	1514-1520
,	O	1520-1521
showing	O	1522-1529
that	O	1530-1534
lamin	O	1535-1540
B1	O	1541-1543
is	O	1544-1546
not	O	1547-1550
essential	O	1551-1560
for	O	1561-1564
localization	O	1565-1577
of	O	1578-1580
emerin	O	1581-1587
to	O	1588-1590
the	O	1591-1594
nuclear	O	1595-1602
lamina	O	1603-1609
.	O	1609-1610

Lamin	O	1611-1616
B1	O	1617-1619
is	O	1620-1622
also	O	1623-1627
almost	O	1628-1634
completely	O	1635-1645
absent	O	1646-1652
from	O	1653-1657
skeletal	O	1658-1666
muscle	O	1667-1673
nuclei	O	1674-1680
.	O	1680-1681

In	O	1682-1684
EDMD	B	1685-1689
,	O	1689-1690
the	O	1691-1694
additional	O	1695-1705
absence	O	1706-1713
of	O	1714-1716
lamin	O	1717-1722
B1	O	1723-1725
from	O	1726-1730
heart	O	1731-1736
and	O	1737-1740
skeletal	O	1741-1749
muscle	O	1750-1756
nuclei	O	1757-1763
which	O	1764-1769
already	O	1770-1777
lack	O	1778-1782
emerin	O	1783-1789
may	O	1790-1793
offer	O	1794-1799
an	O	1800-1802
alternative	O	1803-1814
explanation	O	1815-1826
of	O	1827-1829
why	O	1830-1833
these	O	1834-1839
tissues	O	1840-1847
are	O	1848-1851
particularly	O	1852-1864
affected	O	1865-1873
.	O	1873-1874
.	O	1873-1874

Localization	O	0-12
of	O	13-15
human	O	16-21
BRCA1	O	22-27
and	O	28-31
its	O	32-35
loss	O	36-40
in	O	41-43
high	O	44-48
-	O	48-49
grade	O	49-54
,	O	54-55
non	B	56-59
-	I	59-60
inherited	I	60-69
breast	I	70-76
carcinomas	I	77-87
.	O	87-88

Although	O	89-97
the	O	98-101
link	O	102-106
between	O	107-114
the	O	115-118
BRCA1	O	119-124
tumour	B	125-131
-	O	131-132
suppressor	O	132-142
gene	O	143-147
and	O	148-151
hereditary	B	152-162
breast	I	163-169
and	I	170-173
ovarian	I	174-181
cancer	I	182-188
is	O	189-191
established	O	192-203
,	O	203-204
the	O	205-208
role	O	209-213
,	O	213-214
if	O	215-217
any	O	218-221
,	O	221-222
of	O	223-225
BRCA1	O	226-231
in	O	232-234
non	B	235-238
-	I	238-239
familial	I	239-247
cancers	I	248-255
is	O	256-258
unclear	O	259-266
.	O	266-267

BRCA1	O	268-273
mutations	O	274-283
are	O	284-287
rare	O	288-292
in	O	293-295
sporadic	B	296-304
cancers	I	305-312
,	O	312-313
but	O	314-317
loss	O	318-322
of	O	323-325
BRCA1	O	326-331
resulting	O	332-341
from	O	342-346
reduced	O	347-354
expression	O	355-365
or	O	366-368
incorrect	O	369-378
subcellular	O	379-390
localization	O	391-403
is	O	404-406
postulated	O	407-417
to	O	418-420
be	O	421-423
important	O	424-433
in	O	434-436
non	B	437-440
-	I	440-441
familial	I	441-449
breast	I	450-456
and	I	457-460
ovarian	I	461-468
cancers	I	469-476
.	O	476-477

Epigenetic	O	478-488
loss	O	489-493
,	O	493-494
however	O	495-502
,	O	502-503
has	O	504-507
not	O	508-511
received	O	512-520
general	O	521-528
acceptance	O	529-539
due	O	540-543
to	O	544-546
controversy	O	547-558
regarding	O	559-568
the	O	569-572
subcellular	O	573-584
localization	O	585-597
of	O	598-600
BRCA1	O	601-606
proteins	O	607-615
,	O	615-616
reports	O	617-624
of	O	625-627
which	O	628-633
have	O	634-638
ranged	O	639-645
from	O	646-650
exclusively	O	651-662
nuclear	O	663-670
,	O	670-671
to	O	672-674
conditionally	O	675-688
nuclear	O	689-696
,	O	696-697
to	O	698-700
the	O	701-704
ER	O	705-707
/	O	707-708
golgi	O	708-713
,	O	713-714
to	O	715-717
cytoplasmic	O	718-729
invaginations	O	730-743
into	O	744-748
the	O	749-752
nucleus	O	753-760
.	O	760-761

In	O	762-764
an	O	765-767
attempt	O	768-775
to	O	776-778
resolve	O	779-786
this	O	787-791
issue	O	792-797
,	O	797-798
we	O	799-801
have	O	802-806
comprehensively	O	807-822
characterized	O	823-836
19	O	837-839
anti	O	840-844
-	O	844-845
BRCA1	O	845-850
antibodies	O	851-861
.	O	861-862

These	O	863-868
reagents	O	869-877
detect	O	878-884
a	O	885-886
220	O	887-890
-	O	890-891
kD	O	891-893
protein	O	894-901
localized	O	902-911
in	O	912-914
discrete	O	915-923
nuclear	O	924-931
foci	O	932-936
in	O	937-939
all	O	940-943
epithelial	O	944-954
cell	O	955-959
lines	O	960-965
,	O	965-966
including	O	967-976
those	O	977-982
derived	O	983-990
from	O	991-995
breast	B	996-1002
malignancies	I	1003-1015
.	O	1015-1016

Immunohistochemical	O	1017-1036
staining	O	1037-1045
of	O	1046-1048
human	O	1049-1054
breast	O	1055-1061
specimens	O	1062-1071
also	O	1072-1076
revealed	O	1077-1085
BRCA1	O	1086-1091
nuclear	O	1092-1099
foci	O	1100-1104
in	O	1105-1107
benign	O	1108-1114
breast	O	1115-1121
,	O	1121-1122
invasive	B	1123-1131
lobular	I	1132-1139
cancers	I	1140-1147
and	O	1148-1151
low	B	1152-1155
-	I	1155-1156
grade	I	1156-1161
ductal	I	1162-1168
carcinomas	I	1169-1179
.	O	1179-1180

Conversely	O	1181-1191
,	O	1191-1192
BRCA1	O	1193-1198
expression	O	1199-1209
was	O	1210-1213
reduced	O	1214-1221
or	O	1222-1224
undetectable	O	1225-1237
in	O	1238-1240
the	O	1241-1244
majority	O	1245-1253
of	O	1254-1256
high	O	1257-1261
-	O	1261-1262
grade	O	1262-1267
,	O	1267-1268
ductal	B	1269-1275
carcinomas	I	1276-1286
,	O	1286-1287
suggesting	O	1288-1298
that	O	1299-1303
absence	O	1304-1311
of	O	1312-1314
BRCA1	O	1315-1320
may	O	1321-1324
contribute	O	1325-1335
to	O	1336-1338
the	O	1339-1342
pathogenesis	O	1343-1355
of	O	1356-1358
a	O	1359-1360
significant	O	1361-1372
percentage	O	1373-1383
of	O	1384-1386
sporadic	B	1387-1395
breast	I	1396-1402
cancers	I	1403-1410
.	O	1410-1411
.	O	1410-1411

